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ABSTRACT 
Huntington’s disease (HD) is a genetic neurodegenerative disease characterised by 
motor, cognitive and psychiatric symptoms. Atrophy of subcortical brain structures has been 
well characterised and changes in the white matter are being mapped with increasing 
frequency, but structural changes in the cortex have been relatively overlooked in previous 
research. With recently trialled therapies specifically targeting the cortex, a better 
understanding of the pattern and progression of atrophy in this region should provide valuable 
measures for determining the impact of these novel treatments on the degenerative process.  
This thesis performs a methodological comparison aimed at optimising techniques to 
measure cortical characteristics in an HD cohort, and then applies the optimised techniques in 
a group of HD gene carriers undergoing conversion from pre-manifest HD to manifest HD 
quantifying cortical change during this critical period. Several tools for the quantification of 
cortical volume and cortical thickness are examined via detailed analyses using two datasets. 
This investigation results in a series of recommendations for the use of such tools, as well as 
the selection of the most appropriate measures for use in the second part of this thesis. In 
addition, since subcortical atrophy measures are widely used in HD research, the performance 
of one of the segmentation tools was evaluated by comparison with manual segmentations of 
the caudate and putamen. Finally, a novel multivariate analysis method is applied, based on 
the principles of DCM, to measure the rate, timing and acceleration of cortical GM change in a 
subgroup of 49 motor converters from the TRACK-HD cohort. This cortical atrophy is then 
related both to the biological underpinning of the disease in terms of CAG length and also the 
behavioural presentation of motor and cognitive symptoms. These findings present the first 
detailed characterisation of cortical grey matter change in HD, and have important 
implications for the understanding of HD progression. 
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AIMS OF THIS THESIS 
In the period immediately prior to Huntington’s Disease (HD) motor diagnosis there is 
an increase in symptom severity that is thought to be accompanied by an increase in atrophy 
within the cortical grey matter (CGM) in the brain (Tabrizi et al. 2013). The pattern of CGM 
atrophy that occurs during the transition from pre-manifest HD (pre-HD) to manifest HD has 
not been fully characterised and its relationship to the onset of symptoms is currently unclear. 
Magnetic resonance imaging (MRI) can be used to capture images of the brain in vivo across 
many stages of HD, and is subsequently a vital tool in the characterization of atrophy in HD. 
However, it is challenging to accurately quantify cortical change from MRI despite the 
availability of many software tools designed to achieve this goal. Automated tools are regularly 
used to analyse a number of cortical features, such as volume and thickness of the grey 
matter, yet due to a large range of individual differences along with the complicated 
gyrification within the human cortex these tools often suffer from errors in segmentation that 
can result in inconsistent findings between studies. In addition, while previous studies have 
been designed to quantify cortical change in HD the majority of these studies have used mass-
univariate linear methods, which are difficult to apply in cohorts with data from variable time 
points and do not provide information about potential accelerations or decelerations in 
atrophy across disease stages. These issues combined with a number of other methodological 
problems have contributed to a relatively limited understanding about the trajectory of 
cortical change in HD. To understand the relationship between neurological change and HD 
progression, a detailed characterisation of the changes that occur in the cortex during 
symptom onset is required. 
 
OVERALL AIM 
This thesis aims to evaluate and optimise the most accurate tools for quantifying 
cortical atrophy from MRI scans in a large cohort of gene carriers across the HD disease 
spectrum and to undertake a characterisation of CGM change during HD motor onset. 
 
SPECIFIC AIMS 
 To investigate the most appropriate methods to detect and measure CGM changes in 
HD and to optimise these techniques resulting in a ready-to-use pipeline for analysis.  
 To conduct a detailed characterisation of what CGM changes occur during the period 
immediately surrounding HD diagnosis. 
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 To investigate how CGM brain changes relate to the biological underpinning and 
behavioural manifestation of HD. 
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1. INTRODUCTION 
This chapter will provide an overview of key topics covered by this thesis. An 
introduction to Huntington’s disease (HD) will be provided, followed by a summary of the 
process of generating MRI scans. Different MRI analysis techniques will be discussed, and an 
overview of findings from previous work studying neural atrophy in HD using structural MRI 
(sMRI) will be reviewed. Finally, an outline of the current thesis will be provided within the 
context of previous literature. 
1.1. Huntington’s disease 
HD is a genetic neurodegenerative disease characterised by motor, cognitive and 
psychiatric symptoms. The disease is caused by an expanded CAG repeat in the HTT gene and 
it is fully penetrant and incurable (Tabrizi et al. 2012; Tabrizi et al. 2013). An individual can be 
identified as gene positive many years before the onset of symptoms but the formal diagnosis 
is only made in the presence of motor symptoms via use of the Unified Huntington’s Disease 
Rating Scale (UHDRS; Huntington Study Group 1996).  
HD is caused by an expanded CAG trinucleotide repeated in HTT, the gene responsible 
for encoding the protein huntingtin. The expanded CAG repeat results in the production of a 
mutant form of huntingtin that has an unusually long polyglutamine (polyQ) sequence (Bates 
et al. 2015). Mutant huntingtin (mHTT) exhibits toxic properties that cause cellular dysfunction 
and neuronal death. The medium spiny neurons found in the striatum are the most vulnerable 
to damage by mHTT, however neurons in other brain regions are also damaged by mHTT, 
leading to widespread neural atrophy over the course of HD. While HD has typically been 
viewed as a disease affecting the central nervous system, it is now understood to affect the 
whole body, with symptoms such as weight loss, muscle changes and changes to the 
peripheral immune system commonly occurring in patients alongside neurological symptoms 
(Björkqvist et al. 2008; Carroll et al. 2015).  
1.1.1. Mechanisms and pathophysiology 
Within the HTT gene is a CAG repeat that has varying length in the normal population. 
The length of this CAG repeat can be measured in any individual, with the length determining 
penetrance of HD. The healthy length of CAG repeats is between 6-35 repeats. For individuals 
with ≥40 repeats the disease will be fully penetrant. Repeat lengths of 36-39 are classed as 
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reduced penetrance, with some individuals in this range showing no signs of HD throughout 
their lives and others being clinically diagnosed as having HD, although generally later in life.  
HD is autosomal dominant, meaning that if one parent is affected each child has a 50% 
chance of inheriting the expanded CAG repeat. In addition, the CAG repeat shows instability 
between parents and children, with longer CAG repeats often also having greater instability. 
Between generations the repeat can typically increase or decrease by a small number of CAGs, 
although large increases in CAG repeat length are sometimes seen; in some cases this may 
result in the appearance of a new mutation with an unaffected parent passing on a CAG repeat 
length in the pathogenic range.  CAG repeat length not only predicts whether an individual will 
develop HD, but also predicts the age at which symptom onset occurs. Within the most 
common CAG range measured in individuals with HD, 40-55 repeats, approximately 56% of the 
variation in age at motor onset is accounted for by CAG length. Of the remaining variation, a 
large percentage (38-56%) can be attributed to genetic modifiers of onset and progression, 
although little is currently known about genetic modifiers in HD (Moss et al. 2017).  
The normal form of huntingtin is expressed throughout the whole body, with the level 
of expression varying across different regions of the body. The function of huntingtin is not 
well understood, however it is believed to be important for the development of the nervous 
system, for cell adhesion and is understood to affect brain-derived neurotropic factor (BDNF), 
a protein supporting neuronal survival and growth (Bates et al. 2015). Currently, a detailed 
understanding of how huntingtin affects these processes is lacking, but it is hypothesised that 
the polyglutamine expansion results in the loss or modulation of normal huntingtin functioning 
and that a critical level of this abnormal huntingtin causes enough damage to cause symptom 
onset.  
1.1.2. Epidemiology 
Within Western populations, the prevalence of HD is thought to be between 10.6-13.7 
individuals per 100,000 (Fisher & Hayden 2014; Evans et al. 2013; Morrison et al. 2011), with 
higher prevalence in individuals with European ancestry. In Asian and African cultures, there 
are typically lower rates of HD (diagnosis seems to occur around one-tenth as frequently), 
however often the results of epidemiology studies in these regions are based on case studies 
and thus the exact prevalence is unclear. There have also been pockets of extremely high 
prevalence reported, with the most widely studied being the Venezuelan cohort in Maracaibo 
which led to the discovery of the HD gene (The U.S.-Venezuela Collaborative et al. 2004). 
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Over the last few decades, the rates of HD appear to have increased (Bates et al. 
2015). This is likely to be due to the development and subsequent increasing availability of a 
genetic test for HD. Estimations of prevalence described before the development of genetic 
testing possibly underestimated sporadic cases of HD (5-8% of cases). Furthermore, the 
genetic test can now confirm late-onset HD, which may have previously been underestimated 
due to concurrent aging or other related factors. Finally, longer lifespans are also probable 
contributors to increasing rates of prevalence, with longer lifespans resulting in more late-
onset cases of HD.  
1.1.3. Diagnosis and symptomology 
The official clinical diagnosis threshold for HD is based on motor symptoms, however 
there is a long pre-HD phase whereby subtle symptoms of the disease begin to emerge. This 
phase can last for 10-15 years before motor diagnosis and includes psychiatric disturbances 
such as depression, anxiety or aggression, and cognitive symptoms including worsening short-
term memory and attentional deficits. During this phase, subtle and progressively worsening 
motor symptoms are typically experienced. Onset of the pre-HD phase is related to CAG 
length, but typically starts during an individual’s late thirties to mid-forties.  
The initial symptoms of HD experienced during this phase are highly variable between 
patients (Papp et al. 2011), but as the disease progresses symptoms become more consistent; 
with visuomotor performance and working memory largely affected in late premanifest HD 
and motor symptoms beginning to become more obvious (Papp et al. 2011). Diagnosis of HD 
occurs in the presence of irrefutable motor symptoms (as defined by the UHDRS) and a 
confirmed family history of HD or positive genetic test (Huntington Study Group 1996). The 
UHDRS rating scale ranges from 0 to 4, with 0 indicating no motor abnormalities suggestive of 
HD, and 4 indicating motor symptoms that are ≥99% likely to be due to HD. A score of 4 
defines motor onset, and symbolises the period known as ‘manifest’ HD.  
After onset, motor, cognitive and behavioural symptoms continue to advance in a 
variable pattern until death. In addition to being associated with earlier age at onset, longer 
CAG repeat length is associated with faster progression once symptoms have begun, although 
this relationship is not as robust as that between CAG length and onset (Ross et al. 2014).  
The discovery of the HD gene was made in 1993 (MacDonald et al. 1993), and since 
then genetic testing has been used as both a diagnostic tool and a predictive test in HD. If a 
patient comes to a clinic with symptoms that are characteristic of HD, a genetic test might be 
used to diagnose or exclude HD as a cause of these symptoms. Alternatively, genetic testing 
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can be performed as a predictive test many years before onset. The implications of receiving a 
positive genetic test result are significant, and so in 1994 a set of international guidelines were 
developed to reduce negative psychological and physical harm that may be associated with a 
positive result (Anon 1994). These guidelines recommended that in order to undergo 
predictive testing an individual should be given genetic counselling and a psychological 
assessment, along with a neurological examination and time to reconsider whether they 
definitely want the test performed. In addition, the guidelines stipulate that results should be 
provided in person with the opportunity to receive post-test support. Children under 18 should 
not be tested unless they are symptomatic. These recommendations were recently updated 
and now include advice on the provision of information about preimplantation genetic 
diagnosis (PGD; MacLeod et al. 2013). The rate of testing in individuals at risk from HD varies, 
ranging from 3-4% in Germany, Austria and Switzerland to 24% in Denmark. The rate of 
predictive testing in the UK is reported to be around 18% (Tibben 2007).  
1.1.3.1. Motor symptoms 
Motor symptoms are the most widely recognised and visible signs of HD. They 
generally fall into two broad categories. The first category is involuntary movement, with 
chorea being the most common motor symptom of HD (Bates et al. 2015). Chorea is 
characterised by quick, irregular and unpredictable movements, often of the limbs.  The 
second category of motor symptoms is the impairment of voluntary movements, which 
includes lack of coordination and bradykinesia. Bradykinesia refers to the slowing of 
movement, and encompasses an inability to move the body quickly. Bradykinesia is typically 
associated with long CAG repeats, and is especially prevalent in juvenile HD, although it also 
occurs in the later stages of typical HD progression. Motor symptoms are slowly progressing in 
most individuals, and are measured using the Total Motor Score section of the UHDRS 
(Huntington Study Group 1996). This scale examines different features of motor disturbance in 
HD, including chorea, bradykinesia, speech, eye movements, gait and other features.  
1.1.3.2. Cognitive symptoms 
Cognitive symptoms are another key element of HD progression. Similarly to motor 
progression, changes in cognition occur slowly. Subtle cognitive symptoms can be seen around 
10 years prior to clinical diagnosis, with the earliest cognitive signs including problems with 
visuomotor integration, psychomotor speed, emotion recognition and executive functioning 
(Bates et al. 2015).  As a patient progresses, problems are also experienced with attention, 
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mental flexibility, learning, episodic and working memory along with more general slowing in 
cognition. Semantic memory, spatial awareness and language do not show significant 
deterioration as in other neurodegenerative conditions, such as Alzheimer’s.  
1.1.3.3. Psychiatric symptoms 
The psychiatric symptoms associated with HD are much more variable than both 
motor and cognitive symptoms (Bates et al. 2015). Depression is commonly experienced in HD 
gene carriers, both before and after disease onset. In addition, apathy and irritability are both 
seen frequently in HD. Apathy increases with increasing disease progression, getting 
increasingly debilitating.   
1.1.3.4. Impact of Huntington’s disease on quality of life 
As HD progresses, quality of life patients is reduced for many by the increasing severity 
of HD symptoms (Read et al. 2013). Depressive mood and decreases in functional ability 
(ability to work, feed oneself, cook etc.) have been shown as two of the greatest contributors 
to reduced quality of life (Ho et al. 2009), with apathy also being been linked to worse quality 
of life in HD (Ready et al. 2008). By end-stage disease, patients are incapacitated and are often 
receiving care in a specialised care facility. Treatments should aim to improve quality of life 
where possible.   
1.1.4. Models of HD onset and progression 
Due to the strong relationship between age and CAG, these two variables can be used 
to predict estimated disease onset and progression, and to categorise participants on their 
disease severity and exposure to the mutant form of huntingtin. A number of models exist to 
scale participants on these factors, with three commonly used models described here. 
1.1.4.1. Disease-burden score 
One of the commonly used models is the disease-burden score. This model was 
developed by Penney et al. (1997) and is based on the relationship between post-mortem 
striatal atrophy, age at death and CAG repeat length. Their study found that these three 
factors were linearly related and had an intercept at 35.5, and concluded that 35.5 was the 
largest CAG repeat whereby no pathology would develop in the striatum. They also 
hypothesised that the pathological process would develop from birth in a linear way. Thus they 
modelled: disease burden = (CAG – 35.5) x current age. This approximation of disease burden 
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is frequently used as a theoretical model in HD studies, including the TRACK-HD and TrackOn-
HD studies to scale participants based on their approximate exposure to the mutant huntingtin 
protein and thus approximate disease stage. However, the model was based on post-mortem 
data and is thus biased towards end-stage disease, and assumes that atrophy progresses 
linearly from birth. This model also does not take into account other environmental or genetic 
factors, which may influence the progression and onset of HD.  
 
1.1.4.2. Predicted years-to-onset 
In addition, there are models of estimated disease onset. The most widely used is that 
developed by Langbehn et al. (2004). This model is a parametric survival model that estimates 
how far a participant is from clinical onset. Data from approximately 3000 pre-HD and 
manifest participants were used to develop the model.  The calculation uses a conditional 
probability model, which means that given an individual’s CAG repeat and age, and given that 
motor onset has not yet occurred, the probability that they will undergo motor onset by a 
given age can be calculated. A strength of the Langbehn model is that by incorporating a large 
number of both pre-HD and manifest participants selection biases are reduced.  
1.1.4.3. CAG age product scaled 
The CAG age product scaled (CAP) is a more recent method of estimating disease stage. The 
CAP score was developed on PREDICT-HD data, and validated using a longitudinal receiver 
operating characteristic analysis to show that it was a strong predictor of onset, especially if 
onset was within two years of calculation (Zhang et al. 2011). CAP score is often used as a 
normalised measure of onset, and can be used across pre-HD and manifest participants. Figure 
1.1 shows a schematic representing the hypothesised course of HD symptoms with age, 
normalised CAP score and motor diagnosis (Ross et al. 2014).  
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Figure 1.1. A schematic representation of the course of HD, showing the typical adult onset 
and normalised CAP scores vs. symptom onset. Adapted from Ross et al. (2014). 
 
1.1.5. Management and therapeutic trials 
There are currently no disease-modifying treatments for HD. Instead, clinicians focus 
on managing the symptoms of HD. There are two drugs specifically approved for the treatment 
of chorea in HD: tetrabenazine and deutetrabenazine, which show a moderate effect for 
reducing chorea (Rodrigues & Wild 2017). In addition to these drugs, commonly used 
psychiatric drugs are often prescribed to reduce psychiatric symptoms associated with HD.  
Further to treatment with drugs, the management of HD can involve a wide range of 
health professionals since the disease has an impact on many aspects of a patient’s life. In 
addition to neurologists and psychiatrists or psychologists, a patient may also require care 
from occupational health practitioners and physiotherapists to provide help in adjusting to HD-
related movement or balance issues.  
There have been almost 100 clinical trials aimed at testing disease-modifying 
treatments for HD, none of which have been successful (Rodrigues & Wild 2017). There are 
also a number of on-going clinical trials in HD. Some of the most promising approaches include 
targeting the transcription of HTT or the translation of HTT mRNA (Wild & Tabrizi 2017). In 
2016 a landmark clinical trial began aimed at reducing the production of mutant huntingtin by 
targeting the pre-mRNA transcript of the HTT gene. The trial was phase IB/IIA with the initial 
aims being safety and tolerability. Following positive safety results, the study has been rolled 
into an open label extension trial, beginning in late 2017. This is the first trial aimed at this type 
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of intervention, however more trials testing different techniques of HTT lowering are due to 
begin soon.  
1.1.6. Post-mortem results in HD 
The neural atrophy that occurs over the course of HD has been characterised via a 
number of pathological studies measuring the brains of HD patients post-mortem (Vonsattel et 
al. 1985; De La Monte et al. 1988; Mann et al. 1993). While even the earliest post-mortem 
studies report that the most striking feature of these brains is atrophy of the caudate and 
putamen, there is also atrophy of the white matter (WM) and cortex noted in most studies. 
Figure 1.2. shows an example of a post-mortem brain damaged from HD. One study reported 
that the volume of the caudate was reduced by 53% and the putamen by 46% in end-stage HD 
patients compared to controls. This study also showed a reduction of the WM (13%), and 
relatively uniform atrophy of the cortex, with overall cortical volume reduced by 23% 
compared to controls, and only the temporal lobes being relatively spared from atrophy 
(Halliday et al. 1998). Within the cortex, the occipital lobe showed the greatest difference 
compared to controls (28%), frontal and parietal regions were reduced by 22%, and the 
temporal lobe was 17% lower than in control participants. This study also reported that the 
extent of atrophy present in the cortex, but not the subcortical regions, correlated with CAG 
repeat length (Halliday et al. 1998).  
More recently, the cell loss in the motor cortex was associated with level of motor 
dysfunction in HD (Thu et al. 2010). The same study also found that patients rated as having 
more severe mood symptoms had greater cellular loss in the cingulate cortex, a region known 
to process emotion, indicating a link between cortical atrophy and HD symptomology.  
While the majority of post-mortem results are from patients who are at end-stage 
disease, they are indicative of widespread volume loss that occurs over a number of years 
extending beyond the striatum. Due to the small number of post-mortem brains available from 
other stages of HD, it is only via in-vivo techniques including MRI that we can measure the 
progression of atrophy and understand changes occurring in earlier phases of the disease.  
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Figure 1.2. An example of a post-mortem HD brain, left, compared to a healthy brain, right.  
Adapted from https://hbtrc.mclean.harvard.edu/about/tour/slideview.php?page=41. 
 
1.1.1. Biomarkers in HD 
In order to quantify the effects of therapeutic interventions, the validation of accurate 
and sensitive biomarkers is essential. A biomarker is a measureable indicator of a medical state 
or disease. It should be objective, easy to measure and understand, quantifiable, sensitive and 
preferably non-invasive (Paulsen 2009). The TRACK-HD study was designed to test a range of 
potential biomarkers in HD (Tabrizi et al. 2009). By collecting cognitive, psychological, motor 
and imaging data for controls, pre-HD and manifest HD participants over 4 years the best 
markers of disease progression at different stages of HD could be selected.  
In the TRACK-HD analysis conducted after 24 months of data collection the effect sizes 
of potential biomarkers were compared in a large cohort which included 123 controls, 120 pre-
HD and 123 early HD participants at baseline (Tabrizi et al. 2012). Change in caudate volume 
showed the greatest effect size for both pre-HD (1·17) and manifest HD (2.04) groups 
compared to controls. Cognitive biomarkers all had relatively low effect sizes in pre-HD (<.20), 
but the symbol digit modality test (SDMT; Smith 1991), a measure of visuomotor integration 
with components of visual scanning and tracking, was the most sensitive cognitive measure in 
manifest HD (effect size = 1.00). Quantitative motor measures, designed to be objective 
quantitative measures of motor symptoms, were not as robust as imaging measures, with 
speeded-tapping mean inter-tap interval for the non-dominant hand having the largest effect 
size in pre-HD participants (.38), and the log of speeded-tapping tap duration variability for 
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non-dominant hand giving the largest effect size for manifest participants (.68). The clinical 
rating scale of motor progression showed larger effect sizes than quantitative motor 
measures. The UHDRS motor score had an effect size of .79 for pre-HD and .81 for manifest 
HD. Despite these and other results demonstrating that macrostructural MRI biomarkers are 
robust and sensitive measures of HD progression (Georgiou-Karistianis et al. 2013), the most 
widely used biomarkers are still clinical measures of progression that are more relevant to the 
daily life experiences of an HD patient, with MRI biomarkers currently being used as secondary 
endpoints for clinical trials (Scahill et al. 2012).  
Recently, fluid biomarkers for HD have been gaining increased interest. While imaging 
and clinical biomarkers provide indirect measures of the disease, fluid biomarkers offer the 
potential to provide direct measures of biochemical changes occurring during the course of HD 
(Byrne & Wild 2016; Johnson et al. 2018). Biomarkers of cerebrospinal fluid (CSF) and plasma 
are currently being characterised, with neurofilament light protein (NfL), a biomarker thought 
to measure axonal degeneration, hypothesised to be a promising marker of cross-sectional 
disease stage but also a strong predictor of HD progression in the subsequent period (Byrne et 
al. 2017). NfL has also been shown to predict regionally specific atrophy in subcortical regions, 
regions of the cortex and the WM (Johnson et al. 2018). While showing great promise, fluid 
biomarkers require more validation, especially prior to use as surrogate disease markers in 
clinical trials. 
1.1.2. Summary 
HD is a devastating disease, characterised by a triad of slowly progressing motor, 
cognitive and psychiatric symptoms. There is no cure and no effective treatment, however 
clinical trials are underway aimed at developing disease-modifying treatments. At end-stage 
disease, atrophy in the caudate and putamen is the most pronounced neuropathological 
finding, however global neural atrophy suggests a slow progression of widespread neuronal 
damage. By using MRI to measure characteristics of the brain in-vivo, we can hope to better 
understand the trajectory of neural atrophy in HD.  
1.2. MRI methods 
MRI is a technique employed to examine the structure and function of the brain and 
body in-vivo. MRI scans allow measurement of neuropathological change as it occurs over 
repeated time points and without invasive procedures. While MRI scans are not used in the 
diagnosis of HD due to the availability of a genetic test the analysis of MRI data is regularly 
used in HD research studies and clinical trials to monitor the progression of neural change. An 
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MRI scanner is capable of collecting many types of data however this PhD will focus on sMRI 
scans, which provide a way of measuring structure and morphometry of the brain. A brief 
overview of MRI hardware and acquisition of images will be covered, followed by an 
examination of neuroimaging in HD.    
1.2.1. Acquisition of MRI data 
MRI scans utilise a magnet and radiofrequency pulses to change the state of hydrogen 
atoms in the body, and the energy created by these changes in state can be measured and 
outputted in the form of an image (Currie et al. 2013). Varying MRI acquisitions can be used to 
capture different characteristics and functions of the brain.  
1.2.1.1. Hardware 
An MRI scanner consists of two main components; the MRI scanner and the control 
console. The control console is the computer console that allows the programming and 
running of different scans. It is typically in a different room to the MRI scanner. The MRI 
scanner is a machine that uses a strong magnetic field that enables us to capture images.  
The Maxwell equations stipulate that an electric current running through a wire 
creates a magnetic field surrounding the wire (Currie et al. 2013). An MRI scanner makes use 
of this principle, and uses a current running through a series of superconducting metal coils 
cooled to absolute zero to generate strong magnetic fields (called B0). The strength of the 
magnetic field is described in units of Tesla (T), with higher Tesla scanners usually resulting in 
higher resolution images. Most modern scanners are either 1.5T or 3T in strength.  
A set of gradient coils are also present in the scanner, which are used to distort the 
main magnetic field in a predictable pattern and then allows spatial encoding of the measured 
signal so images can be mapped in the x, y and z directions to create 3D images. An MRI 
scanner also has radiofrequency (RF) coils that transmit an RF signal to the tissues being 
examined, and then receives the induced signal from the tissue. Finally, in order to collect 
good quality images, shim coils are used to ensure consistency, known as homogeneity, within 
the magnetic field. This translates to increased homogeneity within the MRI images when 
processed. 
1.2.1.2. Obtaining images 
MRI scanners use the hardware described to create images via the manipulation of 
atoms within the body. The source of most MRI images is the hydrogen nuclei. Within each 
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hydrogen nuclei there is a single proton with a positive electrical charge. Each proton is 
constantly spinning; since a spinning electrical charge is a current, each proton has a tiny 
magnetic field. These magnetic fields are called magnetic moments, and each magnetic 
moment is normally in a random orientation (Currie et al. 2013). However, when a uniform 
magnetic field (such as B0) is applied to magnetic moments they align to B0 in either a parallel 
or an antiparallel fashion. More protons will align parallel to B0 since this is the alignment 
requiring less energy, although the difference between the number of protons in parallel and 
antiparallel alignment depends on factors such as the strength of B0 and the temperature of 
the tissue.   
In addition to aligning with B0, when an external magnetic field is applied to the 
protons they spin in a particular motion, called ‘precession’. The protons precess at a 
frequency determined by the strength of B0 multiplied by , a constant value relative to the 
properties of each type of proton, this is called the Lamor Equation (Currie et al. 2013). The 
protons pointing in parallel and antiparallel directions cancel each other in all directions except 
for the z-axis of B0, so when a person is in B0 their hydrogen protons align with B0 creating a 
magnetic field for the patient aligned with B0. This field is called longitudinal magnetisation.  
To create a signal a brief RF pulse is applied which creates a transfer of energy from 
the RF pulse to the protons, disturbing the protons so they fall out of line with B0 (Currie et al. 
2013). To do this, the RF pulse must be applied at the same frequency as the frequency at 
which protons are precessing.  This RF pulse reduces the longitudinal magnetisation and 
rotates the net magnetisation into the x-y plane as the protons absorb the energy, called 
excitation. It also causes the protons to precess in phase, i.e. in the same direction, at the 
same time. A simple schematic demonstrates this process in Figure 1.3. 
Once the RF pulse has been switched off, the protons begin to return to their original 
alignment with B0 via two types of relaxation (Currie et al. 2013). The energy absorbed from 
the RF pulse is released and the protons move back into the z plane in line with B0. This 
process is called T1 relaxation. Each tissue has a different T1 relaxation time depending on 
how tightly bound the protons are in their environment. For example, within the CSF where 
hydrogen atoms and protons move more freely, the T1 relaxation time is longer. These tissue-
dependent differences in relaxation time result in the ability to distinguish between different 
tissue types from MRI scans.  
The protons also begin to fall out of phase once the RF pulse is switched off. This is 
called T2 relaxation, and is caused by the fact that the magnetic fields from neighbouring 
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protons influence each other and push each other out of phase. When combined with small 
inhomogeneity within B0, the result is differing T2 relaxation across the image.   
T1 and T2 relaxation are independent, but occur at the same time. T1 relaxation 
happens more slowly than T2 relaxation, though.  When the protons undergo T1 and T2 
relaxation, they re-emit the energy absorbed from the RF pulse and this energy is measured by 
the MRI scanner and used to construct an image. The gradient coils described earlier are used 
to collect spatial information from the re-emitted energy. The raw data is captured from the 
scanner and stored in a data matrix called k-space. This data is then converted from k-space 
into an image via an inverse Fourier transform.   
These two types of relaxation can be measured independently to create the most 
commonly used types of structural images, T1 and T2 weighted images. T1 images measure 
the T1 relaxation and T2 images measure the T2 relaxation and have different contrast based 
on the properties of the image acquisition.  Figure 1.4 shows an example of a T1 and T2 image 
from the TRACK-HD study, demonstrating the different contrast seen in these two scan types. 
An MRI acquisition can specify not only the contrast in the image, but the quality of the image, 
and the size of the voxels. Image quality and MRI artefacts are discussed further in Chapter 2.  
 
Figure 1.3. A schematic illustrating the spin of hydrogen atoms before a magnetic field is 
applied, whilst in a magnetic field, and during and after an RF pulse is applied. Adapted from 
https://www.khanacademy.org/test-prep/mcat/physical-processes/proton-nuclear-magnetic-
resonance/a/magnetic-resonance-imaging-mri. 
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Figure 1.4. An example of 3D T1 and T2 weighted images from the TrackOn-HD study showing 
(A) A T1 scan in coronal view, (B) A T1 scan in axial view and (C) A T1 scan in sagittal view, (D) A 
T2 scan in coronal view, (E) A T2 scan in axial view and (F) A T2 scan in sagittal view. 
1.2.1. Types of MRI data 
A number of types of MRI data can be collected from MRI scanners, with each type 
representing different neural characteristics. Three types of data frequently collected for use 
in HD research are structural, diffusion and functional MRI data. 
1.2.1.1. Structural 
sMRI provide static anatomical information about the brain. They are typically used to 
measure characteristics of different brain regions, such as volume, both cross-sectionally and 
longitudinally and will be the main focus of this research. sMRI is currently the most robust 
type of MRI imaging to be replicated reliably across multiple study sites (Georgiou-Karistianis 
et al. 2013), and structural imaging measures show the greatest effect sizes in detecting 
longitudinal HD pathology (Hobbs et al. 2013). The majority of studies that have previously 
reported on sMRI changes within HD participants have used three main techniques: regional 
volumetric, voxel-based morphometry (VBM) and CT analyses, to be discussed in section 1.3.  
1.2.1.2. Diffusion 
Diffusion tensor imaging (DTI) detects the coherence of water flow through tracts of 
the brain, and is hypothesised to reflect aspects of tissue microstructure such as myelination 
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(Le Bihan et al. 2001). A number of different metrics can be extracted from DTI images 
representing different properties of the tracts such as fractional anisotropy, which represents 
overall coherence, and mean diffusivity, which represents mean diffusion along the tracts.  In 
HD individuals, changes in these characteristics are believed to represent underlying pathology 
that precedes change detected in the WM by sMRI.  
1.2.1.3. Functional  
Functional MRI (fMRI) quantifies increases or decreases in blood flow (Blood 
Oxygenation Level Dependent signal) to regions of the brain during rest or the performance of 
different tasks (Ogawa et al. 1990).  The regional changes in blood flow are due to the varying 
demand for oxygen across different brain regions. Differences between groups or over time 
are often attributed to differences in pathology. It is hypothesised that as HD progresses, 
alternative brain networks compensate for damaged networks to complete a task or function 
thus resulting in differences in BOLD signal between controls and HD gene carriers (Klöppel et 
al. 2015; Gregory et al. 2017). fMRI can be collected in a number of ways, with two commonly 
used paradigms. Task based fMRI measures BOLD signal during the completion of a task in the 
MRI scanner, for example, increases or decreases in signal could be measured during a finger 
tapping task. Resting state fMRI (rs-fMRI), in contrast, measures BOLD signal during rest in the 
scanner, and is rs-fMRI data quantifies the underlying blood flow and regional interactions 
taking place at rest. 
1.3. Analysis of sMRI data 
The processing of sMRI data to quantify group differences or longitudinal change can 
be divided into two broad approaches, region of interest (ROI) analyses and whole-brain 
analyses. Both methods offer complementary information, and within these broad techniques 
there are a multitude of different measurements that can be performed.   
1.3.1. Region of interest analysis 
ROI analyses involves the delineation of structural regions, for example the whole-
brain or caudate, to provide precise measurements of differing characteristics of a region. 
Measures such as volume, thickness of the GM cortex or gyrification can all be examined using 
ROI studies. The delineation of ROIs can be performed manually or automatically (see section 
2.3 for an explanation of different processing methods), and after a region is delineated a 
value can be extracted. Figure 1.5A shows an example of a manually delineated caudate ROI 
used to measure caudate volume. ROI studies often show high sensitivity for detecting group 
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differences and longitudinal change and thus can be very useful for examining specific 
hypotheses, however, in order to obtain accurate data the ROIs need to be precisely defined. 
The manual measurement of ROIs is a highly accurate method for measuring the 
characteristics of some regions, yet they are also very time-consuming and can be impractical 
when measuring multiple anatomically complex regions. Automated measures can be 
performed more quickly and easily, however they often bring an increased level of error. 
These costs and benefits should be weighed up for each study using ROI methods. 
In addition to issues with measurement, the nature of ROI studies can result in group 
differences or volumetric change remaining unobserved due to the highly specific nature of 
the analysis. In order to avoid harsh statistical corrections for multiple comparisons, regions 
should be carefully selected for examination prior to analysis based on a priori hypotheses. 
However, this can result in significant results being overlooked if they occur outside of the 
chosen ROIs. ROI examinations are frequently used in HD studies, especially when measuring 
subcortical structures such as the caudate and putamen. A number of HD studies use manual 
ROIs to characterise change (Tabrizi et al. 2009; Tabrizi et al. 2012; Tabrizi et al. 2013; Tabrizi 
et al. 2011), and some of these measures are described in 2.3.3. Often, additional exploratory 
whole-brain methods are used to supplement a priori ROI investigations of sMRI data.  
1.3.2. Whole-brain analysis  
Whole-brain techniques are used to perform comparisons between groups or 
longitudinally across all regions of the brain, Figure 1.5B shows the results of a whole-brain 
group analysis using VBM (section 2.3.4.2.1). Whole-brain analyses involve the statistical 
comparison of every voxel across the brain, and thus the performance of mass-univariate 
statistical tests require strict correction for multiple-comparisons (see section 2.4.4). However, 
whole-brain analyses offer the chance to look for regional differences that may be overlooked 
in ROI analyses. They have been widely used in HD imaging studies to measure both volume 
and cortical thickness (CT), and help to provide an understanding of the different regions that 
may be affected by atrophy in HD. Whole-brain analyses generally offer limited flexibility in 
terms of design (e.g. the options can be limited when using data sets with multiple time points, 
or missing data) and thus can be limited in their applications. 
VBM is the most commonly used whole-brain approach in HD, with SPM the most 
commonly used software. This involves a series of steps (Ashburner & Friston 2000), with the 
first step an integrated process registering all scans to create a template whilst also 
segmenting them into three tissue types (GM, WM and CSF). Following this, the scans are 
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aligned to the template space created in the first step, all voxels are modulated based on the 
warping parameters to account for volumetric changes that may have occurred during 
registration, and smoothed to reduce errors associated with registration. A general linear 
model statistical comparison can then be specified that can be used to compare voxel-wise 
volumetric differences between participants, or to examine associations between volume and 
performance on a cognitive task. 
 
 
Figure 1.5. (A) Shows a manually delineated caudate region on a scan from the TRACK-HD 
study; (B) Shows the results of a cross-sectional whole-brain analysis comparing the volume of 
GM and WM in different HD groups to controls from the TRACK-HD study (Tabrizi et al. 2009). 
 
1.4. sMRI findings in HD 
Both cross-sectional and longitudinal sMRI studies aimed at characterising neural 
atrophy in HD have been performed on a range of cohorts. Generally, the results suggest that 
prior to diagnosis there is significant subcortical GM loss and some WM loss (Tabrizi et al. 
2009; Paulsen et al. 2008), but that cortical atrophy begins closer to the time of diagnosis 
(Tabrizi et al. 2009). Atrophy across all tissue types and regions continues to advance after 
diagnosis and throughout the course of the disease (Tabrizi et al. 2013; Tabrizi et al. 2011; 
Tabrizi et al. 2012; Aylward et al. 1997). These findings will be covered in more detail here.  
1.4.1. Regional atrophy in HD 
A large amount of research has been focused on characterising atrophy in basal 
ganglia regions based on early pathology studies showing that the basal ganglia undergo 
particularly pronounced atrophy in HD (Vonsattel et al. 1985). Findings from MRI studies 
indicate that the striatum is the earliest region to undergo atrophy (Nopoulos et al. 2010; 
Aylward et al. 1997; Aylward et al. 2004; Tabrizi et al. 2009; Tabrizi et al. 2011). Cross-sectional 
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differences between controls and HD gene carriers can be found in the striatum up to 15 years 
prior to disease onset (Paulsen et al. 2010), and work is currently underway to examine 
participants who are even further from onset to determine when differences in the striatum 
can be detected. Putamen volume is also significantly lower in pre-HD participants than in 
control participants more than 15 years prior to symptom onset (Majid et al. 2011; Paulsen et 
al. 2010). There is currently a lack of clarity as to whether the caudate and putamen begin to 
undergo atrophy at the same stage and rate, or whether they progress differently, with 
different studies showing slightly different patterns of atrophy. The divergence between 
results is probably due to differing cohorts and measurement techniques (Georgiou-Karistianis 
et al. 2013). Despite this, it is clear that for both putamen and caudate structural differences 
continue to get more pronounced with increasing disease progression.  
Additionally, longitudinal studies have found significant striatal volume change in HD 
over very short periods of time. While annual rates of change can vary between studies 
depending on the cohort and analysis method, rates of around 3-4% reduction per year have 
been reported (Georgiou-Karistianis et al. 2013). Furthermore, volumetric change in both the 
caudate and putamen is significant over 12 months in both pre-HD and manifest HD compared 
to controls (Tabrizi et al. 2011; Hobbs et al. 2015), and over 6 and 9 months in the caudate in 
manifest HD compared to controls (Hobbs et al. 2015).  
Beyond the striatum, differences in whole-brain volume can also be detected between 
controls and pre-HD participants who are less than 10 years from disease onset (Tabrizi et al. 
2009). Additionally, whole-brain volume change is significant over 1 year in these participants, 
and significant over 6 months in early HD patients (Henley et al. 2006; Tabrizi et al. 2011; 
Hobbs et al. 2015). Change in total WM is also detectable over one year in participants more 
than 10 years from disease onset, with the rate of atrophy increasing closer to and after 
disease onset (Tabrizi et al. 2011). In manifest HD, WM volume shows significantly greater 
decline over 6, 9 and 15 months than in control participants (Hobbs et al. 2015). Small 
differences in total GM volume (with total GM including both subcortical and cortical GM) 
have been found between controls and pre-HD participants who are over 10 years from 
disease onset, however the greatest GM changes occur in participants close to disease onset 
and those with manifest HD (Nopoulos et al. 2010; Tabrizi et al. 2012), with total GM again 
showing significantly greater change in as little as six months in manifest HD compared to 
controls (Hobbs et al. 2015). 
In addition to quantifying change over time, many of the volumetric findings have 
been tested as predictors of disease progression. In the TRACK-HD cohort, striatal and GM 
 44 
volume measures were able to predict diagnosis in pre-HD individuals, and whole-brain, 
caudate, putamen, ventricular and GM volumes can significantly predict decline in total 
functional capacity in early HD participants, supporting a strong relationship between neural 
atrophy and clinical change (Tabrizi et al. 2013). Furthermore, in the PREDICT-HD cohort, cross-
sectional and longitudinal volume of the putamen, hippocampus, CSF, accumbens, globus 
pallidus and caudate could predict motor onset (Paulsen, Long, Ross, et al. 2014). Figure 1.6 
shows a schematic diagram of the hypothesised progression of imaging biomarkers in relation 
to CAP score (Ross et al. 2014).  
 
 
Figure 1.6. A schematic representing hypothesized progression of imaging biomarkers 
commonly used in HD. Adapted from Ross et al. (2014).   
 
1.4.2. Cortical atrophy in Huntington’s disease 
As previously described, widespread cortical atrophy is regularly reported in post-
mortem studies of end-stage HD patients. However, in-vivo imaging studies have found 
inconsistent results when measuring cortical change. While results suggest that atrophy is 
occurring by early-stage HD, the quantification of cortical atrophy in different cohorts via 
different techniques has resulted in a range of findings.  
Most studies examining atrophy in the cortex have been cross-sectional whole-brain 
studies performed using VBM. Within the TRACK-HD study, reduced cortical volume has been 
detected in the cingulate, precentral and prefrontal regions as well as the occipital, parietal, 
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and small regions of the temporal lobes in manifest HD compared to controls (Tabrizi et al. 
2009). In addition to the findings shown in the TRACK-HD cohort, group differences between 
pre-HD and control participants have been described in other cohorts within the motor 
regions, as well as within occipital and frontal regions (Thieben et al. 2002; Gómez-Ansón et al. 
2009; Sormani et al. 2004). Between controls and manifest HD participants, there have also 
been significant differences reported in the precentral and postcentral regions (Douaud et al. 
2006; Kassubek et al. 2004; Wolf et al. 2009), as well as in frontal and parietal regions (Wolf et 
al. 2009; Gavazzi et al. 2007). Atrophy of the frontal lobe has also been reported in an early 
ROI study, with a volume reduction of 17% in early-HD participants compared to controls 
(Aylward et al. 1998). 
Longitudinally, both pre-HD participants nearing onset and manifest participants from 
the TRACK-HD cohort showed significantly greater cortical change than control participants 
over 24 months. Volumetric reduction in the occipital cortex was the most striking change over 
24 months in pre-HD and manifest groups, with additional atrophy occurring in parietal and 
frontal regions in manifest participants (Tabrizi et al. 2012). One other longitudinal study 
reported increased atrophy in the occipital, frontal and parietal cortices over 24 months in 
early-HD participants compared to controls (Hobbs, Henley, et al. 2010).  In addition, another 
VBM study detected atrophy over 12 months in the caudate, pallidum, putamen, insula, 
cingulate cortex, cerebellum, orbitofrontal cortex, medial temporal lobes and middle frontal 
gyri. However, this was in a cohort of 49 participants that included juvenile HD participants (as 
young as 7 years old) who show a different pattern of symptom progression, with juvenile HD 
often undergoing more rapid disease acceleration then adult onset HD. It is likely that 
registering and analysing juvenile and adult HD brain scans together would result in differing 
findings than when just measuring change in adult onset HD, and thus the results are not 
representative of a true pattern of adult onset HD progression (Ruocco et al. 2008).     
To attempt to collate and summarise the results of 17 VBM studies performed on HD 
cohorts a meta-analysis was conducted in 2013. After the results from all studies were 
combined, the only cortical region to show differences between pre-HD and controls was a 
region in the right occipital lobe (Dogan et al. 2013). In manifest HD, there were significant 
differences with controls found in the frontal cortex, primary motor, premotor and 
somatosensory regions, as well as in the intraparietal sulcus, the midcingulate cortex and the 
secondary somatosensory cortex (Dogan et al. 2013). The results from this meta-analysis 
suggest a pattern of atrophy that begins prior to onset in the occipital lobe, and extends to the 
frontal lobe, key motor regions and further into the occipital lobe after onset of HD. Taken 
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together, the results of these studies provide evidence that atrophy is occurring in both pre-
HD and manifest HD participants, with frontal, motor regions and occipital regions showing 
significant group-differences or change in a number of studies. However, they do not provide 
detailed information about the timing or regional progression of atrophy. 
As well as volumetric change, a number of studies have measured CT in pre- and 
manifest HD compared to controls. CT is the distance between the WM/GM boundary and the 
GM/CSF boundary. Significant differences in the thickness of GM have been reported between 
controls and HD gene carriers in both pre-HD and manifest stages of the disease (Rosas et al. 
2008; Rosas et al. 2002; Rosas et al. 2011). Results suggest that the earliest change in CT is in 
the occipital and posterior regions of the brain, with more anterior regions affected later in the 
disease (Rosas et al. 2002; Rosas et al. 2011). However, CT studies are almost exclusively cross 
sectional. One longitudinal study of CT found significant change in early HD participants over 
one year, with the main changes seen in sensorimotor and fronto-parietal motor regions. 
However, the number of participants in this study was small (N=22, split into three groups), 
there was no control group, and the authors did not control for multiple comparisons (Rosas et 
al. 2011). A more recent study using a large cohort to study the effect sizes of different 
imaging biomarkers, reports poor longitudinal sensitivity for CT in HD, especially when 
compared to volumetric measures, indicating that perhaps CT is not a sensitive measure of 
neural change in HD  (Hobbs et al. 2015).  
Recently, more complex methods of characterising GM change have been applied to 
HD cohorts with the aim of better understanding the progression of atrophy in HD. Two 
studies have attempted to map the co-variance of GM changes in HD. Co-variation analyses 
are designed to estimate the dependencies between regions of the brain showing volumetric 
reduction in HD, which are then thought to represent networks that undergo atrophy 
simultaneously. One study conducted a large-scale analysis of pre-HD participants (N=831) 
compared to controls (N=219), initially performing VBM in SPM to determine regions of lower 
GM concentration, and then performing source-based morphometry (SBM; Ciarochi et al. 
2016).  SBM uses a whole-brain multivariate approach to capture co-occurring patterns of 
different GM concentration across the brain in HD compared to controls. SBM analysis involves 
performing the same processing steps as VBM, followed by an independent component 
analysis (ICA) to identify regions of change that occur together, called components (Xu et al. 
2009). An ICA is a statistical approach used to categorise sub-components of a measure into 
larger hidden components that are thought to represent over-arching constructs. Statistical 
analyses can then be used to determine which components show a significant pattern of co-
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occurrence and to test relationships between these components and other variables (Xu et al. 
2009). From the VBM analysis, the authors report significant group differences in GM 
concentration in the caudate, frontal lobe, occipital lobe, as well as the hippocampus and 
thalamus. A number of components were identified by the SBM, and these regions were then 
related to HD disease stage. Participants were divided into groups based on estimated time 
until onset, with far, medium and close to onset groups.  One of the components identified by 
the SBM was made up of frontal and some motor regions (precentral, supplementary motor), 
and this was the earliest component showing atrophy in the far from onset group.  In addition, 
parietal and occipital atrophy was found to be co-occurring, but in those closer to onset. A 
range of other components showed increasing atrophy with proximity to onset. While these 
results indicate interesting patterns of co-occurring GM loss, visual inspection of the VBM 
results suggests a spatial misalignment during processing as the VBM map is poorly aligned 
with the template. This could mean that the results from both the VBM and SBM have been 
mislabelled and thus should be interpreted with caution. In addition, the authors reported GM 
concentration on unmodulated data. Modulation is a processing step that aims to preserve 
differences in morphology which may have been affected by the inter-subject alignment 
performed during processing of VBM data (Henley et al. 2010; Keller et al. 2004). By failing to 
modulate the data these results are likely to be less sensitive to neuroanatomical differences 
than in data that is modulated. Together, these issues mean that the results of both the VBM 
and the SBM analysis could be inaccurate, and thus require further validation. 
A second study with 30 pre-HD participants, 30 HD participants and 30 controls also 
looked at structural co-variance of GM changes, using a similar methodology but via a 
technique included as part of FSL’s software library (Coppen et al. 2016). This study also 
performed VBM first, with the greatest differences between pre-HD and controls seen in the 
caudate and putamen and small differences found in the cortex in the insula and in the 
parietal regions of the planum temporale, parietal operculum as well as the posterior 
supramarginal gyrus. Cortical differences were more widespread when comparing the controls 
to HD participants, with significant differences found in the precentral and postcentral regions, 
supplementary motor cortex, lateral occipital cortex and the frontal pole. The results of the 
SBM identified 10 structural GM networks, with two of these networks showing significantly 
reduced network integrity in both pre-HD and HD compared to controls. One network 
incorporated the caudate, the nucleus accumbens, putamen, pallidum and precuneus. The 
other included the parahippocampul gyrus, the cerebellum, the pallidum and the planum 
polare. Furthermore, one network made up of the precuneus, cuneus, lateral occipital and 
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lingual regions showed significantly lower network integrity in HD compared to controls. The 
reduced structural integrity seen in these three networks was interpreted by the authors as a 
demonstration of the general breakdown of associated GM structures in HD. Again, these 
results demonstrate an interesting pattern of co-variation in GM change, indicating early 
change in parietal, motor and occipital regions, however the linear modelling used in this 
analysis does not allow for possible accelerations or decelerations in change across the 
disease. In addition, by measuring the co-occurrence of regional differences, it is assumed that 
that within each network the regions undergo the same temporal progression within the same 
disease stage. However, it is biologically plausible that different regions show differing rates of 
atrophy and variable patterns of acceleration and deceleration. Until there is a detailed 
understanding of the overall pattern of atrophy, the measurement of network changes could 
also be seen as premature since more basic information about the progression of cortical 
atrophy is not yet well understood.  
Another recent study used a different methodology to examine the pattern of brain 
changes via both sMRI and diffusion MRI on data from the PREDICT-HD cohort. The authors 
used a multivariate linear regression model to detect inflections points (change-points) in 
different measures in relation to predicted years to onset. The change-points represent 
changes in the linear trajectory of a measure, reflecting the disease stage at which each 
measure begins to show significant change in pre-HD. The data was a cross-sectional selection 
of 85 controls and 212 pre-HD participants for the sMRI analysis, and 79 controls and 178 pre-
HD participants for the DTI measures. Significant volumetric loss and significant change points 
were seen in both subcortical and WM regions, suggesting that subcortical and WM regions 
undergo significant volumetric decline in different stages of pre-HD. No cortical regions had 
significant change-points. However, significant volumetric expansion and change-points were 
seen in a number of sulcal regions, including the occipital and Sylvain fissures. The authors 
argued that sulcal expansion is an indirect measure of cortical change. This study used a novel 
framework to compare different neuronal markers of disease progression, and while the 
integrated analysis of subcortical, WM and cortical measures as well as diffusion metrics is 
required to understand the relationship between different indicators of neural change, it is 
possible that the large number of regions and contrasts resulted in poor power to detect 
cortical change, especially based on previous findings suggesting that cortical change is likely 
to be more subtle than that seen in other regions (Tabrizi et al. 2012). It is important that more 
work is done to characterise the overall pattern of CGM change prior to integrating it with 
other metrics of neural change. 
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1.4.3. Limitations of these findings  
Despite the amount of research that has been designed with the aim of characterising 
neural change in the cortex in HD, the conclusions we can draw from these studies are limited 
by several factors. As described, there are a number of different software packages available 
to calculate sMRI measures. While several studies have previously examined methods of 
quantifying these characteristics, it is unclear which CGM characteristics and which software 
packages provide the most accurate and sensitive measures of between-groups differences 
and within-groups change in CGM in HD. The majority of available software used to 
characterise the CGM was developed and validated on healthy participants (Irimia et al. 2012). 
Applying these tools to brains showing neural pathology, such as the scans from HD 
participants, can result in poor performance and inaccurate measures of CGM characteristics 
(Irimia et al. 2012). Recent work has identified poor segmentations as a possible driver in 
variability within volumetric sMRI studies across neuroimaging (Ashburner et al. 2016). 
Furthermore, a number of tools commonly used in HD to quantify cortical atrophy show issues 
with accuracy (Katuwal et al. 2016). It is thus vital that prior to measuring CGM atrophy in HD 
the tools used to calculate CGM characteristics are evaluated.  
Additionally, most previous work has utilised simple univariate analyses calculating 
VBM or CT measures. These investigations do not allow for complex analysis of several time 
points, or for the examination of non-linear patterns of accelerations or decelerations in 
atrophy rates. They can also suffer from potential over- or under-correction for multiple 
comparisons. Multivariate analyses provide a more powerful approach to infer network-wide 
patterns of atrophy and because they are not limited by the use of stringent corrections for 
multiple comparisons (McIntosh & Misic 2013; Habeck 2010). However, to date, the 
multivariate analyses performed examining CGM change have all used cross-sectional data and 
models that make an assumption of linearity in the progression of atrophy. In addition, one of 
the studies has used data from different scanner strengths across >20 sites, with another using 
from 23 sites. While the use of multiple sites is common in neuroimaging studies, there is a risk 
that subtle cortical atrophy may not be detected due to between-scanner variance and noise.  
A final issue that limits the conclusions from these studies concerns the division of 
participants into groups based on estimated years to onset. While group separation in HD 
studies is commonly done via calculated estimates of predicted years to onset, different 
algorithms and variable definitions of groups are used between studies. Furthermore, since 
predicted years to onset is not always an accurate measure of onset, heterogeneity within 
groups could be masking the earliest atrophy in the cortex. Most previous studies in HD have 
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tended to maintain groups based on status at study baseline rather than re-categorising or 
separately examining those participants who undergo diagnosis during the study. A small 
number of studies have observed brain changes over transition to HD (Tabrizi et al. 2013; 
Aylward et al. 2012), with one study investigating global brain change and the other striatal 
change. Since previous results suggest that there is an increase in CGM atrophy around the 
time that symptom severity also increases (Tabrizi et al. 2012), it appears that CGM atrophy 
could be a factor in the progression of HD symptom onset. CGM atrophy has implications for 
biomarker development, the timing of interventions and even the identification of new 
therapeutic targets, thus it is important that a thorough examination of participants 
undergoing the transition from pre-HD HD to manifest HD is conducted.  
1.5. Theories of the progression of neural pathology in HD 
There are a number of theories of how HD pathology develops throughout the brain. 
These have been generated from current understandings of HD biology, as well as from 
imaging findings in HD and other neurodegenerative diseases. Most theories first depend upon 
an understanding of basal ganglia cortical networks, described briefly here. 
The basal ganglia includes the striatum (caudate and putamen), substantia nigra, the 
subthamanic nucleus and the globus pallidus (Jahanshahi et al. 2015). The basal ganglia was 
initially thought to be involved only in motor tasks, but is now understood to also contribute 
during both cognitive and emotional processing, such as during reinforcement learning, 
decision making and a number of other tasks. There are three main circuits that are thought to 
be driving performance on these domains, the motor, associative (cognitive) and limbic 
(emotional) circuits (Jahanshahi et al. 2015). These three networks utilise the basal ganglia and 
different cortical regions, and are often required to integrate in order to successfully perform 
actions. Figure 1.7 shows a schematic of these three networks.  
In HD, a number of theories have been hypothesised that link GM, WM and functional 
changes to a disruption within these circuits. One theory that was proposed for multiple 
neurodegenerative diseases suggested that pathology might spread based on a prion 
hypothesis of disease progression. The hypothesis of prion-like disease progression argues that 
pathology spreads throughout the brain in a cell-to-cell manner, and thus brain regions that 
are close to the epicentre of disease or that are strongly linked to that area will undergo 
degeneration prior to those further away or less closely linked. While a number of researchers 
have argued that their work demonstrates evidence of this theory (Raj et al. 2012; Raj et al. 
2015; Zhou et al. 2012) because they have shown that regions in close proximity to the disease 
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epicentre or highly connected regions undergo damage earlier than unconnected regions, this 
theory has not been directly demonstrated, especially in HD. 
Alternatively, McColgan et al.  (2017; 2015) proposed that instead of prion-like spread, 
the progression of atrophy in HD could be related to connectivity across the brain, with regions 
that have more connections to other brain regions (rich club regions) undergo greater damage 
due to the metabolic demand placed on these regions and connections. McColgan (2015) 
found that cortico-striatal regions were more affected in those with HD, showing reduced 
connectivity between striatal regions and both frontal and parietal/occipital regions. These 
regions are rich club regions, and also part of the motor and associative circuits, and could 
indicate a susceptibility for degeneration in HD within these two networks that are frequently 
recruited in day-to-day functioning.  
These theories do not explain the degeneration commonly reported within other 
regions in HD, especially within the occipital cortex. There is no hypothesis that has provided 
sufficient evidence to explain degeneration in this region, especially given that visual 
disturbances are not typically reported in HD. The most commonly cited suggestion is that 
atrophy within this region is due to high metabolic demand placed on this region (Rosas et al. 
2008; Feigin et al. 2001).  While there is no conclusive evidence to explain the pattern of 
pathological spread in HD, as imaging methodology advances it is hoped that new techniques 
will continue to improve our understanding and to support work investigating the biological 
components of HD. 
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Figure 1.7. A schematic demonstrating the three proposed circuits connecting basal ganglia to the cortex 
(Jahanshahi et al. 2015).  
 
1.6. The current thesis  
The aims of this thesis have been motivated by the lack of research that has 
performed detailed characterisations of the cortical changes in the period surrounding HD 
motor diagnosis. While a range of work has studied atrophy in pre- and manifest HD, most 
analyses have utilised univariate techniques applied on cross-sectional cohorts, offering 
limited conclusions. More recently there has been a shift towards multivariate techniques, 
albeit mostly still using linear models, however the range of participants included in these 
studies and the use of a predicted onset could mask the detection of cortical atrophy. 
Furthermore, the techniques commonly used to quantify CGM in these studies require 
detailed validation in HD. This work aims to undertake a comparison of CGM methods and to 
then provide a detailed analysis of CGM changes in HD motor converters. 
First, a thorough validation of the available tools for CGM measurement will be 
undertaken. Using the results of this validation, the most sensitive and accurate methods for 
quantifying disease-related CGM change in HD will be selected. These methods will then be 
applied in an examination of the distribution and trajectory of CGM atrophy during motor 
onset in HD. The investigation of cortical atrophy will be performed on a sub-set of pre-HD 
participants who underwent conversion to manifest-HD during data collection for the TRACK-
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HD and TrackOn-HD studies. The analysis will use a dynamical approach to perform structural 
modelling. This newly developed technique enables the quantification of net atrophy in a given 
time period, the rate of linear atrophy as well as non-linear accelerations or decelerations of 
atrophy. By understanding the progression of transition phase cortical change, we gain a 
greater understanding of the progression of HD more generally. The results will provide novel 
and clinically relevant information helping to characterise and understand the process of 
neural atrophy in HD. 
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2. GENERAL METHODOLOGY 
This chapter will describe the general methodology used throughout this thesis. 
Further elaboration will be provided within each chapter for the specific application of these 
methods. The cohorts used in the analyses will be covered, along with information on the MRI 
acquisition parameters, pre-processing steps and methods of quantifying outcomes from sMRI 
data. Finally, some of the statistical methods used in this thesis will be described. 
2.1. Cohorts 
MRI data from four sources were used during this thesis. Freely available phantom 
data from the BrainWeb dataset were used for the methodological comparisons conducted in 
Chapter 3. Data from the TRACK-HD, TrackOn-HD and PADDINGTON studies were also used 
throughout this thesis. Descriptions of these cohorts and the data are provided here.  
2.1.1. BrainWeb 
Due to the nature of in vivo MRI scans it is impossible to measure the ground truth 
(GT) of various brain characteristics, such as the ‘true’ value of GM volume. Even established 
manual brain measures are likely to include some degree of error. Because of this, a number of 
the comparisons included in the methodological development section of this thesis were 
initially run on simulated data from the BrainWeb dataset 
(http://www.bic.mni.mcgill.ca/brainweb/; Aubert-Broche et al. 2006). The simulated data 
provides artificially created MRI scans and corresponding GT segmentations. The GT 
segmentations are regions used to create the phantom MRI scans and are designed to enable 
comparison with the performance of different software tools.  The BrainWeb phantom data 
can be processed by different software, and the results can be compared to the GT regions to 
determine the accuracy of the tools. The BrainWeb data is artificial and based on healthy 
brains and so is not a true representation of human MRI data, especially in brains with 
abnormal pathology, yet it is a useful way of examining software performance. The BrainWeb 
dataset used in the current study contains a set of 20 freely available simulated brains (Aubert-
Broche et al. 2006). The participants were 10 females and 10 males, with a mean age of 29.6 
years and an age range of 24-37 years. Construction of the data is detailed in section 2.2.1.1.  
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2.1.2. TRACK-HD 
TRACK-HD was a longitudinal multi-site observational study that began in 2008. 
Participants returned on a yearly basis, with the concluding visit in 2011. TRACK-HD aimed to 
recruit 360 participants at baseline, 120 control participants, 120 pre-HD participants, who had 
tested positive for the genetic expansion that causes HD but were not yet symptomatic, and 
120 participants with manifest HD.  
Recruitment of people at risk from HD was limited to those who had previously 
undergone genetic testing, with preliminary screening involving the self-report of genetic 
result. At baseline of TRACK-HD, gene positive participants were required to have a positive 
genetic test of ≥40 CAG repeats, which was confirmed via a blood test conducted at their first 
visit.  
Pre-HD and HD participants were also required to have a burden of pathology score > 
250 (as described in section 1.1.4.1; Penney et al. 1997). The burden of pathology score uses 
two of the most significant predictors of disease onset, age and CAG repeat, to estimate the 
burden of disease. A higher score indicates a higher burden and represents an individual’s 
lifetime exposure to MTT.  This criterion ensured that pre-HD participants were not too far 
from predicted disease onset to detect meaningful group differences when compared to 
controls; including participants who were further away from disease onset would have 
required larger group sizes to detect differences. Pre-HD participants were also required to 
have a Total Motor Score (TMS) on the Unified Huntington’s Disease Rating Scale (UHDRS) of < 
5 (Huntington Study Group 1996). The TMS measures the presence of motor symptoms with a 
score of <5 indicating no substantial motor symptoms.  
The pre-HD cohort was separated into two groups based on the median expected 
years to disease onset as calculated by a survival analysis formula previously described 
(Langbehn et al. 2010);  those estimated to be more than 10.8 years from disease onset were 
classified as the preHD-A and those less than 10.8 years from estimated onset preHD-B. Using 
the UHDRS (Huntington Study Group 1996) the HD cohort was also split into two groups. The 
participants were classified based on their Total Functional Capacity (TFC) scores as stage 1 
(HD1:TFC=11-13) or stage 2 (HD2:TFC=7-10). TFC measures someone’s ability to perform 
everyday activities such as domestic tasks, handling finances and working. The HD1 group 
included participants who showed higher functioning and were thus less affected by HD, and 
the HD2 group consisted of participants who were more affected by HD and had lower daily 
functioning scores. Since TMS <5 for this study, no participants showed substantial motor 
symptoms at baseline. Education was measured using the International Standard Classification 
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of Education (ISCED; UNESCO 1997). The ISCED comprises seven levels of education ranging 
from 0 ("pre-primary education") to 6 ("second stage of tertiary education, leading to an 
advanced research qualification"). 
Participants in the control group were selected to maintain as much consistency as 
possible with the gene carriers in terms of shared environment and thus the group was 
comprised of age- and sex-matched partners, spouses and gene-negative siblings of the gene-
carriers. In addition to the criteria described, participants were required to be aged between 
18-65, be able to tolerate both MRI and biosample collections and be suffering from no major 
psychiatric disorder or have a history of significant head injury at the time of recruitment. 
Generally, medication was not an exclusion factor unless it was medication being taken as part 
of a therapeutic trial.  Other comorbid medical conditions were also generally accepted, unless 
they were deemed to impact upon a participant’s ability to take part in the study. Ethical 
approval was given by the local ethical committees and written informed consent was 
obtained from each participant according to the Declaration of Helsinki.  Full selection criteria 
and data collection processes have been published previously (Tabrizi et al. 2009).  
At the end of the baseline visit, the TRACK-HD study had successfully enrolled 366 
participants, made up of 123 controls, 120 pre-HD and 123 HD participants.  
Table 2.1 shows demographic information for the full cohort at baseline, and the 
number of participants who returned for subsequent study visits. The most common reason 
for failing to participate in further visits was due to worsening of HD symptoms, with control 
participants most unlikely to return if their partner withdrew from the study or if they were 
experiencing relationship issues with their partner. During the course of TRACK-HD, 19 pre-HD 
participants converted to manifest HD as defined by having a new Diagnostic Confidence Score 
(DCS) score of ≥4, as described in section 1.1.3 (Huntington Study Group, 1996). At each visit, 
participants underwent a comprehensive battery of neuroimaging, cognitive, oculomotor, 
quantitative motor and neuropsychiatric testing. Many of the participants who were in TRACK-
HD followed on to complete TrackOn-HD (see section 2.1.3). 
2.1.3. TrackOn-HD 
TrackOn-HD began in 2012 with a focus on the pre-HD phase of the disease process 
and included 3 visits, conducted at yearly intervals. At baseline, TrackOn-HD had 112 controls, 
110 pre-HD and 21 early HD participants. Of these, 79 controls and 102 pre-HD participants 
were previous participants of TRACK-HD (with some pre-HD participants now classed as HD 
participants). An additional 33 controls and 30 pre-HD participants were also recruited. 
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Selection criteria were the same as for TRACK-HD, but participants who had previously taken 
part in TRACK-HD and who were older than 65 were able to enrol in TrackOn-HD. Demographic 
information for the baseline of TrackOn-HD is provided in Table 2.2. The range of assessments 
completed in TrackOn-HD was similar to that of TRACK-HD, but with more advanced imaging 
techniques, including task and resting state fMRI and diffusion imaging, performed at baseline, 
12 and 24 months (See Figure 2.1).  At 24 months two novel imaging sequences, Neurite 
Orientation and Dispersion Diffusion Imaging (NODDI; Zhang et al. 2012) and Chemical 
Exchange Saturation Transfer (CEST; Jones et al. 2006), were introduced. There were also some 
minor changes made to the cognitive, motor and neuropsychiatric batteries. 
2.1.3.1. TrackOn-HD data collection  
For the TrackOn-HD 2014 time point, data collection was performed as part of the 
work contributing to this thesis. Cognitive data collection and scoring for all participants who 
took part in the study at London was performed by myself as was over half of the MRI 
scanning (split with another team member). 
 
 
Figure 2.1. A schematic showing the participants and MRI modalities collected in TRACK-HD and 
TrackOn-HD. 
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Table 2.1 Demographic information for the TRACK-HD cohort at baseline. Data are mean (SD, 
range) or number (%). Disease-burden score=age x (CAG length - 35·5). Table adapted from 
Tabrizi et al. (2009).  
 Controls 
(n=123) 
preHD-A 
(n=62) 
preHD-B 
(n=58) 
HD1 
(n=77) 
HD2 
(n=46) 
Age (years) 46·1 
(10·2, 23·0–65·7) 
41·1 
(8·6, 18·6–59·4) 
40·6 
(9·2, 22·3–64·1) 
47·2 
(10·3, 22·8–64·1) 
51·4 
(8·6, 33·3–63·3) 
Women 68 (55%) 33 (53%) 33 (57%) 46 (60%) 21 (46%) 
Education 
(ISCED score) 
4·0 (1·3) 4·1 (1·1) 3·8 (1·3) 3·8 (1·3) 3·2 (1·4) 
Disease-burden 
score 
- 259·1 (30·1) 333·1 (30·0) 364·1 (74·3) 397·6 (67·5) 
Site (n) 
Leiden   30   16   14   16   14 
London   30   14   16   19   11 
Paris   30   14   16   26 4 
Vancouver   33   18   12   16   17 
Time point (n)      
Baseline   123   62   58   77   46 
12 Month   116   62   55   71     43 
24 Month   110   60   51   70   41 
36 Month 97  58 46 66 31 
 
 
Table 2.2. Demographic information for the TrackOn-HD cohort at baseline. Data are mean 
(SD, range) or number (%). Disease burden = (CAG – 35.5) x current age. 
 Controls 
(n=112) 
preHD 
(n=110) 
HD1 
(n=21) 
Age (years) 
48.14 (10.70) 
25.41-67.52 
42.88 (9.10) 
22.62-68.29 
44.92    (7.96) 
32.14-63.66 
Women 67 (60%) 55 (50%) 14 (67%) 
Education (ISCED 
score) 
3.94 (1.04)         
1-6 
4.02 (1.00) 
2-6 
3.74 (1.01) 
2-5 
CAG - 
42.93 (2.27)         
39-50 
44 (2.59) 39-50 
Disease-burden 
score 
- 
302.12 (53.04) 
178.91-443.00 
364.23 (56.69) 
222.81-466.02 
Site (n) 
Leiden 28 24 8 
London 29 27 5 
Paris 29 30 5 
Vancouver 26 29 3 
Time point (n)    
Baseline 112 110 21 
12 Month 105 101 20 
24 Month 101 99 18 
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2.1.4. PADDINGTON 
PADDINGTON (‘Pharmacodynamic Approaches to Demonstration of Disease-
Modification in Huntington’s Disease by SEN0014196’) was a follow up from TRACK-HD with a 
focus on manifest HD patients. The data used in this thesis comes from work package two 
(WP2), which was a subcomponent of the PADDINGTON study designed to further validate 
imaging measures for use in short-interval clinical trials (Hobbs et al. 2013). There were 40 
controls and 61 early HD participants in WP2. For this study there was a visit at baseline, 6 
months and 15 months.  
Participants were recruited across four sites: Leiden, London, Paris and Ulm. HD 
participants were required to have had a positive genetic test (CAG>36), be able to tolerate an 
MRI scan and sample donation and have no clinically significant and relevant history that could 
affect their involvement in the study. Control participants were mostly spouses or siblings of 
the HD participants who were tested negative for the expanded HD gene. Full selection criteria 
for the Paddington study is available (Hobbs et al. 2013). All participants gave written informed 
consent in accordance with the Decleration of Helsinki.  
 
2.2. MRI Imaging 
2.2.1. Acquisition  
2.2.1.1. BrainWeb 
The BrainWeb data is constructed from real MRI data, which was registered (aligned; 
see section 2.3.1), segmented and submitted to an MR simulator to create a ‘phantom’ version 
of the data. To create the 20 phantoms, 20 participants were scanned. All participants were 
scanned on a 1.5T Siemens Sonata Vision scanner. The T1 scan had 1mm isotropic voxels, with 
a 3-D spoiled gradient echo sequence (TR=22ms, TE=9.2ms). The scan was repeated four times 
to increase the signal-to-noise ratio and these four scans were averaged. All native images 
were corrected for intensity nonuniformity N3 bias correction (Sled et al. 1998). Registration 
was performed by randomly selecting one T1 from each subject and linearly registering this to 
the International Consortium for Brain Mapping (ICBM) average space. The remaining T1 
images were linearly registered (rigid body, six parameters) to the first native T1, and from 
native space they were then registered to ICBM space. Finally, the volumes for each 
participant were averaged to create one image. 
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Next, each of the 20 average images was classed into 11 tissue classes; GM, WM, CSF, 
skull, marrow, dura, fat, fat2, muscles, skin/muscle and vessels (Aubert-Broche et al. 2006). 
The voxel intensity modelled tissue contributions within the voxel ranging from 0 to 1.  The 
fuzzy volumes (PVE) defined the digital phantom. The next step was running the MR 
simulations to generate realistic 3-D images using both the PVE volumes from the anatomical 
phantom and parameters related to tissue, scan and coil aimed at making the simulation as 
realistic as possible.  The MR simulator used a three step process. Briefly, the initial step was 
calculation of the signal intensities for different tissue types. Following this, the PVE volumes 
were used to weight the tissue intensities for each tissue type. The last step was to correct the 
images based on scan-dependent effects including noise and inhomogeneity. 
Figure 2.1. shows the simulated MRI of one subject, alongside their real MRI and the 
phantom data on which the simulation was based. It should be acknowledged that there are 
discrepancies between the simulated data and the real data indicating that simulated data is 
not a perfect representation of a real MRI scan. 
 
 
Figure 2.2. Simulated data (left), real data (middle) and phantom data (right) for one subject 
from the BrainWeb dataset (Aubert-Broche et al. 2006). 
 
2.2.1.2. TRACK-HD, TrackOn-HD and PADDINGTON 
3T T1-weighted scans were acquired from four scanners for both TRACK-HD and 
TrackOn-HD. Two were Siemens and two were Philips scanners. The parameters for Siemens 
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were TR = 2200ms, TE = 2.2ms FOV = 28cm, matrix size = 256x256, 208. For Philips TR = 7.7ms, 
TE = 3.5ms, FOV = 24cm, matrix size = 242x224, 164. The acquisition was sagittal to cover the 
whole-brain. There was a slice thickness of 1mm, with no gap between slices. These 
acquisition protocols were validated for multi-site use (Tabrizi et al. 2009). All images were 
visually assessed for quality; specifically artefacts such as motion, distortion and poor tissue 
contrast (IXICO Ltd. and TRACK-HD imaging team, London, UK). Acquisition protocols were the 
same for both studies.  
For PADDINGTON, the scanners and imaging acquisition protocols were matched to 
those used in TRACK-HD for Leiden, London and Paris, for Ulm a Siemens Allegra scanner was 
used with slightly different acquisition paremeters, however this data will not be used in this 
thesis.  
 
2.2.2. Pre-processing 
2.2.2.1. BrainWeb 
BrainWeb scans and associated GM regions were downloaded from 
http://brainweb.bic.mni.mcgill.ca/brainweb/anatomic_normal_20.html and converted from 
minc file format to Neuroimaging Informatics Technology Initiative (NIfTI) format using the 
visualisation software MIPAV (McAuliffe et al. 2001). The GT segmentations provided by 
BrainWeb were initially of a different resolution to the native space simulated T1 images. They 
were resampled via FSLmaths (Jenkinson & Smith 2001; Jenkinson et al. 2002). All outputs 
were visually checked to ensure successful resampling. Images were processed in NIfTI format.  
2.2.2.2. TRACK-HD and TrackOn-HD 
Images underwent initial quality control (QC) consisting of meta-data checks and visual 
QC to ensure that scan parameters were correct and to ensure no gross artefacts or errors 
were present, including motion artefacts and incorrect field of view placement (IXICO, London, 
UK). Examples of motion artefact are shown in Figure 2.3. Image data were archived at the 
Laboratory of Neuroimaging (LONI), University of California Los Angeles. Images from all sites 
were then downloaded from the LONI website for processing by the UCL TRACK-HD imaging 
team.  
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Figure 2.3. An example of a T1 scan from the TRACK-HD study that failed visual quality control 
because of a significant movement artefact. 
 
Once downloaded, images were converted from dicom format to analyse format. MR 
images suffer from an artefact called intensity non-uniformity. This refers to the varying signal 
intensity that occurs across an MRI image, meaning that tissues of the same class have 
differing signal across T1-weighted scans. While this artefact has little impact on the ability to 
visually interpret an MRI scan, it can result in the failure of software to accurately delineate 
different tissue types. This is especially true for automated tools. Tissue non-uniformity is 
caused by a number of factors including radiofrequency coil homogeneity, local flip angle 
variations and participant anatomy (Sled et al. 1998; Boyes et al. 2008). To correct for this, 
images undergo a process called bias correction. This is a post-scanning process that calculates 
and corrects for the bias field within an image, Figure 2.4 shows a T1 scan both before and 
after bias correction. In the raw data, regions of high intensity can be seen in the medial 
sections of the scan. The bias corrected data appears to have more uniform tissue contrast 
across the brain. The non-parametric non-uniform intensity normalization (N3) method was 
used for all images in TRACK-HD, TrackOn-HD and PADDINGTON (Sled et al. 1998), with 
optimised parameters for 3T data as outlined in Boyes et al. (2008).  Following conversion and 
bias correction, images were again examined by the team at UCL, and excluded from analysis if 
artefacts that were expected to affect analysis were present. Table 2.3 shows how many scans 
were excluded due to motion at each site for both TRACK-HD and TrackOn-HD.  
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Figure 2.4. An example of a T1 scan (A) before and (B) after undergoing N3 bias correction, 
taken from the TrackOn-HD study. 
 
Table 2.3. The number of scans at each time point that failed due to the presence of severe motor 
artefacts for the TRACK-HD and TrackOn-HD studies. 
 2008 2009 2010 2011 2012 2013 2014 
Number of scans failed due to motion 7 11 12 6 3 5 1 
Total number of scans acquired 358 332 316 286 240 226 211 
 
 
2.3. Structural MRI analysis tools 
Measurement of different brain characteristics from sMRI can be performed using a 
number of different tools and techniques, including registration, segmentation and 
quantification of results. Throughout this thesis there are a number of methods consistently 
used to process T1 MRI scans. The most common methods are described here. 
2.3.1. Image space and registration 
MRI scans can be processed in a range of ‘spaces’, with a space referring to the 
position of the head within the 3D field of view (FOV). Native space is the space in which the 
scan was acquired, with the FOV and head in the position that the radiographer collected the 
data. Native space will be different for each scan collected, even for scans within the same 
scanning session if the FOV position was not copied between scans or the participant moved 
between scans. Standard space refers to a number of commonly used positions that are widely 
used across neuroimaging, which provide a common space to align different datasets to. The 
Montreal Neurological Institute space (MNI) is the most commonly used standard space. In 
addition, it is also possible to create a group template by concatenating all scans used in a 
particular study into a single study-specific template. 
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Typically, scans are aligned to a common space when performing cross-sectional group 
comparisons as this enables the direct comparison between different groups and participants. 
To align the position of a brain within the FOV to standard or template space, a registration 
needs to be performed. This is a process of alignment whereby a scan is moved from one 
space to another. Registrations can also be used to help quantify longitudinal change, 
especially for volumetric measures. During registration, Jacobian maps can be output and 
these can be used to quantify change. A Jacobian map is a 3D representation of voxel-wise 
contraction or expansion that occurs between each registered scan, and is based on the voxel-
intensity of two scans. By multiplying the Jacobian map by the voxel-wise tissue maps output 
from a segmentation (section 2.3.2), change within each voxel can be quantified. 
There are different types of registration and a number of different tools to perform 
these registrations, yet all registrations consist of two steps: a) calculation of registration 
parameters, b) application of these parameters to a scan.  
2.3.1.1. Linear registrations 
Linear registrations aim to achieve an alignment between scans, yet are restricted in 
the number of deformations that are performed. They aim to achieve a point-to-point 
mapping of two scans, however they will not correspond exactly especially when registering 
two brains from a longitudinal study that have undergone atrophy over time. Linear 
registrations perform the same action on all voxels and thus the content of the voxels 
themselves are not changed. During a linear registration, an MRI scan can be transformed via 
rotations, translations, shears and zooms, but not by the non-linear warping of the scan. The 
most basic type of linear registration is a rigid-registration, which uses 6 degrees of freedom 
allowing for three rotations and three translations to align the moving image to the target. 
Affine registration uses 12 degrees of freedom, which allows for three translations, three 
rotations, three shears and three zooms and enables more advanced co-registration of the 
scans. However, it may also result in some loss of information, particularly when registering 
atrophied brains that may show change over time.  
2.3.1.2. Non-Linear registrations  
Non-linear registrations allow for the scan to be warped in many dimensions, and they 
aim to achieve an exact correspondence between two or more images. A non-linear 
registration often initially starts with a linear registration step to roughly align the images, and 
then proceeds to a more detailed registration involving a large number of degrees of freedom 
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and warping in any direction. There are a number of types of non-linear registrations, with 
three methods used in this thesis described here. 
2.3.1.2.1. Fluid registration 
Fluid registration uses a model of a compressible viscous fluid to calculate the 
deformation (Crum et al. 2001; Freeborough & Fox 1998). Fluid models are typically performed 
on within-subject data, between two longitudinal scans consisting of a baseline and follow-up 
time points. This type of registration provides a good approximation of the gradual change 
seen in degenerating brains, whilst maintaining scan topology. Fluid registration is an iterative 
process that warps the follow-up scan to the baseline scan within the confines of the fluid 
model, while maximizing the correspondence within voxels of the two images. The result of a 
fluid registration is a follow-up scan that should correspond exactly to the baseline scan, along 
with a voxel-wise Jacobian deformation field mapping the transformations applied to each 
voxel. From this deformation field voxel compression maps can be calculated which enable 
visualization of voxel-wise expansion or contraction across the brain. In addition, volumetric 
change can be calculated between two scans by multiplying the baseline volumetric region by 
the Jacobian deformation field to quantify change. This is the method employed throughout 
TRACK-HD and TrackOn-HD studies to quantify regional change (Tabrizi et al. 2012; Tabrizi et 
al. 2013; Tabrizi et al. 2011).  
2.3.1.2.2. DARTEL 
Diffeomorphic Anatomical Registration Through Exponential Lie Algebra (DARTEL; 
Ashburner 2007) is a method of non-linear registration and template creation applied for 
between-subject normalization. It is included as part of the SPM toolbox, from version of 
SPM5, to improve between-subject registration prior to performing VBM (section 2.3.4.2). By 
using DARTEL, the scans from different participants are not only aligned but also used to 
create a study-specific template. When registering pathological brains to a standard template, 
errors can be introduced since the brains do not achieve good correspondence. By creating a 
study-specific template these biases and errors can be reduced. DARTEL aims to create a 
continuous and smooth one-to-one mapping that is invertible (reversible) and maintains 
topology.  
Images are first segmented into GM, WM and CSF tissue classes using SPM segment 
(section 2.3.4.2). During this process, the images are roughly aligned and deformation 
parameters are saved. When performing DARTEL, the tissue classes are first combined using 
the deformation parameters to create a mean image used as an initial template. Deformations 
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between this rough template and the individual images are computed, and the template is re-
generated using the inverse deformations to the images, and this is averaged. This is repeated 
7 times (by default) to iteratively improve the template.  The output is a GM and WM 
template, along with flow fields that contain the parameters to warp between the native scans 
and the template. 
2.3.1.2.3. Longitudinal serial registration 
A further registration that is applied in the current thesis is longitudinal serial 
registration. When performing quantification of atrophy across time points, it is important to 
ensure that between-scan noise and bias are reduced as much as possible. Previous methods 
of longitudinal registration were criticized for introducing additional bias by the process of 
registering all follow-up scans to the baseline scan (Ashburner & Ridgway 2012). It was 
suggested that the process of applying a non-symmetrical registration pipeline could result in 
the detection of false positive differences. Similarly to DARTEL, this technique uses generative 
modelling to create an average of multiple scans. However, here the scans are within-subject. 
Along with registering the scans and creating an average, the approach also includes an 
integrated correction for between-scan (differential) intensity homogeneity (Ashburner & 
Ridgway 2012). The method first applies a rigid-body transformation to ensure scans are in 
rough alignment, and then enters into a process of between-scan diffeomorphic iterative 
registration to create an average image and deformation parameters. These parameters can 
then be used to calculate longitudinal volumetric change across multiple time points. The 
method has been validated previously, and was shown to be a consistent method with 
biologically plausible results (Ashburner & Ridgway 2012). 
2.3.2. Partial volume effects 
The partial volume effect (PVE) refers to the inability of MRI to represent the true 
proportion of each tissue type within a voxel due to the resolution of voxels (Tohka 2014). For 
example, a 1x1x1mm voxel may contain only GM or a proportion of WM or GM. Partial volume 
of voxels is typically accounted for by giving each voxel a likeliness of belonging to each tissue 
type ranging from 0-1. Most segmentation techniques calculate probabilistic segmentation 
voxel-wise maps, which account for partial volume effects, whereby different tissue maps are 
created (e.g. for GM, WM, CSF) and for each tissue map every voxel is given a likelihood of 
belonging to that tissue ranging from 0-1. For example, we would expect a voxel within the 
middle of the lateral ventricles to be given a value of 1 for the CSF tissue map, but 0 for the 
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WM tissue map. Many tools also output ‘discrete’ volumes whereby each voxel is assigned to a 
particular tissue type in a binary 1 or 0 method. It is widely accepted that partial volume maps 
result in more accurate quantification of tissue volumes (Tohka 2014). Figure 2.5 shows 
examples of partial volume maps and discrete tissue maps for the same participant.  
 
 
Figure 2.5. A scan from the TRACK-HD study, showing a partial volume map of the cortex in (A) 
coronal, (B) axial and (C) sagittal views, and a discrete tissue map in (D) coronal (E) axial and (F) 
sagittal views. 
 
2.3.3. Manual delineation of regions using MIDAS 
Often considered a ‘gold standard’, manual delineation of brain regions can be 
performed to outline regions of interest and calculate the volume of these regions. This can be 
done in a variety of ways, but the method used in this thesis makes use of an in-house UCL 
software that has been used in a large number of studies examining brain volume in 
Alzheimer’s Disease and HD. The Medical Image Display and Analysis Software (MIDAS; 
Freeborough et al. 1997) is an interactive software that enables 3D processing of MRI scans. It 
has a wide variety of options for viewing and segmenting scans. Most processes begin with an 
intensity-based thresholding step defined by a pre-specified mean-brain intensity, followed by 
manual editing of the region. The use of pre-defined mean-brain intensity values ensures that 
consistent delineation can be performed on a particular scan. The first step is typically to 
measure the whole-brain volume, and this can then be used to calculate thresholds for other 
regions. After whole-brain segmentation is performed, the brain region is registered to 
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MNI305 standard space. By registering the whole-brain region and scan to standard space 
landmark-based cut-off points used when segmenting the other regions can be applied 
consistently within subsequent scans for the same participant and between all participants.  
The process of performing manual segmentation generally results in a high degree of 
reliability both within and between raters, and the regions tend to be visually accurate. 
However, it is also labour intensive and involves a rigorous period of training. In order to be 
qualified to segment images for a study within the HD Centre, a rater needs to pass a ‘test set’ 
of five scans, performing segmentation of the test set twice with a week in between the two 
repeated segmentations. The volumes for these five scans are required to be in line with set 
reliability thresholds, which are set at 1% difference for global measures, such as brain, total 
intracranial volume (TIV) and ventricle volumes, and 3% difference for regional segmentations 
such as the caudate.  Despite the intensive training and high reproducibility, it is important to 
acknowledge that while raters are blinded to disease stage of the participants, it is sometimes 
possible to determine disease status from scans in particularly atrophied brains, introducing 
possible rater bias.  
2.3.3.1. Whole-brain segmentation 
Whole-brain segmentation is performed in native space, with the first step being the 
selection of an appropriate threshold that excludes most non-brain tissue via an interactive 
threshold-selection process. The rater then manually edits this region where required, with the 
aim to perform as little manual editing as possible in order to limit rater bias. Whole-brain 
segmentations take between 45-60 minutes. Manual delineation of the whole-brain is 
performed at baseline, with baseline regions then propagated (i.e. registered and applied) to 
follow-up time points and manually edited where necessary if the propagation has leaked into 
non-brain regions. Figure 2.6 shows an example of whole-brain segmentation.  
To measure longitudinal atrophy, the Brain Boundary Shift Integral (BBSI) is calculated. 
This involves fluid registration of the follow-up scan and region to baseline, differential bias 
correction to adjust for any differences in intensity between the two scans, dilation of the 
baseline region, and quantification of the change in the boundary of the baseline region 
compared to the follow-up region (Freeborough & Fox 1997). Whole-brain segmentation has 
been demonstrated as a sensitive measure of group differences between pre-HD, HD and 
controls, and the BBSI has been found to be sensitive to longitudinal brain-atrophy in HD 
(Tabrizi et al. 2009; Tabrizi et al. 2012). It is currently being used in a number of on-going 
clinical trials for HD.  
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Figure 2.6. An example of a whole-brain segmentation from the TrackOn-HD study, shown in 
(A) coronal, (B) axial and (C) sagittal views. 
 
2.3.3.2. Ventricle segmentation 
Following whole-brain segmentation, the region is registered to standard space and 
ventricle segmentation is performed in standard space. A pre-specified upper intensity 
threshold of 60% of the mean brain intensity is used (measured from the previously 
segmented brain region). The lower threshold is set at the minimum possible value. Ventricle 
segmentation includes the lateral ventricles and temporal horn of the lateral ventricles, but 
not the third or fourth ventricles (Scahill et al. 2003). Figure 2.7 shows an example of a 
ventricle segmentation, which takes between 10-15 minutes to complete.  The ventricles were 
segmented at each time point in TRACK-HD. The Ventricle BSI (VBSI) is used to measure 
ventricle expansion, with a similar method to the BBSI applied. Again, ventricular volume and 
ventricular expansion are sensitive to between-groups differences and longitudinal change in 
HD (Tabrizi et al. 2009; Tabrizi et al. 2012). 
 
 
Figure 2.7. An example of a ventricle segmentation from the TrackOn-HD study, shown in (A) 
coronal, (B) axial and (C) sagittal views. 
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2.3.3.3. Caudate segmentation 
Caudate segmentation was performed on the standard-space registered scan, and 
includes the head and body of the caudate. The intensity thresholds are set at lower and upper 
values of 62% and 111% of the mean brain intensity respectively (Hobbs et al. 2009). The 
caudate regions generally require more manual editing than whole-brain and ventricular 
regions due to the reduced contrast between the caudate and WM. An example of a caudate 
segmentation is shown in Figure 2.8, and segmentations take between 60-90 minutes. The 
caudate was only segmented at baseline, and the Caudate BSI (CBSI) was used to measure 
caudate atrophy (Hobbs et al. 2009). Caudate atrophy is one of the most significant measures 
of structural volume change in HD (Tabrizi et al. 2013). 
 
 
Figure 2.8. An example of a caudate segmentation from the TrackOn-HD study, shown in (A) 
coronal, (B) axial and (C) sagittal views. 
 
2.3.3.4. Putamen segmentation 
Similarly to caudate segmentation, segmentation of the putamen is performed on the 
whole-brain registered to standard space. While this protocol has not been published, it 
underwent similar validation to the other methods cited here and has been applied in a 
number of research studies and HD trials (Hobbs et al. 2013; Hobbs et al. 2015). Intensity 
thresholds are set to 90% and 112% of the mean brain intensity, and the region extends 
superiorly until the last slice clearly containing putamen and inferiorly until the last slice in 
which the putamen is clearly separated from the caudate by the internal capsule. An example 
of a putamen segmentation is shown in Figure 2.9, and segmentations take between 60-90 
minutes. 
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Figure 2.9. An example of a putamen segmentation from the PADDINGTON study, shown in (A) 
coronal, (B) axial and (C) sagittal views. 
 
2.3.3.5. Total intracranial volume segmentation  
Total intracranial volume (TIV) is a measure of the total volume within the skull, 
including brain, meninges and CSF. TIV is regularly used to control for inter-subject variability 
in head size (see section 2.4.3), since it is associated with total and regional brain volumes 
(Malone et al. 2015). TIV is measured via first setting pre-specified thresholds of a lower 
threshold of 30% of the mean brain intensity, and an upper threshold at the maximum 
possible value. Starting at the base of the cerebellum, one slice every 10 slices is seeded 
resulting in selection of the outside of the dura, as shown in Figure 2.10. These regions are 
then filled and propagated, to create a region that fills the whole intracranial space. TIV 
segmentations take between 10-15 minutes. This measure has been demonstrated as highly 
reliable and preferable to performing automated quantification of TIV (Malone et al. 2015). 
 
 
Figure 2.10. An example of a TIV segmentation from the TrackOn-HD study, shown in (A) 
coronal, (B) axial and (C) sagittal views. The slices are filled to calculate volume within the 
region. 
 
2.3.3.6. Role within TrackOn-HD data processing  
For the TrackOn-HD 2013 visit I performed T1 data processing. This included data 
download, conversion and bias correction, visual QC and manual segmentation of the whole-
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brain and ventricles for all 2013 scans (see section 2.3.3). Furthermore, I performed 
retrospective segmentations for the 2012 time point, including all manual TIV and caudate 
segmentations, along with some brain and ventricle segmentations. Segmentations for other 
time-points and regions were performed by the TRACK-HD, TrackOn-HD and PADDINGTON 
imaging teams. 
2.3.4. Automated Delineation of Regions 
In addition to manual segmentation, there are a number of techniques that 
automatically delineate different brain regions. These techniques have varying requirements 
and can perform a number of different measurements, including measures of volume, CT and 
surface-based characteristics of the brain such as curvature. The measurement of volume and 
CT using these techniques is covered in more detail in Chapters 3 and 4, however a brief 
description of the most common methods referred to in this thesis are below.  
2.3.4.1. FMRIB Software Library 
The FMRIB Software Library (FSL; Jenkinson et al. 2012; 
https://fsl.fmrib.ox.ac.uk/fsl/fslwiki) is a suite of tools for functional, structural and diffusion 
MRI analysis and statistical analysis. Within FSL, the FMRIB’s Automated Segmentation Tool 
(FAST) is frequently used to segment different regions of the brain. FAST corrects for 
inhomogeneity within the images and uses a hidden Markov random field model and an 
associated expectation-maximisation algorithm to segment an image into tissue types (Zhang 
et al. 2001). The segmentation process generates tissue classes (including GM, WM, CSF), and 
once the tissue classes are segmented masks can be applied to calculate volumes from sub-
regions of these tissues.   
2.3.4.2. Statistical Parametric Mapping 
The Statistical Parametric Mapping (SPM; http://www.fil.ion.ucl.ac.uk/spm/) 
programme is another tool that offers analysis options for structural, functional and diffusion 
data, as well as MEG and EEG data. It is frequently used in HD studies to perform volumetric 
segmentation, and was used throughout the TRACK-HD and TrackOn-HD studies to measure 
WM and GM total volume (Tabrizi et al. 2011; Tabrizi et al. 2009; Tabrizi et al. 2012; Tabrizi et 
al. 2013). Once segmentation has been run on an image, the tissues can also be used to 
perform a VBM analysis, see section 2.3.4.2. Tissue segmentation involves modelling of 
intensity distributions within the scan via Gaussians and tissue probability maps, with priors 
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used to weight classification (Ashburner & Friston 2005). This approach combines 
normalisation and segmentation. The two most commonly used versions of SPM currently in 
use are SPM8 and SPM12. SPM8 has two segmentation procedures, Unified Segment and New 
Segment. SPM12 has one main procedure, Segment, although it also provides access to 
Unified Segment.  
Unified Segment was first released in 2005 (Ashburner & Friston 2005) and it combines 
tissue classification, bias correction and image registration to segment the GM, WM and CSF 
via a voxel-wise approach. The tissue classification phase uses intensities to classify voxels into 
a tissue category. The intensity distributions are modelled by a mixture of Gaussians, and 
tissue probability maps (TPMs) registered to standard space (ICBM152) are used to improve 
classification (Ashburner & Friston 2005). The TPMs give the prior probability of any voxel 
being a member of GM, WM, or CSF. To align the TPMs with each individual brain, initial affine 
registrations are performed followed by non-linear registration to improve the fit, and the 
inverse of these registrations is used to align each brain to standard space. The output tissue 
values range from 0-1 and represent the probability that each voxel belongs to a certain tissue 
class.  
The New Segment toolbox is an extension of Unified Segment. This method is designed 
to treat the mixing proportions differently, use an improved registration model and process 
multi-spectral data (i.e. both T1 and T2 images). It also has an extended set of tissue 
probability maps allowing for voxels outside of the brain to be treated differently. The 
segmentation option in SPM12 is a modified version of New Segment, with some new default 
options.  
SPM is freely available, although it does require Matlab (which is not freely available). 
It is widely used within the neuroimaging field.   
2.3.4.2.1. Voxel Based Morphometry 
VBM is a voxel-wise approach to examining brain differences in sMRI. By registering 
the MRI scans for all participants to a template and then smoothing the scans, differences in 
brain volume can be compared between groups or across time within individuals at each voxel. 
VBM allows for examination of volumetric differences without specification of ROIs and can 
detect small regions of difference that may be overlooked when using larger regions to 
compare between groups. Different software can be used to perform VBM analyses, but here 
the application of SPM VBM is covered (Ashburner & Friston 2000). To perform VBM within 
SPM, images are first segmented in native space using SPM Segment as described previously. A 
group template is also created using the DARTEL toolbox (Ashburner 2007). The segmented 
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regions are then warped to the DARTEL template and modulated and smoothed to account for 
any changes that occurred during normalisation to the template. Following this, a statistical 
model is specified and group differences can be compared across the whole-brain. Regions of 
interest can also be specified using a mask, if there are a priori hypotheses about the location 
of group differences.  
2.3.4.3. BRAINS 
BRAINS (Brain Research: Analysis of Images, Networks, and Systems; Magnotta et al. 
2002) is another freely available automated technique that utilizes data from both T1- and T2-
weighted scans to perform brain segmentation. It uses a neural net trained on human rater 
definition of the putamen and atlas-based structure identification, followed by an additional 
boundary correction to ensure no structural overlap. While BRAINS has been used in a number 
of studies investigating the brain in HD (Nopoulos et al. 2011; Paulsen et al. 2006), including 
the TRACK-HD study (Tabrizi et al. 2009; Tabrizi et al. 2011; Tabrizi et al. 2012; Tabrizi et al. 
2013), it is not widely used. 
2.3.4.4. FreeSurfer   
FreeSurfer (https://surfer.nmr.mgh.harvard.edu/) is a widely used software that aims 
to segment, measure and analyse neuroimaging data. It has a volume-based stream and a 
surface-based stream. The volume-based stream aims to process MRI volumes and classify 
subcortical regions (Fischl et al. 2002; Fischl et al. 2004). The brain is affine registered to 
Talairach space (a frequently used standard space), and then an initial volumetric labelling step 
is performed followed by intensity correction. Following this, a high dimensional nonlinear 
volumetric alignment to a Talairach atlas is performed. In the final phase the volume is 
labelled. The volume-based stream has evolved separately to the surface-based stream and a 
number of the stages are different (i.e. the registration and bias field correction). The surface-
based stream measures features such as CT, surface area and curvature of the brain. Briefly, 
after correction for field inhomogeneity, affine-registration and skull stripping, the WM voxels 
are classified based on their intensity, their neighbours’ intensity, and their position. A 
triangular mesh is built around the WM, which is then smoothed and topologically corrected. 
The external cortical surface is created via expansion of the WM surface until it reaches a point 
of maximal contrast between the GM and CSF. 
FreeSurfer is widely used, and has been applied within HD research a number of times, 
although mostly for CT analysis or to use regional volumes as a seed region or an extraneous 
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variable in analyses (Rosas et al. 2008; McColgan et al. 2015). There are standard pipelines 
available and FreeSurfer is easy to implement.  
2.3.4.5. Advanced Normalization Tools (ANTs) 
ANTs is a more recently developed tool, and while the segmentation method has not 
been used in neurodegeneration research to date it is freely available and gaining popularity 
within the neuroimaging community. A fully automated stream that outputs volumetric 
measures and CT is available (Diffeomorphic Registration-based Cortical Thickness, DiReCT) 
along with a separate volumetric stream (Atropos; Das et al. 2009; Tustison et al. 2014). Firstly 
N4 bias correction (Tustison et al. 2010) is performed on the raw MRI image, followed by brain 
extraction. The brain segmentation uses a mixed segmentation and template-based extraction. 
Following this, tissue segmentation is performed via alternating between prior-based 
segmentation and N4 bias correction. To calculate CT a prior-constrained estimate of the 
distance between the GM/WM boundary and the GM/CSF boundary is used. ANTs pipelines 
are freely available and online support is provided.  
2.3.4.6. Multi-Atlas Label Propagation with Expectation-
Maximisation based refinement (MALP-EM) 
MALP-EM is another recently developed tool aimed at providing a fully automated 
segmentation method able to cope with severe brain pathologies (Ledig et al. 2015). It utilises 
a previously described registration approach (Heckemann et al. 2012), atlas-based 
segmentation, and intensity-based expectation maximisation to segment the brain into cortical 
and subcortical regions (Ledig et al. 2015). MALP-EM has been validated on traumatic brain 
injury patients and is able to stratify patients into favourable vs. unfavourable outcomes based 
on MALP-EM segmentations (Ledig et al. 2015). It is freely available and has recommended 
usage included.  
2.4. Statistical Analysis 
Different statistical analyses were used throughout this thesis. This section covers 
some of these methods, with further information provided where relevant later in the thesis. 
All statistical analyses were performed within STATA version 12.1, or within a neuroimaging 
analysis tool such as SPM.  
2.4.1. Measures of accuracy and reliability 
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Chapter 3 of this thesis aims to compare various tools that perform automated 
segmentation of MRI scans. Measuring the reliability of these tools is a recognised challenge 
(Bouix et al. 2007). If two tools produce volumetric values for a tissue type that correspond, 
there is no guarantee that they spatially overlap. Because of this, both real study MRI data 
from TRACK-HD and phantom data with corresponding GT segmentations were used in this 
thesis to assess the accuracy and reliability of segmentation tools. These statistical methods 
are described here, with implementation discussed in Chapter 3. 
When using data such as the BrainWeb dataset, which has a corresponding GT 
segmentation for each scan, overlap scores (the dice coefficient) can be calculated on a voxel-
wise basis as discussed in Crum, Camara and Hill (2006). The dice coefficient is a measure of 
spatial overlap and has been used to validate segmentation techniques in a number of studies 
previously (Zou et al. 2004). The technique developed by Crum et al. compares the voxel-map 
output by each segmentation tool to the corresponding GT in a voxel-by-voxel method to 
determine the overlap of whole images. It accounts for partial volume estimates thus enabling 
a precise measure of spatial overlap in MRI. In addition to spatial overlap, when using a GT 
measure of brain volume, paired t-tests can be performed to determine whether there are 
significant differences between the GT and a segmentation method. Finally, Bland Altman 
plots and Pitman’s Test of difference measure the agreement between the GT and the output 
from a segmentation tool. 
When calculating the reliability from back-to-back measurements, as also done in 
Chapter 3 on the TRACK-HD data, reliability can be measured using the intraclass correlation 
(ICC; Bartko, 1966). ICC measures the agreement between repeated ratings, and ranges from 
0-1 with higher values demonstrating better reliability. Mean repeatability for back-to-back 
scans was also calculated as percent variability error (Function 1; Jovicich et al. 2013; Tustison 
et al. 2014). This measure provides a percentage value of variability between repeated 
applications on the same cohort for each tool; lower values represent less variation. Finally, 
Spearman’s Rho was also used to test the correlation between each set of volumes extracted 
using each segmentation tool. 
 
 
Function 1: Mean repeatability calculation used on back-to-back scans from 2008. VolA 
represents the first baseline back-to-back scan, VolB Represents the second baseline back-to-
back scan.  
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2.4.2. Multiple regression 
Multiple regression uses a general linear model (GLM) to estimate the relationship 
between predictor variables (e.g. Huntington’s disease stage) and measured (criterion) 
variables (e.g. GM volume). Multiple regression enables the specification of multiple criterion 
variables so the unique contribution of variables to a predictor can be understood. Multiple 
regression is used throughout this thesis to understand different relationships between 
variables.   
2.4.3. Covariates 
Covariates are confounding variables that may be related to a variable of interest, but 
are not of interest in themselves. They can be statistically controlled for during analysis, 
resulting in a more direct measurement of the relationship between variables of interest. All 
analyses in this thesis controlled for age and sex, due to the known effects of these two 
variables on brain size (Barnes et al. 2010) In addition, site was used as a covariate to control 
for the multi-site nature of TRACK-HD and TrackOn-HD with the aim of reducing variance due 
to site. However, it should be noted that this does not fully account for effects of site, as sites 
are differentially affected by artefacts such as scanner drift, software upgrades and field 
inhomogeneity. All participants were scanned at the same time of day. Education was used as 
a covariate when examining cognitive variables, due to the relationship between education 
level and cognitive performance (Beeri et al. 2006), however was not used as a covariate in 
other analyses. This was done to maintain consistency with previous TRACK-HD analyses, 
which do not control for education unless performing analyses that include cognitive variables. 
This decision was made by the TRACK-HD steering committee in early TRACK-HD meetings. It 
was widely discussed by the imaging and cognitive teams prior to a decision being made. 
Medication was not included as a covariate. Due to the large number of medications being 
taken by participants throughout data collection of the TRACK-HD and TrackOn-HD studies, 
along with the variable doses taken across time-points, the data could not be accurately 
controlled for and was thus excluded from the covariates.  
TIV is a measure that has been frequently discussed as a potential covariate in 
neuroimaging literature (Malone et al. 2015; Barnes et al. 2010). TIV acts as a proxy to 
‘healthy’ brain volume, since TIV measures the total intracranial space and has been 
demonstrated to remain constant despite increasing neural atrophy (Whitwell et al. 2001; 
Matsumae et al. 1996). By controlling for TIV, variables of interest can be compared whilst 
taking into account differences due to head size. The TIV can be measured via manual 
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delineation of the region (Section 2.3.3.5), which has been demonstrated a valid method of 
calculating TIV (Malone et al. 2015). This technique was used for all data in this thesis. TIV was 
controlled for by either using it as a regressor in the statistical model, or a by expressing 
volume as a percentage of TIV. 
2.4.4. Correction for multiple comparisons 
The results of statistical analyses are prone to both Type I and Type II errors. A Type I 
error refers to the incorrect rejection of a true null hypothesis (a false positive). A Type II error 
is the acceptance of the null hypothesis when a true effect is present (a false negative). The 
more statistical comparisons performed in a given analysis, the more likely a Type I or Type II 
error is to occur. While an understanding of these two scenarios is relevant to all researchers 
undertaking statistical analysis, the nature of neuroimaging analysis and the sheer volume of 
statistical comparisons conducted during many types of neuroimaging analyses mean that they 
are more likely to occur than within other fields (Lindquist & Mejia 2015; Hupé 2015).  For 
example, when performing a group comparison using VBM via a GLM analysis, all of the voxels 
within a given region are statistically compared between groups to find regions of significant 
difference. This involves performing a univariate test at every voxel, resulting in thousands of 
comparisons.  
By performing correction for multiple comparisons, a researcher reduces the 
likelihood of Type I or Type II errors occurring. Correction for multiple comparisons is typically 
performed by adjusting a statistical threshold based on the number of comparisons being 
performed, with the Bonferroni correction the most widely known (Lindquist & Mejia 2015). 
Within neuroimaging there are two commonly used methods of correction: correction for 
family-wise error rate (FWE) and correction for false discovery rate (FDR).   
FWE refers to the likelihood of making one or more Type I errors in a family of tests 
(i.e. multiple tests), it includes the Bonferroni method. Correcting for FWE assumes that we 
want to limit the chance of a Type I error in any of our statistical tests, and is often too 
stringent, thus increasing Type II errors. FDR, in comparison, controls for the number of Type I 
errors across all significant results, and aims to reduce the number of false positives only 
within the subset of voxels found to be significant.  
2.5. Dynamic causal modelling 
It is known that while brain regions have functional specificity, they also interact with 
each other both functionally and structurally. The connections and strength of interaction 
between regions is dependent on the neural activity being performed. However, traditional 
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GLM methods and connectivity techniques used to analyse both sMRI and fMRI data cannot be 
used to estimate causal interactions between variable brain networks. Instead they are used to 
correlated volume or activity in different regions with each other or with external variables, 
such as task performance. Post hoc interpretations can then be drawn on the existence of 
inter-regional networks. Because of this limitation, a number of techniques have been 
developed to estimate models that enable the testing of hypothesised inter-connecting brain 
networks. In 2003 Dynamic causal modelling (DCM) was developed for this purpose (Friston et 
al. 2003). DCM is an analysis technique, typically used with fMRI or electrophysiological data, 
which aims to infer causal relationship between distributed neuronal populations. Different 
network models are hypothesised and tested, and Bayesian model selection (BMS) is then 
used to compare the different generative models in order to find the most appropriate model 
to fit the measured fMRI or electrophysiological data. Based on the strongest model, 
inferences can then be drawn on the biological structure of neuronal networks. Recently, the 
models and assumptions applied in DCM have been adapted for application to sMRI data in 
order to perform more powerful characterisations of both within-region and inter-regional 
atrophy than approaches such as VBM (Ziegler et al. 2017). 
DCM was developed to quantify effective causality, that is, to examine the causal 
influence that neuronal systems exert over each other. The model estimates the relationships, 
referred to as coupling, between brain regions and enables examination of how the coupling is 
influenced by changes in the experimental context. DCM creates realistic models of the 
temporal evolution of a set of neuronal states (x). The change within a region is dependent on 
the current state of the region (x), external inputs (C) that cause network-wide changes and 
the context-dependent connections to other regions (A), and modulatory parameters (B) 
which are factors that modulate activity  (Friston et al. 2003). These expressions are the main 
components of the basic DCM model, called the bilinear model, shown in Figure 2.11.  
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Figure 2.11. Shows (A) the bilinear state equation of DCM for fMRI, with an example (B) of the 
dynamics in a hierarchical visual system consisting of areas V1 and V5 and the superior parietal 
cortex (SPC). Each region has a state variable (x1, x2, x3), and connections between regions are 
represented by the black arrows. The external inputs are represented by grey arrows, and 
dotted arrows indicate the transformation from neural states into haemodynamic 
observations. Visual stimuli (photic) drives activity in V1 which is then propagated to V5 and 
the SPC, with the V1-V5 connection changing when stimuli are moving, and the SPC-V5 
connection is modulated by attention. The state equation for this scenario is shown on the 
right. Adapted from Stephan et al. (2007). 
 
DCM combines the bilinear model with a validated hemodynamic model, which 
describes the process of a BOLD signal being generated from neuronal activity. The 
hemodynamic model defines the change in blood volume and deoxyhaemoglobin, the basis of 
an fMRI signal, that is predicted when changes in regional neural activity result in vasodilation 
and a subsequent increase in blood flow.  
A model is specified based on the hypothesised hemodynamic model, and parameters 
are estimated such that both the modelled and measured BOLD signals reach maximal 
agreement. The model is grounded in priors that contain previous knowledge about the 
model, including the hypothesised hemodynamic response within regions but also the neural 
interactions between regions. The process of model estimation is iterative; the estimation is 
modelled based on the current parameters, results are then compared to the measured data, 
improvements are made on the model parameters and the cycle repeats. Different 
hypothesised models can be specified and estimated, with the final estimated models 
statistically compared. Bayesian model selection (BMS) is then used to determine the 
hypothesis that best explains the measured BOLD signal. 
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While this type of classical DCM is typically used in functional or electrophysiological 
data, recent work has adapted the framework to permit the application of similar 
methodology to sMRI data. The approach enables linear and non-linear modelling of 
longitudinal change in multiple structural regions, offering a unique approach to quantify 
structural change (Ziegler et al. 2017). Mass univariate methods of quantifying neural change 
typically involve whole-brain analyses, which can identify linear change associated with 
different correlates. The model by Ziegler et al. (Ziegler et al. 2017) uses similar principles as in 
DCM and the bilinear model to study structural changes in a systems-based perspective. This 
approach avoids issues of multiple comparison corrections that arise from mass-univariate 
methods, but also enables the comparison of multiple hypothesised models of neuronal 
change via BMS. Briefly, the model uses a hierarchical system to perform first- (individual) 
level and second- (group) level modelling. Similarly to DCM for functional data, a bilinear 
model is used that specifies the temporal progression of states, in this case volume, over time 
(multiple scanning sessions). The states are influenced by within-region connections (atrophy) 
and between-region influences, that is, the effect that regions have upon each other. The 
examination of between-region connections should be hypothesis driven since the model is 
specified by the user, and thus a good empirical basis for this model is essential. The 
trajectories of the volumetric states are also influenced by external factors, which can include 
known influences, such as genetic factors that may be related to neural atrophy and can be 
included in the model. External factors can also include unknown influences, for example 
unknown hormonal influences that could impact on atrophy.  
First-level individual models can be applied and compared, for example a quadratic fit 
could be compared to a linear fit to determine which model might best explain the data. 
Following selection of a first-level model the model is applied to all data and then second-level 
models can be used to construct group-wise progression trajectories. The second-level model 
also incorporates covariates to account for individual differences in age, sex and other 
variables that are not of interest.  
This analysis can be used to study within-region trajectories of change and also the 
interactions between regions, and can tolerate variability within time points and some missing 
data. This thesis uses the approach to undertake structural dynamical modelling of atrophy in 
the cortex in HD. See Chapter 6 for detailed information on the implementation of the model 
in this thesis.  
 82 
3. COMPARISON OF AUTOMATED GREY MATTER 
SEGMENTATION TOOLS 
Grey matter volume is a frequently used measure of brain morphology; it is typically 
reliable and able to discriminate between healthy controls and clinical groups (Schwarz et al. 
2016). It is most often measured using automated software tools that separate GM from other 
tissue types. Thus, high quality delineation (segmentation) of GM, WM and cerebrospinal fluid 
(CSF) is critical in achieving accuracy for volumetric analyses. Recent work has demonstrated 
that variability between volumetric tools can result in inconsistencies within the literature, 
driving false conclusions about neurological conditions (Katuwal et al. 2016). There are a 
number of automated tools that can be used for performing GM segmentation, with each tool 
having differing characteristics. Methodological comparisons of these tools have focused on 
either comparing the automated segmentation software within standard neuroimaging 
analysis packages including SPM, FSL and FreeSurfer or on the optimisation of a single 
application (Clarkson et al. 2011; Eggert et al. 2012; Fellhauer et al. 2015; Gronenschild et al. 
2012; Iscan et al. 2015; Katuwal et al. 2016; Kazemi & Noorizadeh 2014; Klauschen et al. 2009; 
McCarthy et al. 2015). In short, using these methods on phantom data has shown that both 
SPM8 and FSL FAST (version 4.1) are reliable and accurate, whereas FreeSurfer (version 4.5) 
appears to be highly reliable but not necessarily accurate for measuring GM volume (Eggert et 
al. 2012), whereas SPM 5 and FSL were recommended for GM sensitivity in phantom and 
control data (Klauschen et al. 2009). 
Typically, GM segmentation tools have been developed and optimised for use on 
healthy brains (Irimia et al. 2012), and therefore may not show the same level of accuracy and 
reliability when used in clinical cohorts. Given the challenges associated with performing MRI 
scans in clinical groups, such as the effects of movement, the scans from a clinical research 
study may be of lower quality due to increased movement and reduced tissue contrast (Kong 
et al. 2012). Klauschen et al. (2009), for example, found that GM volume is often 
underestimated in poor quality images with poor contrast and noise, and overestimated in 
good quality images, indicating possible bias towards reduced GM in patient populations. 
Furthermore, greater anatomical variability is likely due to pathology in clinical cohorts leading 
to poor segmentation performance, particularly if software was not designed to cope with 
pathological abnormalities (Irimia et al. 2012). These key factors are thought to lead to 
inconsistent findings within clinical neuroimaging studies (Ashburner et al. 2016; Katuwal et al. 
2016).  
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There is evidence that some GM segmentation tools are sensitive to volumetric 
change in clinical populations, despite their validation in non-clinical populations. SPM8, 
SPM12, FSL 4.1.9, FreeSurfer 5.1.0 are all sensitive to disease-related change in Alzheimer’s 
disease (Fellhauer et al. 2015). SPM shows the best results for scans with increasing noise 
(Fellhauer et al. 2015), but performs with greater accuracy for CGM than subcortical GM as 
shown in Multiple Sclerosis patients (Derakhshan et al. 2010). However, SPM, FSL and 
FreeSurfer have all shown significant bias in GM measurements when comparing participants 
with Autism Spectrum Disorder to control participants, indicating that group differences may 
be due to segmentation related effects rather than true differences (Katuwal et al., 2016); and 
SPM has been demonstrated to overestimate group differences in healthy elderly participants 
with atypical anatomy, although this was in a VBM study (Callaert et al. 2014). Although these 
studies provide some explanation for the difficulty experienced with replication in sMRI 
studies, especially in clinical participants, these tools are regularly applied to patient cohorts 
without optimisation for unique brain pathology. 
In the following project a number of software tools used to process GM volume were 
examined to find the most reliable and sensitive means of detecting CGM change in HD 
participants from the TRACK-HD cohort. Initially, the methods were validated on the BrainWeb 
dataset, a set of 20 phantom scans with corresponding ‘ground truth’ segmentations (Aubert-
Broche et al. 2006). Following this, 100 TRACK-HD participants were processed to examine 
performance of the tools in both controls, pre-HD and manifest HD gene carriers. In the 
baseline 2008 TRACK-HD visit, all 100 participants had back-to-back MRI scans collected in the 
same scanning session. These back-to-back scans were used to determine the reliability of all 
tools. The 2011 follow-up scans allowed a comparison of sensitivity to change in the 
segmentation tools. Both qualitative and quantitative analyses were conducted to ensure that 
all aspects of performance were examined.  Following the analysis, a number of methods have 
been selected to apply to the clinical cohort in subsequent chapters of this research. 
3.1. Aims 
This project aimed to investigate the most accurate, reliable and sensitive methods of 
measuring cross-sectional CGM volume and longitudinal CGM volume change in HD. There was 
a focus on comparing methods that can be applied by a novice user rather than someone with 
advanced technical skills. It was deemed important that the results represent common clinical 
users of neuroimaging software in order to be replicable to the wider community, rather than 
users who can create their own software or perform detailed optimisation of the available 
software. In this way, the study aims to encourage use of more consistent methods within the 
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field and thus allow for better reproducibility of neuroimaging findings, whilst still being 
appropriate for further projects in this thesis. Total, cortical and lobular grey matter metrics 
were examined. 
3.2. Methods 
3.2.1. Segmentation techniques considered 
A number of methods are available for delineating (segmenting) GM volume and many 
of these were considered for inclusion in the study with a final selection made after initial 
review. 
3.2.1.1.  Manual delineation via MIDAS  
Manual delineation of CGM was initially proposed for comparison. It would be 
performed using MIDAS, previously described in Chapter 2 (Freeborough et al. 1997). While 
semi-automated whole-brain segmentation is often considered a ‘gold standard’ of volumetric 
segmentation, there is currently no validated technique for measuring only the CGM via 
MIDAS. Some initial testing was performed to ascertain the feasibility of developing a manual 
measure. Previously segmented whole-brain regions, which already have the surface between 
the CSF and GM delineated, were loaded. Thresholds, based on mean brain intensity, were 
applied to these regions to try to exclude WM. It was possible to achieve a GM region via this 
method, however different scanner types resulted in different contrast between the GM and 
WM and thresholds did not perform consistently for all brains. In addition, this technique was 
labour intensive with each slice requiring checking and manual editing due to the convolutions 
of the cortex, particularly where there was poor grey/white matter contrast. Due to the 
considerable time investment required for development, validation and application of a 
reliable technique using MIDAS, it was ruled out for inclusion in this study. In addition, since 
MIDAS is not currently a widely available software any measure developed would not be easily 
reproducible for other research groups. Manual GM measures were excluded from the analysis 
from this point onwards. 
3.2.1.2. FAST (FSL)  
As mentioned in Chapter 2, FSLs FAST segmentation procedure is a frequently used 
software tool (Zhang et al. 2001). FSL is freely available, commonly used in neuroimaging 
research and easy to implement. 
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3.2.1.3. SPM  
SPM is freely available, although it does require Matlab (which is not freely available) 
in order to run. It is widely used within neuroimaging research and has been used in a number 
of HD studies previously (Tabrizi et al. 2009; Hobbs, Henley, et al. 2010; Tabrizi et al. 2011) 
3.2.1.4. BRAINS 
While BRAINS has been used in some previous HD studies, particularly to quantify 
subcortical volume of the caudate and putamen, (Nopoulos et al. 2011; Paulsen et al. 2006), 
and was used in the TRACK-HD and TrackOn studies to measure volume of the putamen 
(Tabrizi et al. 2009; Tabrizi et al. 2011; Tabrizi et al. 2012; Tabrizi et al. 2013), it is not widely 
used, is not easy to use, and is somewhat out-dated. Discussion with the software developer 
responsible for implementing BRAINS in the TRACK-HD study prompted the decision to exclude 
it from the current study, after the suggestion that it has been surpassed by software that is 
more capable of accurately measuring GM volume. 
3.2.1.5. FreeSurfer   
FreeSurfer is commonly used, and has been applied within HD research a number of 
times, although most analyses are used to perform CT analysis. There are standard pipelines 
available, and FreeSurfer is easy to implement and freely available.    
3.2.1.6. ANTs 
Although ANTs is a more recently developed tool and has not been used in HD studies 
previously, it is freely available and becoming more widely cited in neuroimaging literature. It 
has variable options for processing datasets, with some fully automated streams available. 
ANTs pipelines are freely available and online support is provided.  
3.2.1.7. MALP-EM 
MALP-EM is another more recently developed tool that provides a fully automated 
segmentation, and has been demonstrated as able to cope with severe brain pathologies 
(Ledig et al. 2015). It has not been used in HD research to date, but it is freely available and has 
a recommended pipeline.  
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3.2.1.8. Final Measures 
The final methods for this analysis were selected based on ease of access, frequency of 
use within the literature and usability of the software. The final measures selected for the GM 
volumetric methodology comparison were: FSL FAST using FSL version 5.0.9, SPM version 8 
Unified Segment, SPM version 8 New Segment, SPM version 12 Segment, FreeSurfer version 
5.3.0, ANTs version 2.1.0 (final application compiled on 13-October-2015), and MALP-EM 
version 1.2.  
3.2.2. Cohorts 
3.2.2.1.  BrainWeb 
The BrainWeb cohort was used for an initial analysis. The cohort is described in section 
2.1.1. 
3.2.2.2. TRACK-HD  
Following on from the BrainWeb data analysis, the tools were applied to a subset of 
the TRACK-HD cohort in order to study the performance of these segmentation measures on 
atypical brains. The TRACK-HD cohort is described in section 2.1.2. Back-to-back scans from the 
baseline of TRACK-HD were used to examine the consistency of these tools. As there is no GT, 
importance was placed on visual checking of the output of all processing pipelines to examine 
accuracy.  The same participants were also examined at their 2011 time point to assess 
longitudinal change. 
100 participants from the TRACK-HD 2008 time point were selected for this study. 
Twenty controls, 20 pre-A, 20 pre-B, 20 HD1 and 20 HD2 participants were used. The 
participants were initially considered for inclusion based on whether they had back-to-back 
scans at baseline of TRACK-HD and follow up scans at the 2011 time point. Following this 
criteria, participants were randomly selected whilst trying to maintain an approximate age 
matching between the groups. Controls were examined first, followed by HD gene carriers to 
highlight potential issues that may occur when applying standard segmentation tools to 
patients. 
3.2.3. Segmentation, quality control and volume calculation  
Segmentations for FSL, FreeSurfer, ANTs and MALP-EM were run on a computer 
cluster (Legion@UCL). All SPM segmentation methods the segmentations were run on a Dell 
 87 
Precision Power 7810 desktop computer. Following any manipulation of the images, scans 
were visually examined for quality. For this study, a processing step was categorised as a ‘fail’ 
if there was gross failure in performing the extraction or segmentation (Figure 3.1), rather than 
for more minor errors. Gross failures at any stage were initially checked to rule out user error. 
Processing changes were made to rectify software-based gross errors in two cases. Firstly, 
delineation of the GM performed by SPM8 Unified Segment may fail if the orientation of the 
brain deviates noticeably from the standard SPM templates (Figure 3.1). In a few cases 
adjustments were performed to shift the brain within the field of view to achieve a better 
match with standard space. Secondly, prior to segmentation using FSL, the Brain Extraction 
Tool (BET; Smith 2002) was run on all data. Using standard parameters BET failed to extract 
brains satisfactorily on the TRACK-HD cohort (Figure 3.1) and optimised BET parameters were 
substituted (see section 3.4.2). In addition to a small number of gross errors, all tools showed 
minor errors in segmentation, as discussed in the results (also shown in Figure 3.4). No manual 
intervention was made in the case of errors in segmentation because this would introduce 
increased subjectivity to the comparison. Recommendations for manual intervention are 
provided in the discussion.  
 
 
Figure 3.1. (A) An example of a gross failure on a TRACK-HD scan when using SPM8 Unified 
Segment. (B) An example of a gross failure on a TRACK-HD scan when using FSL BET brain 
extraction and FAST segmentation procedures.  
 
Partial volume estimates (PVE) were used for all tools except FreeSurfer, which instead 
of outputting either partial volume or discrete tissue maps outputs text files with regional 
volumes listed. These are calculated to account for PVE. Due to this, FreeSurfer volumes were 
calculated differently to other techniques in this analysis (see section 3.2.3.3 for details). 
Whilst probabilistic segmentation maps were used throughout this analysis as they should 
more accurately represent brain volume (Tohka 2014) for the first part of the analysis 
examining total GM volume in BrainWeb data two analyses were run in parallel. The first 
analysis was run on the discrete volumes and the second on partial volume segmentations. 
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This was done to allow for some understanding of how PVE and discrete volumes perform. 
Detailed information on the processing for each programme follows. 
3.2.3.1. SPM 
All versions of SPM were applied in native space and with default settings for both 
BrainWeb and TRACK-HD data. SPM only outputs partial volume maps, and so for the first 
BrainWeb analysis, all grey-matter segmentations were binarised at a threshold of 0.5 via 
FSLmaths in order to only include voxels that were classed as a majority grey-matter. For the 
remaining analyses the partial volume GM maps were used. 
3.2.3.2. FSL 
Prior to FAST being run, the Brain Extraction Tool (BET) was run on all data. For the 
BrainWeb data this was done with default settings in native space, but as previously 
mentioned optimised parameters were used for TRACK-HD data. The commands were: 
1. London and Paris participants: 
bet <input> <output> -f 0.65 -R -c 104 128 128 
2. Leiden participants: 
bet <input> <output>  -f 0.3 -R -c 82 120 120 
3. Vancouver participants:  
bet <input> <output> -f 0.3 -R -c 82 112 112 
Following BET, FAST was run with default settings in native space. FAST outputs both 
partial volume tissue classes and discrete tissue classes for each image. For the first BrainWeb 
analysis the discrete GM was used, for all subsequent analyses partial volume maps were used. 
3.2.3.3. FreeSurfer  
FreeSurfer was run via the default recon-all pipeline, with a flag that specifies that the 
scans were collected on a 3T scanner. The surface-based stream is mainly used for measuring 
CT and the volume-based stream is mainly used for calculating volume. Volumetric maps 
displaying PVE results are not output, meaning that a user cannot simply output the volume of 
a map. However, the FreeSurfer pipeline includes the automatic calculation of the volume of 
different regions. It combines the CT and volumetric results during processing and outputs a 
text file for each participant containing volumetric results. For example, CGM volume is output 
by FreeSurfer, but it is not calculated by simply measuring the size of the volumetric 
segmentation, instead it is calculated via a combination of volumetric and surface-based 
factors (https://surfer.nmr.mgh.harvard.edu/fswiki/MorphometryStats).  
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This means that it is difficult to replicate the volumes output from the FreeSurfer 
pipeline via manual extraction from the segmentations, and it is impossible to view the 
segmentations that contain the exact volume output within the volumetric text files. Based on 
the recommendations of FreeSurfer developers, the automatically optimised volumes were 
extracted for each participant and used in the current analysis 
(https://surfer.nmr.mgh.harvard.edu/fswiki/MorphometryStats). See section 3.2.4 for more 
detail. 
3.2.3.4. ANTs  
ANTs requires a template and priors to calculate volumes and thickness. The 
recommended default pipeline was followed and study-specific templates and priors were 
created for both datasets in this study (Avants, Tustison, Wu, et al. 2011). 
3.2.3.4.1. ANTs BrainWeb processing 
First, a template was created using all 20 BrainWeb scans. This was done using the 
command antsMultivariateTemplateConstruction.sh, which is included with ANTs. All settings 
were default, except that the options to allow for parallel computation were enabled. 
Following this, study-specific priors were created from the template. This was done via running 
the command antsCorticalThickness.sh on the template, using a downloaded template and 
priors as the required input for the brain mask and priors. The resulting tissue segmentations 
output from this command were then smoothed, and the CSF segmentation was subtracted 
from the other 5 segmentations, as recommended by the developers of ANTs (Tustison et al. 
2014). The study-specific template, extracted template brain and the corresponding priors 
could then be used to segment the 20 BrainWeb scans.  
ANTs has a segmentation pipeline, Atropos, which can be run in isolation but is also 
integrated into the CT pipeline along with brain extraction. After preliminary testing it was 
decided that the CT pipeline would be used for the BrainWeb data as segmentation was not 
successful using the Atropos pipeline on BrainWeb data. When using the Atropos pipeline, 
ANTs was unable to accurately distinguish between GM and WM on the BrainWeb scans and 
resulted in the failure of processing. Instead, the CT pipeline was run with default settings and 
the template-specific brain mask and priors were included. From the CT pipeline both partial 
volume tissue classes and regions with each voxel classified as a discrete tissue class are 
output. For the first analysis the discrete GM was used. For the second analysis, partial volume 
was used. 
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3.2.3.4.2. ANTs TRACK-HD processing 
For the TRACK-HD processing, a template was created for both of the back-to-back 
datasets from baseline, and an additional template was created for the final time point using 
the same participants. The templates and priors were created as described above using a 
subset of 25 TRACK-HD scans, 5 from each group following the process recommended in 
(Tustison et al. 2014). Following template creation, ANTs brain extraction was run on each 
participant using the brain mask from the study-specific template and study-specific priors. 
Atropos was run on the TRACK-HD data as it was easy to run and segmented the regions 
successfully. To run Atropos the extracted brain mask for each participant was used with the 
study-specific priors. 
3.2.3.5. MALP-EM  
MALP-EM was run using the default settings on both datasets. MALP-EM outputs both 
discrete and partial volume maps. 
3.2.4. Mask selection and registration  
A number of the selected segmentation software output combined cortical and 
subcortical GM segmentations, and it was decided that for the CGM and lobular volumes 
masks would be overlaid on total GM for each segmentation to output regional volumes rather 
than using each tools’ own regions. While possibly reducing the performance of some tools 
slightly by using a mask not optimised to that technique, consistency between techniques was 
ensured this way. One mask for each region was registered to each participant’s native space 
scan and used for all segmentation outputs.   
Time was spent selecting both the best registration tools and the best cortical and 
lobular GM masks to use. The CGM mask had to incorporate total CGM and exclude subcortical 
GM and cerebellar GM. In addition, the mask needed to be loose enough to capture any 
regions in the dura or WM that were incorrectly classified as CGM, as often happens in these 
segmentation techniques. Initially, the Harvard Oxford cortical mask was applied (Desikan et 
al. 2006). This was extracted in MNI space and registered via FLIRT and FNIRT to native space. 
The cortical coverage was good and it provided a balance between too loose and too tight. 
However, the mask included a lot of cerebellar GM. A cerebellum mask was then used to 
exclude cerebellar GM. Initially, the MNI cerebellar mask was used. After registration this mask 
was too loose, and overlapped the occipital CGM. Instead, a binary mask of the Buckner tight 
cerebellar segmentation was used (Buckner et al. 2011). This was downloaded in FreeSurfer-
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conformed space, and registered to MNI before being registered to native space for FSL and 
SPM outputs. It overlaid the cerebellum reasonably well, although in posterior regions it 
missed some sections of the cerebellum.  
It was noted that during registration, the masks were undergoing warping around the 
exterior surfaces and so following selection of the most appropriate cortical mask and 
cerebellar exclusion mask, a different registration tool was tested. The ants command, 
antsRegistrationSyNQuick.sh was used with default settings to convert the standard MNI 1mm 
brain from MNI space to native space for each participant. The resulting warp was then 
applied to the Harvard Oxford cortical mask and the cerebellar mask, with much greater 
alignment seen than when using FLIRT and FNIRT. This registration was also faster to perform 
and apply. An example of the CGM mask is shown in Figure 3.2. 
 
 
Figure 3.2. The CGM mask for BrainWeb scan 04, overlaid on the native T1 image shown in (A) 
coronal, (B) axial and (C) sagittal views. 
 
After the initial analysis, it was also decided that a lobular analysis would be 
performed to provide additional information on the performance of these tools. However, the 
Harvard Oxford cortical mask does not provide lobular regions. Due to this, it was decided that 
the MNI GM template included with the FSL package would be applied to output lobular 
volumes (Mazziotta et al. 2001). This mask was registered to the output images in the same 
manner as the MNI mask and the frontal, temporal, parietal, occipital and insular regions were 
extracted. An example of the lobular masks is shown in Figure 3.3. 
The only exception to this was FreeSurfer, as mentioned previously, where total GM 
and CGM volumes were extracted from an automatically created text file. The volumes used in 
this study were taken from the aseg.stats file created for each participant. The volumes were 
treated as partial volumes, as it is stated on the FreeSurfer website that the aseg.stats file does 
control for PVE (https://surfer.nmr.mgh.harvard.edu/fswiki/FsTutorial/QuestionAnswers).   
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However, the lobular volumes were calculated differently for the BrainWeb and 
TRACK-HD datasets. FreeSurfer provides additional steps to output lobular volumes, using pre-
defined regions of interest. For the BrainWeb study, the default FreeSurfer lobular values were 
extracted. Based on the results of this analysis, it was decided that for the TRACK-HD analysis 
the lobular masks used to calculate lobular volume for all other techniques should be used 
(see section 3.2.4). To do this, the lobular masks for each participant were transformed from 
native space into each subject’s FreeSurfer analysis space 
(https://surfer.nmr.mgh.harvard.edu/fswiki/FsAnat-to-NativeAnat) and used to extract 
volumes. As FreeSurfer regions have undergone significant optimisation during development, 
we would expect that FreeSurfer may have an advantage over the other tools and this should 
be considered when exploring the results. 
 
 
Figure 3.3. The lobular masks for BrainWeb scan 04, overlaid on the native T1 image shown in 
(A) coronal, (B) axial and (C) sagittal views. 
 
3.2.5. Analysis 
A qualitative examination of the data was performed prior to the quantitative analysis. 
There are various features of these segmentations that can only be understood by examining 
the volumetric maps. For example, minor but consistent over- or underestimation of GM 
within automatically- identified anatomical regions may not be detected by quantitative 
methods, but can be easily recognised by a neuroanatomical expert during visual examination. 
All scans were examined blinded to group and all errors were noted. From this, trends within 
each tool were detected. Over- and under-segmentation refers to regions whereby the 
boundary of the segmented region differed from the visible boundary on the T1. All 
segmentation tools also showed minor errors as discussed in the results section.  
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3.2.5.1. BrainWeb 
Initially, summary statistics and plots were output to get an overview of the data.  
Paired t-tests were also conducted to determine whether differences between the GT and 
segmentation procedures were statistically significant. Scatterplots were produced for a 
visualisation of the relationship between the volume of the GT and each segmentation 
procedure. Following this, Bland Altman plots were output along with Pitman's Test of 
difference in variance to test the agreement between the ground-truth and each segmentation 
method. Overlap scores (dice coefficient) were also calculated on a voxel-wise basis as 
discussed in Crum, Camara and Hill (2006). These were calculated for both discrete GM 
volumes and partial volume maps, but were not calculated for FreeSurfer as voxel-wise maps 
are not available for the FreeSurfer data.  
3.2.5.2. TRACK-HD 
Total and CGM volumes were examined in all analyses, and a subset of analyses also 
examined lobular GM volume. First, summary statistics, including means, ranges and standard 
deviations for demographic information were calculated and between-group differences 
derived. Total, cortical and lobular GM mean volumes were calculated for both baseline and 
the follow-up scan for each participant. Additionally, reliability was tested for the back-to-back 
baseline scans using intraclass correlation (ICC; Bartko 1966). Mean repeatability for back-to-
back scans was also calculated as percent variability error, as shown in Function 1 in section 
2.4.1 (Jovicich et al. 2013; Tustison et al. 2014). Spearman’s Rho was also used to test the 
correlation between each set of volumes extracted using each segmentation tool. 
To measure the longitudinal sensitivity of each segmentation tool the control group 
was compared to all HD groups. Follow-up volume of total GM, CGM and lobular volumes were 
expressed as a percentage of baseline volumes and regression analyses were performed to 
determine whether there were significant differences in the rate of change between controls 
and each HD group. All results were adjusted for age, sex and site. 
3.3. Results 
3.3.1. Qualitative Results 
The output for each BrainWeb and TRACK-HD dataset and each tool were visually 
inspected. Notes were taken for every segmentation examined, and common themes were 
noted for the different segmentations. This examination was focused on CGM, with subcortical 
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structures not examined in detail. Table 3.1 provides a description of the performance of each 
tool on both datasets, and Figure 3.4 contains examples. 
3.3.2. BrainWeb Quantitative Results 
3.3.2.1. Whole-brain results  
Table 3.2 shows summary statistics for discrete and PVE total GM volumes, results of 
paired t-tests and summary statistics for the dice score. All techniques significantly 
underestimated grey matter compared to the GT in discrete segmentations (Figure 3.5 A); 
however the dice overlap values were still high for all techniques, ranging from .890 for ANTs 
to .920 for FAST.  
Figure 3.6 shows the relationship between the discrete GT volumes and discrete 
volumes output by each segmentation technique, indicating good correspondence for all 
techniques. In the discrete volumes, bias was detected via Pitman’s test of variance in all 
techniques excluding SPM8 Unified Segment (Figure 3.7). This indicates that the software had 
a tendency to underestimate GM volume compared to the GT in small brains, and 
overestimate it in larger brains. 
For PVE volumes, all versions of SPM, FAST and FreeSurfer significantly 
underestimated GM volume whereas ANTs and MALP-EM overestimated GM volume (Figure 
3.5 B). The overestimation for ANTs was significant but not for MALP-EM. Again overlap values 
were high, this time ranging from .882 for FAST to .904 (SPM8 New Segment).  
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Figure 3.8Figure 3.8 shows the relationship between the discrete GT volumes and 
discrete volumes output by each segmentation technique. There was again bias in all 
techniques for the PVE volumes (Figure 3.9). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.1. A description of the performance of each tool, with most common issues outlined. 
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Segmentation BrainWeb Performance Track-HD Performance 
Ground Truth  In a number of cases dura and skull 
was included in the volumes.  
 The GT volumes are somewhat 
inaccurate, and may over-estimate the 
actual GM volume in some cases. 
-- 
SPM8 Unified 
Segment 
 SPM8 Unified segment performed well 
on the BrainWeb scans 
 Tight around the GM/CSF lateral 
boundaries 
 Some WM voxels classed as GM 
 Good delineation of the sulci 
 Poor temporal delineation very common. 
 Occipital spillage and underestimation of 
frontal lobes in a number of scans.  
 6/400 scans segmented excluded from 
analysis due to gross failure (1 for 2008 
A, 2 for 2008 B non-registered, 2 for 2008 
B registered, 1 for 2011). 
SPM8 New 
Segment 
 Large number of voxels located within 
the skull and dura consistently classed 
as GM, could erroneously inflate the 
value total volume 
 
 Poor temporal delineation very common 
 Occipital spillage in a number of scans 
 Classified voxels in the skull and dura as 
GM in almost all segmentations  
 No scans failed segmentation  
ANTs Atropos  GM segmentations accurate overall, 
with good delineation of the sulci 
 Some overestimation of GM on 
WM/CSF boundary 
 Variable performance 
 Brain extraction determined 
segmentation quality; e.g. large brain 
mask meant dura included in the 
segmentation 
 Frequent overestimation of occipital GM 
and poorly delineated temporal lobes 
 No segmentation fails 
MALP-EM 
 
 Performed well overall, some GM cut-
off in a small number of scans due to 
tight brain mask 
 
 Fewer issues with overestimation of the 
occipital lobe  
 Generally better temporal lobe 
delineation  
 CGM underestimated in superior regions 
in a small number of cases 
 No segmentation fails 
FSL FAST 
 
 Performed well overall, clean 
boundaries although some 
segmentations classified skull as GM 
 Standard BET provided poor brain 
extractions on Track-HD data and was re-
run with an optimised BET procedure, 
although results of the optimised BET 
were still sub-optimal 
 Often underestimated GM volume, with 
occasional overestimation due to poor 
brain extraction 
 As a result, difficult to characterise GM 
segmentation 
 Two scans were rated as a complete fail 
FreeSurfer  Performed very poorly overall, large 
regions of the frontal, temporal and 
occipital lobes were regularly 
underestimated and missing from the 
segmentation.  
 GM tended to be very tight along CSF 
boundary, with a layer of voxels on the 
GM/CSF boundary typically excluded 
from the volume based segmentation  
 Within FreeSurfer volume is calculated 
via a combination of the volume and 
surface- based segmentations and so 
some of these excluded voxels would be 
included in the calculation if they are 
within the cortical surface 
 Spillage into the temporal CSF and 
occipital dura regularly seen with some 
cases classifying skull as GM 
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Figure 3.4. Examples of the GM output from each tool overlaid on one participant from the 
TRACK-HD study. The figure shows three coronal views, with Figure (A) showing the same 
slices with no segmentation. The first slice shows the frontal and temporal regions, the second 
slice is towards the middle of the brain, and the last slice shows the occipital lobe. All figures 
show default probabilistic segmentation maps for each software except for FreeSurfer, which 
shows volumetric and surface based regions. For the probabilistic segmentation maps, the 
brighter the yellow within a voxel, the more likely that the voxel contains GM. 
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Table 3.2. Discrete and PVE total GM volumes for the Ground Truth and all segmentation 
techniques, paired t-tests showing significant differences between the total GM Ground Truth 
volume and all segmentation techniques, for discrete and PVE volumes and summary statistics 
for the overlap metrics between Ground Truth and all techniques for both discrete and PVE 
volumes. 
 Discrete Volumes 
(ml) 
Mean 
(st Dev) 
Min-Max 
Discrete 
Volumes  
Paired t-tests 
 
Discrete 
Volumes Overlap 
Mean 
(st Dev) 
Min-Max 
PVE Volumes  
Mean 
(st Dev) 
Min-Max 
PVE Volumes  
Paired t-tests 
 
PVE Volumes 
Overlap 
Mean 
(st Dev) 
Min-Max 
Ground 
Truth 
1123.26 
(50.58) 
1028.46-1249.82 
-  
968.54 
(54.93) 
875.71-1093.04 
-  
SPM8 
Unified 
Segment 
950.54 
(42.65) 
864.73-1030.22 
-172.713 
t = -30.66 (19) 
p = .0000 
0.904 
(0.014) 
0.867-0.926 
947.90 
(42.06) 
861.36-1023.02 
-20.64 
t = -3.21 (19) 
p = .0046 
0.903 
(0.010) 
0.880-0.914 
SPM8 New 
Segment 
954.04 
(31.84) 
887.93-1016.01 
-169.22 
t = -29.87 (19) 
p = .0000 
0.902 
(0.010) 
0.873-0.920 
950.53 
(28.10) 
889.18-1007.49 
-18.01 
t = -2.36 (19) 
p = .0292 
0.904 
(0.007) 
0.888-0.914 
 
SPM12 
Segment 
945.52 
(38.18) 
863.20-1020.92 
-177.73 
t = -35.35 (19) 
p = .0000 
0.896 
(0.013) 
0.861-0.919 
941.67 
(37.81) 
857.29-1012.36 
-26.88 
t = -4.38 (19) 
p = .0003 
0.900 
(0.008) 
0.885-0.910 
 
ANTs 
1031.50 
(34.82) 
949.57-1096.22 
-91.75 
t = -16.39 (19) 
p = .0000 
0.890 
(0.016) 
0.855-0.919 
1041.76 
(31.21) 
967.25-1091.67 
73.22 
t = 8.94 (19) 
p = . 0000 
0.898 
(0.008) 
0.884-0.913 
 
MALP-EM  
949.32 
(368) 
862.65-995.46 
-173.94 
t =  -25.42 (19) 
p = .0000 
0.891 
(0.011) 
0.864-0.912 
984.84 
(36.45) 
893.97-1038.23 
16.29 
t = 1.87 (19) 
p = .0777 
0.886 
(0.010) 
0.859-0.899 
 
FAST 
906.10 
(41.99) 
832.49-1002.41 
-217.15 
t = -56.59 (19) 
p = .0000 
0.920  
(0.012)  
0.889-0.940 
957.07 
(47.80) 
876.51-1057.84 
-11.47 
t = -3.72 (19) 
p = .0015 
0.882 
(0.008) 
0.867-0.897 
FreeSurfer - - - 
919.91 
(40.77) 
851.88-1014.43 
-48.63 
t = -9.64 (19) 
p = .0000 
- 
 
 
 
 
Figure 3.5. (A) Boxplots showing total GM discrete volume for BrainWeb Ground Truth vs. 
segmentation methods (B) Boxplots showing partial volumes estimates for total GM volume 
for BrainWeb Ground Truth vs. segmentation methods. 
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Figure 3.6. Scatterplots showing the relationship between Ground Truth total discrete GM 
volume and discrete total GM volume for all segmentation techniques. Associated t-statistics 
and p values are shown for the results of paired t-tests comparing ground truth values and 
segmented values. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
t = -30.66,  
p = .0000 
t = -29.87,  
p = .0000 
t = -35.35,  
p = .0000 
t = -16.39,  
p = .0000 
t = -25.42,  
p = .0000 
t = -56.59,  
p = .0000 
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SPM8 Unified Segment 
r =  0.325, n = 20, p = 0.161 
 
 
SPM8 New Segment 
r =  0.756, n = 20, p = 0.000 
 
SPM12 Segment 
r =  0.564, n = 20, p = 0.010 
 
 
ANTs 
r =  0.646, n = 20, p = 0.002 
 
MALP-EM 
r =  0.546, n = 20, p = 0.013 
 
FAST 
r =  0.507, n = 20, p = 0.023 
 
Figure 3.7. Bland Altman plots and Pitman's test of variance for the relationship between 
Ground Truth total discrete GM volume and discrete total GM volume for all segmentation 
techniques. 
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Figure 3.8. Scatterplots showing the relationship between Ground Truth total PVE GM volumes 
and PVE total GM volume for all segmentation techniques. Associated t-statistics and p values 
are shown for the results of paired t-tests comparing ground truth values and segmented 
values. 
 
 
 
 
 
 
 
 
 
 
 
 
t = -3.21,  
p = .0046 
t = -2.36,  
p = .0292 
t = -4.38,  
p = .0003 
t = 8.94,  
p = .0000 
t =1.87,  
p = .0777 
t = -3.72,  
p = .0015 
t =-9.64,  
p = .0000 
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SPM8 Unified Segment 
r =  0.465, n = 20, p = 0.039 
 
SPM8 New Segment 
r =  0.812, n = 20, p = 0.000 
 
SPM12 Segment 
r =  0.641, n = 20, p = 0.002 
 
ANTs 
r =  0.685, n = 20, p = 0.001 
 
MALP-EM 
r =  0.511, n = 20, p = 0.021 
 
FAST 
r =  0.520, n = 20, p = 0.019 
  
FreeSurfer 
r =  0.639, n = 20, p = 0.002 
 
Figure 3.9. Bland Altman plots and Pitman's test of variance for the relationship between 
Ground Truth total PVE GM volume and PVE total GM volume for all segmentation techniques. 
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3.3.2.2. Cortical GM Results 
All segmentation methods except ANTs underestimated CGM, as shown in Table 3.3 
and Figure 3.10. The difference between the GT mean volume and the mean volumes for each 
technique were significant for SPM8 Unified Segment, SPM12, ANTs and FAST at p <.05. Dice 
scores measuring the overlap between the GT and segmentations indicated that while all 
techniques showed substantial overlap with the GT, the lowest average overlap was seen in 
SPM8 New Segment (0.899), FAST had the largest overlap with total CGM (0.922). Scatterplots 
showing the relationship between the GT and each technique suggest that FAST also had the 
closest relationship with the GT (Figure 3.11). Furthermore, Pitman’s test of variance indicated 
bias in measuring CGM for all techniques excluding SPM8 Unified Segment (Figure 3.12). All 
techniques displaying bias in segmentation overestimated CGM in brains whereby the GT was 
large and underestimated CGM in brains whereby the GT was small.  
 
Table 3.3. Descriptive statistics for CGM volume in the BrainWeb dataset, paired t-test results 
showing significant differences between the cortical GT volume and all segmentation pipelines 
and dice scores for the overlap between each segmentation procedure and the GT for CGM. 
 Cortical Volumes (ml) 
Mean 
(st Dev) 
Min-Max 
Cortical Volumes  
Paired t-tests 
 
Cortical Volumes 
Overlap 
Mean 
(st Dev) 
Min-Max 
Ground Truth 
765.47 
(44.11) 
692.89-867.36 
- - 
SPM8 Unified 
Segment 
750.34 
(35.68) 
676.73-814.57 
-7.88 
t = -3.36 (19) 
p =.0033 
0.907 
(0.013) 
0.873-0.928 
SPM8 New 
Segment 
755.43 
(22.6) 
720.71-805.01 
-15.13 
t = -3.07 (19) 
p = .0063 
0.907 
(0.01) 
0.882-0.926 
SPM12 
Segment 
746.43 
(33.51) 
690.81-809.78 
-10.04 
t =  -1.67 (19) 
p = .1122 
0.899 
(0.012) 
0.868-0.922 
ANTs 
787.18 
(26.97) 
740.68-836.33 
-19.04 
t = -4.16  (19) 
p = .0005 
0.904  
(0.013) 
0.875-0.928 
MALP-EM 
761.64 
(29.58) 
701.22-809.94 
21.71 
t = 3.90 (19) 
p = .0010 
0.904 
(0.01) 
0.882-0.922 
FSL FAST 
757.59 
(39.13) 
685.55-841.65 
-3.83 
t = -0.58 (19) 
p = .5671 
0.922 
(0.011) 
0.895-0.942 
FreeSurfer 
699.32 
(34.07) 
639.91-779.9 
-66.15 
t = -18.53 (19) 
p = .0000 
- 
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Figure 3.10. Boxplots showing CGM volume for BrainWeb GT vs all segmentation methods 
 
 
 
 
Figure 3.11. Scatterplots showing the relationship between CGM PVE Ground Truth volumes 
and CGM PVE for all segmentation techniques. Associated t-statistics and p values are shown for 
the results of paired t-tests comparing ground truth values and segmented values. 
 
 
 
t = -3.36,  
p = .0033 
t = -3.07,  
p = .0063 
t = -1.67,  
p = .1122 
t = -4.16,  
p = .0005 
t = 3.90,  
p = .0010 
t = -0.58,  
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p = .0000 
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A: SPM8 Unified Segment 
r =  0.395, n = 20, p = 0.085 
 
B: SPM8 New Segment 
r =  0.823, n = 20, p = 0.000 
 
C: SPM12 Segment 
r =  0.531, n = 20, p = 0.016 
 
D: ANTs 
r =  0.711, n = 20, p = 0.000 
 
 
E: MALP-EM 
r =  0.527, n = 20, p = 0.017 
 
 
F: FAST 
r =  0.477, n = 20, p = 0.033 
 
 
G: FreeSurfer 
       r =  0.637, n = 20, p = 0.003 
 
Figure 3.12. Bland-Altman plots showing the agreement between each measure and the 
Ground Truth for CGM. 
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3.3.2.3. Lobular GM Results 
Volumes, paired t-tests and overlap values are shown in Table 3.4. Mean volumes for 
the frontal lobe were all underestimated compared to the GT, except for the ANTs 
segmentation, which overestimated the volume. Frontal volume was significantly 
underestimated for all versions of SPM, FAST and FreeSurfer, and significantly overestimated 
for ANTs. The largest difference was between the GT and FreeSurfer. The overlap between GT 
and segmentations for the frontal lobe was highest for MALP-EM (.934).  
Temporal volumes were slightly overestimated by all segmentation techniques, and 
FreeSurfer greatly overestimated temporal volumes. This overestimation was significant for 
FreeSurfer, ANTs and FAST.  Again the overlap was highest for MALP-EM (dice score = .935), 
with other techniques also showing high overlap with the GT. 
Parietal volume was underestimated in all techniques except MALP-EM and ANTs, with 
significant underestimation in SPM8 Unified Segment, SPM12, FAST and FreeSurfer, and 
significant overestimation in ANTs. Overlap values ranged from 0.898 for SPM8 New Segment 
to .936 for MALP-EM. 
Occipital lobes were all underestimated compared to the GT, again with the exception 
of ANTs, which slightly overestimated the volumes. FreeSurfer, again, greatly underestimated 
occipital lobe volumes. The occipital lobe differences were significant for all techniques except 
SPM8 New Segment. MALP-EM showed the highest overlap with the GT. 
Insula lobe volumes were overestimated by all techniques, except FreeSurfer, with 
significant overestimation for SPM8 New Segment, ANTs, MALP-EM and FAST and significant 
underestimation for FreeSurfer. The overlap with GT was highest for MALP-EM, but again was 
high for all techniques. 
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Table 3.4. Descriptive statistics for GM lobes in the BrainWeb dataset, paired t-test results showing significant differences between the Ground Truth and all 
segmentation pipelines, and dice scores for the overlap between each segmentation tool and the Ground Truth. 
  Ground Truth 
SPM8 Unified 
Segment 
SPM8 New 
Segment 
SPM12 Segment ANTs MALP-EM FAST FreeSurfer 
Frontal 
Lobe 
Volume 
Mean (st Dev) Min-Max 
298.45 (20.68) 
264.21-351.21 
289.04 (17.08) 
257.27-322.37 
291.63 (13.26) 
270.77-321.49 
287.72 (16.06) 
259.19-320.78 
303.52 (14.26) 
278.54-330.62 
295.11 (15.25) 
263.34-321.68 
293.84 (18.43) 
262.78-335.59 
268.52 (14.02) 
249.97-302.92 
Paired t-tests - 
-9.41 
t = -5.06 (19) 
p = .0001 
-6.82 
t = -3.07 (19) 
p = .0063 
-10.73 
t = -6.01 (19) 
p = .0000 
5.07 
t = 2.29 (19) 
p = .0339 
-3.34 
t = -1.16 (19) 
p = .2613 
-4.61 
t = -4.98 (19) 
p = .0001 
-29.93 
t = -14.57 (19) 
p = 0.000 
Overlap  
Mean (st Dev) Min-Max 
- 
0.898 (0.020) 
0.852-0.921 
0.898 (0.015) 
0.874-0.924 
0.905 (0.020) 
0.858-0.941 
0.905 (0.015) 
0.876-0.931 
0.934 (0.012) 
0.907-0.955 
0.923 (0.012) 
0.895-0.942 
- 
Temporal 
Lobe 
Volume 
Mean (st Dev) Min-Max 
99.67 (8.68) 
84.49-116.62 
101.69 (8.43) 
87.28-123.55 
99.98 (7.42) 
89.14-122.10 
100.31 (8.74) 
84.57-124.10 
107.73 (7.02) 
95.29-126.47 
101.48 (7.49) 
89.02-119.99 
100.90 (9.08) 
85.06-123.82 
155.69 (7.73) 
144.45-169.69 
Paired t-tests - 
2.02 
t = 1.93 (19) 
p = .0689 
.30 
t = .28 (19) 
p = .7824 
.64 
t = .71 (19) 
p = .4868 
8.05 
t = 7.45 (19) 
p = . 0000 
1.81 
t = 1.66 (19) 
p = .1130 
1.23 
t = 2.23 (19) 
p = .0378 
56.02 
t = 27.74 (19) 
p = 0.000 
Overlap  
Mean (st Dev) Min-Max 
- 
0.898 (0.018) 
0.874-0.926 
0.897 (0.019) 
0.844-0.930 
0.906 (0.020) 
0.859-0.936 
0.906 (0.013) 
0.886-0.936 
0.935 (0.011) 
0.912-0.955 
0.923 (0.012) 
0.901-0.948 
- 
Parietal 
Lobe 
Volume 
Mean (st Dev) Min-Max 
172.18 (13.34) 
150.52-203.15 
167.93 (10.97) 
145.56-192.22 
170.11 (8.67) 
154.69-187.40 
166.90 (10.23) 
149.67-188.27 
176.82 (8.70) 
163.33-195.05 
175.35 (9.28) 
157.81-194.78 
169.39 (12.03) 
147.63-196.49 
161.66 (11.93) 
143.81-187.48 
Paired t-tests  
-4.25 
t = -3.26 (19) 
p = .0041 
-2.07 
t = -1.28 (19) 
p = .2175 
-5.28 
t = -4.26 (19) 
p = .0004 
4.64 
t = 3.03 (19) 
p = . 0070 
3.17 
t = 1.98 (19) 
p = .0627 
-2.79 
t = -4.48 (19) 
p = .0003 
-10.51 
t = -9.97 (19) 
p = .0000 
Overlap  
Mean (st Dev) Min-Max 
 
0.900 (0.017) 
0.869-0.935 
0.898 (0.021) 
0.843-0.935 
0.907 (0.021) 
0.851-0.952 
0.907 (0.015) 
0.871-0.942 
0.936 (0.013) 
0.900-0.964 
0.924 (0.011) 
0.892-0.946 
- 
Occipital 
Lobe 
Volume 
Mean (st Dev) Min-Max 
175.25 (9.52) 
154.19-193.17 
172.25 (8.27) 
156.88-190.23 
174.78 (7.38) 
157.46-186.79 
171.93 (8.10) 
155.88-188.12 
178.15 (7.95) 
162.44-192.53 
170.73 (7.44) 
154.06-183.17 
173.70 (8.42) 
156.19-190.75 
65.08 (5.60) 
55.59-74.11 
Paired t-tests  
-3.00 
t = -3.50 (19) 
p = .0024 
-.47 
t = -0.41 (19) 
p = .6828 
-3.32 
t = -4.22 (19) 
p = .0005 
2.90 
t = 3.24 (19) 
p = . 0043 
-4.52 
t = -3.85 (19) 
p = .0011 
-1.55 
t = -3.64 (19) 
p = .0017 
-110.17 
t = -54.95 (19) 
p = 0.000 
Overlap  
Mean (st Dev) Min-Max 
 
0.896 (0.024) 
0.841-0.929 
0.899 (0.019) 
0.855-0.927 
0.907 (0.020) 
0.877-0.942 
0.904 (0.015) 
0.881-0.928 
0.935 (0.009) 
0.916-0.953 
0.923 (0.014) 
0.897-0.956 
- 
Insula 
Volume 
Mean (st Dev) Min-Max 
21.27 (1.59) 
18.17-25.39 
21.29 (1.57) 
17.91-25.13 
21.60 (1.53) 
18.28-25.06 
21.30 (1.49) 
18.02-25.11 
22.12 (1.53) 
18.90-25.80 
21.73 (1.57) 
18.37-25.24 
21.56 (1.59) 
18.34-25.70 
20.18 (1.09) 
17.99-22.17 
Paired t-tests  
.03 
t = 0.38 (19) 
p = .7166 
.33 
t = 3.15 (19) 
p = .0053 
.03 
t = 0.41 (19) 
p = .6830 
.85 
t = 9.62 (19) 
p = . 0000 
.47 
t = 4.47 (19) 
p = .0003 
.30 
t = 7.65 (19) 
p = .0000 
-1.09 
t = -3.42 (19) 
p = .0000 
Overlap  
Mean (st Dev) Min-Max 
 
0.896 (0.021) 
0.846-0.924 
0.898 (0.017) 
0.851-0.921 
0.906 (0.022) 
0.858-0.942 
0.906 (0.013) 
0.878-0.928 
0.932 (0.012) 
0.908-0.949 
0.923 (0.015) 
0.892-0.956 
- 
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3.3.3. TRACK-HD quantitative results 
Participant demographics are given in Table 3.5. Age for the two HD groups was 
slightly higher than for controls and the pre-HD groups, but this difference was not significant. 
CAG was significantly higher in PreHD-B, HD1 and HD2 than in PreHD-A, and significantly 
higher for HD1 and HD2 than for PreHD-B. As would be expected, DBS was also increased in 
the HD groups. DBS in PreHD-B, HD1 and HD2 were all significantly higher than PreHD-A, and 
burden in HD1 and HD2 was significantly higher than PreHD-B.  
 
Table 3.5. Demographics for the participants included in the TRACK-HD analysis. 
 Controls 
(N=20) 
PreHD-A 
(N=20) 
PreHD-B 
(N=20) 
HD1 
(N=20) 
HD2 
(N=20) 
Age  48.32 (9.28) 
30.73-62.97 
48.48 (6.70) 
37.27-59.41 
47.74 (7.72) 
38.11-64.13 
49.10 (8.19) 
31.11-59.63 
50.14 (8.94) 
33.26-62.41 
Sex  Females N=13 Females N=10 Females N=12 Females N=9 Females N=8 
Education 4.05 (1.28) 2-6 4.30 (2.27) 2-6 4.1 (2.03) 2-5 4.2 (1.36) 2-6 3.55 (2.32) 2-6 
CAG N/A 41 (1.21) 39-43 42.35 (1.27) 40-
44 
43.35 (1.90) 40-
47 
43.75 (2.45) 
41-52 
DBS N/A 259.80 (29.50) 
171-290.75 
318.43 (23.99) 
267.6-356.03 
372.35 (52.05) 
264.75-472.91 
399.15 (70.31) 
287.31-548.74 
  
3.3.3.1.  Volumetric measures 
Volumes of the total, cortical and lobular GM were extracted for control participants 
and participants at different stages of HD. Total, CGM and lobular volumes are described for 
both baseline and follow-up time points for each segmentation tool (Table 3.6), and Figures 
3.13 and 3.14 show volumes for total and cortical GM. For all techniques, both total and CGM 
volumes were lower in participants with more advanced disease stage.  
For lobular volumes, all tools showed more discrepancies in raw volume (Table 3.6). 
For the frontal lobe all techniques estimated higher GM volume in PreHD-A participants than 
in controls, with some techniques also estimating higher GM volume in PreHD-B compared to 
controls. Frontal lobe volume was reduced in HD1 and HD2 groups compared to control and 
pre-HD groups. Temporal lobe volumes were also higher in PreHD-A than in controls for all 
segmentation tools, with both SPM12 and MALP-EM estimating higher temporal volume in all 
groups compared to controls. Other tools showed slightly lower volumes in PreHD-B, HD1 and 
HD2 than in controls. Parietal lobe volumes showed more uniform volume differences 
between each technique, with all techniques except for FreeSurfer measuring higher parietal 
lobe volumes in PreHD-A, PreHD-B and HD1 compared to controls, and lower volume in HD2 
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compared to controls. FreeSurfer showed lower volumes in all groups from PreHD-B when 
compared to controls. For the occipital lobe, the results were variable for each technique, with 
most techniques showing higher volumes in PreHD-A than in controls, and slightly reduced 
volume with increasing disease progression. Only FreeSurfer showed large reductions in 
volume between each group. Finally, insula volume was largest in PreHD-B for all techniques 
except FreeSurfer, with between-group differences appearing minimal for most tools.  
 
 
Figure 3.13. Box plots showing total grey matter volumes for all groups and all tools for 2008 
and 2011 time points. Boxes show the first quartile, median, and third quartile, with whiskers 
representing the smallest and largest value not classified as an outlier. Dots represent outliers. 
 
 
 
Figure 3.14 Box plots showing cortical grey matter volumes for all groups and all tools for 2008 
and 2011 time points. Boxes show the first quartile, median, and third quartile, with whiskers 
representing the smallest and largest value not classified as an outlier. Dots represent outliers. 
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Table 3.6. GM Volumes for all regions, groups, techniques and time points.  
  Controls (N=20) PreHD-A 
(N=20) 
PreHD-B 
(N=20) 
HD1 
(N=20) 
HD2 
(N=20) 
 
Total GM 
SPM8 
Unified 
2008 Scan A 644.72 (77.40) 
517.51-784.50 
667.41 (64.63) 
582.46-818.97 
650.36 (72.40) 
535.75-800.05 
617.39 (60.66) 
527.10-802.07 
598.58 (48.13) 
540.66-766.59 
2008 Scan B 642.71 (75.91) 
529.61-789.18 
668.16 (69.54) 
582.38-832.93 
651.36 (69.07) 
556.09-804.35 
616.83 (62.97) 
522.50-818.28 
597.25 (48.72) 
533.81-770.85 
2011 642.88 (77.28) 
511.55-791.30 
653.41 (67.68) 
549.42-831.86 
637.43 (81.73) 
508.94-795.31 
583.76 (53.99) 
491.05-673.19 
577.33 (51.22) 
517.65-757.70 
SPM8 New 
Segment 
2008 Scan A 678.94 (71.25) 
580.01-852.75 
703.62 (66.95) 
594.52-805.85 
683.88 (63.96) 
591.00-864.42 
682.13 (57.10) 
611.38-834.77 
673.07 (47.86) 
598.17-798.72 
2008 Scan B 679.28 (72.29) 
580.84-859.30 
702.94 (67.23) 
592.78-810.64 
684.49 (64.82) 
591.12-870.01 
682.36 (57.61) 
610.99-835.37 
672.53 (47.82) 
597.21-797.95 
2011 675.48 (67.24) 
598.10-851.22 
692.85 (64.90) 
592.63-791.93 
675.12 (63.58) 
592.57-855.63 
669.83 (54.54) 
604.48-817.85 
653.26 (55.78) 
506.65-788.99 
SPM12 2008 Scan A 671.50 (72.43) 
542.23-831.21 
691.43 (60.49) 
602.55-811.37 
663.25 (57.93) 
579.39-817.00 
629.56 (72.22) 
556.09-857.89 
607.31 (58.86) 
523.90-801.68 
2008 Scan B 671.98 (72.57) 
548.55-832.24 
689.10 (58.37) 
599.37-806.38 
661.92 (55.87) 
577.99-820.37 
628.62 (71.94) 
548.74-854.13 
604.27 (60.21) 
522.27-801.91 
2011 665.82 (70.42) 
557.72-826.72 
680.32 (59.33) 
610.00-806.47 
645.14 (61.23) 
573.01-805.50 
601.98 (72.38) 
525.19-818.94 
578.07 (61.30) 
482.20-771.05 
ANTS 2008 Scan A 619.58 (58.45) 
519.03-760.16 
631.63 (54.56) 
549.13-746.23 
610.96 (58.83) 
512.86-776.31 
596.48 (64.76) 
519.36-764.84 
587.03 (53.28) 
498.50-745.08 
2008 Scan B 614.92 (61.17) 
510.65-764.75 
624.97 (55.05) 
540.81-740.83 
607.81 (57.48) 
515.70-774.35 
592.71 (62.51) 
504.09-764.36 
581.45 (57.93) 
473.80-745.80 
2011 611.35 (63.58) 
507.70-763.61 
620.91 (53.98) 
553.39-730.49 
601.04 (61.41) 
514.44-765.50 
578.62 (64.08) 
503.29-735.35 
568.61 (65.08) 
424.38-740.74 
MALP-EM 2008 Scan A 690.71 (69.12) 
587.04-871.31 
716.21 (62.02) 
612.20-825.52 
699.34 (69.17) 
621.59-910.91 
688.33 (59.38) 
606.16-874.72 
673.63 (52.88) 
585.90-824.78 
2008 Scan B 689.55 (69.06) 
589.57-868.85 
713.93 (61.38) 
606.27-821.37 
698.56 (69.70) 
619.76-904.05 
686.89 (58.58) 
609.34-873.16 
672.44 (54.60) 
579.62-824.89 
2011 687.95 (65.36) 
582.47-849.07 
706.87 (59.69) 
608.90-810.98 
689.91 (70.09) 
609.88-893.67 
671.31 (58.60) 
592.95-854.57 
658.50 (59.41) 
516.56-821.83 
FAST 2008 Scan A 585.23 (55.70) 
502.10-723.89 
594.94 (43.79) 
540.27-695.97 
577.22 (50.07) 
500.41-722.76 
556.48 (55.90) 
495.60-737.27 
544.08 (42.93) 
478.45-684.04 
2008 Scan B 581.02 (55.94) 
495.50-724.37 
592.16 (42.67) 
538.38-682.38 
575.24 (50.79) 
496.78-725.17 
553.50 (56.12) 
490.22-739.64 
542.90 (44.63) 
482.26-685.93 
2011 582.28 (59.24) 
501.16-742.31 
583.09 (56.16) 
493.89-720.33 
566.74 (54.15) 
461.80-701.45 
543.78 (54.71) 
436.44-672.62 
510.72 (49.95) 
436.44-672.62 
FreeSurfer 2008 Scan A 600.05 (56.70) 
527.34-748.92 
611.24 (53.11) 
533.30-728.35 
595.52 (57.52) 
516.49-752.72 
576.89 (52.61) 
505.51-740.96 
550.74 (46.71) 
461.37-686.31 
2008 Scan B 596.88 (56.96) 
522.55-754.38 
607.92 (49.83) 
537.04-710.30 
592.10 (56.76) 
519.86-749.38 
574.23 (52.68) 
502.84-742.53 
549.92 (47.50) 
465.66-686.73 
2011 597.41 (56.33) 
526.80-749.19 
600.51 (53.06) 
529.69-715.26 
583.12 (56.77) 
501.32-732.18 
559.12 (50.66) 
487.13-719.53 
531.77 (47.57) 
435.12-676.07 
  Controls (N=20) PreHD-A 
(N=20) 
PreHD-B 
(N=20) 
HD1 
(N=20) 
HD2 
(N=20) 
 
Cortical GM 
SPM8 
Unified 
2008 Scan A 512.77 (68.98) 
373.73-628.56 
533.18 (51.24) 
478.05-654.50 
516.45 (60.60) 
424.98-638.92 
488.49 (55.33) 
403.99-660.65 
473.58 (41.97) 
422.11-620.20 
2008 Scan B 510.38 (67.91) 
383.03-632.56 
533.88 (55.06) 
475.51-664.79 
517.41 (58.61) 
442.98-643.06 
487.34 (57.17) 
400.61-674.21 
472.44 (42.15) 
416.66-623.85 
2011 505.72 (68.05) 
372.24-631.09 
524.44 (51.07) 
464.23-662.46 
510.59 (65.15) 
420.43-629.71 
460.43 (50.64) 
369.75-536.01 
454.58 (43.52) 
400.37-609.44 
SPM8 New 
Segment 
2008 Scan A 536.43 (62.37) 
452.89-683.11 
559.21 (51.87) 
487.27-650.20 
541.97 (52.80) 
468.18-690.29 
539.74 (50.30) 
473.83-684.56 
533.95 (40.36) 
469.86-645.25 
2008 Scan B 536.32 (63.46) 
455.09-689.86 
558.47 (52.10) 
485.55-650.99 
542.70 (53.96) 
466.88-694.94 
539.28 (50.29) 
474.23-685.15 
533.77 (40.47) 
469.95-645.02 
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2011 535.67 (63.61) 
459.16-689.79 
555.14 (52.30) 
484.16-647.05 
538.91 (52.49) 
468.62-685.50 
534.52 (48.84) 
471.89-669.97 
525.03 (47.10) 
404.13-640.42 
SPM12 2008 Scan A 533.51 (65.41) 
389.73-666.73 
552.73 (49.76) 
473.23-655.70 
526.07 (48.46) 
460.87-652.17 
498.74 (65.09) 
428.26-705.08 
480.93 (50.88) 
407.50-647.96 
2008 Scan B 533.76 (65.64) 
394.15-668.75 
550.80 (47.79) 
471.59-645.80 
525.06 (46.78) 
459.22-655.18 
497.70 (64.62) 
423.09-701.96 
478.57 (51.57) 
406.43-648.08 
2011 528.20 (63.27) 
403.20-662.02 
542.72 (48.25) 
481.15-642.66 
509.88 (51.62) 
449.76-638.26 
473.94 (65.99) 
396.61-670.31 
455.94 (52.03) 
380.94-619.42 
ANTS 2008 Scan A 495.87 (54.37) 
389.28-622.33 
509.72 (44.12) 
455.01-611.42 
489.45 (48.51) 
405.19-620.96 
477.14 (56.81) 
409.16-635.36 
466.91 (45.54) 
389.93-604.35 
2008 Scan B 491.64 (56.78) 
382.09-628.22 
503.79 (44.09) 
449.15-605.89 
487.12 (48.13) 
404.60-619.20 
473.74 (54.49) 
401.01-634.44 
462.73 (48.51) 
376.62-605.35 
2011 488.38 (58.86) 
387.97-630.09 
498.77 (44.12) 
445.98-594.11 
479.69 (49.48) 
408.16-605.48 
461.18 (55.20) 
388.52-606.14 
451.16 (53.24) 
336.37-596.95 
MALP-EM 2008 Scan A 530.51 (59.82) 
437.13-676.95 
555.69 (50.24) 
487.11-657.42 
539.48 (55.25) 
475.98-702.28 
533.19 (50.60) 
468.57-696.92 
522.94 (43.59) 
444.29-646.02 
2008 Scan B 529.34 (60.07) 
435.90-675.24 
553.63 (49.68) 
482.71-654.95 
539.16 (56.15) 
476.11-696.51 
532.20 (49.99) 
472.30-695.76 
521.89 (44.94) 
439.33-646.89 
2011 527.67 (56.78) 
443.05-660.08 
547.99 (48.50) 
484.60-646.25 
531.68 (56.27) 
471.96-685.57 
519.58 (50.34) 
444.61-678.12 
511.12 (47.08) 
403.89-641.53 
FAST 2008 Scan A 469.53 (53.49) 
374.92-598.60 
479.12 (35.49) 
434.02-561.92 
463.95 (41.39) 
411.23-577.65 
447.26 (50.14) 
390.53-613.65 
435.76 (36.32) 
374.94-553.17 
2008 Scan B 465.54 (54.05) 
368.99-600.62 
476.73 (34.58) 
428.84-555.23 
462.65 (42.40) 
406.44-579.29 
444.91 (50.00) 
391.75-615.45 
435.25 (37.43) 
378.74-555.11 
2011 466.03 (56.25) 
378.26-613.36 
460.96 (38.77) 
404.72-544.14 
454.14 (46.04) 
357.59-553.83 
427.99 (51.13) 
353.00-584.79 
408.29 (43.91) 
340.86-539.01 
FreeSurfer 2008 Scan A 443.98 (46.48) 
390.66-557.74 
456.79 (41.53) 
401.60-528.21 
438.76 (46.32) 
383.69-569.80 
425.94 (48.04) 
374.81-581.65 
409.85 (40.17) 
331.48-528.49 
2008 Scan B 440.27 (47.23) 
384.36-563.17 
453.61 (39.45) 
400.90-533.17 
435.40 (46.04) 
374.25-566.91 
423.04 (47.57) 
368.04-583.23 
412.64 (39.10) 
339.36-530.62 
 2011 441.53 (46.83) 
386.74-558.92 
448.86 (42.55) 
390.67-522.61 
428.95 (45.78) 
369.63-548.28 
410.99 (46.52) 
362.78-563.30 
394.04 (40.47) 
318.51-518.13 
  Controls (N=20) PreHD-A 
(N=20) 
PreHD-B 
(N=20) 
HD1 
(N=20) 
HD2 
(N=20) 
 
Frontal GM 
SPM8 
Unified 
2008 Scan A 180.98 (28.52) 
106.22-230.90 
189.90 (19.38) 
166.41-232.57 
184.76 (23.46) 
151.79-234.20 
174.68 (20.13) 
143.83-241.28 
170.53 (14.84) 
153.66-219.99 
2008 Scan B 180.14 (27.91) 
109.01-227.44 
190.17 (21.37) 
167.69-238.79 
185.67 (23.05) 
156.12-234.68 
174.00 (21.14) 
143.06-246.39 
170.15 (15.15) 
151.22-221.86 
2011 177.48 (28.29) 
107.34-228.77 
186.98 (18.77) 
159.57-233.12 
182.80 (24.52)  
148.94-227.21 
164.39 (17.52) 
133.36-189.41 
163.63 (15.01) 
145.85-216.00 
SPM8 New 
Segment 
2008 Scan A 189.39 (25.88) 
137.26-245.25 
199.62 (20.12) 
173.83-231.57 
193.43 (20.41) 
164.85-249.67 
193.31 (19.55) 
169.09-252.14 
191.08 (14.61) 
162.67-230.14 
2008 Scan B 189.11 (26.30) 
136.85-247.62 
199.37 (20.41) 
173.04-232.53 
194.08 (20.83) 
165.29-251.63 
193.07 (19.69) 
169.42-253.10 
191.11 (14.69) 
162.34-229.87 
2011 188.58 (26.26) 
139.07-246.89 
197.99 (20.37) 
170.54-229.86 
192.02 (20.24)  
163.16-245.60 
191.83 (18.95) 
166.05-246.06 
187.54 (16.33) 
150.15-228.48 
SPM12 2008 Scan A 187.68 (27.48) 
110.47-235.58 
196.61 (18.85) 
164.94-232.57 
187.52 (18.47) 
163.93-236.62 
178.26 (23.41) 
150.27-257.28 
172.80 (17.64) 
149.93-229.21 
2008 Scan B 187.69 (27.58) 
112.51-237.05 
195.78 (18.45) 
165.42-229.56 
187.67 (18.10) 
164.62-238.58 
177.69 (23.27) 
148.61-256.47 
171.98 (18.08) 
148.73-229.93 
2011 185.36 (26.89) 
115.06-233.49 
193.05 (17.87) 
167.97-226.18 
181.59 (19.53) 
157.27-229.42 
169.97 (23.42) 
135.86-244.01 
163.97 (17.56) 
140.67-219.26 
ANTS 2008 Scan A 175.75 (22.96) 
113.82-221.10 
182.93 (16.80) 
164.09-216.83 
175.84 (18.75) 
144.59-228.82 
171.78 (21.20) 
142.45-232.90 
169.39 (16.87) 
134.05-216.09 
2008 Scan B 174.07 (23.98) 
113.52-225.03 
180.40 (17.34) 
158.33-215.03 
175.53 (18.61) 
145.47-228.63 
170.40 (20.55) 
143.43-232.99 
167.87 (17.88) 
130.33-216.77 
2011 172.02 (25.88) 
114.78-226.42 
178.42 (16.72) 
155.15-210.80 
172.64 (18.96) 
145.31-220.67 
166.58 (20.25) 
133.86-221.28 
163.66 (18.72) 
127.13-212.46 
MALP-EM 2008 Scan A 191.50 (26.06) 
127.79-246.67 
203.47 (19.52) 
178.88-239.10 
197.69 (21.66) 
173.33-259.88 
195.12 (19.63) 
167.21-259.26 
191.73 (15.84) 
167.38-233.41 
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2008 Scan B 190.85 (26.08) 
128.02-245.99 
202.74 (19.66) 
178.61-238.75 
198.10 (21.77) 
174.69-257.95 
194.67 (19.57) 
167.57-259.11 
191.29 (16.37) 
164.06-234.06 
2011 189.58 (24.80) 
131.21-237.91 
199.72 (18.69) 
175.11-233.90 
194.38 (21.24) 
169.81-247.90 
190.07 (19.33) 
160.37-250.80 
186.87 (16.63) 
154.65-231.24 
FAST 2008 Scan A 163.82 (22.16) 
106.03-208.91 
167.73 (13.40) 
148.21-199.57 
163.68 (15.99) 
145.72-210.57 
157.54 (19.32) 
130.85-222.20 
155.82 (13.72) 
138.43-194.28 
2008 Scan B 162.41 (22.53) 
104.96-211.24 
166.96 (13.35) 
146.69-195.40 
163.76 (16.52) 
144.24-211.70 
156.47 (19.39) 
131.16-223.71 
155.96 (14.38) 
135.82-195.55 
2011 162.78 (24.11) 
106.91-218.66 
161.48 (13.90) 
138.58-192.57 
160.58 (17.43) 
127.55-199.38 
152.57 (17.96) 
122.21-210.93 
144.40 (18.81) 
102.41-188.63 
FreeSurfer 2008 Scan A 164.48 (21.29) 
111.40-206.85 
171.86 (16.65) 
147.76-203.70 
165.86 (19.12)  
140.52-218.79 
162.12 (17.95) 
140.99-221.62 
156.63 (15.08) 
130.10-199.35 
2008 Scan B 163.60 (21.65) 
111.06-209.39 
168.27 (17.08) 
144.17-202.28 
162.38 (18.21)  
140.12-208.54 
156.95 (16.93) 
134.95-212.67 
151.26 (14.77) 
127.40-195.32 
 Controls (N=20) PreHD-A 
(N=20) 
PreHD-B 
(N=20) 
HD1 
(N=20) 
HD2 
(N=20) 
 
Temporal GM 
SPM8 
Unified 
2008 Scan A 120.97 (17.93) 
71.48-146.20 
127.51 (10.36) 
112.63-146.96 
123.21 (14.15) 
99.59-153.25 
116.77 (13.11) 
97.60-158.18 
115.02 (10.21) 
104.52-148.72 
2008 Scan B 120.82 (16.18) 
80.55-146.52 
127.08 (10.86) 
112.65-147.87 
123.11 (13.13) 
105.97-153.93 
116.76 (13.41) 
96.78-160.93 
114.77 (10.48) 
104.32-149.66 
2011 118.98 (18.33) 
68.84-146.83 
125.47 (10.19) 
112.77-148.60 
121.96 (16.18) 
100.22-154.86 
110.31 (11.60) 
87.95-124.77 
110.68 (10.90) 
97.95-147.70 
SPM8 New 
Segment 
2008 Scan A 129.44 (16.30) 
90.86-161.29 
136.18 (11.80) 
116.62-153.60 
132.04 (13.21) 
114.01-167.99 
131.30 (12.11) 
112.70-165.40 
131.83 (10.63) 
111.46-155.37 
2008 Scan B 129.71 (15.72) 
97.54-163.58 
135.91 (11.63) 
117.24-153.54 
132.04 (13.02) 
114.95-167.95 
131.30 (12.12) 
112.75-164.55 
131.78 (10.77) 
111.26-155.84 
2011 128.59 (17.20) 
87.26-163.60 
135.57 (11.74) 
116.93-153.61 
131.54 (13.47) 
116.55-168.75 
130.35 (11.77) 
112.59-163.60 
129.96 (12.45) 
99.14-156.36 
SPM12 2008 Scan A 127.74 (17.34) 
78.29-157.50 
133.53 (10.37) 
119.30-154.39 
127.45 (12.42) 
108.11-158.60 
121.01 (14.21) 
103.23-168.38 
118.64 (11.60) 
102.63-155.45 
2008 Scan B 128.16 (16.16) 
86.97-157.33 
132.89 (9.85) 
120.00-153.77 
127.18 (11.81) 
107.87-158.84 
121.03 (14.10) 
103.65-167.46 
118.21 (11.86) 
102.05-155.69 
2011 125.99 (17.66) 
76.24-157.23 
131.45 (9.81) 
119.97-152.03 
124.35 (13.39) 
108.65-158.07 
115.89 (14.91) 
99.06-163.07 
112.99 (12.15) 
91.59-150.99 
ANTS 2008 Scan A 118.96 (15.20) 
75.80-148.50 
124.00 (9.77) 
107.60-143.07 
118.83 (12.36) 
99.04-150.52 
116.12 (12.85) 
98.43-154.42 
114.89 (10.87) 
93.56-145.76 
2008 Scan B 118.34 (14.41) 
81.52-148.51 
122.45 (9.25) 
107.41-142.14 
118.22 (11.91) 
99.27-149.84 
115.58 (12.34) 
98.76-153.45 
113.98 (11.74) 
90.55-146.42 
2011 116.05 (16.90) 
72.29-149.85 
121.32 (9.31) 
107.30-139.22 
116.90 (12.76) 
99.72-149.76 
112.58 (12.72) 
95.98-149.51 
111.12 (13.20) 
81.55-146.39 
MALP-EM 2008 Scan A 120.61 (15.37) 
78.39-150.22 
127.41 (10.43) 
109.65-146.95 
123.95 (13.56) 
108.43-162.17 
121.95 (12.17) 
104.51-160.46 
121.97 (11.22) 
102.86-149.50 
2008 Scan B 120.45 (14.50) 
84.61-150.00 
126.60 (10.01) 
108.76-145.78 
123.70 (13.46) 
108.43-160.55 
121.79 (11.88) 
106.99-160.14 
121.54 (11.87) 
100.46-150.04 
2011 119.15 (15.51) 
75.05-147.63 
125.74 (10.25) 
108.10-144.92 
122.45 (14.43) 
106.35-161.88 
119.08 (12.57) 
96.72-158.21 
119.39 (12.37) 
90.74-149.86 
FAST 2008 Scan A 113.51 (14.88) 
72.60-144.30 
117.72 (7.96) 
104.82-132.29 
113.73 (10.31) 
101.20-140.26 
110.45 (11.86) 
95.34-150.09 
108.67 (9.25) 
94.83-135.59 
2008 Scan B 112.68 (13.70) 
78.93-143.45 
116.75 (7.35) 
105.28-131.02 
113.20 (10.23) 
100.74-139.91 
110.33 (11.62) 
95.07-149.58 
108.44 (9.69) 
92.85-136.24 
2011 111.88 (15.48) 
70.35-147.91 
113.33 (9.02) 
98.09-130.50 
112.00 (11.32) 
94.81-137.92 
106.09 (12.87) 
81.21-144.88 
103.72 (8.91) 
92.69-134.05 
FreeSurfer 2008 Scan A 106.88 (12.25) 
73.24-129.97 
111.19 (8.50) 
96.37-124.84 
106.40 (11.35) 
92.06-135.95 
102.95 (11.84) 
89.00-142.54 
100.99 (9.07) 
83.29-127.77 
2008 Scan B 105.75 (13.22) 
67.72-129.51 
109.48 (8.05) 
97.48-123.75 
104.75 (11.77) 
91.29-135.46 
99.55 (11.57) 
86.87-139.14 
96.92 (9.22) 
77.98-125.87 
  Controls (N=20) PreHD-A 
(N=20) 
PreHD-B 
(N=20) 
HD1 
(N=20) 
HD2 
(N=20) 
 
Parietal GM 
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SPM8 
Unified 
2008 Scan A 115.01 (13.95) 
89.95-152.64 
117.89 (15.58) 
95.11-146.54 
121.34 (12.66) 
105.21-152.64 
117.97 (14.25) 
97.86-147.60 
110.74 (12.89) 
89.95-144.75 
2008 Scan B 116.94 (15.88) 
95.27-147.28 
121.60 (13.49) 
105.22-154.63 
117.88 (13.77) 
100.64-148.25 
110.43 (13.22) 
89.12-147.97 
106.98 (9.75) 
91.54-138.53 
2011 116.75 (15.11) 
95.26-148.23 
119.05 (12.57) 
102.71-153.81 
116.13 (14.61) 
96.62-144.24 
104.72 (12.72) 
83.10-129.14 
103.14 (10.00) 
88.11-134.68 
SPM8 New 
Segment 
2008 Scan A 124.02 (12.62) 
101.06-160.24 
123.51 (15.65) 
101.20-160.24 
128.21 (12.34) 
108.70-147.85 
124.11 (12.47) 
108.55-158.98 
122.90 (11.91) 
105.71-151.24 
2008 Scan B 123.41 (15.83) 
102.32-161.06 
128.13 (12.46) 
108.37-148.48 
124.28 (13.19) 
108.28-159.96 
122.76 (11.89) 
105.66-151.80 
121.25 (10.21) 
102.32-146.77 
2011 123.11 (12.67) 
90.36-162.22 
123.96 (15.75) 
103.50-162.22 
127.17 (12.40) 
107.32-148.16 
123.34 (12.11) 
108.48-157.08 
121.58 (11.56) 
103.84-148.09 
SPM12 2008 Scan A 116.99 (14.45) 
86.12-153.77 
121.34 (14.76) 
101.06-153.41 
124.82 (12.22) 
103.00-149.48 
118.79 (11.36) 
104.84-148.29 
112.15 (15.47) 
94.80-153.77 
2008 Scan B 121.14 (15.15) 
100.60-153.20 
124.63 (11.66) 
103.29-148.02 
118.42 (11.09) 
104.39-148.85 
111.85 (15.41) 
94.57-153.48 
107.35 (12.16) 
86.20-143.52 
2011 113.40 (15.10) 
84.14-153.40 
120.62 (14.26) 
99.82-153.40 
122.57 (11.57) 
105.86-147.62 
114.89 (11.71) 
101.51-143.97 
106.40 (15.68) 
89.46-145.79 
ANTS 2008 Scan A 111.28 (12.40) 
87.01-146.34 
114.25 (13.21) 
96.43-146.34 
116.18 (11.09) 
100.40-140.44 
111.81 (11.30) 
94.34-143.47 
108.56 (13.48) 
90.78-139.49 
2008 Scan B 112.90 (13.78) 
89.78-146.87 
115.21 (10.80) 
99.01-139.28 
111.23 (11.70) 
94.38-142.84 
107.66 (12.88) 
90.95-139.47 
104.58 (11.42) 
86.25-135.21 
2011 108.72 (12.86) 
75.84-148.00 
113.70 (13.25) 
94.40-148.00 
113.84 (10.84) 
99.54-137.42 
109.06 (11.38) 
95.15-138.12 
104.74 (13.43) 
86.88-132.96 
MALP-EM 2008 Scan A 128.68 (13.28) 
100.96-171.44 
128.51 (15.76) 
107.34-166.99 
133.19 (12.95) 
111.67-157.42 
129.25 (14.00) 
114.14-171.44 
127.62 (11.97) 
112.08-163.43 
2008 Scan B 128.36 (15.82) 
108.56-165.23 
132.99 (12.88) 
110.71-157.08 
129.16 (14.58) 
113.72-169.92 
127.40 (11.85) 
112.79-163.15 
124.68 (11.23) 
101.35-153.79 
2011 126.98 (13.19) 
94.89-166.33 
128.34 (15.14) 
105.49-163.52 
131.86 (12.51) 
110.97-155.82 
127.44 (13.74) 
112.28-166.33 
124.78 (11.97) 
108.64-158.58 
FAST 2008 Scan A 105.40 (11.45) 
79.20-142.62 
108.77 (13.33) 
92.09-142.62 
110.26 (9.35) 
97.87-131.35 
106.65 (9.91) 
93.53-133.99 
102.51 (11.85) 
86.09-135.15 
2008 Scan B 107.71 (13.41) 
90.41-142.31 
109.93 (9.03) 
97.17-128.13 
106.28 (10.41) 
92.49-133.95 
101.73 (11.82) 
85.67-135.66 
98.65 (9.35) 
80.43-123.57 
2011 102.59 (12.27) 
77.32-147.36 
108.67 (14.04) 
90.60-147.36 
106.62 (9.55) 
91.76-125.41 
103.91 (10.16) 
83.14-126.64 
98.60 (12.39) 
81.72-128.59 
FreeSurfer 2008 Scan A 105.34 (12.16) 
88.40-133.55 
106.83 (10.30) 
91.71-125.28 
104.04 (11.30) 
90.43-138.07 
99.33 (11.99) 
85.11-133.53 
95.51 (10.42) 
73.41-122.91 
2008 Scan B 104.84 (12.06) 
88.65-134.08 
105.29(10.37) 
88.88-124.18 
100.97 (11.16) 
85.43-130.83 
95.56 (11.65) 
82.21-129.22 
91.82 (10.41) 
72.02-119.97 
  Controls (N=20) PreHD-A 
(N=20) 
PreHD-B 
(N=20) 
HD1 
(N=20) 
HD2 
(N=20) 
 
Occipital GM 
SPM8 
Unified 
2008 Scan A 81.47 (9.82) 
62.78-101.30 
82.01 (10.19) 
69.74-107.25 
78.28 (8.65) 
64.63-94.07 
74.65 (10.20) 
58.66-100.64 
69.51 (9.31) 
56.92-97.25 
2008 Scan B 80.90 (10.05) 
63.16-102.25 
82.56 (10.57) 
70.01-108.06 
78.43 (8.51) 
64.57-93.39 
74.53 (10.38) 
59.24-102.89 
69.25 (9.30) 
56.77-97.68 
2011 80.94 (9.33) 
63.60-101.97 
80.63 (10.91) 
68.29-111.57 
77.41 (9.57) 
63.09-92.09 
69.83 (10.00) 
52.28-90.05 
66.12 (9.92) 
53.65-95.33 
SPM8 New 
Segment 
2008 Scan A 83.36 (8.97) 
71.69-103.91 
83.61 (9.48) 
69.29-104.35 
80.94 (7.14) 
67.62-100.31 
81.02 (8.10) 
70.00-101.82 
78.34 (7.83) 
65.28-97.80 
2008 Scan B 83.24 (8.91) 
70.93-105.39 
83.44 (9.48) 
69.11-103.94 
80.80 (7.30) 
66.53-101.79 
81.03 (7.96) 
70.38-102.00 
78.19 (7.79) 
65.19-97.74 
2011 83.90 (9.05) 
72.03-105.30 
82.83 (9.79) 
69.23-102.81 
80.60 (6.94) 
68.49-99.86 
79.59 (8.07) 
69.17-99.05 
76.59 (9.57) 
55.48-97.59 
SPM12 2008 Scan A 84.39 (8.73) 
71.15-106.01 
84.49 (10.05) 
71.30-108.76 
79.53 (6.62) 
68.82-94.83 
75.13 (12.29) 
57.08-108.49 
69.92 (10.88) 
55.83-102.09 
2008 Scan B 84.26 (8.82) 
71.39-106.62 
84.27 (9.65) 
70.86-106.87 
79.04 (6.40) 
68.60-95.10 
75.01 (12.18) 
57.19-107.75 
69.33 (10.96) 
55.98-101.75 
2011 83.82 (8.23) 
68.72-103.74 
82.55 (10.57) 
66.99-107.84 
76.51 (7.48) 
65.74-92.72 
69.92 (12.49) 
52.90-101.33 
65.13 (11.60) 
50.50-96.45 
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ANTS 2008 Scan A 76.52 (6.94) 
66.52-94.94 
75.39 (9.09) 
64.84-99.30 
71.99 (6.79) 
56.89-86.68 
69.77 (10.13) 
57.48-94.04 
66.02 (9.93) 
53.06-92.53 
2008 Scan B 75.83 (7.04) 
64.54-95.67 
74.56 (9.04) 
63.80-97.44 
71.18 (6.53) 
56.08-85.74 
69.36 (9.53) 
57.71-94.14 
65.34 (10.12) 
52.37-92.35 
2011 76.21 (6.87) 
65.75-94.43 
73.96 (9.38) 
62.28-94.63 
69.97 (6.90) 
56.71-84.46 
66.51 (9.72) 
53.45-88.89 
63.19 (11.42) 
42.58-91.34 
MALP-EM 2008 Scan A 80.33 (8.04) 
70.21-100.69 
80.95 (9.45) 
67.11-102.78 
78.11 (7.29) 
66.93-100.00 
77.90 (8.10) 
65.76-100.17 
74.22 (8.52) 
60.68-95.42 
2008 Scan B 80.05 (7.80) 
69.42-101.04 
80.67 (9.33) 
66.51-102.08 
77.68 (7.38) 
65.48-98.47 
77.79 (7.83) 
65.93-100.01 
74.15 (8.49) 
61.67-95.56 
2011 80.88 (7.80) 
70.39-98.78 
80.03 (9.18) 
67.27-100.26 
76.96 (7.79) 
65.25-98.43 
75.12 (8.06) 
64.76-97.58 
72.12 (9.52) 
54.74-94.83 
FAST 2008 Scan A 73.46 (7.46) 
59.83-92.11 
72.38 (8.19) 
63.11-91.62 
69.23 (6.11) 
60.51-81.93 
66.32 (9.25) 
53.29-91.62 
62.13 (8.40) 
49.91-85.26 
2008 Scan B 72.75 (7.29) 
57.90-92.49 
72.12 (7.95) 
62.27-90.17 
68.73 (6.09) 
59.24-82.21 
65.94 (9.16) 
53.22-91.90 
61.85 (8.42) 
50.62-85.35 
2011 72.92 (7.86) 
60.31-91.98 
68.72 (9.47) 
49.13-87.01 
66.89 (8.31) 
41.90-79.72 
60.66 (11.95) 
31.04-86.52 
55.42 (12.33) 
34.97-82.97 
FreeSurfer 2008 Scan A 66.30 (7.74) 
57.48-85.09 
66.07 (7.47) 
56.14-83.26 
61.89 (6.19) 
52.82-76.74 
59.68 (8.89) 
45.74-83.49 
54.85 (8.43) 
42.19-76.40 
2008 Scan B 66.26 (7.12) 
56.46-83.60 
65.00 (7.87) 
54.31-81.47 
60.02 (6.45) 
49.60-72.51 
57.10 (8.36) 
45.10-80.61 
52.23 (8.95) 
40.04-74.45 
  Controls (N=20) PreHD-A 
(N=20) 
PreHD-B 
(N=20) 
HD1 
(N=20) 
HD2 
(N=20) 
 
Insula GM 
SPM8 
Unified 
2008 Scan A 81.47 (9.82) 
62.78-101.30 
82.01 (10.19) 
69.74-107.25 
78.28 (8.65) 
64.63-94.07 
74.65 (10.20) 
58.66-100.64 
69.51 (9.31) 
56.92-97.25 
2008 Scan B 80.90 (10.05) 
63.16-102.25 
82.56 (10.57) 
70.01-108.06 
78.43 (8.51) 
64.57-93.39 
74.53 (10.38) 
59.24-102.89 
69.25 (9.30) 
56.77-97.68 
2011 80.94 (9.33) 
63.60-101.97 
80.63 (10.91) 
68.29-111.57 
77.41 (9.57) 
63.09-92.09 
69.83 (10.00) 
52.28-90.05 
66.12 (9.92) 
53.65-95.33 
SPM8 New 
Segment 
2008 Scan A 83.36 (8.97) 
71.69-103.91 
83.61 (9.48) 
69.29-104.35 
80.94 (7.14) 
67.62-100.31 
81.02 (8.10) 
70.00-101.82 
78.34 (7.83) 
65.28-97.80 
2008 Scan B 83.24 (8.91) 
70.93-105.39 
83.44 (9.48) 
69.11-103.94 
80.80 (7.30) 
66.53-101.79 
81.03 (7.96) 
70.38-102.00 
78.19 (7.79) 
65.19-97.74 
2011 83.90 (9.05) 
72.03-105.30 
82.83 (9.79) 
69.23-102.81 
80.60 (6.94) 
68.49-99.86 
79.59 (8.07) 
69.17-99.05 
76.59 (9.57) 
55.48-97.59 
SPM12 2008 Scan A 84.39 (8.73) 
71.15-106.01 
84.49 (10.05) 
71.30-108.76 
79.53 (6.62) 
68.82-94.83 
75.13 (12.29) 
57.08-108.49 
69.92 (10.88) 
55.83-102.09 
2008 Scan B 84.26 (8.82) 
71.39-106.62 
84.27 (9.65) 
70.86-106.87 
79.04 (6.40) 
68.60-95.10 
75.01 (12.18) 
57.19-107.75 
69.33 (10.96) 
55.98-101.75 
2011 83.82 (8.23) 
68.72-103.74 
82.55 (10.57) 
66.99-107.84 
76.51 (7.48) 
65.74-92.72 
69.92 (12.49) 
52.90-101.33 
65.13 (11.60) 
50.50-96.45 
ANTS 2008 Scan A 76.52 (6.94) 
66.52-94.94 
75.39 (9.09) 
64.84-99.30 
71.99 (6.79) 
56.89-86.68 
69.77 (10.13) 
57.48-94.04 
66.02 (9.93) 
53.06-92.53 
2008 Scan B 75.83 (7.04) 
64.54-95.67 
74.56 (9.04) 
63.80-97.44 
71.18 (6.53) 
56.08-85.74 
69.36 (9.53) 
57.71-94.14 
65.34 (10.12) 
52.37-92.35 
2011 76.21 (6.87) 
65.75-94.43 
73.96 (9.38) 
62.28-94.63 
69.97 (6.90) 
56.71-84.46 
66.51 (9.72) 
53.45-88.89 
63.19 (11.42) 
42.58-91.34 
MALP-EM 2008 Scan A 80.33 (8.04) 
70.21-100.69 
80.95 (9.45) 
67.11-102.78 
78.11 (7.29) 
66.93-100.00 
77.90 (8.10) 
65.76-100.17 
74.22 (8.52) 
60.68-95.42 
2008 Scan B 80.05 (7.80) 
69.42-101.04 
80.67 (9.33) 
66.51-102.08 
77.68 (7.38) 
65.48-98.47 
77.79 (7.83) 
65.93-100.01 
74.15 (8.49) 
61.67-95.56 
2011 80.88 (7.80) 
70.39-98.78 
80.03 (9.18) 
67.27-100.26 
76.96 (7.79) 
65.25-98.43 
75.12 (8.06) 
64.76-97.58 
72.12 (9.52) 
54.74-94.83 
FAST 2008 Scan A 73.46 (7.46) 
59.83-92.11 
72.38 (8.19) 
63.11-91.62 
69.23 (6.11) 
60.51-81.93 
66.32 (9.25) 
53.29-91.62 
62.13 (8.40) 
49.91-85.26 
2008 Scan B 72.75 (7.29) 
57.90-92.49 
72.12 (7.95) 
62.27-90.17 
68.73 (6.09) 
59.24-82.21 
65.94 (9.16) 
53.22-91.90 
61.85 (8.42) 
50.62-85.35 
2011 72.92 (7.86) 
60.31-91.98 
68.72 (9.47) 
49.13-87.01 
66.89 (8.31) 
41.90-79.72 
60.66 (11.95) 
31.04-86.52 
55.42 (12.33) 
34.97-82.97 
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FreeSurfer 2008 Scan A 66.30 (7.74) 
57.48-85.09 
66.07 (7.47) 
56.14-83.26 
61.89 (6.19) 
52.82-76.74 
59.68 (8.89) 
45.74-83.49 
54.85 (8.43) 
42.19-76.40 
2008 Scan B 66.26 (7.12) 
56.46-83.60 
65.00 (7.87) 
54.31-81.47 
60.02 (6.45) 
49.60-72.51 
57.10 (8.36) 
45.10-80.61 
52.23 (8.95) 
40.04-74.45 
 
3.3.3.2.  Reliability measures 
3.3.3.2.1.  Controls 
For controls, ICC values for baseline scan pairs were above 0.90 for total, cortical and 
lobular GM volume using each segmentation tool (Table 3.7) Mean repeatability (indexing 
variability), was lowest in total GM for all techniques, ranging from 0.35% (SPM8 New 
Segment) to 1.36% (FreeSurfer), as shown in Table 3.7. CGM showed only slightly higher 
variability than total GM for all techniques. Lobular regions generally had higher repeatability 
values than total and cortical GM, indicating more variability between the lobular volumes for 
the first and second back-to-back baseline scans. 
Spearman’s Rho correlations showed that there were strong relationships between 
the volumes extracted using the seven different tools, with most values above 0.90 (Table 3.8). 
Correlations were higher for CGM than for total GM. Spearman’s Rho for lobular regions are 
not shown, but relationships > .75 were seen for all measures for controls across all regions, 
with most results > .90, indicating a high level of agreement between tools. Overall, SPM8 
Unified Segment showed the lowest relationships with other measures.  
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Table 3.7. Intraclass correlation coefficients and confidence intervals for control participants 
for back-to-back segmentations of total GM, cortical GM, frontal lobe GM, temporal lobe GM, 
parietal lobe GM, occipital lobe GM, and insula GM included in the current study. Repeatability 
values are also displayed for back-to-back segmentations of total GM, cortical GM, frontal lobe 
GM, temporal lobe GM, parietal lobe GM, occipital lobe GM, and insula GM for all control 
participants included in the current study, showing means, standard deviations and ranges. 
Intraclass Correlations 
Confidence Intervals 
 SPM8 Unified 
Segment 
SPM8 New 
Segment 
SPM12 
Segment 
ANTs Atropos MALP-EM FSL FAST FreeSurfer 
  
Total GM .994 
.985-.998 
.999 
.997-1.000 
.997 
.993-.999 
.982 
.951-.993 
.998 
.995-.999 
.986 
.960-.995 
.978 
.947-.991 
Cortical GM .994 
.985-.998 
.999 
 .998-1.000 
.997 
.993-.999 
.985 
.958-.994 
.998 
.995-.999 
.988 
.964-.996 
.967 
.918-.987 
Frontal Lobe 0.996 
0.990-0.998 
0.999 
0.997-.000 
0.997 
0.991-0.999 
0.983 
0.955-0.993 
0.997 
0.993-0.999 
0.989 
0.969-0.996 
0.960 
0.902-0.984 
Temporal 
Lobe 
0.989 
0.973-0.996 
0.994 
0.986-0.998 
0.992 
0.980-0.997 
0.990 
0.975-0.996 
0.994 
0.984-0.997 
0.985 
0.963-0.994 
.975 
0.936-0.990 
Parietal Lobe 0.995 
0.986-0.998 
0.997 
0.993-0.999 
0.996 
0.990-0.998 
0.976 
0.931-0.991 
0.996 
0.990-0.998 
0.984 
0.954-0.994 
0.956 
0.886-0.983 
Occipital 
Lobe 
0.994 
0.985-0.998 
0.993 
0.984-0.997 
0.995 
0.988-0.998 
0.971 
0.922-0.989 
0.992 
0.981-0.997 
0.978 
0.936-0.992 
0.962 
0.906-0.985 
Insula 0.977 
0.941-0.991 
0.979 
0.948-0.992 
0.979 
0.948-0.992 
0.982 
0.955-0.993 
0.985 
0.962-0.994 
0.979 
0.947-0.991 
0.975 
0.938-0.990 
Mean Repeatability  
(Standard Deviation)  
Range 
 SPM8 
Unified 
Segment 
SPM8 New 
Segment 
SPM12 
Segment 
ANTs 
Atropos 
MALP-EM FSL FAST FreeSurfer 
Total GM 1.08  
(0.82) 
0.18-2.88 
0.35 
(0.34) 
0.01-1.00 
0.69 
(0.48) 
0.12-1.77 
1.14 
(1.65) 
0.00-6.44 
0.41 
(0.53) 
0.02-2.07 
0.91 
(1.33) 
0.05-4.99 
1.36 
(1.43) 
0.05-5.77 
Cortical GM 1.06 
(0.82) 
0.02-2.72 
0.36 
(0.25) 
0.00-0.98 
0.79 
(0.50) 
0.07-1.96 
1.23  
(1.71) 
0.03-6.81 
0.49 
(0.57) 
0.01-2.18 
1.14 
(1.36) 
0.03-4.81 
1.82 
(2.09)  
0.06-8.05 
Frontal Lobe 1.13 
(0.93) 
0.00-3.09 
0.50 
(0.43) 
0.05-1.48 
1.09 
(0.67) 
0.20-2.45 
1.50 
(2.28) 
0.02-9.65 
0.67 
(0.74) 
0.00-2.67 
1.43 
(1.49) 
0.01-5.72 
2.33 
(3.05) 
0.01-11.04 
Temporal 
Lobe 
1.50 
(2.63)  
0.03-11.93 
0.82 
(1.52)  
0.02-7.09 
1.06  
(2.27)  
0.04-10.50 
1.25 
(1.86)  
0.00-7.27 
0.90 
(1.71)  
0.00-7.62 
1.54 
(2.07) 
0.02-8.36 
1.80 
(2.36) 
0.22-9.56 
Parietal Lobe 1.07  
(0.88) 
0.01-3.29 
0.59  
(0.79) 
0.04-3.72 
0.88  
(0.87) 
0.14-3.78 
1.57 
 (2.35) 
0.01-7.25 
0.80  
(0.75) 
0.00-2.74 
1.29 
(1.91) 
0.11-6.03 
2.21 
(2.79) 
0.10-8.84 
Occipital 
Lobe 
1.02 
(0.96) 
0.07-3.53 
0.85 
(0.82) 
0.04-3.29 
0.88 
(0.63) 
0.15-2.51 
1.36 
(1.79) 
0.07-6.57 
0.75 
(0.86) 
0.07-3.93 
1.29 
(1.63) 
0.03-6.00 
2.23 
(1.86) 
0.00-6.56 
Insula  1.73 
(2.42)  
0.08-10.97 
1.48 
(1.66) 0.05-
7.91 
1.44 
(2.13) 0.22-
9.90 
1.51 
(1.76) 0.21-
8.32 
1.31 
(1.88)  
0.01-8.44 
1.58 
(2.21) 
0.09-10.55 
2.07 
(1.91) 
0.09-7.43 
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Table 3.8. Spearman’s rank correlation for control participants for total GM and cortical GM. 
 
 
3.3.3.2.2. HD gene-carrier participants 
Reliability for total, cortical and lobular GM as measured by ICC was above 0.90 for 
most tools across all regions and the disease subgroups (Table 3.9 and Appendix 1, Table 1). 
Repeatability values were more variable than ICC values. Repeatability was lower with 
increasing disease stage for total and cortical GM (Table 3.10). For individual lobes, it was 
more variable across disease stages, lobes, and tools, but showed a small range of mean values 
(Appendix 1, Table 2). Values ranged from 0.37% (parietal lobe volume measured by MALP-EM 
in HD1 participants) to 2.72% (insula volume measured by FreeSurfer in PreHD-B participants).  
For total and cortical GM Spearman’s correlation between measures tended to be 
lower for the HD2 group, indicating that the techniques perform differently on more atrophied 
brains (Table 3.11 and Table 3.12). SPM8 Unified Segment again had lower values than other 
techniques for Spearman’s Rho, especially with SPM8 New Segment in HD2 participants, 
whereby correlations of 0.441 and 0.411 were seen for total and cortical GM respectively. For 
lobular regions, the relationships between measures were generally lower than those in 
control participants, with more correlations between 0.7-0.9 (Appendix 1, Tables 3-8).  
  
 
 
 
 
Total GM 
 
SPM8 
Unified 
Segment 
SPM8 
New 
Segment 
SPM12 
Segment 
ANTs 
Atropos 
MALP-EM FSL FAST 
SPM8 Unified Segment 1      
SPM8 New Segment 0.761 1     
SPM12 Segment 0.904 0.857 1    
ANTs Atropos 0.788 0.920 0.929 1   
MALP-EM 0.812 0.958 0.928 0.967 1  
FSL FAST 0.867 0.896 0.956 0.929 0.944 1 
FreeSurfer 0.874 0.904 0.884 0.874 0.905 0.920 
Cortical GM 
SPM8 Unified Segment 1      
SPM8 New Segment 0.798 1     
SPM12 Segment 0.918 0.971 1    
ANTs Atropos 0.809 0.976 0.934 1   
MALP-EM 0.861 0.932 0.953 0.974 1  
FSL FAST 0.897 0.932 0.947 0.944 0.967 1 
FreeSurfer 0.844 0.910 0.893 0.919 0.962 0.956 
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Table 3.9. (A) Intraclass correlation coefficients and confidence intervals for HD participants for 
all tools measuring total GM volume in back-to-back 2008 scans (B) Intraclass correlation 
coefficients and confidence intervals for HD participants for all tools measuring CGM volume 
for back-to-back 2008 scans. 
 PreHD-A 
(N=20) 
PreHD-B 
(N=20) 
HD1 
(N=20) 
HD2 
(N=20) 
Total GM 
Intraclass Correlations 
Confidence intervals 
SPM8 Unified 
0.993 
0.982-0.997 
0.977 
0.943-0.991 
0.984 
0.960-0.994 
0.989 
0.973-0.996 
SPM8 New 
Segment 
0.999 
0.998-10.000 
0.999 
0.998-10.000 
0.999 
0.998-10.000 
0.999 
0.998-10.000 
SPM12 
 
0.989 
0.972-0.995 
0.990 
0.974-0.996 
0.997 
0.994-0.999 
0.994 
0.982-0.998 
Atropos 
 
0.975 
0.912-0.991 
0.994 
0.981-0.998 
0.989 
0.970-0.996 
0.986 
0.938-0.995 
MALP-EM 
 
0.996 
0.989-0.998 
0.998 
0.996-0.999 
0.999 
0.996-0.999 
0.996 
0.990-0.998 
FAST 
 
0.989 
0.970-0.996 
0.997 
0.989-0.999 
0.995 
0.982-0.998 
0.994 
0.985-0.998 
FreeSurfer 
0.988 
0.967-0.995 
0.988 
0.968-0.995 
0.992 
0.979-0.997 
0.993 
0.983-0.997 
Cortical GM 
Intraclass Correlations 
Confidence intervals 
 SPM8 Unified 
0.993 
0.982-0.997 
0.979 
0.947-0.992 
0.987 
0.967-0.995 
0.991 
0.977-0.996 
SPM8 New 
Segment 
0.999 
0.998-10.000 
0.999 
0.998-10.000 
0.999 
0.998-10.000 
0.999 
0.998-10.000 
SPM12 
 
0.988 
0.971-0.995 
0.991 
0.978-0.996 
0.998 
0.995-0.999 
0.995 
0.984-0.998 
Atropos 
 
0.970 
0.893-0.990 
0.995 
0.984-0.998 
0.991 
0.974-0.997 
0.990 
0.947-0.997 
MALP-EM 
 
0.995 
0.986-0.998 
0.998 
0.994-0.999 
0.999 
0.997-10.000 
0.996 
0.991-0.999 
FAST 
 
0.986 
0.961-0.994 
0.996 
0.989-0.998 
0.995 
0.985-0.998 
0.995 
0.987-0.998 
FreeSurfer 
0.985 
0.957-0.994 
0.983 
0.955-0.993 
0.989 
0.970-0.996 
0.992 
0.981-0.997 
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Table 3.10. (A) Repeatability values for back-to-back segmentations of total GM for all HD 
participants included in the current study, showing means, standard deviations, and ranges (B) 
Repeatability values for back-to-back segmentations of CGM for all HD participants included in 
the current study, showing means, standard deviations, and ranges. 
 
SPM8 
Unified 
SPM8 
New 
SPM12 Atropos MALP-EM FAST FreeSurfer 
A) Total GM 
PreHD-A Total GM 
0.89 (0.80) 
0.01-3.05 
0.27 (0.19)  
0.02-0.80 
0.97 (0.86)  
0.01-2.93 
1.26 (1.63)  
0.07-5.61 
0.58 (0.53)  
0.02-2.22 
0.82 (0.67)  
0.00-2.42 
0.90 (0.87)  
0.03-2.69 
PreHD-B Total GM 
1.61 (1.83) 
0.24-7.03 
0.28 (0.22)  
0.02-0.70 
0.83 (0.88)  
0.02-3.15 
0.78 (0.72)  
0.07-2.45 
0.40 (0.40)  
0.01-1.37 
0.54 (0.51)  
0.02-1.75 
1.15 (0.98)  
0.03-3.85 
HD1 Total GM 
1.13 (1.33) 
0.04-6.22 
0.29 (0.24) 
0.01-0.75 
0.64 (0.54)  
0.08-1.80 
1.00 (1.27)  
0.02-4.45 
0.39 (0.27)  
0.08-1.20 
0.82 (0.68)  
0.13-2.20 
0.91 (0.74)  
0.15-3.55 
HD2 Total GM 
0.94 (0.77) 
0.07-2.90 
0.22 (0.12)  
0.03-0.37 
0.86 (0.71)  
0.03-3.20 
1.24 (1.33)  
0.02-5.08 
0.57 (0.50)  
0.01-1.87 
0.65 (0.70)  
0.00-3.06 
0.80 (0.72)  
0.05-2.54 
B) Cortical GM 
PreHD-A Cortical 
GM 
0.91 (0.76) 
0.05-2.82 
0.33 (0.22)  
0.04-0.75 
1.03 (0.89)  
0.10-3.32 
1.31 (1.77)  
0.09-6.19 
0.67 (0.64)  
0.05-2.72 
1.01 (0.70)  
0.02-2.41 
1.08 (1.03) 
0.03-3.15 
PreHD-B Cortical 
GM 
1.61 (1.90) 
0.09-7.24 
0.31 (0.27)  
0.00-1.10 
0.86 (0.81)  
0.06-2.91 
0.77 (0.69)  
0.15-2.60 
0.47 (0.47)  
0.02-1.70 
0.65 (0.53)  
0.00-1.86 
1.49 (1.28) 
0.23-5.22 
HD1 Cortical GM 
1.14 (1.44) 
0.11-6.76 
0.35 (0.25)  
0.03-0.88 
0.67 (0.55)  
0.06-1.71 
1.02 (1.09) 
 0.00-3.69 
0.37 (0.31)  
0.03-1.43 
0.87 (0.66)  
0.11-2.35 
1.30 (1.11) 
0.27-5.16 
HD2 Cortical GM 
0.96 (0.78) 
0.04-2.74 
0.22 (0.16)  
0.02-0.61 
0.86 (0.70)  
0.02-3.10 
1.13 (1.11)  
0.04-3.47 
0.61 (0.49)  
0.09-1.85 
0.66 (0.63)  
0.11-2.77 
1.04 (0.96) 
0.04-3.17 
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Table 3.11. Spearman’s ranked correlation for segmentations of total GM for all HD 
participants included in the current study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 SPM8 
Unified 
Segment 
SPM8 New 
Segment 
SPM12 
Segment 
ANTs 
Atropos 
MALP-EM FSL FAST 
PreHD-A 
SPM8 Unified Segment 1      
SPM8 New Segment 0.777 1     
SPM12 Segment 0.896 0.666 1    
ANTs Atropos 0.732 0.833 0.737 1   
MALP-EM 0.808 0.950 0.749 0.844 1  
FSL FAST 0.741 0.785 0.770 0.926 0.874 1 
FreeSurfer 0.865 0.959 0.752 0.805 0.952 0.802 
PreHD-B 
SPM8 Unified Segment 1      
SPM8 New Segment 0.770 1     
SPM12 Segment 0.932 0.889 1    
ANTs Atropos 0.726 0.934 0.851 1   
MALP-EM 0.842 0.964 0.941 0.919 1  
FSL FAST 0.883 0.848 0.917 0.857 0.878 1 
FreeSurfer 0.871 0.925 0.952 0.838 0.938 0.887 
HD1 
SPM8 Unified Segment 1      
SPM8 New Segment 0.737 1     
SPM12 Segment 0.857 0.672 1    
ANTs Atropos 0.847 0.818 0.779 1   
MALP-EM 0.793 0.955 0.702 0.886 1  
FSL FAST 0.845 0.731 0.815 0.917 0.841 1 
FreeSurfer 0.884 0.857 0.875 0.829 0.895 0.826 
HD2 
SPM8 Unified Segment 1      
SPM8 New Segment 0.441 1     
SPM12 Segment 0.758 0.555 1    
ANTs Atropos 0.644 0.820 0.671 1   
MALP-EM 0.633 0.917 0.719 0.860 1  
FSL FAST 0.827 0.738 0.768 0.908 0.853 1 
FreeSurfer 0.605 0.802 0.796 0.681 0.883 0.726 
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Table 3.12. Spearman’s ranked correlation for segmentations of cortical GM for all HD 
participants included in the current study.  
 SPM8 
Unified 
Segment 
SPM8 New 
Segment 
SPM12 
Segment 
ANTs 
Atropos 
MALP-EM FSL FAST 
PreHD-A 
SPM8 Unified Segment 1      
SPM8 New Segment 0.815 1     
SPM12 Segment 0.883 0.722 1    
ANTs Atropos 0.865 0.901 0.844 1   
MALP-EM 0.836 0.970 0.755 0.886 1  
FSL FAST 0.848 0.848 0.847 0.920 0.874 1 
FreeSurfer 0.868 0.955 0.811 0.917 0.973 0.923 
PreHD-B 
SPM8 Unified Segment 1      
SPM8 New Segment 0.747 1     
SPM12 Segment 0.926 0.863 1    
ANTs Atropos 0.762 0.943 0.896 1   
MALP-EM 0.830 0.974 0.922 0.947 1  
FSL FAST 0.818 0.934 0.925 0.916 0.955 1 
FreeSurfer 0.887 0.836 0.935 0.848 0.874 0.925 
HD1 
SPM8 Unified Segment 1      
SPM8 New Segment 0.734 1     
SPM12 Segment 0.868 0.716 1    
ANTs Atropos 0.869 0.898 0.844 1   
MALP-EM 0.735 0.973 0.711 0.914 1  
FSL FAST 0.820 0.764 0.862 0.902 0.782 1 
FreeSurfer 0.820 0.893 0.898 0.910 0.901 0.854 
HD2 
SPM8 Unified Segment 1      
SPM8 New Segment 0.411 1     
SPM12 Segment 0.826 0.576 1    
ANTs Atropos 0.692 0.814 0.741 1   
MALP-EM 0.638 0.910 0.749 0.869 1  
FSL FAST 0.803 0.699 0.835 0.919 0.860 1 
FreeSurfer 0.729 0.729 0.887 0.832 0.868 0.880 
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3.3.3.3. Longitudinal results 
3.3.3.3.1. Total GM volume 
Total GM volume change (as a percentage of baseline volume) for all tools was smaller 
in controls than that of the HD gene-carrier groups (Table 3.13 and Figure 3.15). However 
when total GM volume change within each HD group was statistically compared to controls, 
MALP-EM and FreeSurfer were the only two tools that detected significantly greater change in 
all disease groups. All other tools detected significantly greater change in HD1 and HD2 
compared to controls, with SPM12 and FAST also showing greater change in PreHD-B 
compared to controls. 
 
 
Figure 3.15. Mean values for all tools and groups showing 2011 volume as a percentage of 
baseline volume in total GM. Significant change difference relative to controls after controlling 
for age, sex and site are represented by * p<.05, **p<.01.   
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Table 3.13. Mean % change (difference between 2011 and baseline volume as a percentage of 
baseline volume), standard deviation and ranges for all tools and groups in total GM. Positive 
values represent volumetric decreases over time. Results of regression analyses comparing 
rate of change in controls to HD groups, with significantly greater change in HD groups 
represented by * p<0.05 (light grey), **p<0.01 (dark grey). Age, sex and site were controlled 
for. 
  Controls PreHD-A PreHD-B HD1 HD2 
SPM8 
Unified 
Segment 
% Decrease 2008 to 2011 
0.67 
 (3.05) 
-5.42-7.93 
2.11 
 (3.06) 
-2.13-11.07 
2.08 
 (4.53) 
-7.22-14.38 
5.15 
 (6.97) 
-7.37-30.87 
3.58 
 (2.06) 
-0.53-6.28 
Significant difference 
- 1.12 
(-0.75-3.00) 
p = 0.239 
0.62  
(-0.55-1.79) 
p = 0.299 
1.71  
(0.65-2.76) 
p = 0.002 
0.53  
(0.06-1.00) 
 p = 0.027 
SPM8 New 
Segment 
 
% Decrease 2008 to 2011 
0.43 
 (2.41) 
-7.93-3.23 
1.51 
 (1.09) 
-0.32-3.30 
1.28 
 (0.76) 
-0.26-2.60 
1.78 
 (1.04) 
0.14-4.12 
3.00 
 (3.39) 
-0.28-16.62 
Significant difference 
- 1.05 
 (-0.05-2.16) 
 p = 0.062 
0.44 
 (-0.07-0.95) 
 p = 0.089 
0.41 
 (0.06-0.76) 
 p = 0.021 
0.59 
 (0.09-1.08) 
 p = 0.021 
SPM12 
Segment 
% Decrease 2008 to 2011 
0.80 
 (2.29) 
-4.79-3.97 
1.54 
 (3.61) 
-7.49-7.29 
2.77 
 (1.64) 
0.28-5.89 
4.42 
 (2.06) 
0.82-7.80 
4.87 
 (2.50) 
0.98-9.65 
Significant difference 
- 0.43 
 (-1.40-2.26) 
 p = 0.646 
1.00 
 (0.42-1.58) 
 p = 0.001 
1.21 
 (0.78-1.65) 
 p = 0.000 
0.78 
 (0.36-1.19) 
 p = 0.000 
ANTs 
% Decrease 2008 to 2011 
1.39 
 (2.38) 
-0.83-9.69 
1.67 
 (2.57) 
-2.79-6.97 
1.65 
 (2.18) 
-2.17-7.17 
3.00 
 (1.96) 
0.10-7.09 
3.28 
 (4.26) 
-1.40-18.87 
Significant difference 
- 0.59 
 (-0.90-2.08) 
 p = 0.435 
0.20 
 (-0.44-0.84) 
 p = 0.544 
0.58 
 (0.16-1.00) 
 p = 0.006 
0.75 
 (0.18-1.31) 
 p = 0.009 
MALP-EM 
% Decrease 2008 to 2011 
0.35 
 (1.36) 
-3.81-2.55 
1.28 
 (1.29) 
-1.28-4.68 
1.37 
 (1.20) 
-1.08-3.59 
2.45 
 (2.36) 
-3.34-9.15 
2.31 
 (2.72) 
-1.76-11.83 
Significant difference 
- 0.89 
 (0.06-1.72) 
 p = 0.036 
0.47 
 (0.10-0.85) 
 p = 0.013 
0.65 
 (0.28-1.02) 
 p = 0.001 
0.39 
 (0.02-0.75) 
 p = 0.039 
FAST 
% Decrease 2008 to 2011 
0.49 
 (3.57) 
-7.91-8.88 
1.90 
 (7.83) 
-26.04-11.48 
2.57 
 (3.02) 
-0.72-12.70 
4.38 
 (4.47) 
-4.55-12.72 
6.70 
 (5.81) 
0.32-18.59 
Significant difference 
- 0.30 
 (-2.62-3.23) 
 p = 0.839 
1.15 
 (0.44-1.86) 
 p = 0.002 
1.05 
 (0.56-1.55) 
 p = 0.000 
0.85 
 (0.37-1.33) 
 p = 0.001 
FreeSurfer % Decrease 2008 to 2011 
0.42 
 (1.90) 
-5.96-2.51 
1.75 
 (1.62) 
-2.15-4.86 
2.08 
 (1.54) 
-0.97-4.98 
3.06 
 (1.70) 
-0.16-5.95 
3.46 
 (1.80) 
0.13-6.30 
 Significant difference - 
1.13 
 (0.06-2.21) 
 p = 0.039 
0.87 
 (0.37-1.37) 
 p = 0.001 
0.85 
 (0.49-1.22) 
 p = 0.000 
0.64 
 (0.31-0.97) 
 p = 0.000 
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3.3.3.3.2. Cortical GM volume 
The same analysis was conducted in CGM showing that CGM change was inconsistent 
across tools (Table 3.14 and Figure 3.16). Except for SPM8 New Segment, all tools showed 
significantly greater change in HD1 and HD2 compared to controls, SPM8 New Segment only 
showed greater change in HD1. MALP-EM, FAST and FreeSurfer all showed greater change in 
PreHD-B than controls, and only MALP-EM and FreeSurfer showed greater change in PreHD-B 
than controls.  
 
 
Figure 3.16. Mean values for all tools and groups showing 2011 volume as a percentage of 
baseline volume in CGM. Significant difference in longitudinal change relative to controls after 
controlling for age, sex and site are represented by * p<.05, **p<.01.   
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Table 3.14. Mean % change (difference between 2011 and baseline volume as a percentage of 
baseline volume), standard deviation and ranges for all tools and groups in cortical GM. 
Positive values represent volumetric decreases over time. Results of regression analyses 
comparing rate of change in controls to HD groups, with significantly greater change in HD 
groups represented by * p<0.05 (light grey), **p<0.01 (dark grey). Age, sex and site were 
controlled for. 
 
 
 Controls PreHD-A PreHD-B HD1 HD2 
SPM8 
Unified 
Segment 
% Decrease 2008 to 2011 
.94 
(3.06) 
-5.17-8.55 
2.05 
(2.17) 
-2.37-5.99 
1.73 
(3.71) 
-7.96-8.46 
4.55  
(4.11) 
-7.45-10.73 
4.03 
(2.30) 
-0.71-7.24 
Significant difference 
 .89 
(-.82-2.59) 
p = 0.309 
.40 
(0.63-1.42) 
p = 0.447 
1.26 
(.56-1.97) 
p = 0.000 
.55 
(.06-1.03) 
p = 0.028 
SPM8 New 
Segment 
 
% Decrease 2008 to 2011 
0.16 
(0.93) 
-1.52-1.84 
0.74 
(0.90) 
-1.21-2.79 
0.56 
(0.62) 
-0.87-2.26 
0.95 
(0.74) 
-0.29-2.60 
1.74 
(3.22) 
-0.82-14.87 
Significant difference 
 -0.56 
(-1.07--0.06) 
 p = 0.030 
-0.20 
(-0.39-0.00) 
 p = 0.046 
-0.31 
(-0.46--0.15) 
 p = 0.000 
-0.29 
(-0.65-0.07) 
 p = 0.114 
SPM12 
Segment 
% Decrease 2008 to 2011 
0.93 
(2.35) 
-4.68-4.25 
1.73 
(3.87) 
-7.83-7.98 
3.14 
(1.71) 
0.58-6.16 
5.06 
(2.39) 
1.17-9.06 
5.24 
(2.61) 
1.30-10.43 
Significant difference 
 -0.50 
(-2.42-1.42) 
 p = 0.608 
-1.13 
(-1.72--0.53) 
 p = 0.000 
-1.38 
(-1.86--0.91) 
 p = 0.000 
-0.83 
(-1.26--0.40) 
 p = 0.000 
ANTs 
% Decrease 2008 to 2011 
1.58 
(2.75) 
-1.25-11.81 
2.13 
(2.55) 
-2.21-7.71 
2.01 
(1.90) 
-2.00-5.84 
3.34 
(1.79) 
0.26-6.61 
3.51 
(3.95) 
-0.81-17.69 
Significant difference 
 -0.81 
(-2.44-0.83) 
 p = 0.335 
-0.27 
(-0.95-0.42) 
 p = 0.446 
-0.64 
(-1.09--0.18) 
 p = 0.006 
-0.71 
(-1.28--0.13) 
 p = 0.017 
MALP-EM 
% Decrease 2008 to 2011 
0.48 
(1.24) 
-3.13-2.49 
1.36 
(1.26) 
-1.13-4.08 
1.47 
(1.24) 
-0.73-3.82 
2.54 
(2.69) 
-3.65-10.92 
2.32 
(2.10) 
-1.37-9.09 
Significant difference 
 -0.78 
(-1.55--0.01) 
 p = 0.047 
-0.45 
(-0.80--0.09) 
 p = 0.013 
-0.66 
(-1.05--0.26) 
 p = 0.001 
-0.33 
(-0.62--0.04) 
 p = 0.027 
FAST 
% Decrease 2008 to 2011 
0.74 
(3.41) 
-6.63-8.33 
3.77 
(4.51) 
-2.62-12.54 
2.77 
(3.55) 
-0.36-15.00 
4.78 
(4.88) 
-3.85-14.14 
7.00 
(6.34) 
-0.09-20.82 
Significant difference 
 -1.96 
(-3.48--0.45) 
 p = 0.011 
-1.12 
(-1.83--0.41) 
 p = 0.002 
-1.09 
(-1.59--0.59) 
 p = 0.000 
-0.85 
(-1.37--0.33) 
 p = 0.001 
FreeSurfer 
% Decrease 2008 to 2011 
0.55 
(1.49) 
-3.32-2.26 
1.75 
(1.77) 
-1.94-6.24 
2.23 
(1.86) 
-1.37-5.69 
3.49 
(2.04) 
-0.50-6.51 
3.87 
(2.04) 
-0.13-7.69 
Significant difference 
 -0.98 
(-1.98-0.03) 
 p = 0.057 
-0.85 
(-1.33--0.37) 
 p = 0.000 
-0.93 
(-1.28--0.58) 
 p = 0.000 
-0.70 
(-1.00--0.40) 
 p = 0.000 
 
3.3.3.3.3. Lobular GM volume 
Longitudinal change within the lobes was variable for all groups with the parietal and 
occipital lobes showing the most consistent patterns of group differences across most 
techniques.  
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3.3.3.3.3.1. Frontal lobe volume 
Table 3.15 shows the longitudinal change in the frontal lobe. SPM8 New Segment and 
ANTs showed no significantly different change in any group compared to controls. MALP-EM 
and SPM8 Unified Segment only detected significant change in HD1 compared to controls, and 
SPM12 detected change in PreHD-B, HD1 and HD2 compared to controls. Both FSL FAST and 
FreeSurfer found significant differences in longitudinal change in all HD groups. 
3.3.3.3.3.2. Temporal lobe volume 
For the temporal lobe, SPM8 New Segment, MALP-EM and ANTs showed no significant 
differences in volumetric change. FSL FAST and SPM8 Unified segment found significant 
differences in HD1 compared to controls, and FreeSurfer and SPM12 found differences in HD1 
and HD2 compared to controls (Table 3.16). 
3.3.3.3.3.3. Parietal lobe volume 
Change in the parietal lobe was more widely detected across groups, with all 
techniques except SPM8 Unified Segment showing significantly greater volume reduction in 
HD1, HD2 and PreHD-B compared to controls, which only showed a difference between HD1 
and controls. SPM8 New Segment, MALP-EM, FAST and FreeSurfer detected significantly 
greater change over time in all HD groups (Table 3.17).  
3.3.3.3.3.4. Occipital Lobe Volume 
Occipital lobe change was again widespread across all tools in HD groups compared to 
controls (Table 3.18). SPM8 New Segment, MALP-EM, FSL FAST and FreeSurfer found 
significantly greater change in all HD groups compared to controls. SPM12 and ANTs found 
significantly greater change in all PreHD-B, HD1 and HD2 compared to controls and SPM8 
Unified Segment found greater change in HD1 and HD2. 
3.3.3.3.3.5. Insula Volume 
Finally, within the insula SPM8 New Segment and MALP-EM found no differences in 
change between any group and controls, SPM8 Unified Segment, ANTs, FAST and FreeSurfer 
found greater change in HD1 and HD2 than controls, and SPM12 found greater change in 
PreHD-B, HD1 and HD2 (Table 3.19). 
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Table 3.15. Mean % change (difference between 2011 and baseline volume as a percentage of 
baseline volume), standard deviation and ranges for all tools and groups in frontal lobe GM. 
Positive values represent volumetric decreases over time. Results of regression analyses 
comparing rate of change in controls to HD groups, with significantly greater change in HD 
groups represented by * p<0.05 (light grey), **p<0.01 (dark grey). Age, sex and site were 
controlled for. 
 
 
 
Controls PreHD-A PreHD-B HD1 HD2 
 
SPM8 Unified 
Segment 
% Decrease 2008 to 
2011 
1.24 
(3.38) 
-5.62-8.99 
2.01 
(2.51) 
-3.26-6.17 
1.82 
(3.62) 
-8.46-8.73 
4.21 
(4.37) 
-8.55-11.33 
4.05 
(2.29) 
-1.57-7.31 
Significant difference  
0.30 
(-1.53-2.12) 
p = 0.751 
0.23 
(-0.81-1.27) 
p = 0.662 
1.10 
(0.34-1.85) 
p = 0.004 
0.38 
(-0.12-0.87) 
p = 0.137 
SPM8 New 
Segment 
% Decrease 2008 to 
2011 
0.44 
(1.50) 
-1.75-3.92 
0.83 
(1.13) 
-2.16-3.31 
0.73 
(1.03) 
-0.85-2.82 
0.75 
(0.90) 
-0.94-2.41 
1.90 
(3.11) 
-0.32-14.45 
Significant difference  
0.32 
(-0.35-0.98) 
p = 0.349 
0.12 
(-0.22-0.46) 
p = 0.488 
0.18 
(-0.04-0.40) 
p = 0.115 
0.23 
(-0.16-0.61) 
p = 0.250 
SPM12 Segment 
% Decrease 2008 to 
2011 
1.15 
(2.51) 
-5.25-4.17 
1.69 
(4.34) 
-9.59-8.19 
3.22 
(2.03) 
0.26-6.40 
4.72 
(2.59) 
-0.16-9.58 
5.12 
(2.64) 
0.87-11.27 
Significant difference - 
0.22 
(-1.84-2.27) 
p = 0.838 
1.03 
(0.37-1.69) 
p = 0.002 
1.23 
(0.73-1.73) 
p = 0.000 
0.73 
(0.29-1.17) 
p = 0.001 
ANTs Atropos 
% Decrease 2008 to 
2011 
2.23 
(5.15) 
-2.41-22.35 
2.45 
(2.41) 
-1.78-8.09 
1.83 
(2.26) 
-2.78-5.97 
3.00 
(1.95) 
-0.86-6.03 
3.46 
(3.86) 
-0.66-17.44 
Significant difference - 
0.39 
(-2.07-2.85) 
p = 0.756 
-0.15 
(-1.32-1.02) 
p = 0.799 
0.32 
(-0.46-1.10) 
p = 0.423 
0.56 
(-0.25-1.37) 
p = 0.173 
MALP-EM 
% Decrease 2008 to 
2011 
0.91 
(1.98) 
-4.01-3.70 
1.81 
(1.38) 
-0.36-4.33 
1.67 
(1.71) 
-1.03-4.92 
2.56 
(3.01) 
-3.95-12.09 
2.57 
(1.91) 
0.40-8.28 
Significant difference - 
0.76 
(-0.25-1.77) 
p = 0.141 
0.28 
(-0.24-0.79) 
p = 0.293 
0.54 
(0.08-1.01) 
p = 0.022 
0.23 
(-0.11-0.56) 
p = 0.181 
FSL FAST 
% Decrease 2008 to 
2011 
0.71 
(3.59) 
-5.53-8.23 
3.62 
(5.60) 
-6.95-18.21 
2.52 
(4.06) 
-4.16-13.94 
3.60 
(5.91) 
-7.84-12.75 
7.74 
(9.14) 
-3.01-32.70 
Significant difference - 
1.70 
(0.00-3.39) 
p = 0.050 
0.94 
(0.19-1.68) 
p = 0.014 
0.77 
(0.20-1.34) 
p = 0.008 
0.96 
(0.21-1.71) 
p = 0.012 
FreeSurfer 
% Decrease 2008 to 
2011 
0.55 
(1.68) 
-1.68-3.49 
2.11 
(1.84) 
-1.37-6.96 
2.05 
(2.28) 
-1.59-6.33 
3.14 
(2.43) 
-1.39-7.06 
3.41 
(2.00) 
0.26-6.45 
 
Significant difference  
1.35 
(0.30-2.41) 
p = 0.012 
.71 
(0.17-1.24) 
p=.010 
.86 
(.48-1.23) 
p = .000 
.61 
(.31-.91) 
p = .000 
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Table 3.16. Mean % change (difference between 2011 and baseline volume as a percentage of 
baseline volume), standard deviation and ranges for all tools and groups in temporal lobe GM. 
Positive values represent volumetric decreases over time. Results of regression analyses 
comparing rate of change in controls to HD groups, with significantly greater change in HD 
groups represented by * p<0.05 (light grey), **p<0.01 (dark grey). Age, sex and site were 
controlled for. 
 
 
 Controls PreHD-A PreHD-B HD1 HD2 
 
SPM8 Unified 
Segment 
% Decrease 2008 to 2011 
1.47 
(3.00) 
-5.72-7.56 
1.92 
(1.93) 
-1.79-4.96 
1.27 
(4.02) 
-10.16-7.24 
4.27 
(3.82) 
-6.00-11.03 
3.82 
(2.42) 
-0.65-6.72 
Significant difference - 
0.46 
(-1.12-2.03) 
p = 0.569 
-0.07 
(-1.06-0.91) 
p = 0.887 
0.90 
(0.25-1.55) 
p = 0.006 
0.36 
(-0.10-0.83) 
p = 0.122 
SPM8 New 
Segment 
% Decrease 2008 to 2011 
0.75 
(1.53) 
-1.63-3.97 
0.44 
(1.29) 
-1.67-3.40 
0.39 
(0.99) 
-2.22-1.71 
0.70 
(1.21) 
-1.97-4.11 
1.48 
(3.90) 
-3.90-16.23 
Significant difference - 
-0.16 
(-0.95-0.63) 
p = 0.692 
-0.16 
(-0.48-0.16) 
p = 0.330 
-0.06 
(-0.31-0.18) 
p = 0.617 
0.05 
(-0.40-0.49) 
p = 0.839 
SPM12 
Segment 
% Decrease 2008 to 2011 
1.41 
(2.35) 
-5.56-5.02 
1.49 
(3.21) 
-5.70-6.56 
2.49 
(2.03) 
-1.48-6.04 
4.31 
(2.58) 
0.70-10.08 
4.80 
(3.20) 
-0.51-10.75 
Significant difference - 
-0.13 
(-1.81-1.55) 
p = 0.882 
0.56 
(-0.04-1.16) 
p = 0.067 
0.88 
(0.43-1.32) 
p = 0.000 
0.60 
(0.16-1.03) 
p = 0.008 
ANTs Atropos 
% Decrease 2008 to 2011 
2.63 
(3.50) 
-0.91-15.76 
2.11 
(2.80) 
-2.32-8.83 
1.64 
(1.98) 
-1.96-5.58 
3.06 
(1.81) 
-0.02-6.48 
3.43 
(4.62) 
-2.50-19.77 
Significant difference - 
-0.11 
(-1.95-1.72) 
p = 0.904 
-0.42 
(-1.18-0.35) 
p = 0.284 
0.10 
(-0.44-0.64) 
p = 0.721 
0.47 
(-0.18-1.12) 
p = 0.160 
MALP-EM 
% Decrease 2008 to 2011 
1.26 
(1.54) 
-3.59-4.26 
1.29 
(1.75) 
-1.64-5.62 
1.28 
(1.54) 
-1.49-5.11 
2.34 
(3.95) 
-8.26-14.21 
2.19 
(3.20) 
-4.65-12.75 
Significant difference - 
-0.03 
(-1.02-0.95) 
p = 0.950 
0.00 
(-0.40-0.40) 
p = 0.998 
0.19 
(-0.38-0.77) 
p = 0.512 
0.04 
(-0.35-0.43) 
p = 0.829 
FSL FAST 
% Decrease 2008 to 2011 
1.47 
(3.32) 
-5.72-7.87 
3.72 
(4.27) 
-3.02-10.72 
2.13 
(2.79) 
-1.40-11.11 
4.38 
(4.92) 
-3.65-17.89 
5.13 
(3.90) 
-1.31-14.52 
Significant difference - 
1.33 
(-0.41-3.07) 
p = 0.135 
0.43 
(-0.30-1.15) 
p = 0.248 
0.65 
(0.05-1.25) 
p = 0.035 
0.34 
(-0.09-0.78) 
p = 0.124 
FreeSurfer % Decrease 2008 to 2011 
1.18 (2.43) -
3.25-7.54 
1.49 
(2.55) 
-4.84-6.39 
1.58 
(1.92) 
-1.87-5.11 
3.42 
(1.73) 
1.19-7.38 
4.04 
(2.45) 
-2.29-7.79 
 Significant difference  
.23 
(-1.26-1.72) 
p = 0.762 
.28 
(-.32-.87) 
p = 0.364 
.71 
(.71-1.12) 
p = 0.001 
.63 
(.24-1.02) 
p = 0.002 
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Table 3.17. Mean % change (difference between 2011 and baseline volume as a percentage of 
baseline volume), standard deviation and ranges for all tools and groups in parietal lobe GM. 
Positive values represent volumetric decreases over time. Results of regression analyses 
comparing rate of change in controls to HD groups, with significantly greater change in HD 
groups represented by * p<0.05 (light grey), **p<0.01 (dark grey). Age, sex and site were 
controlled for. 
 
 
 
Controls PreHD-A PreHD-B HD1 HD2 
SPM8 
Unified 
Segment 
% Decrease 2008 to 2011 
0.44 
(3.19) 
-4.34-8.36 
2.24 
(2.06) 
-2.31-5.63 
2.13 
(3.59) 
-6.23-9.01 
4.60 
(4.06) 
-7.72-10.10 
3.81 
(2.69) 
-1.66-7.53 
Significant difference - 
1.62 
(-0.06-3.31) 
p = 0.059 
0.85 
(-0.21-1.90) 
p = 0.115 
1.48  
(0.76-2.19) 
p = 0.000 
1.62 
(-0.06-3.31) 
p = 0.059 
SPM8 New 
Segment 
% Decrease 2008 to 2011 
-0.37 
(1.67) 
-3.77-2.14 
0.81 
(0.97) 
-1.07-2.37 
0.60 
(0.84) 
-1.24-1.86 
1.05 
(1.13) 
-1.31-2.93 
1.56 
(2.29) 
0.03-10.58 
Significant difference - 
1.05 
(0.36-1.74) 
p = 0.003 
0.45 
(0.11-0.78) 
p = 0.009 
0.55 
(0.31-0.80) 
p = 0.000 
0.36 
(0.04-0.67) 
p = 0.027 
SPM12 
Segment 
% Decrease 2008 to 2011 
0.51 
(3.00) 
-7.75-4.38 
1.70 
(3.61) 
-8.07-7.88 
3.33 
(1.48) 
0.91-6.51 
5.22 
(2.28) 
1.25-9.39 
4.95 
(2.91) 
0.59-9.92 
Significant difference - 
0.83 
(-1.15-2.81) 
p = 0.412 
1.42 
(0.75-2.10) 
p = 0.000 
1.61 
(1.06-2.15) 
p = 0.000 
0.80 
(0.30-1.30) 
p = 0.002 
ANTs 
Atropos 
% Decrease 2008 to 2011 
0.47 
(1.94) 
-2.63-5.38 
1.98 
(2.68) 
-4.78-7.28 
2.46 
(2.28) 
-1.66-8.58 
3.54 
(2.10) 
-0.37-6.95 
3.30 
(3.24) 
-2.03-12.84 
Significant difference - 
1.29 
(-0.18-2.75) 
p = 0.085 
0.96 
(0.35-1.57) 
p = 0.002 
1.11 
(0.74-1.48) 
p = 0.000 
0.68 
(0.22-1.13) 
p = 0.003 
MALP-EM 
% Decrease 2008 to 2011 
0.07 
(1.57) 
-3.95-2.40 
0.97 
(1.00) 
-1.03-3.07 
1.39 
(1.22) 
-0.65-3.56 
2.23 
(1.68) 
-0.59-7.16 
1.94 
(1.55) 
-0.60-6.01 
Significant difference - 
0.77 
(0.05-1.48) 
p = 0.036 
0.60 
(0.21-0.99) 
p = 0.003 
0.76 
(0.48-1.03) 
p = 0.000 
0.34 
(0.08-0.60) 
p = 0.011 
FSL FAST 
% Decrease 2008 to 2011 
0.09 
(3.41) 
-9.04-5.46 
3.27 
(3.93) 
-2.64-11.00 
3.15 
(2.96) 
-0.48-11.11 
4.24 
(3.65) 
-4.03-11.29 
5.30 
(4.42) 
0.72-17.44 
Significant difference - 
2.23 
(0.54-3.92) 
p = 0.010 
1.54 
(0.77-2.32) 
p = 0.000 
1.25 
(0.72-1.78) 
p = 0.000 
0.80 
(0.24-1.36) 
p = 0.005 
FreeSurfer 
% Decrease 2008 to 2011 
0.45 
(1.41) 
-2.55-2.50 
1.45 
(1.94) 
-2.51-5.97 
2.96 
(2.14) 
-1.60-7.27 
3.89 
(2.54) 
0.33-9.60 
3.86 
(2.38) 
-0.78-9.35 
Significant difference  
.60 
(-.40-1.61) 
p = 0.239 
1.21 
(.70-1.72) 
p = 0.000 
1.06 
(.67-1.44) 
p = 0.000 
.65 
(0.35-0.94) 
p = 0.000 
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Table 3.18. Mean % change (difference between 2011 and baseline volume as a percentage of 
baseline volume), standard deviation and ranges for all tools and groups in occipital lobe GM. 
Positive values represent volumetric decreases over time. Results of regression analyses 
comparing rate of change in controls to HD groups, with significantly greater change in HD 
groups represented by * p<0.05 (light grey), **p<0.01 (dark grey). Age, sex and site were 
controlled for. 
 
 
 
Controls PreHD-A PreHD-B HD1 HD2 
 
 
SPM8 
Unified 
Segment 
% Decrease 2008 to 2011 
0.35 
(4.42) 
-11.14-9.57 
2.18 
(3.12) 
-4.03-8.78 
1.88 
(4.26) 
-8.03-9.34 
6.06 
(4.87) 
-7.32-15.50 
5.01 
(3.26) 
-0.43-9.77 
Significant difference - 
1.81 
(-0.79-4.41) 
p = 0.173 
0.90 
(-0.46-2.26) 
p = 0.197 
1.95 
(1.01-2.89) 
p = 0.000 
1.31 
(0.48-2.14) 
p = 0.002 
SPM8 New 
Segment 
% Decrease 2008 to 2011 
-0.66 
(2.13) 
-7.72-1.27 
0.96 
(1.95) 
-3.02-4.27 
0.39 
(1.60) 
-1.81-3.56 
1.78 
(1.22) 
-0.16-4.12 
2.40 
(4.68) 
-2.66-20.47 
Significant difference - 
1.85 
(0.60-3.11) 
p = 0.004 
0.56 
(0.01-1.11) 
p = 0.047 
0.83 
(0.47-1.19) 
p = 0.000 
0.76 
(0.18-1.34) 
p = 0.010 
SPM12 
Segment 
% Decrease 2008 to 2011 
0.58 
(3.47) 
-9.26-4.94 
2.28 
(5.04) 
-7.40-11.37 
3.88 
(2.72) 
-0.14-9.25 
7.11 
(3.24) 
2.44-15.85 
7.12 
(3.32) 
1.68-12.39 
Significant difference - 
1.59 
(-1.11-4.30) 
p = 0.248 
1.74 
(0.83-2.66) 
p = 0.000 
2.15 
(1.47-2.83) 
p = 0.000 
1.42 
(0.82-2.03) 
p = 0.000 
ANTs 
Atropos 
% Decrease 2008 to 2011 
0.35 
(2.95) 
-8.51-6.80 
1.90 
(3.98) 
-3.01-8.94 
2.79 
(2.95) 
-2.22-8.53 
4.64 
(2.58) 
0.59-10.90 
4.65 
(5.08) 
-2.34-22.64 
Significant difference - 
1.69 
(-0.44-3.82) 
p = 0.119 
1.32 
(0.46-2.18) 
p = 0.003 
1.45 
(0.91-1.98) 
p = 0.000 
1.21 
(0.51-1.91) 
p = 0.001 
MALP-EM 
% Decrease 2008 to 2011 
-0.73 
(2.10) 
-7.74-1.90 
1.10 
(2.05) 
-3.06-4.50 
1.52 
(2.16) 
-4.24-5.23 
3.57 
(2.56) 
-0.53-9.38 
2.99 
(3.04) 
-3.59-11.72 
Significant difference - 
1.93 
(0.66-3.19) 
p = 0.003 
1.17 
(0.54-1.80) 
p = 0.000 
1.36 
(0.90-1.81) 
p = 0.000 
0.92 
(0.48-1.36) 
p = 0.000 
FSL FAST 
% Decrease 2008 to 2011 
0.63 
(6.00) 
-18.17-13.82 
5.17 
(6.56) 
-3.67-22.14 
4.22 
(6.99) 
-0.25-31.20 
9.45 
(10.13) 
0.13-44.52 
12.09 
(12.81) 
-1.89-37.55 
Significant difference - 
3.47 
(0.52-6.41) 
p = 0.021 
2.13 
(0.71-3.55) 
p = 0.003 
2.26 
(0.99-3.53) 
p = 0.000 
1.82 
(0.75-2.88) 
p = 0.001 
FreeSurfer 
% Decrease 2008 to 2011 
-0.08 
(2.84) 
-10.87-2.81 
1.68 
(2.54) 
-3.08-6.66 
3.06 
(2.99) 
-3.23-7.75 
4.71 
(2.49) 
-1.62-8.27 
4.96 
(3.43) 
0.17-11.70 
Significant difference 
 
1.74 
(0.12-3.37) 
p = 0.036 
1.71 
(0.88-2.54) 
p = 0.000 
1.57 
(1.02-2.11) 
p = 0.000 
1.28 
(0.73-1.84) 
p = 0.000 
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Table 3.19. Mean % change (difference between 2011 and baseline volume as a percentage of 
baseline volume), standard deviation and ranges for all tools and groups in insula lobe GM. 
Positive values represent volumetric decreases over time. Results of regression analyses 
comparing rate of change in controls to HD groups, with significantly greater change in HD 
groups represented by * p<0.05 (light grey), **p<0.01 (dark grey). Age, sex and site were 
controlled for. 
 
 
 
Controls PreHD-A PreHD-B HD1 HD2 
SPM8 
Unified 
% Decrease 2008 to 2011 
0.28 
(3.39) 
-9.01-5.73 
1.50 
(2.35) 
–3.92-5.17 
1.68 
(2.59) 
-3.62-5.56 
3.97 
(3.19) 
-4.54-8.96 
4.11 
(3.36) 
-2.20-13.00 
Significant difference - 
0.75 
(-1.14-2.65) 
p = 0.438 
0.74 
(-0.19-1.67) 
p = 0.118 
1.22 
(0.58-1.86) 
p = 0.000 
1.07 
(0.44-1.70) 
p = 0.001 
SPM8 New 
% Decrease 2008 to 2011 
-0.77 
(2.95) 
-11.79-2.19 
0.17 
(1.20) 
-2.01-1.94 
0.54 
(1.69) 
-2.97-4.18 
0.23 
(1.24) 
-3.30-2.12 
1.35 
(5.08) 
-3.15-21.44 
Significant difference - 
0.86 
(-0.51-2.23) 
p = 0.218 
0.65 
(-0.05-1.35) 
p = 0.070 
0.32 
(-0.12-0.77) 
p = 0.154 
0.62 
(-0.09-1.33) 
p = 0.086 
SPM12 
% Decrease 2008 to 2011 
-0.13 
(3.01) 
-9.85-3.30 
1.55 
(3.02) 
-5.67-7.31 
2.64 
(1.84) 
0.00-6.52 
4.49 
(2.42) 
-0.47-8.85 
5.27 
(4.37) 
0.22-16.80 
Significant difference - 
1.39 
(-0.45-3.24) 
p = 0.138 
1.41 
(0.68-2.14) 
p = 0.000 
1.52 
(0.98-2.06) 
p = 0.000 
1.32 
(0.65-1.99) 
p = 0.000 
Atropos 
% Decrease 2008 to 2011 
-0.23 
(3.71) 
-13.19-4.79 
0.25 
(2.10) 
-4.82-3.59 
0.51 
(1.66) 
-3.63-3.92 
1.85 
(1.73) 
-0.97-4.60 
3.16 
(5.20) 
-1.54-21.45 
Significant difference - 
0.41 
(-1.33-2.14) 
p = 0.645 
0.40 
(-0.44-1.23) 
p = 0.351 
0.69 
(0.18-1.20) 
p = 0.008 
1.20 
(0.42-1.98) 
p = 0.003 
MALP-EM 
% Decrease 2008 to 2011 
-1.65 
(6.72) 
-23.50-10.04 
1.07 
(2.94) 
-1.91-10.41 
1.18 
(3.22) 
-2.53-12.26 
1.07 
(4.21) 
-8.27-8.34 
1.47 
(3.70) 
-3.90-11.62 
Significant difference - 
2.96 
(-0.16-6.08) 
p = 0.063 
1.30 
(-0.27-2.86) 
p = 0.104 
0.72 
(-0.37-1.82) 
p = 0.196 
0.77 
(-0.24-1.78) 
p = 0.136 
FAST 
% Decrease 2008 to 2011 
-0.72 
(5.10) 
-19.77-4.00 
1.99 
(2.83) 
-2.61-8.31 
1.71 
(2.12) 
-1.16-8.53 
2.90 
(1.91) 
-1.34-5.73 
3.49 
(2.41) 
0.59-9.00 
Significant difference - 
1.97 
(-0.11-4.04) 
p = 0.063 
1.19 
(0.13-2.25) 
p = 0.028 
1.13 
(0.44-1.81) 
p = 0.001 
0.93 
(0.21-1.64) 
p = 0.011 
FreeSurfer 
% Decrease 2008 to 2011 
-0.69 
(4.26) 
-16.16-3.23 
1.29 
(2.49) 
-1.88-7.00 
1.13 
(2.47) 
-4.12-5.36 
1.74 
(2.42) 
-1.79-6.90 
3.43 
(3.51) 
-3.24-14.01 
Significant difference  
1.56 
(-0.45-3.56) 
p = 0.128 
0.84 
(-0.18-1.87) 
p = 0.106 
0.72 
(0.03-1.41) 
p = 0.041 
0.95 
(0.27-1.63) 
p = 0.006 
 
3.4. Discussion 
The detailed analysis of GM segmentation techniques undertaken in this research has 
provided useful insight into the measurement of grey matter volume within HD, especially for 
measurement of the CGM. The combined qualitative and quantitative analyses conducted on 
two different datasets provided great depth of information that allows informed choices to be 
made on the best techniques for use on the TRACK-HD cohort, but also offers lessons for 
researchers working on other cohorts. The results demonstrate that most tools show good 
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reliability when assessed via quantitative measures, but that visual QC highlights variability 
between tools. Furthermore, the tools show different patterns of results when using them to 
measure longitudinal change, supporting previous work that highlights the impact of different 
methods on the conclusions drawn in neuroimaging (Katuwal et al. 2016). 
An initial finding that warrants discussion is that the user input required for each tool 
varies widely. Some tools required processing steps prior to the segmentation (e.g. ANTs), 
whereas others did not (e.g. SPM, FreeSurfer). In addition, some required the ability to 
optimise the pipeline for different datasets by creation of a template or probability priors. 
While some users may prefer greater flexibility and customisation options from a tool, others 
may want a more simple application with limited options. Based on the experience of running 
seven tools on both BrainWeb and TRACK-HD datasets, all tools except ANTs were user-
friendly and understandable. Despite having experience in some coding and an understanding 
of concepts related to the processing of MRI data, ANTs was still difficult to optimise and 
obtain satisfactory results from. While there is evidence that ANTs is reliable and accurate 
(Tustison et al. 2014; Avants, Tustison, Wu, et al. 2011; Schwarz et al. 2016), these results were 
not replicated and it is assumed that this was because of the difficulty experienced when 
trying to apply the tool to the current datasets. Whilst satisfactory results were achieved, it 
involved a lot of experimentation, and the results were inferior to what was expected given 
the previously reported performance of ANTs. Interestingly, this replicates a recent study 
which also found poorer performance on ANTs than anticipated (Righart et al. 2017) For a 
novice user with little understanding of the multitude of options required to run tools such as 
ANTs, optimisation can be a long process of trial and error rather than making informed 
choices about the best options to select for each dataset. Most other tools provided default 
options that were largely successful.  
Another difference between tools that is important to recognise is that many define 
GM regions differently; some include subcortical structures, cerebellar GM and brainstem, and 
some do not. In addition, some only provide whole-brain results and some divide the GM into 
large or small regions. The use of PVE GM versus discrete GM volumes is inconsistent between 
the tools, with most tools outputting both partial volume corrected maps and discrete tissue 
maps (FSL, ANTs, MALP-EM) but some outputting more complex volumetric maps (FreeSurfer). 
Some software also output pre-calculated volumes for the segmentations and regions in text 
files. Table 3.20 shows a summary of these factors for the software included in this analysis.  
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Table 3.20. A summary of some characteristics of the tools included in the current study.  
 
SPM8 
Unified 
Segment 
SPM8 New 
Segment 
SPM12 
Segment 
ANTs MALP-EM FAST FreeSurfer 
Total GM 
volume? 
Yes Yes Yes Yes Yes Yes Yes 
Regional Volume 
as default? 
No No No 
No 
(additional 
steps 
required) 
Yes No Yes 
Partial Volume 
Maps? 
Yes Yes Yes Yes Yes Yes No 
Discrete Volume 
Maps? 
No No No Yes Yes Yes No 
Volumes 
automatically 
output in text 
file? 
No No No No Yes No Yes 
 
Qualitative analysis was done prior to quantitative analysis for both datasets. For the 
BrainWeb data initial examination of the output enabled greater understanding of the 
performance of each technique in a near perfect dataset. While the quantitative analysis can 
measure the performance of a number of metrics, only visual QC can detect subtle and 
persistent factors in the regions, such as over- or underestimation of the GM. Whilst reviewing 
the segmentations, the GT for each scan was examined and it became clear that GT regions are 
slightly inaccurate. The segmentations included dura in a moderate number of scans, and this 
should be considered whilst drawing conclusions from this analysis. Due to the errors 
associated with the BrainWeb GT, a total overlap between the GT and segmentation tools 
should not be expected as some of the tools may more accurately delineate the cortical 
surface.   
SPM8 Unified Segment was the first tool to be examined. The border between WM 
and GM was gradual, with a large number of voxels classified as having some proportion of GM 
although upon visual inspection they were WM voxels. In the BrainWeb dataset the GM/CSF 
boundary was tight, although this was not an issue in the TRACK-HD cohort. While the 
software performed well in the artificial BrainWeb data, in the TRACK-HD cohort SPM8 Unified 
Segment poorly segmented the occipital GM and temporal poles, with these areas frequently 
being overestimated. There was also occasional underestimation of the frontal lobes. This 
indicates that on a real dataset with increased noise and movement the software suffers from 
increased errors in segmentation. SPM8 Unified Segment also had the highest rate of 
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segmentation failures, with 11 initial fails in the TRACK-HD data (3.67% of the dataset), 
reducing to 6 total fails (2% of the dataset) after re-aligning and re-running the data in the 
TRACK-HD cohort.  
In both the BrainWeb and TRACK-HD segmentations SPM8 New Segment introduced 
significant error through the incorrect classification of voxels in the dura, skull and outside the 
skull as GM. While the PVE for these voxels were low, this error was persistent and if these 
segmentations were used for a whole study it is likely that the results would be less sensitive 
to group differences or longitudinal change due to the incorrect classification of non-brain 
tissue. In addition, SPM8 New Segment also showed problems with overestimation of the 
occipital and temporal lobes. 
 SPM12 showed an improvement on both earlier versions of SPM. The boundaries 
between GM/WM were clearer and for the TRACK-HD cohort the delineation in occipital and 
temporal regions was improved, although there was still minor overestimation and spillage 
into the dura in these regions. Based on visual inspection, SPM12 output the most accurate 
version of SPM.  
ANTs was the most variable software, likely due to the increased user input required 
to process scans using this software. While this allows for more flexibility and greater 
applications of the software, it can also result in variable results due to minor differences in 
steps such as template creation or registration. For the BrainWeb dataset ANTs performed 
well, showing good delineation of the sulci and no persistent errors. Performance in the 
TRACK-HD dataset appeared to be highly dependent on brain size, with small brains including 
more dura. For this cohort a standard group template was created resulting in a template that 
was too large for the HD participants, but it is possible that if a template was created for each 
HD group the results could be improved. Similarly to SPM, the most common regions for errors 
were the occipital and temporal lobes – with overestimation the most persistent error, 
although the amount of overestimation varied largely. 
MALP-EM was the most visually consistent software both within and between the two 
cohorts. In the BrainWeb dataset it suffered from minor underestimation of the temporal 
regions in some cases, but performed well otherwise. In the TRACK-HD cohort the consistent 
errors associated with occipital and temporal segmentation in other techniques appeared 
much more infrequently in MALP-EM regions. There were minor examples of dura inclusion or 
exclusion in some scans around the superior boundaries.  
FAST performed very differently on the BrainWeb and TRACK-HD cohorts. The 
segmentations on the BrainWeb dataset were very good, with good delineation of the surface 
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and only minor spillage in occipital and temporal lobes. Comparatively, FSLs FAST performed 
very poorly on the TRACK-HD cohort. This was mostly due to the failure of the initial brain 
extraction, BET, to successfully detect and extract the brains in this dataset despite using an 
optimised procedure. Large chunks of the frontal and occipital lobes were often omitted from 
the segmentations, and spillage into other brain regions was also a problem for these 
segmentations. The contrast between these two scenarios highlight the importance of testing 
all tools before applying them to different datasets, since software which performs very well in 
one dataset may perform poorly in another due to the large variability associated with MRI 
scanning parameters and different cohorts.  
FreeSurfer performed very poorly on the BrainWeb data. Large regions of the GM 
were omitted from almost every segmentation, especially in occipital, frontal and temporal 
lobes. While FreeSurfer segmentations for the TRACK-HD data were an improvement, the 
regions were generally tight, suggesting overall underestimation of the GM, and there were a 
number of segmentation errors, with the most common error being overestimation of the 
occipital and superior regions of the brain.  
The qualitative results showed large variability in performance, with SPM12 Segment 
and MALP-EM appearing as the most consistent and accurate methods after visual QC. In 
addition, with further optimisation of the group template and segmentation procedure on the 
TRACK-HD cohort it is likely that the results from ANTs could be improved to reduce errors 
associated with inclusion of extra dura. Of these tools, MALP-EM performed the most 
consistently in the TRACK-HD cohort with less overestimation of occipital and temporal 
regions, and only rare cases of the GM region extending into dura or cortical volume excluded 
from the region. Throughout this process, over 2000 segmentations were reviewed and it 
quickly became apparent how vital the visual QC process is. A number of scans failed 
processing initially, either due to user error such as the incorrect parameters being specified or 
due to failure in the software. When examining the volumetric values output from failed 
segmentations it was not always obvious from these values that the segmentation was very 
poor. This supports one previous study in which outliers were used to select the scans that 
require visual QC. The authors found that this technique resulted in a large number of 
segmentation errors being missed, and concluded that all data should undergo visual QC 
(Waters et al. 2017). Our results confirm this, as often when the volumetric values of a failed 
segmentation were compared to other values for the same region, they did not appear to be 
quantitative outliers. When performing a longitudinal or regional analysis, the inclusion of 
failed data would have a large impact of the results. While only a small number of scans did 
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completely fail processing in the current study, there were a greater proportion of poor 
segmentations – especially for FAST and FreeSurfer and particularly in the occipital and 
temporal lobes. When performing analysis on a small cohort or trying to detect subtle brain 
changes within a group these poor segmentations would likely have a large impact on the 
sensitivity of tools. In these instances, more stringent inclusion criteria would be beneficial. 
The quantitative results from the BrainWeb analysis provide evidence on the accuracy 
of these tools. Initially, the BrainWeb cohort was used to compare both partial volume maps 
and discrete volume maps to the GT.  For all segmentation techniques that provided partial 
volume maps, the values were much closer to those of the GT, and mean differences were 
generally lower, suggesting a higher level of accuracy. This is consistent with previous reports 
(Tohka 2014). While the dice scores for most measures were slightly lower for partial volume 
maps, it is likely that this is due to the voxel-wise calculation of dice scores in this study. For 
discrete volumes the voxel values were either 1 or 0, corresponding to GM or not GM, 
whereas for partial volume maps the voxels could vary between 0 and 1 and thus a lower level 
of overlap in the partial volume scores is unsurprising.  
Total and cortical GM results for the BrainWeb analysis suggested that while there was 
good correspondence between BrainWeb values and the output volumes for the different 
tools, there were still large differences in the raw volumes. This was especially apparent for 
FreeSurfer, which had a much greater difference than any other method for cortical GM, 
significantly under-estimating cortical GM. While a complete overlap was not expected due to 
the errors in BrainWeb segmentations previously mentioned, the large divergence between 
BrainWeb and FreeSurfer is concerning, and supports the poor results of the qualitative 
analysis examining FreeSurfer. The other tools overall performed well on the BrainWeb data, 
with small, albeit significant, differences between the GT volumes and segmented volumes. 
The ICC values from all tools provided evidence that there is good overlap despite the 
significant differences in raw volumes.  
The lobular results provide more specific information on the performance of these 
tools, especially FreeSurfer. The values for most tools were close to the expected values based 
on the GT. Differences between the raw GT and lobular volumes for most tools were around 3-
4%, and although these differences were significant in a number of cases, as measured by 
paired t-tests, the overlap measures indicated voxel-wise correspondence of around 0.90. This 
demonstrates very high quantitative overlap with the GT. FreeSurfer showed large differences 
to the lobular GT volumes for all lobes. While it is likely that this is, in part, due to the fact that 
the automatically calculated regions were used for the FreeSurfer lobular analysis (see section 
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3.2.4), it also demonstrates the poor performance of FreeSurfer on the BrainWeb data as 
verified by the visual QC. Unfortunately, it is impossible to calculate voxel-wise overlap for 
FreeSurfer as voxel-wise maps are not output during processing. However, the visual and 
quantitative results provide enough evidence to demonstrate very poor performance of 
FreeSurfer on the BrainWeb data.  
The wide variation in the quality of segmentation performance on the TRACK-HD data 
is further demonstrated by the quantitative results, which showed large differences in 
segmentation across tools for raw total, cortical and lobular GM volumes. Longitudinal analysis 
demonstrated that while the pattern of total and cortical GM change was similar across tools, 
when GM change in HD participants was statistically compared to GM change in controls, the 
tools detected differing degrees of change. In addition, for lobular volumes the tools showed 
different patterns of change in a number of regions. Despite the variability in raw volumes and 
sensitivity to change, all tools generally showed high reliability across groups and regions, as 
measured by ICC and repeatability metrics, and extracted volumes were typically highly 
correlated between different tools.  
For controls and HD participants, GM regions derived using MALP-EM were 
consistently larger than those for other tools, likely due to the regions having higher overall 
probabilistic GM segmentation values. SPM also outputted comparatively large regions, with 
FSL FAST and FreeSurfer outputting the lowest; a discrepancy that has been previously noted 
(Katuwal et al. 2016). SPM regularly over-estimated both occipital and temporal lobe regions, 
this was particularly noticeable for larger brains and in earlier versions of SPM, indicating that 
SPM may over-estimate between-group differences when comparing healthy to atrophied 
brains. Low volumes output from FSL segmentations can be explained by regular 
underestimation of the cortical GM, partly resulting from poor brain extraction in this cohort. 
It is important to note that the poor performance of BET should not rule out the use of FSL in 
other cohorts, since it is known to perform well on other data (Smith 2002). Lower volumes 
output by FreeSurfer are possibly due to subtle underestimation of the GM occurring at the 
cortical boundary with CSF. While the partial volume included via calculation of FreeSurfer 
regions would account for some of these voxels, the regions remained tight along the outer 
boundary after accounting for this. ANTs showed average values that were in the middle of 
most tools, possibly due to the variable performance of this tool. 
Although all tools demonstrated errors using the default pipelines, in this analysis no 
manual intervention was performed to improve the quality of segmentation due to the 
increased subjectivity involved in manual intervention. However, it is important to note that all 
 138 
 
tools offer some opportunity to improve the issues described above via optimisation of the 
segmentation and/or manual intervention after segmentation. For example, FreeSurfer allows 
editing of the segmented region to improve regions with over- or under- segmentation, MALP-
EM, FAST, SPM and ANTs can all be used with highly optimised masks to improve 
segmentation, or can be manually edited after segmentation.  
Despite the lack of optimisation and manual editing it is reassuring to note good 
reliability for back-to-back scans across tools using ICC and a repeatability metric. These 
findings support the results of previous studies comparing SPM, FSL and FreeSurfer (Katuwal et 
al. 2016) and provide new results validating ANTs and MALP-EM. Most tools were also highly 
correlated, again supporting previous studies (Katuwal et al. 2016). Furthermore, there was no 
indication from the quantitative results that the tools have any difference in reliability 
between control participants and HD participants. Although correlations between the 
techniques tended to decrease with increasing disease progression, indicating some 
divergence of performance between the tools on brains with more advanced atrophy, 
particularly for SPM8 Unified Segment, which resulted in smaller volumes for HD participants 
and may indicate an under-estimation of GM in HD. This result is similar to a previous study, 
which indicated possible over-estimation of group differences in SPM (Callaert et al. 2014). 
Using optimised brain masks or performing manual editing may improve performance on 
atypical brains, but generally the tools performed as well on HD participants as they did on 
control participants.  
Different techniques showed different longitudinal sensitivity to GM change in HD 
groups compared to controls, especially within the five lobes. For total and cortical GM, all 
techniques showed decreasing volume with increasing disease progression. While SPM8 
Unified Segment, SPM12 and FAST showed the largest decreases in total GM volume over 
time, MALP-EM and FreeSurfer both showed significant change across all disease stages, 
possibly indicating greater sensitivity to small changes. In cortical GM, SPM8 Unified Segment, 
SPM12 and FAST showed large decreases in raw GM volume, but again MALP-EM and 
FreeSurfer showed statistical sensitivity to small changes. MALP-EM was developed for use in 
clinical cohorts, which could partly explain the sensitivity of MALP-EM in an HD cohort (Ledig 
et al. 2015).  
The results of the longitudinal lobular analysis indicate large differences between the 
tools on each lobe, with particular divergence between tools in the frontal lobe, temporal lobe 
and insula. The results of this analysis emphasise the importance of good quality 
segmentations, with some significant results being driven by participants with very high rates 
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of change. For example, a significantly greater volumetric loss in PreHD-A compared to 
controls in the frontal lobe as measured by FSL FAST was possibly driven by a percentage loss 
in one participant of 18% between baseline and follow-up. Re-examination of the 
segmentations revealed underestimation of the frontal lobe in the follow-up time point rather 
than a true volumetric change. If manual editing had been performed this result would be 
accounted for, and a more biologically plausible rate of change measured. The impact of 
segmentation errors is reduced in large cohorts or with whole-brain analyses, but when 
examining regional change the quality of every slice of the segmentation is paramount. This 
result supports the work of (Iscan et al. 2015) who found that by including scans which have 
poorly delineated FreeSurfer regions in an analysis, the sample size required to detect a true 
effect increases. It is possible that the results shown in the parietal and occipital lobe are more 
uniform across tools as this is a region that is thought to undergo the most atrophy within 
cortical GM in pre-HD and early HD (Johnson et al. 2015; Rüb et al. 2015; Tabrizi et al. 2012; 
Wolf et al. 2014), and so statistical sensitivity to change in these regions is more robust when 
segmentation quality is sub-optimal and variability is high. In comparison, regions that may 
have slower rates of change in HD (e.g. frontal lobe) are more easily biased by poor 
segmentations and thus different techniques identify different patterns of atrophy. 
Interestingly, all techniques found a higher volume in PreHD-A than in controls. This result is 
consistent with TRACK-HD, and may indicate a compensatory mechanism in the pre-HD group 
However, the raw volumes are not corrected for TIV and so these findings should be further 
investigated. This study is underpowered to draw conclusions on the true nature of lobular 
progression of GM atrophy in HD, the results provide a useful demonstration on the 
importance of selecting a segmentation tool that performs well on a particular dataset. 
3.4.1. Suggestions for the selection of a segmentation tool  
The results of this study can inform the selection of a GM segmentation tool for use in 
the TRACK-HD cohort, but they can also be generalised to other clinical cohorts, particularly 
neurodegenerative diseases. All tools showed consistently high reliability when used with 
clinical data. However, there were a significant number of segmentation errors and while 
segmentation quality for each tool can be optimised, it is important to note variable results are 
likely depending on factors including scanner parameters, quality of data and researcher 
expertise. This analysis can help to provide a set of guidelines on how to select of the most 
appropriate segmentation tool in different types of datasets, as described here. 
3.4.1.1. Which segmentation tool best answers your question? 
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It is important to consider which software tools contain features that are most 
appropriate for addressing your question or hypothesis. For example, if regional GM volume is 
the main focus, considering software that includes the option to perform regional analysis and 
atlas optimisation can potentially reduce errors otherwise introduced when applying a mask to 
your cohort. Some tools (for example, SPM, ANTs, FSL, MALP-EM) are suitable for extracting 
volumes from customised regions or atlases applied to volumetric maps, while others, such as 
FreeSurfer, recommend using default atlases. Furthermore, the intended use of other 
structural analyses such as CT or VBM should also be considered.  
3.4.1.2. Are your knowledge, experience and resources 
sufficient to use the tool?  
 While some tools offer numerous options for customisation, this often requires an 
appropriate level of analysis and computing expertise. Without full understanding of the 
changes being applied to a pipeline, there is a risk of producing results that are not accurate, 
reliable or reproducible. Conversely, some tools provide little or no customisation, and thus 
are simple to apply yet may be limited in the range of appropriate applications. If available, 
use your chosen tool to analyse test data with the same MRI acquisition parameters as those 
in your study prior to beginning the analysis on a full cohort of participants. This will reduce 
delays due to errors or complexity of technique when applying it to a large cohort.  
As an example, ANTs has previously been validated with impressive results for both 
registration and CT using default pipelines in a healthy cohort (Avants, Tustison, Song, et al. 
2011; Tustison et al. 2014). However, due to the number of possible optimisations for a clinical 
cohort, such as creation of a study-specific template and priors, an inexperienced user may 
find using this tool challenging. When applying ANTs to the TRACK-HD cohort, the large 
variation in brain sizes within each patient group meant that when using the study-specific 
brain mask to extract the brain, dura was often erroneously classified as GM. Group-specific 
templates may have been more suitable here, but this would have required more time and 
expertise to create and optimise. 
  Another consideration is the variable nature of processing time necessary for 
each tool, which can range from 5 minutes per brain (SPM) to 24 hours (FreeSurfer). In 
addition, a number of registration or segmentation tools require high levels of processing 
power and may not run locally on desktop/laptop machines. Access to a high-powered 
computer cluster or just a single laptop with limited processing resources might determine 
which tool you choose. Financial costs also warrant consideration. While all tools examined for 
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this case study are freely available for academic purposes, SPM works on a MATLAB platform 
that is not freely available. In addition, some tools require a licence for use in industry settings 
and if developing methodology for later use within clinical trials, industry costs of these tools 
should be considered.  
3.4.1.3. Which segmentation tools are most reliable? 
A number of studies have previously demonstrated that some of the tools discussed in 
the current study have high reliability (Eggert et al. 2012; Klauschen et al. 2009). These findings 
were supported by current results in the TRACK-HD cohort. Current versions of all tools, 
including two not previously validated in this way (ANTs Atropos and MALP-EM), 
demonstrated high reliability. While repeatability was more variable, and lower in early-HD 
participants, the values were still very good for most tools. While reliability can be established 
for all tools in this and previous studies, accuracy is more difficult to determine – see 3.4.1.4.  
3.4.1.4. Which segmentation tools are most accurate? 
While phantom data can be used to examine the accuracy of volumetric measurement 
tools in healthy models, the results of phantom analyses do not always represent performance 
when applied to clinical cohorts. In HD, for example, where the pattern of neural change is not 
well understood it is challenging to define the tool that provides the greatest accuracy. Often, 
measures are examined in terms of their overlap to estimate accuracy – however since all 
tools showed consistent errors (e.g. over-segmentation in occipital and temporal regions) this 
could falsely inflate accuracy results. How do we determine which is the most accurate result? 
Visual QC was an important factor when assessing accuracy in this study. MALP-EM appeared 
to be the most visually accurate tool, with SPM12 also performing well despite some 
segmentation errors in temporal and occipital regions. By comparing the results of longitudinal 
change in this sample to other previously published values of longitudinal GM change in larger 
HD cohorts (measured by various techniques), it appears that a number of techniques over-
estimate GM change in this small cohort. SPM8 New Segment, MALP-EM, ANTs and FreeSurfer 
produced values in line with previous studies suggesting that they may be able to detect 
accurate results from a small sample (Juan et al. 2016; Tabrizi et al. 2012). Since 
inconsistencies between volumetric neuroimaging tools are thought to result in contradictions 
within clinical neuroimaging research (Ashburner et al. 2016), it is imperative that the accuracy 
of each tool is visually examined within a cohort to ensure good performance of the tools on 
each dataset.  
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3.4.1.5. Should I perform visual QC of my data? 
This is a necessary step in the processing of any data. All registrations, segmentations 
and masks in this study were visually checked. Errors in processing, complete segmentation 
failures or patterns in segmentation errors were only detected by viewing the data. While total 
failure of a tool to segment an image was rare, consistent errors in segmentation were 
common. In cases where segmentation did fail completely, the volumetric measurements for 
total GM and CGM were often not out of line with expected values and so may not be 
detected in a quantitative check of extreme values, but would not provide reliable data on 
pathology or longitudinal sensitivity to change. This replicates previous findings (Waters et al. 
2017). 
In this study, for cases where segmentation was poor but not classified as a fail the 
data were included in the final analysis but for an analysis aiming to quantify group 
differences, including this data would mean that a larger sample size would be required to 
detect true effects (Iscan et al. 2015). The process of performing visual QC and rejecting or 
editing poor quality data is likely to be easier than recruiting and scanning more patients. 
When investigating GM volume in a cohort with subtle disease effects such as pre-HD HD 
patients, the benefits of visual QC are likely to be substantial. 
In addition to visual QC, manual editing can be performed where appropriate to 
improve results. In large cohorts this may be unfeasible, however as all techniques showed 
some segmentation errors in the TRACK-HD cohort and all offer options for manual editing this 
should be considered. It is particularly important for studies in which subtle group differences 
or longitudinal change is expected or when sub-regions are being examined. Manual editing 
requires the user to have in-depth knowledge of anatomy and to use a consistent procedure 
for specifying when manual editing should be performed. 
One issue associated with visual QC is performing QC on ‘big data’ cohorts. Big data 
cohorts are increasing in availability, and consist of datasets whereby thousands of scans have 
been collected, for example the UK biobank study which aims to collect data from 100,000 
participants (Alfaro-Almagro et al. 2018). This data is then often available to download and 
use. However, when processing data from so many participants visual QC is impossible. It is 
unclear how this issue can be managed, however since large datasets are likely to be more 
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robust to the effect of segmentation errors on analysis results, the issue may also be less 
important in these cohorts. While automated tools may be developed to assist with QC, it is 
unlikely that these will ever be as successful as visual QC performed by a trained human rater.  
UK Biobank is currently developing tools to perform automated QC (Alfaro-Almagro et al. 
2018) and as these tools are validated against manual QC this issue will no doubt gain further 
attention.  
3.4.1.6. How similar are results across the different tools? 
For control participants all tools appeared to produce very similar results for both total 
GM and CGM; with between–technique correlation coefficients generally high, although 
slightly higher for CGM volume, indicating that techniques show greater variation in 
subcortical segmentation.  
However, in HD participants the correlations were more variable, indicating that some 
techniques appear to detect disease-related change to a greater extent than others. In total 
GM volume, the relationships between techniques were generally lower than in controls. For 
CGM correlation coefficients were higher and more stable than for total GM, indicating that 
measurement of the subcortical grey matter may be more variable than CGM across different 
tools. As marked subcortical atrophy in the caudate and putamen is a defining feature of HD, it 
is unsurprising that the techniques may perform differently when segmenting this region, 
especially for tools developed on healthy controls. These results suggest that care should be 
taken when applying techniques in regions of severe atrophy or change, with much more 
divergent performance apparent in the use of the tools in these circumstances. 
3.4.2. Limitations 
The results of this study are limited by a few factors. Firstly, the aim was to examine 
segmentation procedures as non-technical users would routinely apply them and thus default 
brain extraction was used for each tool. This introduces additional variability to the 
comparison, and between-technique differences would likely be reduced if the same brain 
extraction was used prior to segmentation. In addition, the longitudinal pipelines offered by 
some tools were not compared (e.g. FreeSurfer, SPM, FSL) as not all tools currently offer a 
longitudinal pipeline.  
There are a number of additional limitations in the examination of BrainWeb data. 
Firstly, the GT segmentations were not provided in the same resolution as the T1 scans that 
were downloaded; the T1 scans had a voxel size of 1x1x1mm whereas the GM volumes had a 
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voxel size of .5x.5x.5mm.  Resampling was applied to the GM volumes to change the voxel size 
of the images. A number of different resampling methods were tested, with the most 
appropriate selected after careful examination of the output, and comparison of extracted GT 
volumes to previously published volumes for the GT segmentations showing an exact match 
(Klauschen et al. 2009). Finally, this comparison is limited by the absence of FreeSurfer in the 
partial volume analysis. FreeSurfer does not provide partial volume maps and so was excluded 
from the second analysis. Finally, in this study scans were used from multiple sites that could 
impact the performance of different techniques. However, this is also a relevant point given 
the increasing number of multi-site studies.  
While as much consistency was maintained as possible during this analysis, some 
differences in performance were introduced by the differences described above, especially in 
the case of FreeSurfer. The developers of FreeSurfer recommend using the automatically 
output volumes provided in a text output for all participants. These values are calculated via 
correcting the volumetric regions for partial volume, and cannot easily be reproduced 
manually. Due to the difficulty in extracting GM volume from volumetric masks for FreeSurfer, 
total GM and CGM values were the values supplied automatically from FreeSurfer processing. 
Since the CGM volumes for FreeSurfer were output without overlaying the same mask used to 
extract values from the output of all other tools, the results cannot be directly compared to 
the other methods, and thus FreeSurfer is likely at an advantage for these results. For the 
lobular analysis, BrainWeb lobes were calculated using the automatic FreeSurfer methodology, 
but because the results were very different to the GT volumes, the TRACK-HD analysis used the 
lobular masks that were applied to the other segmentations. These were registered to 
FreeSurfer space and values were extracted using FreeSurfer commands. While this is possible, 
it required a number of posts on a FreeSurfer help list to output these values and the process 
was not always clear. All other techniques were examined using the partial volume maps in 
native space, with the same masks applied to the output of each technique.  
3.4.3. Segmentation selection for the current work 
When selecting a technique to use it is of course important that the question being 
asked is considered in relation to the type of measure provided by a tool; for the present 
research, CGM is the focus and the ideal measure would only output CGM without the need to 
use a manually registered mask to extract the cortical region. The use of a manual mask 
introduces a degree of measurement error as it is unlikely that manual masking of subcortical 
or cerebellar GM would be superior to a pre-optimised technique that extracts CGM. Another 
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issue to consider is that some measures do not provide regions that can be masked or that 
volumes can be extracted from, and indeed FreeSurfer makes this very difficult to do. It is not 
always clear how the volumes automatically output by the FreeSurfer pipeline are calculated, 
and it is often impossible to manually reproduce these volumes from the segmentations. If a 
proposed analysis does not use an already available FreeSurfer region then different software 
should be considered.   
A final point to reiterate is regarding the use of these tools is how user-friendly they 
are. While most tools were fairly straightforward to apply, ANTs took a lot of time to 
understand and apply. Despite the large investment required to apply ANTs, the results were 
substandard, although it is possible that with a greater ability to optimise this tool the results 
could be improved. This tool may not always be appropriate for a novel user. In contrast, 
MALP-EM was the easiest method to use; it comes in an easy-to-install package, and since it is 
aimed at novice users there are no optional flags to adjust other than the use of a 1.5T vs. 3T 
flag.  
Based on the qualitative and quantitative results MALP-EM demonstrated the most 
accurate and reliable performance for both the BrainWeb and TRACK-HD cohorts. MALP-EM 
will therefore be used for the CGM analysis in this thesis. It is hoped that because MALP-EM 
performed well on both datasets, is easy to use and freely available other neuroimaging users 
may be able to apply MALP-EM and undertake replication of the work completed in this thesis.  
3.4.4. Conclusions 
With a multitude of tools available to measure the volume of GM using MRI scans, the 
selection of the most appropriate tool can be a challenging first step in a research project, and 
one that may have a marked effect on the results of research. By using seven segmentation 
tools to quantify GM volume in a cohort including controls and participants with pathology, 
with both back-to-back and longitudinal data, a number of key points related to the 
measurement of GM volume could be highlighted. Table 10 provides some characteristics of 
the tools included in this study that can help to guide the initial decision making process in GM 
volumetric selection. 
All methods compared in this work showed high reliability, supporting the results of 
previous studies and adding new information for the use of ANTs and MALP-EM, which have 
not been compared in this way previously. For the current cohort, the tools that detected the 
greatest raw change over a three-year follow-up period were not always the most sensitive to 
significant change in this period, indicating that higher variability in performance of these tools 
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reduced their sensitivity to subtle disease-related change. Despite this, all tools detected 
significant longitudinal change in GM when comparing the most advanced patients in the 
cohort to controls, meaning that all tools are sensitive to more advanced neural pathology 
across the whole cortex. Subtle regional differences were not detected by all tools, however. 
One of the most significant findings from this study is the importance of visual QC of GM 
segmentations. Poorly segmented and inaccurate data can easily be included in neuroimaging 
research if visual QC is omitted. While time consuming, the results of research that uses visual 
QC will be more sensitive and accurate than if it is not performed.  
No one tool is more appropriate for analysis of every type of dataset or cohort. Several 
key considerations for the selection of the most appropriate grey matter segmentation tool 
have been identified. The scientific question, level of expertise and available resources are 
naturally paramount, while comparison of two or three different tools for ease and success of 
application is recommended and visual QC essential. For the current work, MALP-EM has been 
selected as the most appropriate GM segmentation tool. 
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4. EVALUATION OF CORTICAL THICKNESS MEASURES 
In addition to volume, thickness of the CGM can be measured via MRI. CT is the 
distance between the WM/GM boundary and the GM/CSF boundary, and post mortem studies 
indicate that thickness ranges from approximately 1mm to 4.5mm, with an average across the 
cortex of 2.5mm (Fischl & Dale 2000). CT varies between individuals, shows changes across the 
lifespan and is hereditable (Panizzon et al. 2009; Fjell et al. 2015; Winkler et al. 2010; Winkler 
et al. 2009; Thambisetty et al. 2010; Storsve et al. 2014).  
GM volume is a product of both the thickness and surface area of the cortex (another 
hereditable cortical characteristic genetically independent to CT), and thus it has been 
suggested that measuring cortical volume alone may not be sensitive enough to detect subtle 
disease-related brain changes, and that CT should also be examined (Panizzon et al. 2009). 
However, CT is challenging to calculate from MRI scans. Highly accurate delineations of the 
cortical surfaces are required, which is difficult to achieve in the complex sulci and gyri of 
brains. CT is calculated at every point in the cortex and errors in the delineation of the cortical 
surfaces can result in large overestimations of thickness. Even if overestimations only occur in 
a small number of regions they can result in large artificial inflations of global CT measures. 
These potential issues mean that the measurement tools used to calculate thickness are highly 
important.   
CT is typically measured via either surface-based or voxel-based techniques, with an 
example of these two measures shown in Figure 4.1 (Clarkson et al. 2011). Surface-based 
measurement involves the construction of a meshed surface, typically on the GM/WM 
boundary, which is then expanded to encompass the outer surface between GM and CSF. The 
distance between these two surfaces can then be measured at each vertex or averaged across 
the whole cortex and sub-regions (Dale et al. 1999; Fischl et al. 1999; Fischl & Dale 2000). 
Surface-based methods tend to rely heavily on prior information about the brain to guide 
segmentation, known as probabilistic segmentation (Clarkson et al. 2011). Voxel-based 
techniques use the voxel-wise grid to first classify GM, WM and CSF and then measure the 
distance between WM and GM using Laplacian, registration, morphological or other 
techniques (Clarkson et al. 2011). Surface-based techniques are more computationally 
demanding, however they can overcome issues associated with the partial volume of voxels as 
the surface is not limited to follow voxel boundaries (Winkler et al. 2010). Due to this, they are 
considered more accurate than voxel-wise measures of thickness (Clarkson et al. 2011). 
Although they are affected by intensity non-uniformity and often perform poorly in areas with 
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low resolution and/or high curvature, due to the large amount of natural variation not covered 
in the probabilistic model. Furthermore, the use of probabilistic methods, which were created 
using a healthy-brain atlas, may not be appropriate for brains with pathological or anatomical 
differences. Despite these issues, surface-based methods are more often used to measure 
thickness largely due to a number of freely available and accessible measurement tools, with 
the most commonly used being FreeSurfer (Fischl & Dale 2000). Recently, however, voxel-
based methods are becoming more popular due to the speed at which the data can be 
processed, lower segmentation failures and higher reliability than FreeSurfer (Schwarz et al. 
2016).   
 
 
Figure 4.1. An example demonstrating the difference between surface- and volume-based 
methods of measuring CT (Winkler et al. 2010). 
 
One major problem relevant to measuring CT is that of the failed segmentation of 
deep sulci (Clarkson et al. 2011). Deep, narrow sulci can be incorrectly classified as GM, 
resulting in an overestimation of thickness, as seen in Figure 4.2. If sulci are not separated via 
the segmentation process, CT is calculated spanning the two regions of CGM on either side of 
the sulci, creating in extremely large values for thickness at these points. This problem arises 
due to the inherently complicated pattern of cortical folding present in the brain, and although 
some methods aim to combat this problem via the use of limits that do not allow CT to be 
above a maximum biologically plausible threshold, it is a recognised difficulty within the field 
(Das et al. 2009; Clarkson et al. 2011).  
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Figure 4.2. Examples of a segmentation whereby (A) sulci have been incorrectly classified as 
GM, shown by the red arrows, resulting in an overestimation of cortical thickness and (B) the 
sulci have been correctly classified, shown by the green arrows, resulting in a more accurate 
measure of cortical thickness (Clarkson et al. 2011). 
 
Despite the use of MRI phantoms and models in a number of CT validation studies to 
try and assess accuracy of segmentation (Clarkson et al. 2011; Lee et al. 2006), it is difficult to 
establish a validate the performance of CT tools on real brain data. The complex nature of the 
convoluted cortex, the range of different definitions of the GM/CSF border and the WM/GM 
border, and different techniques and equations for calculating the distance between the two 
means that it is a complex metric to measure. Furthermore, post-mortem analyses of CT may 
not be accurate due to tissue shrinkage and so is not generally used as a comparison. Instead, 
thickness tools are often assessed for reliability, reproducibility and sensitivity. Some methods 
apply constraints in order to limit the maximal and minimal thickness values to values 
considered biologically plausible in order to try and aid accuracy, although using the same 
maximal and minimal values in healthy and very atrophied brains may not be appropriate (Das 
aet al. 2009).  
A number of studies comparing CT measures have been performed, with some 
examining test-retest reliability of different tools (Iscan et al. 2015; Han et al. 2006; 
Wonderlick et al. 2009; Gronenschild et al. 2012; Schwarz et al. 2016) and some comparing the 
performance of thickness measures on their ability to separate participants by disease status 
(Tustison et al. 2014). FreeSurfer generally performs well when test-retest reliability is 
examined (Han et al. 2006; Jovicich et al. 2013; Liem et al. 2015), with  previous studies 
reporting ICC values of  >0.95 (Wonderlick et al. 2009). However, reliability for FreeSurfer 
varies across the cortex, with the orbito-temporal lobes often showing much lower reliability 
than other cortical regions (Han et al. 2006; Wonderlick et al. 2009; Schnack et al. 2010). A 
more recently developed voxel-based CT pipeline that uses ANTs software has given variable 
results during validation. When compared to FreeSurfer by the developers of ANTs, both 
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approaches showed good repeatability; with high intraclass coefficient values (ICC; ANTs=.98, 
FreeSurfer=.97) and low mean repeatability error for two databases (ANTs=3.2%, 3.3%, 
FreeSurfer=2.5%, 2.8%), with no significant difference between the two techniques for 
repeatability error. As a proxy for accuracy, the authors modelled age vs. CT using a ‘training 
and test’ paradigm to determine which measure produced better predictive ability. The ANTs 
model showed lower relative mean square error rates (Tustison et al. 2014). However 
subsequent validation has demonstrated that ANTs does not perform as well as initially 
reported, with reliability proving to be variable across different datasets (Tustison et al. 2014; 
Schwarz et al. 2016).  
As with cortical volume, visual QC of CT measures is essential to detect failures in 
segmentation. Iscan et al. (2015) performed detailed QC on FreeSurfer segmentations for 40 
participants conducted at two time points (80 total). They concluded that for 15 out of 40 
participants there were errors in segmentation in either one time point or both that were 
severe enough to impact on the results. In contrast, Schwarz et al. (2016) reported that out of 
452 scans processed with FreeSurfer, only 3 failed QC – although their criteria for failure was 
not provided. The authors also reported that FreeSurfer errors were seen more often in brains 
showing Alzheimer’s pathology, suggesting a potential bias in thickness measurement. Few 
other studies have reported information on the quality of segmentations; however as with the 
measurement of GM volume it is vital that the most accurate tools are used to examine the 
thickness of the cortex in HD and other diseases. The process of performing QC on over 1000 
FreeSurfer CT regions processed for the TRACK-HD and TrackOn-HD studies was performed 
prior to undertaking this thesis, and based on this experience it was clear that FreeSurfer CT 
regions are often inaccurate and output poorly delineated cortical surfaces. While CT offers a 
promising measure of cortical change for HD, the performance of CT tools on the TRACK-HD 
cohort required further investigation.   
Despite these limitations, studies measuring CT have reported significant cortical 
thinning in pre-HD and HD participants (Rosas et al. 2002; Rosas et al. 2008; Harrington et al. 
2014). When HD participants were separated into three groups based on their disease stage 
(with lower stages representing lower disease progression), the results suggested that thinning 
began in the primary motor area, sensory area, visual area and portions of the precuneus in 
stage I (Rosas et al. 2008). This thinning extended throughout the cortex in stage II and by 
stages III/IV most of the cortex had begun thinning, excluding the frontal cortex, which was 
relatively preserved. These studies are widely cited within the HD literature, however a 
number of the studies were conducted in small groups of participants, for example one study 
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had groups of N=8, N=14 and N=9 (Rosas et al. 2008). Furthermore, a number of widely cited 
results were not corrected for multiple comparisons (Rosas et al. 2008; Rosas et al. 2002). In 
addition, a recent study compared imaging biomarkers in the PADDINGTON cohort found that 
FreeSurfer was not a sensitive marker for detecting cortical change in manifest HD participants 
(Hobbs et al. 2015), raising doubt about the validity of using CT measures in HD studies. 
4.1. Aims 
This study aims to compare the performance of three CT measures on a subset of the 
TRACK-HD data. CT is a measure that potentially offers more sensitivity than volume; however 
it is a difficult characteristic to measure accurately. Prior to applying CT tools on the TRACK-HD 
data for examination of CGM they require detailed validation in this cohort. 
4.2. Methods 
4.2.1. Participants 
The participants used in this study were the same participants used in the comparison 
of volumetric measures. 100 participants with data from 2008 and 2011 were randomly 
selected from the TRACK-HD study. Twenty control participants, 20 PreHD-A, 20 PreHD-B, 20 
HD1 and 20 HD2 participants were included, see section 3.2.2.2 for further information, and 
Table 3.5 for demographics information.  
4.2.2. Cortical thickness measurements 
Three methods of measuring CT were examined: A) CT measured via FreeSurfer, B) CT 
measured via ANTs, C) CT measured using MALP-EM volumetric segmentations input to the 
ANTs Kelly Kapowski pipeline that calculates CT from volumetric regions. These methods were 
selected due to a number of considerations. FreeSurfer is the most commonly used software 
for CT measurements, despite concerns about the accuracy of FreeSurfer segmentations, and 
was thus included in this comparison. As previously mentioned, ANTs has been more recently 
developed yet it has been used in a growing number of publications characterising CT. It has a 
pipeline that includes brain extraction, segmentation and measurement of thickness. Finally, 
the cortical segmentations from Chapter 3 delineated using MALP-EM were combined with the 
calculation of CT implemented in ANTs. 
The longitudinal analysis was conducted twice: first, the two longitudinal scans were 
analysed in native space. This resulted in large longitudinal change in CT measures for some 
tools, with biologically implausible changes in thickness found. Since most automatic 
 152 
 
longitudinal pipelines either include or recommend a registration step, the data was also 
registered and re-analysed. The 2008 and 2011 scans were registered using the SPM 
longitudinal registration pipeline described in 2.3.1.2.3 (Ashburner & Ridgway 2012). Default 
parameters were used to create an average image for each participant. The warping 
parameters were applied to the native scans to align them with the template for each 
participant, and these warped scans were then segmented independently.  
FreeSurfer version 5.3.0 was used, with the default processing pipeline. MALP-EM was 
run using the default settings, with a flag to specify 3T scans. Following this, the ANTs 
KellyKapowski pipeline was run on the MALP-EM regions using default settings. ANTs was run 
using the study-specific templates created in section 3.2.3.4.2, with the CT command, 
antsCorticalThickness.sh, then applied with default settings.  
Following registration and any processing, images were visually checked for 
segmentation errors, with only gross-errors as described in section 3.2.3 excluding scans from 
analysis.  
4.3. Results 
4.3.1. Quality Control 
As in Chapter 3, visual QC was important for interpretation of the thickness results. 
Upon inspection, ANTs segmentations were inconsistent and a high number of segmentations 
had considerable errors, especially within the occipital and temporal GM. The most common 
errors were the over-inclusion of non-brain tissue in the cortical segmentation and were 
particularly pronounced for brains showing a lot of atrophy, as shown in Figure 4.3. The quality 
of MALP-EM segmentations was better than ANTs, with minor over-inclusion occasionally seen 
in occipital and temporal lobes (Figure 4.4). FreeSurfer regions were also variable, with errors 
in both the WM boundary and the external CSF boundary common (Figure 4.5). The FreeSurfer 
segmentations had less obvious errors in segmentation, yet there were often large chunks 
excluded from both internal GM (WM overestimation extended into the GM) and more 
external GM (WM classified as CSF). In addition, the temporal lobes were often poorly 
delineated as was the occipital lobe.  
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Figure 4.3. An example of an ANTs CT segmentation for a participant showing disease related 
atrophy shown in (A) coronal, (B) axial and (C) sagittal views. Spillage of the CT segmentation 
into the occipital dura is particularly pronounced in the coronal and sagittal views.  
 
 
Figure 4.4. An example of a MALP-EM CT segmentation for a participant showing disease 
related atrophy shown in A) coronal, (B) axial and (C) sagittal views. Spillage of the CT 
segmentation into the occipital dura is particularly pronounced in the coronal and sagittal 
views. 
 
 
Figure 4.5. An example of a FreeSurfer CT segmentation for a participant showing disease 
related atrophy shown in A) coronal, (B) axial and (C) sagittal views. Underestimation of the 
GM is particularly pronounced in the coronal and sagittal views. 
 
In addition to these issues, a more widely accepted problem previously recognised in 
CT measurement was seen during QC. That is, it is very difficult for most tools to accurately 
define the most tightly bound sulci. This is often more problematic in voxel-based techniques, 
and examples from the current study can be seen in Figure 4.6, compared to the processing 
performed via FreeSurfer, the only surface-based technique included in this comparison.  
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Figure 4.6. An example of (A) an ANTs cortical thickness segmentation, (B) a MALP-EM cortical 
segmentation processed with the ANTs cortical thickness calculation, and (C) a FreeSurfer 
segmentation. In both the ANTs and MALP-EM segmentations, sulci are not segmented 
accurately resulting in overestimation of thickness. This can be seen clearly in the inferior 
regions of this scan.  
 
4.3.2. Cross-sectional results 
4.3.2.1. Total thickness 
Table 4.1 shows the results of the test-retest analysis for the three processing 
pipelines, separated into HD groups and controls. For all tools, CT was lower in HD1 and HD2 
than for pre-HD and control participants, but there was inconsistency within both control and 
pre-HD groups across different tools. Overall, FreeSurfer had lower thickness values than both 
ANTs and MALP-EM for all groups.  
The ICC for ANTs was lower than for both MALP-EM and FreeSurfer, ranging from 0.70-
0.87, and repeatability was above 5.00 for all groups. However, confidence intervals (CIs) for 
the ICC ranged from around 0 to >.90, indicating poor reliability. MALP-EM showed better 
reliability, with ICC values above 0.96 (and CIs >.90) and repeatability less than 1.5 for all 
groups. Finally, FreeSurfer ICC values ranged from 0.819-0.944, but with one lower CI falling to 
.599, indicating that true reliability may be lower. Repeatability values were between 0.96-
1.67.  
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Table 4.1. Mean, standard deviations and ranges for cortical thickness in both 2008 scans for 
each group and technique. Intraclass correlations and confidence intervals between these 
scans are also presented, as well as repeatability means, standard deviations and ranges. 
  Scan A Scan B ICC Repeatability 
ANTs Controls 2.96 (0.26) 
2.44-3.47 
2.77 (0.30) 
2.23-3.33 
0.751  
(-0.067-0.936) 
7.12 (3.63) 
2.04-13.81 
PreHD-A 2.94 (0.25) 
2.40-3.35 
2.76 (0.30) 
2.09-3.20 
0.775  
(-0.062-0.946) 
6.77 (3.76) 
0.66-14.08 
PreHD-B 2.88 (0.21) 
2.50-3.30 
2.71 (0.21) 
2.32-3.14 
0.700  
(-0.068-0.923) 
6.23 (2.78) 
1.80-11.61 
HD1 2.73 (0.30) 
2.42-3.46 
2.58 (0.30) 
2.24-3.30 
0.870  
(-0.031-0.973) 
5.90 (2.35) 
2.38-11.93 
HD2 2.75 (0.28) 
2.36-3.40 
2.55 (0.30) 
2.11-3.30 
0.776  
(-0.061-0.946) 
7.44 (3.62) 
2.83-15.51 
MALP-EM 
+ ANTs 
Controls 2.89 (0.27) 
2.42-3.49 
2.90 (0.27) 
2.37-3.49 
0.992  
(0.980-0.997) 
0.93 (0.81) 
0.03-2.59 
PreHD-A 2.93 (0.19) 
2.56-3.22 
2.91 (0.20) 
2.52-3.25 
0.978  
(0.945-0.991) 
1.03 (0.98) 
0.01-3.88 
PreHD-B 2.96 (0.15) 
2.73-3.29 
2.96 (0.17) 
2.70-3.38 
0.962  
(0.906-0.985) 
1.05 (1.13) 
0.01-4.14 
HD1 2.84 (0.29) 
1.99-3.30 
2.84 (0.27) 
2.14-3.29 
0.985  
(0.962-0.994) 
1.28 (1.61) 
0.00-7.16 
HD2 2.79 (0.27) 
2.03-3.20 
2.78 (0.28) 
1.89-3.19 
0.981  
(0.952-0.993) 
1.34 (1.87) 
0.02-7.11 
FreeSurfer Controls 2.46 (0.10) 
2.31-2.66 
2.45 (0.09) 
2.29-2.65 
0.836  
(0.637-0.931) 
1.67 (1.61) 
0.07-5.91 
PreHD-A 2.42 (0.08) 
2.31-2.58 
2.41 (0.09) 
2.29-2.57 
0.934  
(0.842-0.973) 
1.01 (0.75) 
0.01-2.30 
PreHD-B 2.43 (0.08) 
2.30-2.63 
2.41 (0.08) 
2.30-2.55 
0.819  
(0.599-0.924) 
1.46 (1.39) 
0.03-4.75 
HD1 2.35 (0.10) 
2.20-2.56 
2.34 (0.09) 
2.19-2.54 
0.927  
(0.800-0.972) 
1.13 (1.01) 
0.21-4.80 
HD2 2.33 (0.09) 
2.15-2.46 
2.32 (0.09) 
2.10-2.47 
0.944  
(0.864-0.978) 
0.96 (0.94) 
0.13-3.28 
 
4.3.2.2. Regional Thickness  
Table 4.2 shows lobular values for 2008 Scan A and Scan B, and Table 4.3 shows ICC 
and repeatability for these scans. For ANTs CT, the lobular repeatability metrics were generally 
poor. Average thickness values varied, and ICC scores ranged from .456 in the insula (control 
participants) to .927 in the parietal lobe (HD1 participants). Confidence intervals for ICC values 
were very broad, again indicating that reliability was inadequate when using this technique in 
this cohort. Repeatability was low, with the highest values (representing poor repeatability) 
seen in the insula and occipital lobe.  
For MALP-EM, ICC values were again high, with all >.95, and no pattern of lower ICC in 
a particular region. In addition to the high ICC values, the confidence intervals for all regions 
were also very high. Repeatability values were lower than 2 for all regions except for the 
temporal lobe in HD2, which had a value of 2.57. For FreeSurfer, ICC values ranged from 
around .71 to .96, with no clear lobular pattern. However, CIs for the ICC measures showed a 
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wide range, indicating possible lower reliability. Repeatability values were generally <2, with 
the highest value seen in the insula for HD2 (2.93).  
4.3.3. Longitudinal results 
4.3.3.1. Non-registered 
The results from the analysis examining non-registered longitudinal data provided in 
Table 4.4 and Figure 4.7 demonstrated a number of key findings. Firstly, ANTs showed a large 
amount of longitudinal change within controls undergoing a reduction in CT of 3.42%. This was 
larger than the change seen in both PreHD-A and PreHD-B, however HD1 and HD2 both 
underwent greater reductions in CT (5.07% and 4.75% respectively). Only HD1 showed 
significantly greater longitudinal change than controls, at p=.044. The range of CT change for 
each group was large, however, with volume reduction of up to 15.62% seen in one HD1 
participant, and thickness increases of 5.66% seen in one PreHD-B participant. This result 
reflects the poor reliability seen in ANTs in the cross-sectional analyses. 
For MALP-EM, there were extremely wide ranges in the amount of change occurring 
over the 3 year period; with changes of up to 42% seen in HD1 (both increases and decreases 
in thickness). While controls showed a low mean rate of change (0.15%), the range for this 
group was also substantial (19% increases and 18% decreases could be seen). No group 
showed significantly different change when compared to controls, although all groups 
underwent a higher rate of change.  
The range of FreeSurfer rates of change were narrower, with controls showing very 
low change and HD groups undergoing progressively greater thinning of the cortex with 
increasing disease burden. PreHD-B, HD1 and HD2 all underwent significantly greater CT 
reductions than controls, with HD2 undergoing the greatest change. The ranges for FreeSurfer 
were more in line with expectations, showing generally small to moderate change in thickness 
over three years. 
4.3.3.1. Registered 
The scans were registered and re-analysed using the same pipeline. Results are shown 
in Figure 4.5 and Figure 4.7. After registering the scans and re-analysing the data using ANTs, 
controls underwent a large amount of change showing a greater reduction in thickness than 
any HD group (3.60%). There was no significant difference between controls and any HD 
group, with no pattern of greater thickness reduction as disease burden increased. 
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The results from MALP-EM indicated that registration did not improve longitudinal 
performance. Controls showed a large decrease in volume over 3 years (2.94%), with PreHD-A 
only undergoing .25% reduction. PreHD-B, HD1 and HD2 all underwent reductions >3.5%. For 
most groups, the ranges were reduced compared to non-registered scans, although still wide. 
After running FreeSurfer on the registered T1 scans, there was no longer a pattern of 
increasing atrophy with increasing disease burden. Again, controls showed greater change 
than any other group (1.54%), and similarly to other methods there was no pattern of 
increasing rate of change with increasing disease burden. 
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Table 4.2. Mean, standard deviations and ranges of cortical thickness values across different lobes for both 2008 scans for each technique. 
 
 
 
 
  Controls PreHD-A PreHD-B HD1 HD2 
  Scan A Scan B Scan A Scan B Scan A Scan B Scan A Scan B Scan A Scan B 
ANTs 
Frontal 
2.73 (0.28) 2.32-
3.21 
2.55 (0.33) 2.12-
3.13 
2.71 (0.27) 2.17-
3.16 
2.53 (0.32) 1.82-
3.10 
2.69 (0.21) 2.35-
3.11 
2.55 (0.20) 2.20-
2.87 
2.59 (0.29) 2.24-
3.27 
2.44 (0.28) 2.06-
3.10 
2.65 (0.29) 2.24-
3.16 
2.50 (0.31) 2.02-
3.07 
Occipital 
2.86 (0.28) 2.19-
3.56 
2.64 (0.32) 1.97-
3.42 
2.78 (0.36) 2.14-
3.26 
2.57 (0.35) 1.90-
3.09 
2.68 (0.35) 2.26-
3.57 
2.45 (0.33) 2.02-
3.43 
2.38 (0.41) 1.89-
3.31 
2.20 (0.42) 1.69-
3.19 
2.27 (0.39) 1.83-
3.39 
2.04 (0.39) 1.64-
3.27 
Parietal 
2.51 (0.24) 2.06-
2.91 
2.37 (0.25) 1.86-
2.80 
2.48 (0.24) 1.98-
2.88 
2.35 (0.25) 1.73-
2.76 
2.41 (0.17) 2.14-
2.72 
2.29 (0.16) 2.02-
2.61 
2.26 (0.27) 1.93-
2.91 
2.17 (0.27) 1.83-
2.83 
2.31 (0.23) 1.98-
2.76 
2.18 (0.23) 1.80-
2.70 
Temporal 
3.72 (0.29) 3.10-
4.26 
3.48 (0.34) 2.83-
4.04 
3.70 (0.30) 3.12-
4.24 
3.47 (0.35) 2.75-
4.06 
3.64 (0.30) 3.15-
4.29 
3.42 (0.29) 2.95-
4.00 
3.48 (0.34) 3.07-
4.34 
3.28 (0.37) 2.84-
4.13 
3.47 (0.35) 3.00-
4.22 
3.19 (0.38) 2.67-
4.10 
Insula 
3.53 (0.33) 2.99-
4.09 
3.10 (0.34) 2.51-
3.00 
3.74 (0.41) 3.02-
4.59 
3.35 (0.42) 2.72-
4.25 
3.60 (0.35) 2.74-
4.25 
3.22 (0.36) 2.49-
3.81 
3.46 (0.28) 2.98-
3.99 
3.15 (0.37) 2.56-
3.87 
3.62 (0.45) 3.00-
4.43 
3.21 (0.47) 2.59-
4.25 
MALP-EM + 
ANTs 
Frontal 
2.71 (0.27) 2.19-
3.25 
2.73 (0.26) 2.20-
3.23 
2.74 (0.20) 2.29-
3.07 
2.74 (0.22) 2.26-
3.14 
2.78 (0.17) 2.55-
3.19 
2.78 (0.18) 2.49-
3.14 
2.67 (0.23) 1.99-
3.05 
2.68 (0.22) 2.13-
3.04 
2.66 (0.26) 1.97-
3.13 
2.66 (0.26) 1.87-
3.11 
Occipital 
2.77 (0.29) 2.42-
3.31 
2.78 (0.30) 2.41-
3.35 
2.78 (0.28) 2.30-
3.21 
2.76 (0.28) 2.25-
3.21 
2.84 (0.35) 2.16-
3.61 
2.83 (0.36) 2.13-
3.65 
2.60 (0.38) 1.77-
3.20 
2.60 (0.37) 1.75-
3.19 
2.42 (0.32) 1.77-
3.13 
2.41 (0.32) 1.68-
3.11 
Parietal 
2.61 (0.26) 2.21-
3.31 
2.63 (0.26) 2.22-
3.32 
2.62 (0.19) 2.23-
2.88 
2.60 (0.19) 2.22-
2.88 
2.57 (0.14) 2.39-
2.84 
2.58 (0.16) 2.30-
2.95 
2.48 (0.25) 1.85-
2.92 
2.48 (0.24) 1.95-
2.91 
2.44 (0.21) 1.83-
2.74 
2.44 (0.22) 1.67-
2.71 
Temporal 
3.53 (0.32) 2.88-
4.12 
3.51 (0.32) 2.79-
4.13 
3.57 (0.25) 3.15-
4.04 
3.53 (0.26) 3.17-
4.06 
3.64 (0.22) 3.19-
4.16 
3.64 (0.24) 3.19-
4.20 
3.55 (0.45) 2.23-
4.15 
3.54 (0.40) 2.49-
4.11 
3.49 (0.38) 2.48-
4.06 
3.45 (0.41) 2.27-
4.09 
Insula 
3.38 (0.45) 2.52-
4.18 
3.38 (0.47) 2.51-
4.23 
3.69 (0.53) 2.84-
4.57 
3.68 (0.52) 2.90-
4.63 
3.74 (0.55) 3.04-
5.16 
3.76 (0.56) 3.00-
5.23 
3.50 (0.49) 2.19-
4.36 
3.50 (0.46) 2.31-
4.22 
3.52 (0.63) 2.30-
4.73 
3.50 (0.65) 2.10-
4.69 
FreeSurfer 
Frontal 
2.50 (0.11) 2.35-
2.71 
2.48 (0.10) 2.36-
2.70 
2.45 (0.09) 2.31-
2.62 
2.44 (0.10) 2.29-
2.63 
2.46 (0.09) 2.33-
2.60 
2.45 (0.08) 2.31-
2.59 
2.41 (0.09) 2.21-
2.56 
2.39 (0.09) 2.23-
2.55 
2.40 (0.10) 2.19-
2.55 
2.39 (0.12) 2.13-
2.57 
Occipital 
1.98 (0.10) 1.83-
2.20 
1.98 (0.10) 1.80-
2.20 
1.97 (0.11) 1.81-
2.19 
1.96 (0.11) 1.75-
2.19 
1.95 (0.10) 1.78-
2.23 
1.93 (0.10) 1.71-
2.17 
1.85 (0.11) 1.67-
2.07 
1.83 (0.11) 1.66-
2.04 
1.76 (0.09) 1.62-
1.91 
1.76 (0.10) 1.61-
1.92 
Parietal 
2.85 (0.13) 2.62-
3.12 
2.84 (0.12) 2.57-
3.04 
2.81 (0.11) 2.63-
3.05 
2.80 (0.11) 2.63-
2.99 
2.80 (0.10) 2.68-
3.11 
2.79 (0.11) 2.61-
3.03 
2.72 (0.14) 2.43-
3.01 
2.72 (0.13) 2.45-
3.01 
2.71 (0.10) 2.50-
2.87 
2.70 (0.11) 2.48-
2.92 
Temporal 
2.30 (0.11) 2.10-
2.53 
2.28 (0.10) 2.14-
2.54 
2.25 (0.08) 2.13-
2.37 
2.24 (0.09) 2.08-
2.42 
2.27 (0.10) 2.11-
2.45 
2.24 (0.09) 2.12-
2.45 
2.17 (0.11) 2.02-
2.40 
2.15 (0.10) 2.02-
2.37 
2.14 (0.10) 1.96-
2.31 
2.13 (0.10) 1.91-
2.31 
Insula 
2.98 (0.15) 2.78-
3.33 
2.99 (0.14) 2.73-
3.28 
3.03 (0.11) 2.86-
3.28 
3.03 (0.10) 2.92-
3.24 
3.01 (0.15) 2.77-
3.29 
2.99 (0.15) 2.71-
3.30 
3.01 (0.13) 2.69-
3.24 
3.01 (0.11) 2.79-
3.16 
2.96 (0.17) 2.65-
3.22 
2.93 (0.16) 2.65-
3.19 
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Table 4.3. Intraclass correlations and confidence intervals, and repeatability means, standard deviations and ranges for both 2008 scans when measuring 
cortical thickness across different techniques and regions. 
 
  Controls PreHD-A PreHD-B HD1 HD2 
  ICC Repeatability ICC Repeatability ICC Repeatability ICC Repeatability ICC Repeatability 
ANTs 
Frontal 
0.806 
(-0.052-0.953) 
7.15 (3.93) 
0.93-14.83 
0.825 
(-0.047-0.959) 
6.77 (4.13) 
0.35-17.49 
0.764 
(-0.052-0.945) 
5.65 (2.18) 
1.65-9.83 
0.885 
(-0.027-0.977) 
5.64 (2.21) 
1.69-9.09 
0.839 
(-0.032-0.962) 
6.27 (3.72) 
0.33-13.95 
Occipital 
0.716 
(-0.075-0.924) 
8.47 (4.90) 
0.72-19.19 
0.796 
(-0.058-0.951) 
8.48 (4.37) 
1.86-16.36 
0.777 
(-0.059-0.947) 
9.04 (3.94) 
1.14-14.66 
0.893 
(-0.024-0.979) 
8.58 (3.70) 
3.15-20.19 
0.835 
(-0.042-0.964) 
10.71 (4.18) 
3.54-18.21 
Parietal 
0.789 
(-0.029-0.944) 
6.15 (3.70) 
1.89-16.54 
0.843 
(-0.037-0.964) 
5.63 (3.35) 
0.26-13.37 
0.723 
(-0.073-0.928) 
5.16 (2.56) 
0.77-9.89 
0.927 
(0.006-0.985) 
4.53 (2.04) 
2.36-8.60 
0.821 
(-0.040-0.957) 
5.81 (3.33) 
0.69-13.38 
Temporal 
0.707 
(-0.076-0.922) 
7.24 (3.28) 
2.71-12.85 
0.740 
(-0.070-0.934) 
6.83 (3.87) 
0.69-14.07 
0.720 
(-0.074-0.927) 
6.32 (3.25) 
1.89-14.21 
0.824 
(-0.037-0.963) 
6.34 (2.35) 
3.33-12.07 
0.724 
(-0.066-0.931) 
8.63 (4.09) 
2.89-17.10 
Insula 
0.456 
(-0.080-0.811) 
13.04 (6.30) 
6.19-25.20 
0.615 
(-0.090-0.886) 
10.90 (6.32) 
0.43-20.49 
0.522 
(-0.094-0.842) 
11.45 (6.32) 
1.60-26.02 
0.631 
(-0.090-0.892) 
9.48 (5.45) 
2.34-22.47 
0.632 
(-0.086-0.895) 
12.21 (6.48) 
1.54-25.19 
MALP-EM 
+ ANTs 
Frontal 
0.984 
(0.961-0.994) 
1.32 (1.19) 
0.00-3.61 
0.968 
(0.921-0.987) 
1.26 (1.35) 
0.09-5.61 
0.946 
(0.870-0.978) 
1.49 (1.47) 
0.01-6.46 
0.968 
(0.922-0.987) 
1.79 (1.54) 
0.19-6.84 
0.983 
(0.957-0.993) 
1.44 (1.45) 
0.15-5.31 
Occipital 
0.987 
(0.969-0.995) 
1.34 (1.07) 
0.29-4.39 
0.977 (0.942-
0.991) 
1.77 (1.52) 
0.02-5.65 
0.989 
(0.972-0.996) 
1.39 (1.24) 
0.01-5.54 
0.991 
(0.978-0.997) 
1.47 (1.21) 
0.19-3.87 
0.992 
(0.979-0.997) 
1.49 (1.30) 
0.13-5.61 
Parietal 
0.988 
(0.965-0.995) 
1.13 (1.11) 
0.03-3.91 
0.972 
(0.925-0.989) 
1.21 (1.22) 
0.09-5.07 
0.939 
(0.855-0.975) 
1.43 (1.34) 
0.04-5.36 
0.987 
(0.967-0.995) 
1.23 (1.30) 
0.00-5.40 
0.969 
(0.923-0.988) 
1.61 (2.09) 
0.14-8.77 
Temporal 
0.986 
(0.962-0.995) 
1.13 (1.11) 
0.03-3.62 
0.966 
(0.897-0.988) 
1.25 (1.49) 
0.00-5.13 
0.965 
(0.915-0.986) 
1.27 (1.12) 
0.03-4.75 
0.984 
(0.961-0.994) 
1.59 (2.39) 
0.12-11.04 
0.963 
(0.906-0.986) 
2.57 (2.37) 
0.09-8.54 
Insula 
0.985 
(0.963-0.994) 
1.73 (1.39) 
0.38-4.76 
0.987 
(0.968-0.995) 
1.82 (1.47) 
0.07-5.94 
0.990 
(0.974-0.996) 
1.71 (1.22) 
0.21-5.14 
0.986 
(0.966-0.995) 
1.75 (1.64) 
0.04-5.78 
0.995 
(0.986-0.998) 
1.57 (1.99) 
0.08-8.88 
FreeSurfer 
Frontal 
0.710 
(0.406-0.874) 
2.06 (2.34) 
0.01-8.50 
0.932 
(0.836-0.972) 
1.34 (1.16) 
0.01-3.69 
0.914 
(0.799-0.965) 
1.91 (1.67) 
0.08-5.97 
0.796 
(0.558-0.914) 
1.38 (1.14) 
0.10-5.02 
0.916 
(0.803-0.966) 
1.01 (1.02) 
0.11-3.51 
Occipital 
0.893 
(0.754-0.956) 
1.61 (1.12) 
0.08-4.48 
0.966 
(0.918-0.986) 
1.23 (0.91) 
0.00-3.56 
0.911 
(0.792-0.963) 
1.65 (1.20) 
0.30-4.56 
0.924 
(0.821-0.969) 
1.27 (0.77) 
0.15-2.61 
0.784 
(0.529-0.909) 
0.90 (0.56) 
0.21-2.38 
Parietal 
0.721 
(0.424-0.879) 
1.29 (1.31) 
0.02-5.24 
0.922 
(0.785-0.970) 
1.18 (1.19) 
0.05-4.52 
0.858 
(0.679-0.941) 
1.51 (1.35) 
0.00-4.10 
0.807 
(0.565-0.920) 
0.95 (0.77) 
0.08-3.56 
0.851 
(0.667-0.938) 
1.16 (1.18) 
0.01-4.09 
Temporal 
0.893 
(0.703-0.959) 
2.13 (2.11) 
0.18-7.03 
0.969 
(0.687-0.992) 
1.08 (0.99) 
0.06-3.24 
0.969 
(0.925-0.988) 
2.05 (1.70) 
0.14-7.03 
0.878 
(0.699-0.951) 
1.55 (1.80) 
0.17-7.73 
0.827 
(0.613-0.928) 
1.18 (1.28) 
0.08-3.78 
Insula 
0.958 
(0.894-0.983) 
1.71 (1.02) 
0.47-3.90 
0.981 
(0.953-0.993) 
1.90 (1.10) 
0.20-3.92 
0.920 
(0.809-0.968) 
2.19 (1.74) 
0.12-6.09 
0.934 
(0.840-0.974) 
1.92 (1.45) 
0.36-6.29 
0.810 
(0.578-0.921) 
2.63 (2.29) 
0.06-9.05 
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Table 4.4. Mean % change (difference between 2011 and baseline thickness as a percentage of 
baseline thickness), standard deviation and ranges for all tools and groups in average cortical 
thickness. Positive values represent thickness decreases over time. Results of regression 
analyses comparing rate of change in controls to HD groups, with significantly greater change 
in HD groups represented by * p<0.05 (light grey), **p<0.01 (dark grey). Age, sex and site were 
controlled for. 
 Controls PreHD-A PreHD-B HD1 HD2 
ANTs 
% Decrease 2008 to 
2011 
3.42 (2.92) 
-0.65-9.41 
3.20 (4.08) 
-3.89-14.31 
2.52 (3.66) 
-5.66-9.70 
5.07 (3.26) 2.31-
15.62 
4.75 (3.13) 
-3.59-10.95 
Significant 
difference 
 
1.09 
(-2.11-2.18) 
p=0.974 
-0.48 
(-1.36-0.40) 
p=0.284 
0.56 
(0.01-1.11) 
p=0.044* 
0.36 
(-0.08-0.79) 
P=0.109 
MALP-EM 
+ ANTs 
% Decrease 2008 to 
2011 
0.15 (7.32) 
-19.72-18.05 
2.94 (5.91) 
-2.65-22.59 
2.67 (7.29) 
-6.03-25.94 
3.89 (16.20) 
-42.25-42.24 
2.49 (5.79) 
-6.92-22.58 
Significant 
difference 
 
2.97 
(-1.08-7.01) 
p=0.150 
0.92 
(-1.12-2.96) 
p=0.375 
0.88 
(-1.56-3.32) 
p=0.480 
0.15 
(-1.01-1.31) 
p=0.798 
FreeSurfer 
% Decrease 2008 to 
2011 
0.10 (1.12) 
-2.11-2.34 
0.65 (1.22) 
-1.48-3.17 
1.00 (1.57) 
-1.36-3.44 
2.03 (1.62) 
-1.26-4.91 
2.33 (1.81) 
-0.98-5.57 
Significant 
difference 
 
0.37 
(-0.31-1.05) 
p=0.289 
0.45 
(0.09-0.82) 
p=0.015* 
0.54 
(0.27-0.82) 
p<0.001** 
0.46 
(0.21-0.70) 
p<0.001** 
 
Table 4.5. Mean % change in registered scan pairs (difference between 2011 and baseline 
thickness as a percentage of baseline thickness), standard deviation and ranges for all tools 
and groups in average cortical thickness. Positive values represent thickness decreases over 
time. Results of regression analyses comparing rate of change in controls to HD groups, no 
significant group differences were found. Age, sex and site were controlled for. 
 Controls PreHD-A PreHD-B HD1 HD2 
ANTs 
% Decrease 2008 to 
2011 
3.60 (3.10) -
0.62-11.20 
3.28 (4.71) -
3.56-13.47 
2.28 (3.20) -
4.41-11.15 
1.48 (4.47) -
8.37-14.26 
3.13 (2.15) 0.13-
6.79 
Significant 
difference 
 
.18 
(-2.17-2.54) 
p=0.880 
-.65 
(-1.56-.26) 
p=0.163 
-.62 
(-1.37-.12) 
p=0.101 
.05 
(-.44-.55) 
P=0.829 
MALP-EM 
+ ANTs 
% Decrease 2008 to 
2011 
2.94 (8.15) -
25.24-19.08 
0.25 (9.43) -
22.13-13.96 
3.58 (4.14) -
5.97-9.86 
4.28 (7.25) -
15.15-19.42 
3.98 (4.82) -
4.19-14.37 
Significant 
difference 
 
-1.68 
(-7.08-3.72) 
p=.542 
.52 
(-1.23-2.27) 
p=.561 
.69 
(-.78-2.15) 
p=.358 
.85 
(-.30-2.00) 
p=.148 
FreeSurfer 
% Decrease 2008 to 
2011 
1.54 (2.05) -
2.21-5.39 
0.89 (1.89) -
2.15-4.57 
1.44 (1.76) -
0.49-4.86 
0.61 (1.53) -
3.64-3.36 
1.24 (2.12) -
3.55-5.02 
Significant 
difference 
 
-.29 
(-1.56-.97) 
p=.648 
.04 
(-.55-.63) 
p=.893 
-.28 
(-.66-.10) 
p=.142 
-.07 
(-.46-.32) 
p=.733 
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Figure 4.7. The longitudinal results showing change in cortical thickness from 2008 to 2011 time points 
for both A) non-registered and B) registered scan pairs. 
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4.4. Discussion 
The results of this study have highlighted that there are a number of serious concerns 
regarding the current tools used to measure CT from MRI scans. Historically, there have been 
two ways to measure CT: surface-based techniques, such as FreeSurfer, and voxel-wise 
techniques, such as ANTs. While all measures have benefits and drawbacks, these results 
demonstrate that reliability and accuracy remain key issues with both general techniques.  
FreeSurfer, the most commonly used CT measure, showed reasonable cross-sectional 
reliability and longitudinal sensitivity in non-registered scans. However, visual inspection of the 
segmentations indicated that the accuracy of tools was poor in a number of regions. The 
temporal lobes were generally poorly delineated, as has been previously reported (McCarthy 
et al. 2015). In addition, there was often incorrect classification of the cortical GM as WM or 
CSF. Despite these issues, when using the standard pipeline, FreeSurfer did detect significantly 
greater reduction in CT for gene carriers in PreHD-B, HD1 and HD2 compared to controls. This 
indicates some level of sensitivity to change, however it is impossible to tell from the current 
analysis how accurate these results are given the quality of many of the segmentations. There 
is particular concern when also considering the results of the longitudinal analysis measuring 
CT in registered scans, whereby the pattern of greater reductions in CT with increasing disease 
burden was not apparent and a number of participants showed very different rates of 
longitudinal change compared to those seen for the non-registered scans. After the statistical 
analysis was performed showing poor longitudinal results, a selection of segmentations were 
visually re-examined. There was no obvious reason for the differing performance of FreeSurfer 
after registration, that is, there were no visible errors in segmentation in registered scan pairs. 
The different longitudinal results seen in non-registered and registered scans extended across 
all lobes, indicating that these differences were not due to errors in one region. These results 
suggest that by performing registration on the scans prior to segmentation the act of warping 
the scans from native space to a subject specific space negatively affects the FreeSurfer 
segmentation, possibly by making the boundaries between tissue classes less clear. The 
longitudinal FreeSurfer pipeline recommends that segmentations should be performed on 
cross-sectional time points before registering them, however the large difference between the 
two analyses is concerning.  
Both ANTs and MALP-EM showed more significant problems with measurement 
compared to FreeSurfer. ANTs segmentations were visually poor, with frequent 
overestimation of the occipital cortex and temporal lobes. This was more pronounced in 
atrophied brains, indicating a possible disease-related bias in the measurement of CT. In 
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addition, sulci that were tightly compressed were not delineated accurately, with the two sides 
appearing to merge, resulting in ultra-thick measures of the cortex at these points. The poor 
segmentations were reflected in the ICC and repeatability values. ICC values were generally 
between 0.70 and 0.80. While this is typically viewed as representing good reliability, the 
confidence intervals for ICC values for ANTs were very wide, and thus we cannot assume good 
reliability (Koo & Li 2016). In addition, repeatability values were >5 for most ANTs 
comparisons, again indicating poor reliability. Although scans were captured in one session, 
and thus we would expect to see little differences between measurements these values 
suggest that ANTs CT pipeline is difficult to apply reliably. 
The results from the combination of MALP-EM segmented CGM and ANTs 
KellyKapowski CT pipeline, which calculates CT from previously segmented CGM regions, were 
more variable. Visual QC demonstrated that while overall the segmentations were of better 
quality than those produced by ANTs, issues were again seen with delineation in the sulci, 
similar to those seen with ANTs regions. Cross-sectional reliability indicated that MALP-EM 
plus ANTs CT pipeline was highly reliable. ICC values were >.95 for almost all regions, and 
repeatability was <2 for most regions. However, the longitudinal analysis indicated that both 
growth and reduction in CT of up to 42% for non-registered scans, and up to 25% for 
registered scans. Following analysis, post-hoc examination of some of the scans showing the 
most extreme reductions in CT were undertaken. Participants with large increases or 
decreases in thickness tended to have one CGM segmentation that was thicker by a number of 
voxels across the cortex, which could result in large differences between the two time (e.g. 
25% increase in thickness in one registered scan pair). Some of the scan pairs showing large 
discrepancies often had one scan with reduced quality or difference in GM/WM contrast 
between the two scans. For scans showing large differences in thickness, the volumetric 
change calculated in chapter 3 were also re-examined and were not found to be 
disproportionately large (i.e. 1% reduction in volume over time for a scan showing a 25% 
change in CT). These large increases and decreases are likely to be artefacts of the technique 
and the sensitivity of CT to minor changes in scan quality, which have been noted previously 
(Clarkson et al. 2011), rather than real changes in thickness. Since voxel-wise techniques 
calculate thickness based on a value for every voxel in the cortex rather than every vertex in 
the cortical surface, they can be more heavily impacted by a consistent but minor over- or 
under-estimation of the cortex. Overall, the results support previous work indicating that 
volume-based methods are more susceptible to longitudinal instability than surface-based 
methods (Clarkson et al. 2011). 
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One of the most challenging aspects of calculating CT from MRI is creating highly 
accurate delineations of sulci, as described previously (Cardoso et al., 2011). Voxel-wise tools 
suffer from this problem due to the partial volume effect. If a very small sulcus consists of 
mainly GM from either side of the sulcus with a small amount of CSF, voxel-wise methods will 
classify the region as GM. Thus then quantifying CT from the voxel-map the sulcus will be 
missed, leading to very thick values for CT in this region. It is possible that this artefact explains 
the increased thickness values for both ANTs and MALP-EM compared to FreeSurfer. When 
comparing CT in healthy controls to a group with atrophy, such as HD, this artefact might 
artificially inflate group differences. As atrophy progresses and the sulci widen, the sulci might 
be classified more accurately due to increased CSF in the voxels, ultimately resulting in a 
reduction of overall thickness. This is demonstrated in Figure 4.8, which shows baseline and 
follow-up scans from a manifest HD participant in TRACK-HD, and demonstrates that as the 
sulci widen, more voxels are classed as CSF and thus CT measurement undergoes large 
reductions. While the widening of sulci is a disease-related effect, it is not a direct measure of 
CT and so can be considered an artefact rather than a true measure. This is a significant issue 
that surface based methods are less affected by as the delineation of sulci is also improved 
within FreeSurfer by the inclusion of a maximum and minimum value for thickness within the 
pipeline. That is, at no point in the cortex can thickness be >5mm when measured using 
FreeSurfer. Furthermore, the use of a minimum value may mean that the cortex is over-
estimated in scans with extreme atrophy. While the maximum/minimum thickness values 
mean that that for some scans, thickness is likely to be either over- or under-estimated, it 
helps to ensure that the sulci are delineated clearly. 
 
 
Figure 4.8. An example of a key source of variability in thickness measures. Figure (A) shows an 
HD participant at baseline, with Figure (B) showing the same participant three years later. In a 
number of regions, the sulci have widened with increasing atrophy, which causes a sharp 
reduction in thickness measurements at these points.   
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The large increases and decreases seen in some thickness measures over 3 years, 
along with the differing results found when running the analysis on both non-registered and 
registered scan pairs have implications for the measurement of longitudinal change in CT. It is 
important to note that in order to compare techniques more directly, the default FreeSurfer 
longitudinal pipeline was not used in this study. It is recommended that the pre-optimised 
longitudinal pipeline is used when running longitudinal analyses. However, internal evaluation 
comparing results from the cross-sectional FreeSurfer pipeline and the longitudinal pipeline 
has been performed previously on the TRACK-HD cohort, and the results were highly 
comparable and thus the decision was made to only use the cross-sectional pipeline in this 
analysis.  
The results of this study support previous findings that have demonstrated the back-
to-back reliability of FreeSurfer (Han et al. 2006; Tustison et al. 2014), and also one study 
which found that FreeSurfer produced more plausible longitudinal measures of change than 
voxel-wise methods (Clarkson et al. 2011). While these results provide further examples 
demonstrating the reliability of FreeSurfer, as measured quantitatively, this comparison also 
suggests that researchers should proceed with caution when using FreeSurfer to perform 
clinical comparisons, since the qualitative review of all scans demonstrated a high rate of poor 
quality thickness regions.  
Only one recent study has performed an analysis validating similar voxel-wise 
measures to those included in this investigation. The previous study compared the reliability of 
volumetric measures to CT using similar tools in an Alzheimer’s (AD) cohort (Schwarz et al. 
2016). The study looked at a small number of regions related to AD pathology, measured the 
performance of FreeSurfer measures of volume and thickness, ANTs measures of thickness, 
and SPM volumetric measures and a combined SPM and ANTs thickness calculation, similar to 
the current application of MALP-EM and ANTs. Their results showed that thickness was 
generally less reliable than volume, significantly so in some regions, however thickness 
measures showed a stronger relationship to pathological measures of AD. Similar to the 
current analysis, which found high reliability for a combination of MALP-EM regions and ANTs 
thickness metrics, the authors found that the most reliable thickness measures were 
calculated using SPM segmentations and ANTs. They also found that the performance of ANTs 
thickness pipeline was variable, again, similarly to results reported here.  While volumetric 
measures were more reliable, due to issues associated with the co-variation of head size that 
is a necessary requirement for volumetric analyses but not thickness analyses, the authors 
recommended that thickness should be used over volumetric measures. However, this study 
 166 
 
only included cross-sectional analysis. Similarly, the results presented here indicated that 
cross-sectional regions had high reliability for the combined MALP-EM and ANTs pipeline. 
There was also a plausible trend for decreasing thickness with increasing disease burden. 
However, the previous study did not discuss the quality of segmentations other than to 
provide failure rates (classified as a gross failure), and they performed no longitudinal analysis. 
Longitudinally, the results of this analysis showed extreme variability in rates of change – 
indicating that this method is not suitable for longitudinal use, and also adding uncertainty to 
the validity of the cross-sectional findings.  
4.5. Conclusions 
This work has supported a number of previous findings, but also extended the 
literature by adding a longitudinal comparison for one relatively new measure of CT (ANTs) 
and one more experimental measure of CT (MALP-EM+ANTs). FreeSurfer and MALPEM+ANTs 
provided plausible cross-sectional findings, with MALP-EM+ANTs showing particularly high 
back-to-back reliability. Furthermore, FreeSurfer was sensitive to longitudinal change in non-
registered scan pairs. However, a number of issues concerning the reliability and validity of 
these measures were also encountered. The accurate delineation of the cortical surface was a 
problem for all techniques, with voxel-wise measures suffering more from poor sulcal 
delineation, and the surface-based method, FreeSurfer, suffering from general segmentation 
inaccuracies.  While these issues are not as important for cortical volume measurements, the 
accurate delineation of sulci makes a great difference to the calculation of thickness measures. 
Significant longitudinal change with increasing disease progression was only found when using 
FreeSurfer and only when scans were segmented in native space, with a completely different 
pattern of change found when looking at registered scans. When attempting to measure 
subtle cortical changes in a small number of participants it is essential that only the most 
accurate methods are applied. By including thickness measures, it is possible that spurious 
findings could be introduced due to artefacts of the techniques. Based on these results, the 
decision was made to exclude CT measures from the analysis conducted in Chapter 6. It is 
essential that the measures used to quantify CGM during motor onset are the most accurate 
and reliable measures, and this analysis has provided evidence suggesting that there are still 
issues with the use of CT measures.  
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5. VALIDATION OF AUTOMATED MEASUREMENT FOR 
SUBCORTICAL REGIONS 
While cortical volume is the focus of the final analysis in chapter six, subcortical 
regions are well validated, highly sensitive markers of disease progression. The caudate and 
putamen show significant damage in post-mortem studies of HD, indicating the importance of 
these structures (Vonsattel et al. 1985). Furthermore, many studies have identified these 
regions as the earliest brain regions to undergo atrophy, as well as the regions that undergo 
the most rapid atrophy (Tabrizi et al. 2009; Tabrizi et al. 2012). The quantification of 
longitudinal change within both the caudate and putamen are two of the most robust 
biomarkers for observing change in HD gene carriers (Georgiou-Karistianis et al. 2013), as well 
as being strong predictors of disease progression (Tabrizi et al. 2013; Paulsen et al. 2010). 
Thus, it is important that they are included in investigations of disease progression for HD. 
They provide a useful measure of comparison, but also ensure that the group being studied 
are showing typical signs of HD neural changes. By including these measures, a unique 
understanding of the relationship between subcortical atrophy and cortical atrophy will be 
gained.  
A number of HD studies have used validated manual measures of both the caudate 
and putamen to quantify cross-sectional and longitudinal volume in HD (Tabrizi et al. 2012; 
Tabrizi et al. 2009; Tabrizi et al. 2011; Tabrizi et al. 2013; Hobbs et al. 2013; Hobbs et al. 2015). 
In addition, the same measures are now being applied in multiple clinical trials for HD. While 
not an absolute GT, manual measures are often considered to be a ‘gold standard’ for 
segmentation since they are performed by highly trained raters with an understanding of 
neuroanatomical structure, following strictly defined procedures. However, these methods are 
time-consuming to perform and difficult for other research groups to replicate without 
training. Instead, automated measures of subcortical volume are often used in the literature to 
quantify subcortical volume (Paulsen et al. 2006; Domínguez et al. 2013; Aylward, Nopoulos, et 
al. 2011).  
However, as with the segmentation of cortical regions, it is vital that the tools used to 
quantify volume are both reliable and accurate. The use of different tools to measure the 
volume of subcortical regions has resulted in some disparity between studies, with differences 
in atrophy rates for the caudate and putamen reported between different studies (Georgiou-
Karistianis et al. 2013). Some studies have reported faster rates of atrophy in the caudate, and 
some in the putamen. These differences have implications for the selection of biomarkers in 
clinical trials, along with the sample size requirements for these trials (Georgiou-Karistianis et 
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al. 2013). While previous validations have been performed on subcortical regions from other 
tools (Perlaki et al. 2017; Rees 2014), MALP-EM subcortical regions have not been examined. 
After validation and subsequent selection of the MALP-EM cortical regions for inclusion in 
Chapter 6, the use of subcortical volumetric measures that have also been processed via 
MALP-EM would help to reduce inter-region bias introduced by the use of different 
measurement techniques to quantify volume in different regions. However, prior to doing this 
the subcortical regions produced by MALP-EM should be validated to ensure they are of a high 
standard.   
5.1. Aims 
This analysis aims to use previously segmented regions of the caudate and putamen to 
investigate the performance of MALP-EM on subcortical regions on an HD cohort. Scans from 
the PADDINGTON study underwent manual caudate and putamen segmentation at baseline, 
performed by experienced image analysts. The same scans were processed using MALP-EM, 
with qualitative examination of all regions and quantitative comparisons used to compare the 
volumes extracted from these regions. 
5.2. Methods 
Data for this study was taken from the PADDINGTON study (section 3.1.4). Data from 
the PADDINGTON study was used because all participants had both caudate and putamen 
regions manually segmented at baseline, providing a ‘gold-standard’ measure for caudate and 
putamen regions, whereas for TRACK-HD the putamen was not manually segmented. 
5.2.1. Participants 
PADDINGTON data from Leiden, London and Paris was included in this analysis. See 
section 2.1.4 for details on recruitment and data collection. These three sites also participated 
in the TRACK-HD and TrackOn-HD studies, with the same scanners and acquisition protocols. 
All participants who had a baseline scan which passed visual QC and had manual caudate and 
putamen regions were included in the study.  
5.2.2. Segmentations 
Manual segmentations of the caudate and putamen were performed upon data 
collection at the baseline time point of the PADDINGTON study, as described in section 2.3.3. 
Automated segmentation was performed in native space using the default parameters for 
MALP-EM. All regions underwent visual QC upon completion of the segmentation pipeline. 
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Manually measured TIV (section 2.3.3) was used to account for overall head size in group 
comparisons.  
5.2.3. Statistical analysis 
Summary statistics for both manual and automated methods were measured, and t-
tests were performed to compare putamen and caudate volumes (as a % of TIV) between 
controls and HD participants. Intraclass correlations were also calculated to measure the 
consistency of manual and automated measures, with Bland-Altman plots and scatterplots 
used to visualise the relationship between manual and automated measures.  
5.3. Results 
5.3.1. Quality Control 
Overall, the quality of the automated segmentations was high. The caudate regions 
were particularly good, especially given the large amount of atrophy in some scans. Some 
examples of manual and automated segmentations are shown in Figure 5.1 and Figure 5.2. 
However, there were a number of fails. One scan failed processing with MALP-EM due to 
incorrect classification of the GM and WM. The failed scan was examined and was found to be 
poorly position within the FOV. The scan was re-oriented and segmentation was attempted 
again. This time, processing completed successfully, indicating that the issue was associated 
with the initial registration step completed in MALP-EM. However, the scan was excluded from 
analysis as the manual segmentations were completed on the non-realigned data. In addition, 
there were two caudate segmentations and five putamen segmentations that failed due to 
underestimation of the region. An example of a failed caudate segmentation and a failed 
putamen segmentation are shown in Figure 5.3. These scans were excluded from the analysis.  
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Figure 5.1. An example of automated measures of the caudate and putamen from the 
PADDINGTON study in (A) axial without a segmentation, (B) axial with a segmentation, (C) 
coronal without a segmentation, (D) with a segmentation. 
 
 
Figure 5.2. An example of manual caudate and putamen segmentations. (A) Shows a scan from 
the PADDINGTON cohort prior to segmentation, (B) shows the manually delineated putamen 
region and (C) shows the manually delineated caudate region.  
 
5.3.2. Quantitative analysis 
Participant demographics are shown in Table 5.1, and summary data for manual and 
automated regions is shown in Table 5.2. For both manual and automated techniques, HD 
participants had lower volumes of the caudate and putamen compared to controls (both raw 
volumes and as a percentage of TIV). Putamen and caudate volumes (% of TIV) were 
significantly lower for HD participants than controls for all measures at p<.0001.  
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Bland-Altman plots suggest no clear bias in measurement. Intraclass correlations were 
high, with consistency between putamen measures .943 (CI=.907-.965) and caudate measures 
.944 (CI=.909-.965).  Finally, scatterplots (Figure 5.5) demonstrate a high level of association 
between manual and automated measures for both controls and HD participants. Scatterplots 
visualising the associations between manual and automated measures split by site were 
produced (Figure 5.6), and after visual inspection showing even distribution of data from the 
three sites, no further analysis was performed to examine the impact of site. 
 
 
                    
 
Figure 5.3. An example of failed automated segmentations. (A) Shows a coronal view without a 
segmentation, (B) shows the same view with a failed caudate segmentation, (C) shows an axial 
view without a segmentation, (D) shows the same view with a failed putamen segmentation. 
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Table 5.1. Demographics for the PADDINGTON participants included in the subcortical volume 
comparison. 
 
Controls 
(N=29) HD (N=40) 
Age 53.34 (7.60) 
38.26-66.64 
50.22 (9.99) 
26.77-67.29 
Sex (m/f) 
12/17 9/31 
CAG 
- 
43.35 (2.90) 
39.00-54.00 
Disease Burden 
Score - 
373.08 (87.75) 
230.77-559.18 
Total Functional 
Capacity 
13.00 (0.00) 
13.00-13.00 
11.68 (1.27) 
7.00-13.00 
Total Motor Score 1.45 (2.03) 
0.00-7.00 
19.00 (10.38) 
6.00-58.00 
 
 
Table 5.2. Summary data and intraclass correlation for manual and automated putamen and 
caudate volumes expressed as raw volumes and as a % of TIV. t-tests showing the difference 
between groups for automated and manual measures (as a % of TIV) are also displayed.  
 Controls HD Difference 
Putamen Manual Raw 7.75 (1.18) 
5.17-10.70 
4.97 (1.13) 
3.03-7.11 
- 
Manual % TIV 0.54 (0.07) 0.41-
0.68 
0.36 (0.08) 0.22-
0.51 
t(66)=9.83, 
p<.0001 
Automated Raw 7.59 (1.47) 
4.83-11.44 
4.75 (1.38) 2.47-
7.68 
- 
Automated % TIV 0.53 (0.09) 0.38-
0.76 
0.34 (0.10) 0.18-
0.56 
t(60)=7.77, 
p<.0001 
Caudate Manual Raw 7.49 (7.67) 
6.12-9.11 
4.99 (9.50) 
3.33-7.30 
- 
Manual % TIV 0.52 (0.05) 0.43-
0.62 
0.36 (0.07) 0.23-
0.53 
t(66)=10.63, 
p<.0001 
Automated Raw 6.44 (9.23) 
5.15-8.22 
4.28 (9.38) 
2.84-6.42 
- 
Automated % TIV 0.45 (0.05) 0.36-
0.55 
0.31 (0.06) 0.18-
0.43 
t(63)= 9.84, 
p<.0001 
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Figure 5.4. Bland-Altman plots comparing (A) manual and automated putamen volumes and 
(B) manual and automated caudate volumes. 
 
 
 
Figure 5.5. Scatterplots showing the relationship between manual and automated volumes of 
the (A) putamen and (B) caudate for both control and HD participants. 
 
 
Figure 5.6. Scatterplots showing the relationship between manual and automated volumes of 
the (A) putamen and (B) caudate, for Leiden (green), London (red) and Paris (yellow) sites. 
 
5.4. Discussion 
This analysis aimed to validate an automated measure of the putamen and caudate 
quantified from T1 MRI scans. In Chapter 4, MALP-EM was validated as a sensitive and reliable 
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tool for measuring the volume of CGM in an HD cohort. Based on those results, it was selected 
as a candidate for measuring CGM in the longitudinal analysis to be completed in Chapter 6. 
However, it is important that subcortical GM structures are also included in the analysis for 
Chapter 6 as they provide a robust and sensitive measure of neural atrophy in HD. Ideally, the 
same technique would be used to measure both cortical and subcortical GM to reduce sources 
of bias when drawing conclusions about regional differences. However, subcortical volumetric 
measures extracted from MALP-EM have not been validated to-date. Here both putamen and 
caudate volumetric segmentations from MALP-EM have been successfully validated, 
demonstrating high correspondence with manual measures.  
Similar to manual measures, the automatically segmented regions are highly effective 
at detecting significant group differences between control and HD participants in the 
PADDINGTON cohort.  Automated measures of the caudate and putamen were significantly 
lower in HD than controls at p<.0001. In addition, very high levels of consistency were seen 
between manual and automated volumes, with intraclass correlations >0.94 for both regions.  
However, it is important to recognise that a number of regions failed QC after being 
processed with MALP-EM. Two caudate regions had large holes that meant measurement 
would be incorrect, and six putamen regions were of poor quality, with underestimation of the 
putamen apparent. This failure rate could be problematic in small cohorts with limited data, 
and requires further examination in different cohorts. In the current data, the failures were 
not limited to either the control or HD group, suggesting that this is not an artefact stemming 
from atrophied regions. In addition, the poor segmentations did not appear to be as a result of 
a particular site or scanner type. This highlights the need for careful visual QC of 
segmentations from this pipeline prior to inclusion in future studies. While it is possible to 
perform manual editing on automatically generated regions to improve them, there should be 
strict criteria specifying when and how this should be done. 
Based on the results of this analysis, automated volumetric measurements appear to 
perform to a standard approaching that of the ‘gold-standard’ manual measurements. While 
overall volumes were lower than manual regions, possibly due to the use of PVE on the 
automated regions but not on the manually delineated regions, there was a strong relationship 
between the two measures and automated measures showed highly significant relationships 
to disease stage. Automated measures of the putamen and caudate will be used in the 
following chapters of this thesis.  
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6. CHARACTERISING CORTICAL GREY MATTER ATROPHY 
DURING HUNTINGTON’S DISEASE MOTOR ONSET 
Although many studies have detected significant atrophy within the cortex in pre- and 
manifest HD participants, previous research has been unable to present a thorough 
characterisation of the trajectory of cortical atrophy in HD because of limitations in study 
design and analysis methods that make assumptions about the linear progression of atrophy. It 
is more plausible to assume that neural changes are both linear and non-linear, with 
accelerations and decelerations possible during HD progression. Knowledge about the 
temporal progression of cortical change in HD could provide useful information to help 
understand the relationship between neural changes and HD symptomology. This chapter 
describes work that aims to expand upon previous findings by providing a detailed 
characterisation of CGM atrophy in HD participants using multivariate non-linear analysis to 
examine the progression of volume loss across multiple longitudinal time points. To provide a 
thorough characterisation of atrophy, linear modelling is used to detect regions that undergo 
atrophy at a constant rate (linear atrophy) and, additionally, non-linear models are used to 
track possible accelerations or decelerations in atrophy (non-linear atrophy).  Previous studies 
have used cross-sectional data to make inferences about the progression of atrophy, but here, 
by modelling both linear and non-linear characteristics of atrophy in a carefully selected 
longitudinal cohort, the temporal progression of cortical atrophy can be better understood. 
This can in turn provide information about the impact of cortical atrophy on symptom onset 
and progression that could aid in the targeted development of therapeutic advances for the 
treatment of HD.   
As described in section 1.1.6, at the point of end-stage disease cortical atrophy is 
widespread with only the temporal lobes relatively preserved. However, the nature of the 
progression of this widespread cortical atrophy during the pre- and early stages of manifest HD 
is still not well understood. A number of whole-brain analyses in HD gene-carriers suggest that 
volume loss begins in occipital and posterior regions and slowly progresses into more anterior 
regions of the brain as the disease progresses (Hobbs, Henley, et al. 2010; Tabrizi et al. 2012; 
Tabrizi et al. 2011; Tabrizi et al. 2009; Rosas et al. 2008). However, several studies have also 
indicated that frontal lobe volume is affected across both pre- and manifest disease stages 
(Aylward et al. 1998; Gómez-Ansón et al. 2009; Stoffers et al. 2010). A 2013 meta-analysis 
pooled the results of 17 VBM studies and found that between controls and pre-HD the only 
significant difference in cortical volume was in the occipital lobe, whereas for manifest HD, 
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differences were found in frontal cortex, primary motor, premotor and somatosensory 
regions, as well as in the intraparietal sulcus, the midcingulate cortex and the secondary 
somatosensory cortex (Dogan et al. 2013).  
In an attempt to map the neural changes that occur in pre-HD, a small number of 
studies have used advanced analysis methods, as discussed in section 1.4.2 (Wu et al. 2017; 
Ciarochi et al. 2016; Coppen et al. 2016). To recap, two studies used cross-sectional data to 
infer the co-occurrence of regional change, thought to represent network-based atrophy. The 
results from Ciarochi et al. (2016) indicated co-occurring frontal and motor atrophy in HD 
gene-carriers far from onset, with parietal and occipital atrophy in those closer to onset. 
Coppen et al. (2016) found more widespread patterns of atrophy in pre-HD, but with similar 
occipital regions showing change in manifest HD participants. However, both studies used 
analysis techniques based on the assumption that atrophy both progresses linearly and is 
temporally-correlated between regions. It is more biologically plausible to assume that 
atrophy occurs in both linear and non-linear patterns, and that the rate and pace of atrophy 
differs across regions. Furthermore, methodological issues including the possible mis-
registration of data in one of these studies, as described in 1.4.2, suggest that the findings 
should be interpreted with caution. Finally, a third study attempted to measure cortical change 
in a pre-HD cohort using cut-points - estimated points during disease progression whereby 
specific neural features begin to undergo significant change (Wu et al. 2017). Here, analysis 
including the WM, GM and subcortical structures did not show significant change within 
cortical GM, which may be due to the high variability in disease burden within the pre-HD 
cohort in addition to the use of stringent multiple comparison corrections applied due to the 
inclusion of multiple types of data. These studies were designed to characterise CGM change, 
and while they have expanded the findings of earlier VBM studies, there is still considerable 
inconsistency in terms of the pattern of cortical atrophy shown across the time course of HD 
and the true nature of CGM change in HD remains unknown. 
In addition to the pattern of CGM atrophy during disease progression, there is also 
uncertainty about the effect of CAG on atrophy rate.  Previous evidence suggests that CAG 
length contributes to both disease progression and atrophy rates (Rosenblatt et al. 2006; 
Henley et al. 2009; Hobbs, Henley, et al. 2010; Aylward, Mills, et al. 2011; Ruocco et al. 2008). 
However the exact nature of this effect is not understood, with a small number of studies 
indicating that higher CAG length results in faster atrophy of subcortical structures, as well as 
regions of the occipital, cingulate and frontal lobes (Henley et al. 2009; Hobbs, Henley, et al. 
2010; Ruocco et al. 2008; Aylward, Mills, et al. 2011). The effects of CAG length on both linear 
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and non-linear atrophy have not been examined in detail. Further evidence describing this 
relationship may help to understand the progression of HD, particularly in high CAG individuals 
who tend to show faster clinical progression (Rosenblatt et al. 2006).  
Collectively, the results of previous studies suggest that cortical atrophy generally 
occurs in late pre-HD and early HD, with the first atrophy likely to be occurring within occipital, 
motor and possibly frontal regions. However, the variability in terms of findings from these 
studies limits the conclusions that can be made about the progression of cortical atrophy in 
HD, particularly in pre-HD participants. There are a number of common methodological 
problems that may have contributed to this variability. Most previous studies use cross-
sectional data to draw conclusions about the progression of atrophy, and often make the 
assumption that atrophy progresses linearly; as yet there are no studies that have quantified 
non-linear atrophy in a longitudinal cohort. The use of simple mass-univariate approaches 
means that limited conclusions can be drawn from these analyses (McIntosh & Misic 2013). 
The lack of work measuring non-linear atrophy is partly due to the complicated nature of the 
modelling required to perform analysis of non-linear atrophy across multiple time points. 
While complex modelling methods are widely available for functional and electrophysiological 
data, similar methods have not been commonly applied to sMRI data (Friston et al. 2003; 
Stephan et al. 2007; Friston et al. 2016). However, a recently published framework has been 
developed for analysing changes in brain structure over time using a dynamical systems 
method (Ziegler et al. 2017). Structural Dynamic Causal Modelling (sDCM) enables both linear 
and non-linear modelling of complex longitudinal data (Ziegler et al. 2017), with the option to 
apply variable input factors hypothesised to be driving neural change differentially within 
regions.  Furthermore, change can be quantified within independent regions using a data-
driven approach, but also within networks of regions to test specific network-based 
hypotheses about the causal links between atrophy in different regions. This framework was 
recently validated on pubescent brain changes, demonstrating that cortical growth during 
puberty progressed differentially between regions and that regional change was related to 
explicitly defined growth factors (Ziegler et al. 2017).  Applying this approach to longitudinal 
data with multiple time points provides a powerful method of characterising structural change 
within the cortex in neurodegeneration.  
A further limitation of previous HD studies investigating cortical atrophy is that they 
have applied a series of differing tools for the processing and analysis of MRI data. Recent 
studies have demonstrated that segmentation errors affect the conclusions drawn from 
volumetric neuroimaging studies (Johnson et al. 2017; Katuwal et al. 2016). When different 
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segmentation tools are used to process the same images, volumetric results can be 
significantly different and segmentations are often visually different between tools, with errors 
in segmentation thought to be a driving factor causing between-tool differences (Katuwal et al. 
2016). These findings were supported by the results of Chapter 3, which demonstrated that 
inconsistency between tools can result in variable findings when applied on the same dataset. 
Due to the inconsistency introduced by the differing use of tools and substandard 
segmentations, it is essential that measures are validated as both reliable and accurate prior to 
use. Furthermore, visual QC should be performed on all scans and segmentations to ensure 
that any group differences or longitudinal changes are not just artefacts of poor segmentation 
techniques. 
Another key issue associated with previous studies is the heterogeneity of HD 
symptoms and disease onset/progression across HD gene-carriers. Typically, studies examining 
neural atrophy in pre-HD use an estimated calculation of year to disease onset when grouping 
participants according to disease stage. This calculation is based on a combination of age and 
CAG repeat (Langbehn et al. 2004), and explains around 50-70% of variability in onset 
(Papoutsi et al. 2014).  Although this formula can predict disease onset with moderate 
accuracy, when looking for subtle neural changes, heterogeneity within the groups can reduce 
the ability to detect small changes in the cortex and can result in variable findings across 
studies that have grouped participants differently (Paulsen, Long, Johnson, et al. 2014; Tabrizi 
et al. 2009). Given that a number of longitudinal HD studies have acquired imaging data within 
the same individuals spanning >6 years, it is now possible to select subsets of participants 
based on longitudinal characteristics such as speed of symptom progression (fast vs. slow 
progressors) or time of motor onset. This method of cohort selection can be used to reduce 
heterogeneity within groups, and thus increase the power to detect change within different 
phases of disease progression. However, retrospective grouping has only been used in a small 
number of studies to date and has not been used to study cortical change in detail (Paulsen, 
Long, Johnson, et al. 2014; Tabrizi et al. 2013). 
Additionally, a series of widely-cited findings are based on data collected as part of the 
multi-site observational PREDICT-HD study, which includes MRI data from more than 30 sites, 
and both 1.5 and 3 Tesla scanners. Multi-site studies are important for advancing knowledge 
about HD and enable the recruitment of much larger cohorts; however, data collected from 
multiple sites may also introduce significant noise to later stages of analysis. While key 
measures that show large group differences or change in HD (e.g. caudate volume) are 
generally robust to the effects of using data from multiple sites, more subtle changes may not 
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be detected due to higher level of between-site variability. The inconsistency in previous 
findings for CGM atrophy in HD suggests that cortical change is slowly progressing and thus 
susceptible to the noise introduced by combining data collected from a large number of 
scanners with multiple field strengths, such that the subtle changes are hard to detect. Most 
previous studies have been cross-sectional, and using data from a large number of sites can be 
more problematic when performing cross-sectional analyses since between scanner 
differences in image quality can act as a significant confound for MRI analysis  (Littmann et al. 
2006; Focke et al. 2011). In contrast, longitudinal analyses involving the study of within-
participant data are less affected by the variability introduced by multiple scanner types or 
acquisitions since participants are typically scanned at the same site with the same protocol 
throughout data collection and within-participant measures are used. Longitudinal data also 
accounts for natural variations seen in brain volume that can make group-differences difficult 
to detect in cross-sectional studies, and thus longitudinal analyses are preferable when 
possible. 
6.1. Aims 
In the following study, the aim was to characterise longitudinal linear and non-linear 
structural change within the cortex in HD, addressing a number of the shortfalls described 
above and providing the most detailed characterisation of the progression of CGM atrophy in 
HD to-date. This study uses tools validated in previous chapters to measure GM volume, and 
then applies a multivariate analysis method to quantify cortical GM atrophy in a sub-group of 
participants from the TRACK-HD and TrackOn-HD studies.  
The cohort was selected according to motor symptom onset using a clinically rated 
measure of motor symptoms in HD. As described in 1.1.3, the diagnostic confidence score 
(DCS) quantifies motor symptoms, and is used to define the clinical onset of HD. This inclusion 
criterion was chosen for a number of reasons. Firstly, this period is a critical time in disease 
onset, with the increasing symptom severity an important marker of progression for both HD 
patients and clinicians. Despite the importance of this period in HD, there is little 
understanding about whether the increase in symptom severity is reflective of structural loss 
within the brain. By understanding the relationship between symptom onset and neural 
change, a greater understanding of the progression of HD pathology could be gained. In 
addition, given the heterogeneity of symptoms in HD, the use of DCS as an inclusion criterion 
for this study enables the investigation of neural atrophy during a stage of the disease that 
follows a more predictable pattern of progression and thus improves the likelihood of 
detecting homogenous group-wide cortical change.  
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sMRI data were segmented into cortical sub-regions using MALP-EM, which was 
validated in earlier chapters of this thesis; MALP-EM was also used to segment the caudate, 
putamen and global WM. The resulting cortical, striatal and WM segmentations were then 
modelled using sDCM to map the distribution and rate of cortical atrophy in HD participants in 
the decade surrounding clinical diagnosis. Four main analyses were performed. Firstly, to 
determine which regions underwent the highest overall volumetric reduction, linear models 
were applied to quantify total atrophy occurring over the 11 year period for each participant 
within each brain region. Then, the rate of linear atrophy within each region was measured 
over time to show which regions show the highest and most consistent rates of atrophy.  The 
analysis was also performed to determine whether any regions of the cortex showed a pattern 
of non-linear atrophy, i.e., whether there was acceleration/deceleration of atrophy within 
cortical regions over the 11 year time period and if so, at which point during disease 
progression this acceleration occurred. In addition, since previous evidence suggests that CAG 
length contributes to disease progression and atrophy rates (Rosenblatt et al. 2006; Henley et 
al. 2009; Hobbs, Henley, et al. 2010) the effects of CAG length on both linear and non-linear 
atrophy were measured to determine whether CAG length contributes to atrophy rate. Finally, 
to investigate the association between behavioural change and cortical atrophy, a behavioural 
analysis was performed to map the progression of change in three performance measures, two 
of motor performance (one clinical, Total Motor Score, one behavioural, Speeded Tapping) and 
one measure of cognitive performance (SDMT). By studying the timing of change within these 
measures, the consequences of atrophy can be better understood. 
6.2. Methods 
6.2.1. Participants 
Participants were from the TRACK-HD and TrackOn-HD study cohorts (see 2.1.2). For 
the current study, only participants who were initially included in the pre-HD group in both 
cohorts and subsequently transitioned to manifest HD ('converters') during the course of data 
collection were included. Participants were recruited during data collection for TRACK-HD or 
TrackOn-HD and categorised at recruitment as pre-HD based on the criteria described in 2.1.2. 
Pre-HD participants were included in the current analysis if they received a DCS of 4 at any 
subsequent time point, indicating that they had met clinical diagnostic criteria for manifest HD 
and had therefore converted to the manifest HD stage. Fifty participants met this criterion for 
conversion during TRACK-HD/TrackOn-HD. One additional participant received a DCS of 4 at 
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TRACK-HD visit 4, but then reverted to DCS <4 at a later time point and was excluded from this 
investigation.  
All converters were re-aligned to consolidate year of motor conversion across all 
participants (Figure 6.1). This was done to increase homogeneity of disease progression within 
the group. Motor diagnosis is a disease progression milestone for HD, and thus by aligning the 
participants at time of motor-onset neural atrophy during the transition phase is predicted to 
be more consistent than looking across participants who are aligned differently. The first year 
of DCS = 4 was designated as year of conversion (time point =0), and each year prior to 
conversion labelled as year -1, -2, -3, etc. Every year after conversion was labelled as year 1, 2, 
3, etc. This resulted in a spread of participants with data up to -6 years prior to motor 
diagnosis and 5 years after motor diagnosis, enabling the mapping of cortical changes 
occurring during HD conversion. See Figure 6.1 for a schematic showing the number of data 
points available for each time point after re-alignment of the data. 
6.2.2. Measurement of motor and cognitive symptoms 
In order to link neural changes to HD symptoms, three measures of disease 
progression were selected from the battery of TRACK-HD and TrackON-HD behavioural tests 
that have previously been shown to have strong associations with disease progression in HD 
(Tabrizi et al. 2013). Firstly, Total Motor Score (TMS) was used to approximate clinical motor 
progression (Huntington Study Group 1996). TMS measures the presence of motor symptoms, 
and ranges from 0-60 with a score of <5 indicating no substantial motor symptoms. Since TMS 
is a clinical measure and thus can be subject to rater bias, an additional measure of motor 
progression that is less subjective, speeded tapping variability in inter-onset interval in the 
non-dominant hand was also included.  This measure requires participants to tap in time with 
a beep, and the tapping is measured. From this measurement, motor performance speed and 
accuracy can be assessed, and this measure shows significant disease-related change over 12 
months (Tabrizi et al. 2011) and was predictive of decline on TFC after adjusting for age and 
CAG (Tabrizi et al. 2013). Additionally, the symbol digit modalities test (SDMT) was included as 
a measure of cognitive progression in HD (Smith 1991). The SDMT assesses visuomotor 
integration and has components of visual scanning. It is a pencil-and-paper task during which 
participants view a key showing symbols with the digits 1-9. The participants are then 
presented with symbols above empty box and are given 90 seconds to write the corresponding 
digits in the boxes. The SDMT has been demonstrated as a reliable measure for use in HD 
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studies, and is also related to HD progression (Tabrizi et al. 2013). It is a key cognitive measure 
used in HD studies. 
6.2.3. Longitudinal image processing 
Image processing involved a pipeline with three general steps: the structural data from 
all time points for each individual were registered together and an average scan was created 
for each participant; the average scans were then segmented into cortical and subcortical 
regions using MALP-EM; finally the regions for each participant were multiplied from the 
Jacobian map corresponding to each time point, creating a volumetric map for each 
participant at each time point and within each region.  These steps are explained in more 
detail below.  
For the first step, the longitudinal within-participant registration pipeline included 
within SPM12 (Ashburner & Ridgway 2012) was applied to each individual set of data, i.e. all 
time points for each individual. This process included between–scan registration, creation of 
an average scan (across the time points) and automated differential bias correction for 
between-scan inhomogeneity (Jenkinson et al. 2002). In using this pipeline, variability that is 
commonly seen within longitudinal measures of volume due to inconstant scan alignment or 
differences in inhomogeneity can be removed without introducing bias by selecting an image 
from one time point as a target for registration. The registration process was performed using 
default settings and all native space scans from each participant for each time point.  The 
output included an average image (created by convolving the scans from all time points) as 
well as Jacobean images and warping parameters that were then used to align the native scans 
to the average scan. This allowed for QC on both the average image and the warped native 
image to ensure that registration had completed successfully for each time point. Registration 
initially failed for two participants due to poor initial alignment within the FOV between the 
scans from different time points. For these two participants, the native space scans were 
adjusted to be in rough alignment and registration was re-run successfully.  
Following registration, MALP-EM was run on all average scans.  MALP-EM is a freely 
available segmentation tool aimed at providing a fully automated method able to separate 
tissue classes in healthy brains as well as brains that show severe neural pathologies (Ledig et 
al. 2015). It utilises a previously described registration approach (Heckemann et al. 2012), 
atlas-based segmentation, and intensity-based expectation maximisation to segment the brain 
into cortical and subcortical regions (Ledig et al. 2015). As well as the validation performed as 
part of this thesis, MALP-EM has been validated on traumatic brain injury patients and with 
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successful stratification of patients into favourable vs unfavourable outcomes possible using 
MALP-EM segmentations (Ledig et al. 2015). MALP-EM outputs total volumes for different 
tissue types as well as regional volumes for 138 regions. 
While the MALP-EM standard pipeline generally performs well on the TRACK-HD and 
TrackOn-HD data, minor regions of over-segmentation in the occipital and temporal lobe were 
occasionally seen (Chapter 3; Johnson et al. 2017). Thus to improve delineation of the cortex in 
these regions, manually segmented whole-brain regions created during initial processing for 
the TRACK-HD/TrackOn-HD studies were used as masks during segmentation to improve initial 
brain-extraction and reduce errors in these areas. The process of creating these regions is 
described previously (2.3.3.1; Freeborough, Fox, & Kitney, 1997), but, briefly, the procedure 
uses a semi-automated intensity-based threshold with manual edits to create a highly-
accurate total-brain region in native space. These regions were created at baseline visits for 
TRACK-HD and TrackOn-HD participants, and were visually examined for accuracy prior to use 
in the current study. Minor edits were performed to improve these masks if necessary. The 
masks (in native space) were converted to NiFTI format, binarised and filled to ensure that the 
regions contained no holes. The mask was then registered to the average image for each 
participant using the warps generated during creation of the average image. Once overlaid on 
the average image for each participant, each mask was checked again to ensure that it overlaid 
the brain well. These masks were specified in the MALP-EM pipeline. All other settings for 
MALP-EM were the default values.  
After processing, all segmented regions underwent visual QC to check for errors. One 
scan did not pass QC due to errors in segmentation that could not be rectified, but overall the 
standard of segmentations was high. Figure 6.2 shows a finished MALP-EM segmentation 
demonstrating the high standard of cortical delineation. For each participant, the regions 
segmented on the average scan were then multiplied by the Jacobean maps from each time 
point to create a volumetric map representing the volumes within each region at every time 
point.  
MALP-EM automatically creates 96 default regions during segmentation, however a 
number of regions were combined to reduce the number of ROIs and corresponding noise 
within small cortical regions, and to ensure that results were biologically interpretable. There 
was a focus on an a-priori selection of 54 (27 bilateral pairs) grey matter regions of interest 
(ROI) and one global white matter volume. To create the reduced number of ROIs, default 
MALP-EM regions were combined. They were combined based on anatomical knowledge and 
visual inspection of the regions, with the regions that were combined and the final regions 
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shown in Table 6.1. As discussed previously, the regions were also combined across 
hemispheres. In order to facilitate more straightforward comparisons across regions the 
decision was made to analyse and present results of regional brain volume changes relative to 
volume at time point of motor diagnosis (in percent). Due to the temporal symmetry and the 
year of diagnosis being the only time point with full data availability in all subjects, this 
reference is expected to be more accurate compared to common referencing to volume at 
baseline scan. 
 
Figure 6.1. A schematic showing all data-points available for this analysis. Data is shown re-
aligned so motor diagnosis is consistent between participants. Green represents motor 
diagnosis, yellow represents available MRI data and grey represents missing data. Missing data 
includes time points for which a participant was not yet recruited (e.g. when a participant was 
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recruited at baseline of TrackOn-HD, such as Participant 49), or had dropped out of the study 
(e.g. Participant 16 dropped out at the end of TRACK-HD and did not participate in TrackOn-
HD), and when a participant could not attend a time point (e.g. Participant 26).   
 
 
Figure 6.2. An example of a GM segmentation used in this study shown in (A) Coronal, (B) Axial 
and (C) Sagittal views. The figures show both cortical and subcortical regions. 
 
 
Table 6.1. The final regions measured in this study, and the original regions output by MALP-
EM that were combined to create the final regions.  
Final Region Name Original Combined Regions 
Angular Gyrus Right Angular Gyrus Right 
Angular Gyrus Left Angular Gyrus Left 
Calcarine Cortex Right Calcarine Cortex Right 
Calcarine Cortex Left Calcarine Cortex Left 
Cuneus Right Cuneus Right 
Cuneus Left Cuneus Left 
Entorhinal Area Right Entorhinal Area Right 
Entorhinal Area Left Entorhinal Area Left 
Frontal Pole Right Occipital Frontal Pole Right 
Frontal Pole Left Frontal Pole Left 
Lingual Gyrus Right Lingual Gyrus Right 
Lingual Gyrus Left Lingual Gyrus Left 
Occipital Pole Right Occipital Pole Right 
Occipital Pole Left Occipital Pole Left 
Precuneus Right Precuneus Right 
Precuneus Left Precuneus Left 
Parahippocampal Gyrus Right Parahippocampal Gyrus Right 
Parahippocampal Gyrus Left Parahippocampal Gyrus Left 
Planumtemporale Right Planumtemporale Right 
Planumtemporale Left Planumtemporale Left 
Supplementary Motor Cortex Right Supplementary Motor Cortex Right 
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Supplementary Motor Cortex Left Supplementary Motor Cortex Left 
Supramarginal Gyrus Right Supramarginal Gyrus Right 
Supramarginal Gyrus Left Supramarginal Gyrus Left 
Superiorparietal Lobule Right Superiorparietal Lobule Right 
Superiorparietal Lobule Left Superiorparietal Lobule Left 
Temporal Pole Right Temporal Pole Right 
Temporal Pole Left Temporal Pole Left 
Temporal Gyrus Right Right Inferior Temporal Gyrus; Right Medial Temporal Gyrus; 
Right Planum Polar; Right Superior Temporal Gyrus; Right 
Transverse Temporal Gyrus 
Temporal Gyrus Left Left Inferior Temporal Gyrus; Left Medial Temporal Gyrus; Left 
Planum Polar; Left Superior Temporal Gyrus; Left Transverse 
Temporal Gyrus 
Orbital Gyrus Right Right Anteriororbital Gyrus; Right Gyrus Rectus; Right Lateral 
Orbital Gyrus; Right Medial Frontal Cortex; Right Medial Orbital 
Gyrus; Right Posterior Orbital Gyrus; Right Subcolossal Area 
Orbital Gyrus Left Left Anteriororbital Gyrus; Left Gyrus Rectus; Left Lateral Orbital 
Gyrus; Left Medial Frontal Cortex; Left Medial Orbital Gyrus; Left 
Posterior Orbital Gyrus; Left Subcolossal Area 
Cingulate Gyrus Right Right Anterior Cingulate Gyrus; Right Middle Cingulate Gyrus; 
Right Posterior Cingulate Gyrus 
Cingulate Gyrus Left Left Anterior Cingulate Gyrus; Left Middle Cingulate Gyrus; Left 
Posterior Cingulate Gyrus 
Frontal Gyrus Right Right Superior Frontal Gyrus; Right Superior Frontal Gyrus Medial 
Segment; Middle Frontal Gyrus 
Frontal Gyrus Left Left Superior Frontal Gyrus; Left Superior Frontal Gyrus Medial 
Segment; Middle Frontal Gyrus 
Occipital Gyrus Right Right Superior Occipital Gyrus; Right Inferior Occipital Gyrus; 
Right Middle OccipitalGyrus 
Occipital Gyrus Left Left Superior Occipital Gyrus; Left Inferior Occipital Gyrus; Left 
Middle OccipitalGyrus 
Inferior Frontal Gyrus Right Right Tringular Part Of The Inferior Frontal Gyrus; Right Orbital 
Part Of The Inferior Frontal Gyrus; Right Opercular Part Of The 
Inferior Frontal Gyrus 
Inferior Frontal Gyrus Left Left Tringular Part Of The Inferior Frontal Gyrus; Left Orbital Part 
Of The Inferior Frontal Gyrus; Left Opercular Part Of The Inferior 
Frontal Gyrus 
Operculum Right Right Central Operculum; Right Frontal Operculum; Right Parietal 
Operculum 
Operculum Left Left Central Operculum; Left Frontal Operculum; Left Parietal 
Operculum 
Insula Right Right Posterior Insular; Right Anterior Insula 
Insula Left Left Posterior Insular; Left Anterior Insula 
Postcentral Gyrus Right Post Central Gyrus Right; Right Postcentral Gyrus Medial Segment 
Postcentral Gyrus Left Post Central Gyrus Left; Left Postcentral Gyrus Medial Segment 
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Precentral Gyrus Right Precentral Gyrus Right; Right Precentral Gyrus Medial Segment 
Precentral Gyrus Left Precentral Gyrus Left; Left Precentral Gyrus Medial Segment 
Fusiform Gyrus Right Right Fusiform; Right OccipitalFusiform Gyrus 
Fusiform Gyrus Left Left Fusiform; Left OccipitalFusiform Gyrus 
 
6.2.4. Hierarchical disease progression models 
The framework introduced in section 2.5 for longitudinal modelling of brain 
trajectories using dynamical systems is applied here (Ziegler et al. 2017). This modelling 
approach describes individual as well as group-level (hierarchical) change in regional brain 
volumes during the transition period from pre-HD to manifest HD. Details of the applied 
modelling and inference were previously published (Ziegler et al. 2017). Firstly, to map 
individual progression individual (first-) non-linear models are estimated. These individual 
models are then taken forward to the group (second-) level, where a model (the most 
appropriate for our data being selected using Bayesian Model Comparison; see below) is fitted 
that estimates change across the group whilst accounting for the effects of covariates (such as 
age, gender).  
Individual first-level models were estimated using the established dynamical systems 
framework: 
 
The basic model assumes that  describes the change in regional volumes over time 
for each individual, ie27 bilateral volumes (25 cortical regions, as well as the caudate and 
putamen) and one global WM volume. The progression of  (volume in each region) is 
influenced by both endogenous dynamics, , and external inputs  (Figure 6.3. A). 
Internal dynamics (  can denote regional self-connections and/or connections between 
regions. For this study, only regional self-connections are estimated representing within-region 
atrophy rates. Between-region interactions were not specified here due to a specific interest in 
examining change within all individual cortical regions prior to examining more specific, 
network-based hypotheses.  
External inputs (u) are additional drivers of volumetric change or shrinkage, and in this 
model they represent the unknown underlying factors that may influence atrophy within a 
region. No explicitly defined external input factors, C, were included in the model. 
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This analysis has anticipated bilateral equivalence between the hemispheres and thus 
the volumes were combined across hemispheres, assuming that progression within each 
volume (  describes the same evolution of volumes in both corresponding bilateral grey 
matter ROIs. This bilateral equivalence is based on previous sMRI results reporting largely 
symmetric effects of atrophy in the TRACK-HD cohort and in a meta-analysis of HD studies 
(Tabrizi et al. 2012; Minkova et al. 2017; Minkova et al. 2018).  
Using this framework, the four analyses specified above were addressed to measure 
gross atrophy, linear rate of atrophy, non-linear accelerations in atrophy and the effects of 
CAG length on both linear and non-linear atrophy. The model specifications used to investigate 
these aims are detailed here. 
6.2.4.1. First-level dynamical models of individuals 
As part of the first or individual level analysis, a series of models were explored to 
identify which trajectory of volumetric change best explained the observed data. Seven 
different patterns of change including linear atrophy, as well as non-linear patterns that would 
imply acceleration or deceleration of atrophy during HD progression, each characterised by 
different external inputs, were modelled. The models were as following: 
(a) Linear progression resulting in constant rates of atrophy trajectories;  
(b) Piecewise linear progression assuming a global acceleration phase uniform across 
regions;  
(c) Accelerations progressing in a sigmoidal (s shaped) manner. These accelerations 
can have regionally-specific sensitivity to change and rates of change, but with a global delay 
parameter common across all regions reflecting a delay in the acceleration of atrophy. The 
global delay parameter could be before or after motor diagnosis;  
(d) Accelerations progressing in a sigmoidal (s shaped) manner. These accelerations 
can have regionally-specific sensitivity to change and rates of change, but this time with a 
regional delay parameter that reflects the possibility of a differing delay in the acceleration of 
atrophy across different regions. Again, the regional delay parameters could be before or after 
motor diagnosis; 
(e) Volumetric changes follow a generalized logistic differential equation;  
(f) Volume change follows a simple quadratic polynomial progression;  
(g) Volumetric change evolves without the effects of external inputs.  
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DCM uses a probabilistic Bayesian framework and accordingly, assumptions are applied 
regarding the nature of estimated change in volume.  Priors that reflect empirical or ‘prior’ 
knowledge of the distributions of expected volume change were therefore, included within the 
models, constraining the values of parameters during estimation. Here, only weakly 
informative priors representing data features were used rather than priors with strong 
assumptions about the progression of atrophy. This was because this is the first analysis of this 
type to be performed in HD, and it was unclear what pattern of degeneration might be found. 
Individual level model inversions were performed using previously established Variational 
Laplace methods (Friston et al. 2007). This was performed using the Variational Laplace 
algorithm for Bayesian parameter estimation, inference and model selection tools included n 
SPM12 via the SPM nlsi GN in release 6685 of SPM12 (Wellcome Trust Centre for 
Neuroimaging, London, UK, http://www.fil.ion.ucl.ac.uk/spm). More specifically, model 
inversion and estimation followed a symmetric system from time point of motor diagnosis 
(treated as the initial volume since data was available for all participants) both forward and 
backwards to the earliest time point prior to diagnosis and the latest time point after motor 
diagnosis. A detailed mathematical introduction to Variational Laplace and the applied 
inference using model evidence is provided in Ziegler et al. (2017). Model fitting can be 
potentially problematic, given that a good model may have a poor fit due to high levels of 
observation noise, while a complex model may have a good fit, but be biologically 
uninterpretable (known as overfitting; Stephan et al. 2010). Bayesian model selection guards 
against this problem by selecting a winning model that allows the optimal balance between 
accuracy and complexity (across the models being tested).  It should be noted that while the 
winning model determines the precision of the estimates, it does not need to be considered 
explicitly in the later stages of analysis (Stephan et al. 2010). For this study, the Bayesian 
Model Selection is performed at the second level.  
6.2.4.2. Second-level model of the group 
Since the aim of this analysis is to perform group level disease progression modelling 
whilst accounting for individual level non-linear trajectories, each participant’s first level model 
was embedded in a second (group-) level model. This enables the construction of group-wise 
models whilst controlling for individual level covariates, such as site, sex and age. A recently 
introduced empirical Bayes framework for estimation and inference of hierarchical non-linear 
models was used to estimate the group-level model (Friston et al. 2016). A number of 
participant-specific characteristics were included as covariates in the group-level to explain 
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first-level variability (Figure 6.3. C). These were: CAG length, sex, age (at motor diagnosis), TIV 
and scanning site. Notably, since CAG repeat length and age at diagnosis were highly 
correlated (r=-0.85), as is expected within HD studies, age was entered after orthogonalisation 
with respect to CAG.  
This hierarchical modelling accounts for unexpected variation of first-level parameters, 
increases power for detecting group-level effects by accounting for differences in first-level 
parameters across participants, for example by accounting for participants with a differing 
number of visits, and explicitly allows for further examination of the effects of variables (e.g. 
CAG length) on all model parameters (e.g. atrophy rates). 
Bayesian model selection was conducted comparing the obtained full hierarchical 
(two-level) models with all described first level forms and a second level including a group 
mean parameter and abovementioned individual covariates and confounds. Bayesian model 
evidence both optimises model fit while penalizing complexity and is therefore appropriate for 
model selection in highly parameterized hierarchical disease progression models (Penny 2012). 
Comparisons revealed that the evidence was highest for sigmoidal progression models with 
additional inputs to specify differential regional delays to the onset of accelerations (model (d) 
specified in section 6.2.4.1). The model evidence is shown in Figure 6.3 B. This model was 
subsequently used for the analysis. The regional inputs were specified for both the temporal 
delay of accelerations/decelerations and the sensitivity or amplitude of the accelerations. The 
winning model group results are presented in terms of the posterior distribution (expectation 
± SD) of the group mean parameters. 
6.2.4.3. Analysis of effects of CAG length on trajectories 
As well as characterising overall atrophy, additional analyses were performed to 
examine the contribution of CAG length to the progression of atrophy in this cohort. The 
applied hierarchical disease progression model accounts for inter-subject heterogeneity by 
using covariates to predict first level parameters (Friston et al. 2016). Here, second level 
parameter effects of CAG repeat length were evaluated while accounting for all other 
covariates introduced in the first level. There was a particular focus on whether CAG effects 
were associated with differences in regional rates of atrophy or the amplitude and sensitivity 
to sigmoidal inputs causing accelerations or decelerations of atrophy. Furthermore, the effect 
of CAG length on absolute volume at point of motor diagnosis was measured using first level 
models with additional initial state parameters (volume at motor diagnosis).   
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Since this disease progression model is generative in nature, it allows individual 
trajectory predictions for all regions and participants over the whole decade around diagnosis. 
To further evaluate the relationship of genetic and brain differences as a process of the 
disease unfolding over years, all individual regional volumes were predicted using CAG repeat 
length for all time points independently while accounting for covariates and confounds.  
6.2.4.4. Modelling volumetric change and behavioural results 
The multivariate dynamical disease progression model was complemented by a 
separate model used to examine the change in motor and cognitive performance over time. 
This was done using a simple linear-mixed effects approach (based on Matlab function fitlme 
with Maximum Likelihood estimation). A quadratic model of disease progression (relative to 
time point of diagnosis) was fitted to the data for each behavioural variable independently. 
The quadratic fit was compared to more simple linear progression models using (simulated) 
likelihood ratio tests. The intercepts and slopes were allowed to vary across participants (as 
potential random effects) to account for the substantial heterogeneity in HD progression. The 
participant specific covariates of age at diagnosis, sex, CAG, and site were entered into the 
model as fixed effects. The models were used to determine whether performance on these 
variables accelerates by inspecting the linear and quadratic effects of time.  
 
Figure 6.3. An example of the structural DCM model used in this chapter. (A) Shows the first 
level dynamical model, with the variables shown in the schematic on the right and (B) shows 
the log model evidence from the Bayesian Model Comparison for all models compared here, 
demonstrating that the sigmoidal model with regional delayed acceleration factors had the 
best fit.  
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6.3. Results 
6.3.1. Demographics 
Demographics for the final cohort are shown in Table 6.2. Demographics are the 
values measured at time point reflecting year of motor diagnosis.  
6.3.2. Linear change during motor conversion 
Linear modelling was used to quantify both total volume loss and rate of linear 
atrophy within all regions. Total volume loss (net atrophy) for the group is shown in Figure 
6.4.A. Figure 6.4. A details the overall percent volume loss within each ROI, across the 11 years 
surrounding diagnosis for the group. During motor onset, there was higher volume loss in 
subcortical regions compared to that in cortical regions. Total atrophy for the putamen was 
21.11%, and for the caudate was 19.68%, while within the cortex, motor and frontal regions 
displayed greatest overall atrophy, with the supplementary motor cortex undergoing the 
greatest change of 11.66% reduction in volume, followed by the frontal gyrus, precentral 
gyrus, superior parietal lobule, postcentral gyrus and inferior frontal gyrus, all showing 
between 8.52-10.46% change. Global WM underwent 8.25% change. Temporal lobes showed 
the lowest rates of atrophy, with the parahippocampal gyrus, temporal pole and entorhinal 
cortex showing particularly low levels of volumetric reduction over 10 years.  
Following analysis of total volume loss, the rate of volume loss (‘atrophy rate’) across 
the 11 year period surrounding diagnosis was then examined, as shown in Figure 6.4.B. 
Atrophy rate represents approximate rate of linear change over the total time period 
surrounding diagnosis. Again, this rate was highest in the caudate and putamen, with frontal 
and motor regions showing the greatest rates of atrophy within the cortex. Temporal and 
occipital regions showed the lowest rates of linear atrophy. 
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Table 6.2. Demographics for the converters included in this study. The table shows mean (SD) 
and ranges, or N (%). 
Age 
44.59 (9.28) 
28.65-66.00 
Female 27 (55.10%) 
CAG 
43.67 (2.77) 
39.00-50.00 
Site 
Leiden 22 (44.90%) 
London 10 (20.40%) 
Paris 10 (20.40%) 
Vancouver 7 (14.29%) 
Total Motor Score 
14.82 (5.63) 
7.00-32.00 
Speeded Tapping 
-2.71 (0.52) 
-3.72- -1.49 
Symbol Digit 
Modalities Task 
44.00 (9.52) 
22.00-65.00 
 
6.3.3. Non-linear change during motor conversion 
Next, sigmoidal progression models were used to model non-linear change, that is, the 
accelerations and decelerations of atrophy within each region. Additional inputs were included 
in the model to account for variation in the acceleration/deceleration (signal amplitude) of 
regional atrophy and the timing of these non-linear changes within the 11 year period 
surrounding disease onset.  
Firstly, amplitude of non-linear volumetric change was accordingly calculated for each 
ROI, see Figure 6.5. Greatest acceleration of atrophy, i.e. highest amplitude, was seen in a 
number of motor regions, including the postcentral gyrus, the superior parietal lobule, the 
precentral gyrus and the supplementary motor cortex. Minor accelerations of atrophy were 
also seen in a number of other regions, including frontal and occipital regions and within the 
caudate and putamen. In contrast, minor decelerations of atrophy were shown in temporal 
regions and some medial-occipital regions, including the calcarine cortex.  
For regions showing large accelerations/decelerations of change, timing of the 
accelerations/decelerations were estimated (Figure 6.5). It is important to note that the timing 
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of acceleration is limited to before, after, or around the time of diagnosis rather than a specific 
time point. As shown in Figure 6.5, the caudate, putamen and a number of occipital and 
frontal regions showed accelerated atrophy prior to disease onset. The largest acceleration of 
atrophy was seen in motor regions occurring post-diagnosis.  
Figure 6.6. shows individual-level regional change and the corresponding sigmoid 
model for group-level acceleration of atrophy within each region. The plots demonstrate the 
relationship between individual-level change and group-level model fit, with variability seen 
between the regions. These plots demonstrate that some regions, including regions typically 
difficult to register and process such as the temporal lobes and parahippocampal region, show 
a high amount of noise. In contrast, a number of other regions, particularly subcortical, show 
less noise between time points. Figure 6.7 shows the individual model-change plotted 
alongside the group-model for one region, the caudate.  
6.3.4. Effect of CAG on atrophy 
Additional analysis using CAG as a second level parameter was performed to explore 
the link between CAG and cortical atrophy. Higher CAG length was associated with accelerated 
linear volume loss within occipital and subcortical regions, see Figure 6.8. In terms of non-
linear change, those with higher CAG length displayed reduced acceleration of atrophy over 
the decade surrounding motor diagnosis, especially in sensory-motor regions; conversely, 
participants with lower CAG lengths showed greater acceleration of atrophy in these regions. 
Furthermore, participants with a higher CAG length had substantially lower caudate, putamen 
and WM volume than those with lower CAG length at time of onset, but higher volume within 
some frontal regions. Finally, higher CAG length explained increasing variability in volumetric 
change over time within subcortical and WM regions, but decreasing variability in a number of 
cortical regions. 
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Figure 6.4. Group results showing (A) Surface projection (left panel) and parameter plot ± SD 
(right panel) of the overall percent volume loss of regional brain tissue per decade around 
diagnosis. (B) Rate of atrophy indicating approximately linear tissue atrophy during HD motor 
onset. These results account for the effects of age, sex, site, CAG and TIV. 
 
6.3.5. Motor and cognitive change during motor conversion 
Figures 6.9, 6.10 and 6.11 show the progression of TMS, Speeded Tapping and SDMT 
during the clinical transition from pre-HD to manifest HD in this cohort. For each figure, A 
shows individual-level model fit, and B shows group-level fit. Across the group, TMS began to 
increase thus representing an increase in motor symptoms before diagnosis which continued 
to accelerate after diagnosis. There were also minor increases in the Speeded Tapping score 
prior to diagnosis, indicating poorer motor performance; these increases in score accelerated 
after motor diagnosis. Finally, SDMT scores also began to show minor decreases across the 
group (indicating impairment in cognitive performance) prior to diagnosis, and similarly to 
Speeded Tapping, underwent accelerated decreases in performance across the group after 
diagnosis. 
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Figure 6.5. Group results showing (A) Regional sensitivity to input causing accelerations (red) 
or decelerations (blue) of atrophy (B) Delay parameters (of regions that show accelerated loss) 
showing approximate onset of acceleration. (C-F) Summary of all brain regions explored 
showing between-region differences in the group trajectory of atrophy progression. Regions 
differ qualitatively with evidence for some ROIs (C) showing accelerations before motor 
diagnosis (D) showing accelerations after motor diagnosis, (E) showing decelerations, (F) or no 
sign of non-linear effects (changes of rate of change). The disease model predicts individual 
and group level percent volume relative to volume at motor diagnosis accounting for 
individual variations in cag repeat length, age, sex, TIV and scanning site. Vertical dotted lines 
show the estimated time point of strongest accelerations of progression for each region. 
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Figure 6.6. Examples of regional brain volumes and their progression during transition to HD. Plots show regional longitudinal raw data (percent 
volume relative to volume at year of motor diagnosis) with each black line representing one of the 49 participants. The group level dynamical disease 
progression model with highest Bayesian model evidence is shown in red. With exception of the white matter volume, regional volumes shown here 
refer to the left hemisphere with corresponding right hemispheric volume exhibiting very similar progression (not shown).
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Figure 6.7. An example of the individual and group models, plotted for one region (caudate) to illustrate model fit.  
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Figure 6.8. CAG repeat length is reflected in individual disease progression. (A) Higher CAG 
repeat length increases linear rate of atrophy in a number of regions. Shown is a brain surface 
projection (left panel) and parameter plot ± SD (right panel) indicating that CAG affects first 
level atrophy rate across patients (B) Higher CAG repeat length mainly associates to reduced 
amount of accelerations, rendering progression more linear in high CAG repeat individuals (C) 
Although generally younger, higher CAG participants have substantially reduced striatal and 
global white matter volume at time point of diagnosis. (D) Effect of CAG is also reflected in an 
increasing percent of variance explained in the putamen, caudate and white matter, and (E) a 
decreasing percent of variance explained in cortical areas. 
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Figure 6.9. Graphs showing (A) individual-level and (B) group-level quadratic models representing 
change in Total Motor Score over time in all participants included in this study. 
 
Figure 6.10 Graphs showing (A) individual-level and (B) group-level quadratic models representing 
change in Speeded Tapping over time in all participants included in this study. 
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Fi
gure 6.11. Graphs showing (A) individual-level and (B) group-level quadratic models representing change 
in SDMT over time in all participants included in this study. 
 
6.4. Discussion 
This study presents the first detailed mapping of linear and non-linear structural 
change in the cortex during conversion from pre-HD to manifest HD. Using a novel multivariate 
non-linear modelling approach it was shown that a number of cortical regions, particularly 
within the frontal and motor cortices, underwent significant linear atrophy during the decade 
encompassing clinical disease onset in HD. Concurrently, there was evidence of non-linear 
acceleration of atrophy mainly in motor regions that occurred in the period directly following 
clinical diagnosis. CAG length also had varying effects on linear and non-linear atrophy, with 
higher CAG lengths resulting in greater linear atrophy in subcortical and occipital regions, but 
smaller accelerations of non-linear atrophy in motor regions. A quadratic fit was used to map 
changes in motor and cognitive scores over time, indicating that TMS (a clinical motor score) 
shows accelerated impairment prior to motor diagnosis, whereas Speeded Tapping (a 
quantitative motor score) and SDMT (a cognitive score) begin to show accelerated 
deterioration after motor diagnosis.  These findings are the first to highlight the differential 
patterns of atrophy that cortical regions undergo during motor onset, and have important 
implications for our understanding of the disease.  
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As expected, subcortical striatal regions showed greater overall volumetric reduction 
than cortical regions, with both the caudate and putamen showing total volumetric loss of 
around 20% in the decade surrounding diagnosis, but with the putamen showing slightly 
greater loss than the caudate. Subcortical striatal structures also showed the greatest linear 
atrophy rates and although there was some acceleration of atrophy that occurred around the 
time of diagnosis, overall subcortical atrophy showed a predominantly linear pattern. This 
result supports previous work suggesting that subcortical regions appear to undergo atrophy 
that follows a linear pattern beginning long before motor onset (Hobbs, Barnes, et al. 2010). 
Furthermore, the results provide evidence in support of marginally faster atrophy of the 
putamen than the caudate, similarly to previous TRACK-HD studies (Tabrizi et al. 2012). There 
have been contrasting findings in the literature when comparing rates of caudate and putamen 
atrophy (Georgiou-Karistianis et al. 2013), with differences between studies attributed to the 
varying use of segmentation methods and different cohorts (pre-HD vs manifest HD and 
different datasets). While this study does not provide a definitive answer as to whether the 
caudate or putamen undergoes faster atrophy, and it is possible that rates differ over the 
course of the disease, the results indicate that during transition to manifest HD the putamen is 
undergoing a slightly faster rate of atrophy.  
For the first time, this study has demonstrated that a number of frontal and motor 
regions undergo the greatest total cortical atrophy and the highest linear rates of atrophy 
during conversion to manifest HD (Figure 6.4.). Several regions lost between 8.25-11.66% of 
baseline volume over the 11 year period. While previous work has demonstrated that motor 
and frontal regions are significantly reduced in pre- and manifest-HD compared to control 
participants (Thieben et al. 2002; Gómez-Ansón et al. 2009; Sormani et al. 2004; Wolf et al. 
2009; Gavazzi et al. 2007; Aylward et al. 1998; Tabrizi et al. 2009), the present results provide 
detailed regional rates of progression. The supplementary motor cortex showed the greatest 
net atrophy in this cohort, with the frontal gyrus, precentral gyrus, superior parietal lobule, 
postcentral gyrus and inferior frontal gyrus indicating a distinct pattern of motor and frontal 
change. Furthermore, similar frontal and motor regions also showed a high rate of linear 
atrophy; with frontal regions generally displaying slightly higher rates of linear atrophy than 
motor. Interestingly, both the net atrophy and linear rates of change within the temporal lobes 
indicate that they are relatively spared from degeneration during this time period; a finding 
that is supported by both in-vivo and post-mortem results (Douaud et al. 2006; Tabrizi et al. 
2009). 
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Within some regions, the total amount of atrophy occurring over the 11 years 
measured in this study was much higher than annualized rates typically reported from 
measures of global GM volume in both pre-HD and manifest participants, which has been 
quantified at around 0.5% per year in manifest HD2 participants, and lower in HD1 and pre-HD 
participants (Tabrizi et al. 2012). This is unsurprising when considering the variability of 
atrophy seen within the cortex. Regions undergoing little change, such as the temporal lobe, 
may be diluting the effect of regions undergoing significant atrophy in global GM measures, 
even within manifest HD participants. Thus, previous work quantifying global GM change may 
have under-estimated cortical change and contributed to a view that cortical atrophy in HD 
has little effect on disease progression in comparison to subcortical and WM changes.  
This study also provides novel insight into more complex non-linear patterns of 
atrophy across time, seen in Figure 6.5. Motor regions underwent a striking pattern of 
acceleration of atrophy during transition from pre-HD to manifest HD, with further analysis 
demonstrating that this acceleration occurred shortly after clinical motor diagnosis. Non-linear 
analysis of CGM has not previously been performed in HD, and while this finding is perhaps 
unsurprising as clinical diagnosis occurs at the point of motor conversion, it provides novel 
evidence demonstrating the significant acceleration of atrophy within motor regions over the 
period of conversion. It is interesting that atrophy undergoes acceleration shortly after 
diagnosis, since motor diagnosis occurs at the point in disease progression whereby motor 
symptoms are sufficiently evident to lead to diagnosis and therefore higher acceleration of 
motor cortical atrophy may be expected prior to the point of conversion. However, it seems 
likely that degeneration in the white matter precedes that of cortical grey matter (Tabrizi et al. 
2009; Paulsen et al. 2008; Wu et al. 2017).  As such, the white matter pathways that connect 
cortical grey matter regions could be primarily affected prior to diagnosis; with the atrophy in 
the cortical grey regions occurring later in the disease trajectory of neurodegeneration. Thus, it 
is the changes in white matter or structural connectivity rather than cortical atrophy that drive 
symptom progression. McColgan (2017) demonstrated significant reduction in connection 
strength in WM connections  to posterior regions, including motor regions, over 24 months in 
pre-HD participants. Furthermore, the significant change-points seen in WM volumetric and 
diffusion metrics but not CGM volume across pre-HD participants in the analysis comparing 
volumetric and diffusion metrics by Wu et al. (Wu et al. 2017) provide further support for this 
theory.  Future work should aim to directly address this hypothesis. In this study, the WM 
underwent around an 8% decrease in volume over the period, and showed a predominantly 
linear pattern of atrophy with only minor acceleration in atrophy seen shortly after diagnosis. 
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Previous studies have reported lower cross-sectional WM volume in both pre-HD (Aylward, 
Nopoulos, et al. 2011; Paulsen et al. 2010; Tabrizi et al. 2009) and manifest HD compared to 
controls (Aylward et al. 1998; Halliday et al. 1998; Tabrizi et al. 2009). Longitudinal studies 
have also shown significant change in WM in pre-HD and manifest HD (Aylward, Nopoulos, et 
al. 2011; Ruocco et al. 2008; Tabrizi et al. 2011; Hobbs, Henley, et al. 2010), with rates of 
around 1% WM loss per year in pre-HD and around 2% per year in manifest HD (Tabrizi et al. 
2012), which are in line with the current rates of change. However, it is important to recognize 
that global WM atrophy may not be a true marker of WM progression in HD and that DTI or 
connectivity metrics better reflect WM properties. Because of this, detailed conclusions on the 
rate of WM atrophy cannot be made based on the current results.  
Some frontal, lateral occipital and both striatal regions showed minor acceleration of 
atrophy occurring prior to disease onset, yet these accelerations were much less pronounced 
than those seen in motor regions. The minor accelerations in frontal regions that precede 
those seen in motor regions could help to understand the onset of cognitive disturbance that 
often occurs prior to motor onset in HD, and this could be investigated in a cohort further from 
onset. Finally, temporal and some medial-occipital regions underwent slight deceleration of 
atrophy, however these regions showed lower rates of atrophy and deceleration was less 
pronounced. In addition, as shown in Figure 6.6., some of these regions were particularly noisy 
regions.  
These results reveal an interesting pattern of both linear and non-linear cortical 
change. For the first time, this analysis has highlighted the degree to which sub-regions of the 
cortex are affected differentially by HD motor onset. Both similarities and differences in 
progression can be seen between functionally distinct regions of the cortex, for example 
frontal and motor regions undergo similar rates of linear change, but motor regions show a 
much greater acceleration of atrophy on top of the consistent linear progression seen. Regions 
including the supplementary motor, pre- and post-central gyrus underwent high rates of linear 
atrophy as well as strong accelerations of non-linear atrophy, as shown in Figure 6.4 and Figure 
6.5. In contrast, while the frontal lobe also appeared to undergo significant linear decline, it 
was not as affected by accelerations in atrophy, with more minor accelerations seen prior to 
diagnosis. These results highlight the complex trajectory of CGM change in HD, and provide 
further evidence that previous methods of analysis are unsuitable for characterising this 
change. They also support the work of McColgan et al. (2015; 2017), who showed that WM 
connections between the striatum and cortical regions in the parietal and frontal regions 
appear to deteriorate earlier than other WM connections across the brain in HD. McColgan 
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theorised that early degeneration may be occurring in cortico-striatal tracts that are the most 
highly connected and experiencing the most neural traffic. These are also tracts connecting the 
basal ganglia to regions within the motor and association networks (Section 1.5). In the current 
study, the cortical regions that showed the greatest atrophy were the frontal and parietal 
regions, supporting McColgan’s work and indicating that atrophy is occurring within regions of 
the motor and association networks during HD motor conversion. It is currently unclear why 
these two networks are particularly susceptible to degeneration, and why degeneration 
appears to spread from the basal ganglia towards cortical networks via the WM tracts. Future 
work should be done to further link degeneration within the WM and GM of these networks.  
The effect of CAG length on atrophy was also modelled here. Previous work has 
demonstrated a link between CAG length and HD progression (Rosenblatt et al. 2012; Tabrizi 
et al. 2013) with higher CAG associated with faster HD progression. The results indicate that 
higher CAG lengths are associated with higher rates of linear atrophy within the caudate, 
putamen and across the occipital lobe (Figure 6.8.). This supports the findings of a number of 
previous studies relating higher CAG repeats to greater linear change within the subcortical 
and occipital lobes (Hobbs, Henley, et al. 2010; Ruocco et al. 2008; Henley et al. 2009). Finally, 
higher CAG participants showed lower volume of the caudate, putamen and WM at diagnosis 
than those with lower CAG repeats, although they also had higher volume within a number of 
frontal regions. It could be interpreted from this result that caudate, putamen and WM are 
more severely affected than cortical regions by a higher number of CAG repeats. It is also 
possible that because of the strong association between age and CAG length meaning that 
converters with high CAG repeats were generally younger, frontal regions may be showing a 
protective effect of age. Interestingly, occipital regions typically found to undergo substantial 
atrophy in both pre-HD and manifest-HD showed lower atrophy and rates of atrophy in this 
analysis, despite being named in numerous studies as one of the earliest regions to undergo 
atrophy in HD (Coppen et al. 2016; Hobbs, Henley, et al. 2010; Tabrizi et al. 2009; Tabrizi et al. 
2011). While the occipital lobe did undergo significant atrophy in this study, it was not as 
prominent as previous results suggest. However, the strong association seen between CAG 
length and atrophy in this supplemental analysis suggests that rate of occipital atrophy is 
closely linked to CAG length (which was controlled for in the main analysis). Previous analyses 
showing extensive atrophy in the occipital lobe failed to control for CAG length (Tabrizi et al. 
2009; Tabrizi et al. 2012) and  its inclusion here suggests that the occipital lobe may be more 
susceptible to the negative effects of high CAG than other regions.  
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Finally, the behavioural analysis links change measured within the brain to 
deterioration on motor and cognitive scores. TMS is a clinical measure of motor performance, 
that covers a range of motor domains representing clinical progression in HD, including chorea, 
dystonia, ocular pursuit, and gait. Here, TMS showed accelerated impairment prior to motor 
onset suggesting that performance on this measure, and thus typical HD movement symptoms 
are more closely linked to striatal atrophy than that within the cortex, and more likely the 
result of reduced connectivity as demonstrated by McColgan et al. (2017). In contrast, both 
the Speeded Tapping and SDMT measures showed an accelerated loss in performance mainly 
after clinical diagnosis. Both measures, designed to quantify more discrete aspects of motor 
and cognitive performance than TMS, therefore, begin to show greater impairment as cortical 
motor regions show accelerated volume loss, thus indicating that performance on both the 
Speeded Tapping and SDMT could be more closely linked to cortical atrophy than TMS. 
This work has taken a step towards understanding the progression of cortical atrophy 
in HD and has implications for the treatment of HD. The results suggest that cortical atrophy is 
undergoing significant change in the 5 years preceding clinical diagnosis, and thus support the 
view that administration of a potential therapy aimed at preventing degeneration should be 
timed many years prior to onset. In addition, preclinical work conducted on primates suggests 
that, if successful, the intrathecal administration of HTT lowering drugs currently being trialled 
on early HD participants will have a greater effect on reducing HTT in the cortex than the 
striatum (Wild & Tabrizi 2017). Consequently, characterising the pattern of cortical atrophy in 
HD is essential for understanding the effectiveness of these therapies at slowing or preventing 
atrophy. As research moves towards the development of a successful disease-modifying 
treatment for HD, this knowledge may prove useful for the refinement of the timing and 
administration of a treatment, especially if this type of analyses is conducted on other HD 
cohorts at different disease stages. Although the relationship between neural atrophy and the 
behavioural measures studied here should ultimately be tested more directly, these findings 
have important implications for understanding the association between neural changes and 
commonly used HD biomarkers for measuring symptom progression. Despite its sensitivity to 
early motor symptoms (Tabrizi et al. 2012), TMS is routinely used to measure change in groups 
of HD participants rather than pre-HD participants, and as such is used as an endpoint in 
clinical trials. However, as these findings demonstrate, TMS begins to show increased change 
prior to any significant acceleration in cortical atrophy, and therefore, it is possible that it may 
not be as sensitive to the effects of a drug that targets the cortex. In contrast, changes in 
Speeded Tapping and SDMT suggest a closer association with changes in cortical atrophy of 
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the motor regions, suggesting that they are more sensitive to the effects of the therapies 
currently being tested, and this should, therefore, be considered during analysis of trial 
endpoints. 
This study has improved on previous work by addressing a number of limitations 
observed in other studies. The modelling framework applied here is a previously validated, yet 
novel approach to modelling sMRI data and this study is the first application of this technique 
to neurodegeneration. The method was developed to address weaknesses in previous analysis 
methods and to approach the quantification of GM change via a dynamical systems method. 
The ability to quantify both linear and non-linear CGM change in a group of participants with 
data from variable visits over multiple time points offers a more powerful approach to CGM 
modelling than previous methods. Using this approach, the quantification of linear atrophy as 
well as acceleration of atrophy results in a detailed perspective on the progression of neural 
change than previous methodologies applied in HD. Different generative models were fitted to 
the data and compared, so that traditional models such as a quadratic model fit could be 
compared with more complex models, including the sigmoid model. The sigmoidal model was 
found to have the best data fit once incorporating varying delay and acceleration factors. By 
performing Bayesian model comparison on the different models, it is ensured that the results 
of this comparison are robust. Furthermore, the inclusion of covariates into the first-level of 
this model controls for variability in these parameters, and thus the models are less affected 
by individual differences. While it is essential that this work is replicated using similar 
approaches in other datasets and cohorts, the regional progression observed in these results is 
entirely plausible based on post-mortem data, previous imaging data and disease symptoms.  
By performing this analysis on a subset of TRACK-HD and TrackOn-HD participants who 
underwent conversion, some heterogeneity within the disease progression can be removed. 
All participants in this study were showing clinical progression over this period, thus removing 
the variability introduced by using a predictor of motor onset to categorize participants. The 
final dataset included 286 scans across 49 participants, resulting in over a decade of data 
surrounding motor diagnosis. This timespan and number of participants provides a strong 
dataset for quantifying longitudinal within-participant change. PREDICT-HD investigators 
collected data on over 1000 pre-HD participants for >10 years, and are the only other known 
cohort with such a large extent of imaging data in HD. One study conducted on the PREDICT-
HD dataset examined motor, cognitive and imaging predictors of motor diagnosis (Paulsen, 
Long, Ross, et al. 2014).  Variables quantified at baseline from all three domains were 
significant predictors of conversion from pre- to manifest HD in 225 individuals. A number of 
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brain regions were significant predictors of conversion (including the putamen, caudate, 
hippocampus), but lobular GM was one of the best predictors. However, lobular regions were 
not broken down further, and there has not yet been any analysis that can compare to the 
current longitudinal analysis of cortical sub-regions, however the PREDICT-HD dataset offers 
the potential to replicate this result in a much larger cohort of motor converters. While the 
current analysis shows some interesting results, they require further validation in different 
cohorts and across different stages of HD before generalising them.  
Finally, the application of robust segmentation and analysis methods add support to 
the current findings. By first validating MALP-EM on the TRACK-HD cohort and performing 
detailed visual QC of all scans, the quality of segmentations has been assured. Since it is clear 
that substandard segmentation methods have previously lead to mixed findings in 
neuroimaging studies (Ashburner et al. 2016), the use of accurate tools that were validated on 
the same cohort in which they were then applied is an important strength of this study.  
It is also important to address a number of weaknesses in this study. Firstly, the use of 
clinical motor diagnosis as a criterion for inclusion in this study provides a clinically meaningful 
measure of disease progression, but also introduces a level of subjectivity to the inclusion of 
participants. The Leiden site had many more converters compared to other sites, with 
participants from Leiden almost 45% of participants in this analysis. It is unclear whether this is 
due to differences in clinical diagnosis procedures between raters or countries or whether 
more participants did undergo change in Leiden. In order to control for this where possible, 
site was entered as a co-variate into the analyses. In addition, the inclusion of participants 
within 6 years to motor onset means that it is likely that the very earliest cortical atrophy has 
not been captured by the current analysis. Further analyses could attempt to use pre-HD 
participants to model cortical atrophy in those further from onset, although this re-introduces 
issues associated with using predicted onset as a group classifier. Finally, this analysis 
combined data from two hemispheres, and merged a number of smaller cortical regions into 
larger regions. These decisions were made prior to analysis to reduce the number of regions 
included in the analysis, and were based on previous evidence suggesting that CGM changes in 
HD are bilateral. Some regions that were combined may more effectively represent HD 
without being combined, especially the cingulate gyrus. Analysis should be repeated with 
different parcellations to determine how this affects the results found in the current study. 
Nevertheless, it is possible that subtle hemispheric differences or small regional differences 
were overlooked due to this decision.  
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This analysis has given new insight into the progression of cortical atrophy, yet there 
are a number of future aims that could be addressed to build on these findings and address 
weaknesses in this study.  As discussed, the analysis could be replicated within smaller sub-
regions of the cortex and bilaterally to determine how this might affect the results. In addition, 
future work can build on the current examination by quantifying change within different 
cohorts. For example, a recently developed score of HD progression that was validated on the 
TRACK-HD cohort could be used to select those who undergo fast or slow HD progression 
(Moss et al. 2017). In addition, while there appear to be distinct HD phenotypes that occur 
around the time of conversion that would be interesting to study (McCusker & Loy 2017), it 
can be very challenging to group participants based on symptom progression, especially in a 
relatively small sample size. The present analysis was limited to the analysis of sMRI data with 
a focus on the cortex. Future analyses could work to integrate other subcortical regions and 
imaging metrics or modalities such as measures of diffusion or connectivity into the model. 
This would provide a more complete understanding of the process of neurological change 
occurring in HD, rather than just cortical atrophy. Finally, the behavioural analysis performed 
in this chapter should be combined with the volumetric sDCM modelling. Directed hypotheses 
could be tested based on the preliminary results indicating that TMS may show early changes 
related to WM (i.e. structural connectivity) and striatal changes, but that Speeded Tapping and 
the SDMT may be more closely associated with volumetric loss in the cortex.     
These results provide the most detailed characterization of cortical atrophy in 
participants undergoing transition from pre- to manifest HD to date. By applying a recently 
validated model that is uniquely able to map both linear and non-linear cortical change across 
multiple time points, this analysis expands upon previous work quantifying atrophy within the 
cortex. The results suggest that both linear and non-linear changes contribute to cortical 
atrophy differentially across the brain, and provide preliminary results indicating that different 
behavioural measures are likely to show different associations with cortical atrophy. While 
future work could expand upon these results within different cohorts and by integrating 
different imaging measures, these results presenting the first brain-wide cortical mapping in 
HD provide a comprehensive insight into CGM atrophy at a critical point in HD progression. 
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7. DISCUSSION 
This thesis aimed to evaluate the most accurate tools for measuring cortical atrophy 
from MRI scans in HD and to then apply the validated tools on an HD cohort undergoing motor 
conversion in an attempt to characterise cortical grey matter (CGM) change during this period. 
First, a series of comparisons between commonly used CGM and subcortical GM measurement 
tools were performed. From this, the most appropriate methods to detect and measure GM 
change in HD were selected. These tools were then applied to data from a cohort of HD gene 
carriers who underwent motor conversion during the TRACK-HD and TrackOn-HD studies. The 
data were analysed using a newly developed structural dynamic causal modelling (DCM) 
modelling technique that provided a detailed account of what CGM changes occur during the 
period immediately surrounding HD diagnosis. The results from this thesis provide both 
methodological advances in the analysis of sMRI data and clinically relevant information about 
the progression of atrophy in HD. 
7.1. Methodological comparisons 
Three methodological comparisons were performed in chapters three, four and five. 
Chapter three compared a number of methods that can be used to quantify the volume of the 
CGM. The measurement of brain volume is the most commonly used method of quantifying 
neural atrophy in HD, particularly within subcortical regions of interest (ROIs) (Georgiou-
Karistianis et al. 2013). Previous work has demonstrated that variability in structural brain 
volume measures introduced by the application of different image analysis tools can have 
large effects on the conclusions drawn in neuroimaging studies (Katuwal et al. 2016) and thus 
the use of accurate measures are paramount in quantifying cortical volume change in HD. 
Seven segmentation tools were compared using two datasets; an artificial dataset with 
corresponding ‘ground truth’ (GT) and a subset of TRACK-HD data that included control, pre-
HD and manifest-HD participants. Thorough qualitative and quantitative comparisons were 
undertaken and the results provided specific evidence for the selection of a segmentation tool 
for use in this thesis as well as a series of more widely applicable recommendations for other 
researchers who are also trying to select the most appropriate method of segmentation for 
their data. The comparison demonstrated that while all tools performed reliably across 
multiple scans, accuracy was much more variable. During visual QC it was clear that all tools 
had examples of poor segmentation performance, with some tools generally performing very 
poorly. This is particularly concerning given that some of the most widely used tools 
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(FreeSurfer, FSL FAST, SPM 8 Unified Segment) showed consistent errors in segmentation that 
are likely to have a considerable effect on the results of any study using these techniques. This 
finding was further established by a quantitative analysis that supported previous work in 
showing that the results of statistical comparisons differed between techniques, and thus that 
the application of different tools to measure CGM could result in varying conclusions when 
studying disease progression in HD (Katuwal et al. 2016). For example, when compared to 
controls there was significant longitudinal change in the CGM for pre-HD TRACK-HD 
participants, which was detected by the segmentations from by some tools but not others. 
This result stems from the differences in volumetric regions that are generated from different 
segmentation techniques and highlights the importance of choosing the best segmentation 
tool for the data, and then performing visual QC to ensure that segmentations are accurate 
before drawing conclusions based on the regions.  
The tool that demonstrated the highest standard of segmentation, both quantitatively 
and qualitatively on both datasets was MALP-EM. It is a newly developed, easy-to-use tool that 
was validated for use on traumatic brain injury (Ledig et al. 2015). MALP-EM is a multi-atlas 
based technique that is suitable for use on clinical populations, as demonstrated by the 
previous successful application in patients suffering from severe examples of traumatic brain 
injury (Ledig et al. 2015). It had high accuracy when quantified via comparing the 
segmentations to the BrainWeb GT segmentations, high reliability as demonstrated by test-
retest TRACK-HD data, and was sensitive to volumetric change in the longitudinal TRACK-HD 
analysis. Finally, the segmentations were generally better than most other techniques based 
on visual QC. While MALP-EM did show some errors, particularly in the temporal and occipital 
regions, they were much more infrequent and minor than for other tools and can easily be 
improved via the inclusion of a brain mask in the segmentation pipeline if needed. Based on 
the results from this chapter MALP-EM was selected as the segmentation tool that would be 
used to measure CGM in this thesis. It was the most visually accurate measurement tool, but 
also highly reliable and easy to apply, which will hopefully facilitate easy replication in other 
datasets. 
In chapter four another methodological comparison was undertaken to examine the 
performance of measures of cortical thickness (CT). It has been hypothesised that CT may be a 
more sensitive measure of cortical change than GM since volumetric measures are a function 
of the relationship between the surface area of the brain and CT (Panizzon et al. 2009), yet CT 
is a difficult characteristic to accurately quantify. Due to the complex nature of the cortex, CT is 
often over-estimated. This is largely because it is challenging to accurately delineate the tightly 
 214 
 
bound sulci of a brain. Both surface-based and voxel-based methods of quantifying CT are 
available, with surface-based methods considered to be more accurate but time-consuming to 
process. This chapter compared three measures of CT, one surface-based method and two 
voxel-based methods. While the surface-based tool, FreeSurfer, gave promising longitudinal 
results that indicated the occurrence of cortical thinning with increasing disease progression in 
HD, the segmentations were substandard when visually QCed. There were regular errors in the 
classification of WM and GM, particularly in the occipital lobe, and an overall trend for the 
underestimation of the GM. Of the two voxel-wise measures tested, one was highly reliable 
but showed very poor longitudinal performance (MALP-EM segmentation + ANTs CT 
measurement), and the other was generally unreliable for both cross-sectional and 
longitudinal measurement of CT (ANTs). These disappointing results highlight the need for 
further development of accurate CT measures, and suggest that when using the currently 
available techniques caution should be taken. While FreeSurfer may be able to successfully 
distinguish between different groups and measure changes in CT, as was demonstrated here 
and in previous studies (Righart et al. 2017), the issues associated with the quality of 
segmentations should be considered, especially when comparing a group with neural 
pathology to a healthy control group. The visual examination of all segmentations should be 
performed and the results of a study interpreted with these in mind. While it is possible to 
perform manual edits within FreeSurfer that may improve the segmentations, as research 
studies expand the number of participants recruited and the move to analysing large cross-
study datasets becomes more popular this is an unfeasible solution. While it was initially 
hoped that CT could be used as an additional and potentially more sensitive longitudinal 
measure for detecting cortical change in HD in this thesis, it was instead excluded from 
subsequent chapters based on the results of chapter four.  
The final methodological comparison was performed in chapter five, whereby 
manually delineated volumetric regions of the caudate and putamen were compared to the 
automated segmentations produced by MALP-EM. Manually delineated subcortical regions are 
often considered a ‘gold standard’, but are time-consuming to perform (both in terms of rater 
training and completing the measurements). Automated measures are regularly used within 
HD literature due to their accessibility and speed of use, but the MALP-EM subcortical regions 
have not been used in HD work previously and they have not been compared to manual 
measures. After running MALP-EM on a subset of the data from PADDINGTON, visual QC 
indicated that MALP-EM subcortical regions were generally of high quality. There were a small 
number of failed segmentations, however these could be improved via manual edits to the 
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regions. The quantitative analysis demonstrated good overlap between the manual and 
automatically generated regions, with a very close association between the volumes from both 
tools. The results from this chapter provided validation of the MALP-EM regions for use in this 
study. 
These three analyses were performed to ensure that the investigation undertaken in 
chapter six used highly accurate measures of CGM to characterise GM change. The accurate 
measurement of neural characteristics is of utmost importance when performing sMRI studies, 
especially when researching clinical cohorts whereby conclusions may influence the 
understanding of disease pathology. Previous work has demonstrated that the use of different 
techniques to measure brain volume could be driving variability in neuroimaging findings 
(Katuwal et al. 2016), and encouraged the cross-validation and consistency when using 
segmentation techniques to measure volume. While numerous methodological comparisons 
have been performed to validate both volumetric and CT methods (Clarkson et al. 2011; 
Schwarz et al. 2016; Fellhauer et al. 2015; Kazemi & Noorizadeh 2014; Despotović et al. 2015; 
Klauschen et al. 2009; Eggert et al. 2012), the work undertaken for this thesis also placed 
importance on the visual examination of segmentation quality. The qualitative review of 
segmentations has previously been overlooked during reporting on the performance of many 
tools, with few published studies providing descriptions of the qualitative review of 
segmentation accuracy. Here, the qualitative examination of >3000 segmentations resulted in 
a good understanding of the limits of currently available automated tools. The majority of 
tools, both for the measurement of volume and CT, had issues with delineating the occipital 
and temporal lobes with over-estimation of CGM common within these regions. Despite many 
available software options, automated techniques are not always able to delineate the 
complex structure of the human brain. Understanding the weaknesses of these tools is vital 
when using them, and other users should endeavour to perform careful visual examination of 
both volumetric and CT segmentations prior to publishing studies that use the tools.  
The work in this thesis also identified the strengths of volumetric measurements 
compared to CT measurements, with findings suggesting that while, theoretically, measures of 
volume may be less sensitive to neural change than measures of CT (Panizzon et al. 2009), 
volume is easier to quantify and more robust to errors in segmentation than current CT 
measures. CT measures, especially when quantified longitudinally, are particularly susceptible 
to the influence of errors in segmentation that inflate CT values. Errors include the poor 
delineation of tightly bound sulci as well as general over- or under-estimation of the cortex 
due to noise within scans. While similar findings have been discussed previously (Clarkson et 
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al. 2011; Righart et al. 2017), the current results suggest that the use of recently developed CT 
methods and highly validated cortical regions do not address the shortfalls previously seen in 
CT studies. Until more work is done to improve measures of CT, volumetric measures may be 
more appropriate for the detection of cortical atrophy.  
7.2. Mapping cortical change during HD progression  
The final chapter of this thesis applied the methods validated in chapters three and 
five to a subset of data from the TRACK-HD and TrackOn-HD studies. Atrophy of the cortex has 
not been extensively characterised in HD, with previous work suffering from a range of 
limitations. This study aimed to expand upon past work and present a detailed 
characterisation of cortical atrophy during the transition from pre-HD to manifest HD, a phase 
where cortical atrophy is thought to increase along with increases in HD symptoms. Scans from 
49 participants with multiple time points were segmented, and CGM change during the period 
prior to and after HD motor diagnosis was quantified. A dynamical model using a DCM 
framework was applied that quantified total CGM loss during the period, along with the rate of 
linear (constant) atrophy, the rate and timing of non-linear atrophy (accelerations of atrophy) 
and the relationship between atrophy and CAG across the cortex. This combination of results 
provides the first in-depth understanding of the complexity of regional atrophy in the cortex 
and how this changes over time, particularly around the critical time of symptom onset in HD.  
The results show that volume loss in various regions of the cortex is higher than 
previously thought. A number of frontal and motor regions underwent atrophy totalling 
around 10% during the decade around motor diagnosis. This level of loss is double that at 
which cortical atrophy has previously been estimated (Tabrizi et al. 2012), indicating that 
heterogeneity of atrophy within the cortex influences global rates of cortical atrophy. When 
regional rates of linear atrophy were quantified, regions of the frontal lobe were shown to 
undergo the highest rates of linear atrophy in the cortex. Neuronal loss in the frontal lobe has 
been associated with many of the earliest symptoms of HD (Nana et al. 2014), and reduced 
volume of the frontal  lobe is associated with poorer performance on a number of cognitive 
and motor tasks in HD (Scahill et al. 2013). However, the finding that frontal regions are 
undergoing the highest rate of linear atrophy in this vital period of HD progression has not 
been demonstrated before. In addition, motor regions appear to undergo the greatest 
acceleration of atrophy during transition from pre-HD to manifest HD. The clinical 
categorisation of HD is based upon increasing motor symptoms and it is thus perhaps 
unsurprising that these regions undergo accelerations during this period, yet the extent of 
acceleration in these regions compared to other regions is very striking. In contrast, subcortical 
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regions were undergoing consistently high rates of atrophy during the whole period, with very 
little acceleration present, supporting previous evidence that has suggested low rates of 
acceleration of atrophy in the caudate (Hobbs, Barnes, et al. 2010). The timing of the 
accelerated atrophy in motor regions appears to occur slightly after motor onset, indicating 
that the cause of symptom onset is not CGM atrophy but possibly the breakdown in WM 
connections, as suggested by previous work (Wu et al. 2017; McColgan et al. 2017). Together, 
these two results give an interesting insight into the neural changes underpinning HD 
progression.  
The association between cortical progression and CAG length was also modelled. The 
impact of CAG on neural atrophy has not been extensively characterised, despite evidence that 
CAG length influences both HD onset and progression (Ross et al. 2014). Previous work has 
used VBM and linear models to suggest that there is a relationship between atrophy and CAG 
length, especially in subcortical regions, with some evidence for associations between CAG 
length and atrophy in the occipital lobe. The results confirm that higher CAG length is 
associated with faster progression in the occipital lobe in this cohort. Furthermore, this 
analysis also showed that those with higher CAG lengths underwent less acceleration of 
atrophy. That is, they underwent a more constant rate of atrophy compared to those who had 
lower CAG lengths and showed an acceleration of atrophy. This result is new evidence that 
indicates that there may be a different pattern of atrophy in those with high vs low CAG repeat 
lengths.  
Finally, a behavioural analysis offers preliminary results linking cortical atrophy to 
three commonly used measures of HD progression, the Total Motor Score (TMS), Speeded 
Tapping, and SDMT. While the results require further analysis using a more directed model, 
they provide an indication that Speeded Tapping and SDMT, discrete measures of HD 
progression, are more closely linked to cortical atrophy especially within the motor regions 
than TMS, which undergoes earlier change in this cohort, indicative of a possible link to WM 
connectivity changes described previously.  
The results from this chapter give new insight into the complex nature of regional 
CGM atrophy occurring over disease progression. By using a highly optimised segmentation 
technique with a complex modelling method to expand upon previous work that was 
conducted using linear modelling and more heterogeneous groups this analysis delivers a 
novel approach. The results demonstrate the importance of both frontal and motor regions in 
the progression of HD. Although it is possible that the atrophy within these regions is not 
causing the onset of symptoms, it may hasten their progression. The behavioural analysis 
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warrants further investigation, but suggests that discrete measures of HD progression may be 
more closely linked to cortical change than measures quantifying change across multiple 
domains. That there are significant accelerations of atrophy in sub-regions of the cortex during 
this phase of disease progression indicates that that CGM atrophy is not linear, as previously 
assumed and shown in Figure 1.6 from Chapter One, and that this is an oversimplification. The 
therapeutic trials that are currently underway are likely to target the cortex, and thus by 
having a better understanding of the nature of cortical atrophy and which regions are showing 
the greatest progression, as well as associated change on behavioural biomarkers, a more 
targeted approach to quantifying the effects of the drug could be used.  
7.3. Weaknesses and future work 
It is important to recognise a number of weaknesses in this work, these are covered in 
detail in the preceding chapters, but a few key points are reiterated here. The methodological 
comparisons did not compare longitudinal pipelines, since these were not available for all 
methods. By using longitudinal pipelines the results from some techniques could be improved 
and this should be considered when selecting methods for analysis. Furthermore, the 
methodological validations performed in chapters three and four did not include the 
comparison of automated methods to a gold standard for CGM regions. While a manual 
segmentation technique was tested, it was not found to be a reproducible or reliable measure. 
Future work should continue to develop improved techniques and compare sMRI 
methodology. The work conducted in this thesis has demonstrated that the techniques used to 
measure neural characteristics require improvement, particularly as MRI acquisitions develop. 
The increasing access to 7T data is just one example of a rapidly changing field, and it is 
essential that the tools used to analyse this data are constantly evaluated and improved.  
The TRACK-HD, TrackOn-HD and PADDINGTON studies were multi-site studies. While 
site was controlled for in analyses, there are a number of factors (scanner drift, software 
upgrades) that will not be accounted for by using a dummy variable to control for site. The 
acquisitions were developed for multi-site use and regular quality assurance was performed on 
each scanner to maintain consistency within and between sites, however it is likely that some 
issues are introduced by site differences. 
Replication of the sDCM work conducted in chapter six is important. Ideally, this work 
would be replicated in a different cohort, such as the PREDICT-HD cohort. The addition of 
other imaging data such as connectivity metrics could further enhance the understanding of 
disease progression in this cohort, as would further modelling to directly link behavioural 
change to neural change. By using one model to map the relationship between different 
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measures of neural change and how they change over time a cohesive picture of the 
progression of brain changes in HD can be developed. In addition, the use of different cohorts 
could provide further insight on the findings shown here. The comparison of a high CAG vs low 
CAG group could offer further evidence of the relationship between CAG and atrophy. In 
addition, the relationship between CGM atrophy and change in clinical and cognitive variables 
should be more thoroughly examined.  
 
 
7.4. Conclusions 
This thesis has provided methodological advances on the quantification of neural 
characteristics from sMRI data in HD, with the resulting methods then applied on a clinical 
cohort to conduct a thorough characterisation of the trajectory of CGM atrophy during HD 
motor symptom onset. The results provide important validation of a recently developed and 
easy to use segmentation method, and present important recommendations for the 
application of a number of commonly used sMRI measurement techniques. Most importantly, 
this thesis has advanced the current understanding of CGM atrophy in HD, revealing that rates 
of cortical atrophy are higher than previously thought. The pattern of atrophy seen across the 
cortex reveals the complex nature of cortical change occurring during motor conversion in HD. 
The results have implications for the overall understanding of disease progression, but also 
offer potential value in the monitoring of cortical change during clinical trials aimed at 
developing a treatment for HD.
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9. APPENDICES 
 
Appendix 1 
 
 
Figure 1: Box plots showing frontal GM Volumes for all groups and all tools for 2008 and 2011 
time points. Boxes show the first quartile, median and third quartile, with whiskers 
representing the smallest and largest value not classified as an outlier. Dots represent outliers. 
 
 
 
 
 
Figure 2: Box plots showing temporal GM Volumes for all groups and all tools for 2008 
and 2011 time points. Boxes show the first quartile, median and third quartile, with whiskers 
representing the smallest and largest value not classified as an outlier. Dots represent outliers. 
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Figure 3: Box plots showing parietal GM Volumes for all groups and all tools for 2008 and 2011 
time points. Boxes show the first quartile, median and third quartile, with whiskers 
representing the smallest and largest value not classified as an outlier. Dots represent outliers. 
 
 
 
Figure 4: Box plots showing occipital GM Volumes for all groups and all tools for 2008 and 2011 
time points. Boxes show the first quartile, median and third quartile, with whiskers 
representing the smallest and largest value not classified as an outlier. Dots represent outliers. 
 
 
 
Figure 5: Box plots showing insula GM Volumes for all groups and all tools for 2008 and 2011 
time points. Boxes show the first quartile, median and third quartile, with whiskers 
representing the smallest and largest value not classified as an outlier. Dots represent outliers. 
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Table 1: Intraclass correlations and confidence intervals for all HD groups in frontal, temporal, 
parietal, occipital lobes and the insula in different tools.  
 PreHD-A 
(N=20) 
PreHD-B 
(N=20) 
HD1 
(N=20) 
HD2 
(N=20) 
Frontal GM 
Intraclass Correlations 
Confidence intervals 
SPM 8 Unified 0.991 
0.977-0.997 
0.979 
0.945-0.992 
0.986 
0.967-0.995 
0.990 
0.976-0.996 
SPM 8 New 
Segment 
0.997 
0.994-0.999 
0.999 
0.994-1.000 
0.999 
0.997-1.000 
0.998 
0.994-0.999 
SPM 12 
 
0.987 
0.969-0.995 
0.992 
0.981-0.997 
0.998 
0.994-0.999 
0.994 
0.983-0.998 
Atropos 
 
0.957 
0.868-0.984 
0.995 
0.987-0.998 
0.990 
0.970-0.996 
0.989 
0.952-0.997 
MALP-EM 
 
0.992 
0.981-0.997 
0.998 
0.995-0.999 
0.998 
0.996-0.999 
0.996 
0.990-0.998 
FAST 
 
0.983 
0.959-0.993 
0.993 
0.984-0.997 
0.995 
0.981-0.998 
0.991 
0.977-0.996 
FreeSurfer 0.973 
0.927-0.990 
0.977 
0.942-0.991 
0.984 
0.949-0.994 
0.988 
0.971-0.995 
Temporal GM 
Intraclass Correlations 
Confidence intervals 
SPM 8 Unified  0.992 
 0.979-0.997 
 0.979 
 0.947-0.992 
 0.990 
 0.976-0.996 
 0.993 
 0.982-0.997 
SPM 8 New 
Segment 
 0.999 
 0.996-0.999 
 0.999 
 0.998-1.000 
 0.998 
 0.996-0.999 
 0.998 
 0.996-0.999 
SPM 12 
 
 0.987 
 0.965-0.995 
 0.992 
 0.979-0.997 
 0.997 
 0.992-0.999 
 0.995 
 0.988-0.998 
Atropos 
 
 0.959 
 0.847-0.986 
 0.994 
 0.983-0.998 
 0.995 
 0.985-0.998 
 0.991 
 0.959-0.997 
MALP-EM 
 
 0.991 
 0.962-0.997 
 0.998 
 0.995-0.999 
 0.997 
 0.993-0.999 
 0.994 
 0.984-0.997 
FAST 
 
 0.970 
 0.903-0.989 
 0.993 
 0.981-0.997 
 0.996 
 0.991-0.999 
 0.994 
 0.986-0.998 
FreeSurfer 0.959 
0.894-0.984 
0.979 
0.945-0.992 
0.995 
0.987-0.998 
0.987 
0.968-0.995 
Parietal GM 
Intraclass Correlations 
Confidence intervals 
SPM 8 
Unified 
0.994 
0.984-0.998 
0.984 
0.959-0.994 
0.988 
0.970-0.995 
0.990 
0.976-0.996 
SPM 8 New 
Segment 
0.999 
0.997-1.000 
0.994 
0.986-0.998 
0.998 
0.995-0.999 
0.998 
0.995-0.999 
SPM 12 
 
0.988 
0.970-0.995 
0.992 
0.981-0.997 
0.998 
0.994-0.999 
0.994 
0.985-0.998 
Atropos 
 
0.987 
0.952-0.996 
0.992 
0.978-0.997 
0.989 
0.968-0.996 
0.986 
0.948-0.995 
MALP-EM 
 
0.997 
0.993-0.999 
0.994 
0.984-0.998 
0.999 
0.997-1.000 
0.996 
0.989-0.998 
FAST 
 
0.989 
0.973-0.996 
0.992 
0.980-0.997 
0.990 
0.971-0.996 
0.992 
0.981-0.997 
FreeSurfer 0.991 
0.977-0.996 
0.978 
0.936-0.992 
0.981 
0.945-0.993 
0.987 
0.967-0.995 
Occipital GM 
Intraclass Correlations 
Confidence intervals 
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SPM 8 
Unified 
0.993 
0.982-0.997 
0.968 
0.920-0.988 
0.983 
0.958-0.993 
0.991 
0.978-0.996 
SPM 8 New 
Segment 
0.999 
0.997-1.000 
0.993 
0.983-0.997 
0.998 
0.994-0.999 
0.996 
0.991-0.999 
SPM 12 
 
0.990 
0.976-0.996 
0.973 
0.934-0.989 
0.998 
0.994-0.999 
0.993 
0.979-0.997 
Atropos 
 
0.984 
0.947-0.994 
0.978 
0.913-0.993 
0.991 
0.977-0.996 
0.995 
0.967-0.998 
MALP-EM 
 
0.994 
0.985-0.998 
0.991 
0.974-0.996 
0.994 
0.985-0.998 
0.996 
0.991-0.999 
FAST 
 
0.988 
0.971-0.995 
0.990 
0.958-0.997 
0.995 
0.986-0.998 
0.997 
0.992-0.999 
FreeSurfer 0.987 
0.967-0.995 
0.968 
0.908-0.988 
0.989 
0.973-0.996 
0.995 
0.988-0.981 
Insula 
Intraclass Correlation 
Confidence Intervals 
SPM 8 Unified 0.990 
0.974-0.996 
0.984 
0.960-0.994 
0.994 
0.984-0.997 
0.994 
0.984-0.998 
SPM 8 New 
Segment 
0.995 
0.988-0.998 
0.996 
0.991-0.999 
0.998 
0.996-0.999 
0.998 
0.995-0.999 
SPM 12 
 
0.988 
0.969-0.995 
0.987 
0.968-0.995 
0.997 
0.993-0.999 
0.996 
0.989-0.998 
Atropos 
 
0.988 
0.956-0.996 
0.993 
0.984-0.997 
0.995 
0.987-0.998 
0.993 
0.981-0.997 
MALP-EM 
 
0.996 
0.990-0.999 
0.998 
0.994-0.999 
0.997 
0.992-0.999 
0.996 
0.990-0.998 
FAST 
 
0.992 
0.973-0.997 
0.995 
0.988-0.998 
0.997 
0.993-0.999 
0.997 
0.992-0.999 
FreeSurfer 0.984 
0.960-0.994 
0.970 
0.925-0.988 
0.964 
0.906-0.986 
0.963 
0.910-0.985) 
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Table 2: Repeatability values for back-to-back segmentations of frontal, temporal, parietal, 
occipital and insula GM for all HD participants included in the current study, showing means, 
standard deviations, and ranges. 
 PreHD-A 
(N=20) 
PreHD-B 
(N=20) 
HD1 
(N=20) 
HD2 
(N=20) 
Frontal 
Mean repeatability (Standard Deviation) 
Range 
SPM 8 Unified 
Segment 
1.06 (0.88)  
0.14-3.59 
1.68 (2.09)  
0.05-8.02 
1.11 (1.60)  
0.11-7.42 
0.99 (0.78)  
0.03-2.76 
SPM 8 New 
Segment 
0.55 (0.45)  
0.01-1.44 
0.45 (0.32)  
0.00-1.09 
0.40 (0.25)  
0.05-0.94 
0.44 (0.33)  
0.04-1.30 
SPM 12 
 
1.12 (1.07)  
0.08-4.27 
0.89 (0.78)  
0.04-2.35 
0.71 (0.60)  
0.00-1.93 
0.91 (0.69)  
0.20-3.05 
Atropos 
 
1.72 (2.37)  
0.05-9.03 
0.84 (0.64)  
0.08-2.48 
1.27 (1.18)  
0.04-4.02 
1.22 (1.13)  
0.02-4.16 
MALP-EM 
 
0.76 (0.93)  
0.00-3.92 
0.56 (0.39)  
0.02-1.33 
0.43 (0.37)  
0.01-1.58 
0.57 (0.60)  
0.01-2.01 
FAST 
 
1.22 (0.80)  
0.16-2.95 
0.93 (0.67)  
0.06-2.43 
0.97 (0.77)  
0.19-2.78 
0.93 (0.87)  
0.03-2.69 
FreeSurfer 1.43 (1.71) 
0.00-5.29 
3.21 (5.54) 
0.20-26.01 
1.59 (1.35) 
0.02-5.51 
1.28 (1.02) 
0.10-3.43 
Temporal 
Mean repeatability (Standard Deviation) 
Range 
 
SPM 8 Unified 
Segment 
0.80 (0.76) 
0.02-2.66 
1.49 (1.92) 
0.17-7.06 
1.11 (1.05) 
0.19-4.97 
0.85 (0.72) 
0.03-2.57 
SPM 8 New 
Segment 
0.37 (0.26) 
0.03-0.96 
0.34 (0.29) 
0.03-0.86 
0.38 (0.34) 
0.04-1.33 
0.36 (0.33) 
0.03-1.08 
SPM 12 
 
0.98 (0.74) 
0.10-2.81 
0.81 (0.84) 
0.06-3.22 
0.74 (0.58) 
0.06-2.38 
0.81 (0.55) 
0.10-2.01 
Atropos 
 
1.43 (1.68) 
0.17-5.97 
0.73 (0.79) 
0.03-2.85 
0.75 (0.78) 
0.03-3.33 
1.07 (1.03) 
0.15-3.61 
MALP-EM 
 
0.77 (0.77) 
0.01-2.97 
0.48 (0.40) 
0.00-1.67 
0.52 (0.60) 
0.00-2.64 
0.87 (0.78) 
0.07-2.36 
FAST 
 
1.02 (1.20) 
0.03-5.12 
0.75 (0.78) 
0.03-2.95 
0.69 (0.58) 
0.02-2.13 
0.69 (0.77) 
0.02-3.26 
FreeSurfer 3.15 (2.30) 
0.18-7.87 
3.04 (3.51) 
0.18-15.82 
3.43 (2.33) 
0.26-8.30 
4.51 (2.81) 
0.09-8.49 
Parietal 
Mean repeatability (Standard Deviation) 
Range 
 
SPM 8 Unified 
Segment 
0.89 (0.83) 
0.22-3.39 
1.57 (1.64) 
0.02-6.21 
1.15 (1.37) 
0.01-6.38 
1.04 (0.81) 
0.04-2.66 
SPM 8 New 
Segment 
0.38 (0.33) 
0.02-1.49 
0.54 (0.82) 
0.00-3.79 
0.46 (0.37) 
0.00-1.44 
0.39 (0.39) 
0.00-1.33 
SPM 12 
 
1.10 (1.02) 
0.01-3.89 
0.84 (0.78) 
0.04-2.83 
0.71 (0.65) 
0.05-2.42 
0.90 (0.73) 
0.07-3.40 
Atropos 
 
1.08 (1.12) 
0.10-4.16 
0.98 (0.91) 
0.04-3.15 
1.22 (1.26) 
0.07-4.43 
1.35 (1.45) 
0.09-5.60 
MALP-EM 
 
0.50 (0.53) 
0.05-2.32 
0.72 (0.89) 
0.03-3.79 
0.37 (0.30) 
0.02-1.29 
0.72 (0.43) 
0.14-1.73 
FAST 
 
0.95 (0.75) 
0.09-2.50 
0.94 (0.71) 
0.03-2.43 
1.31 (1.04) 
0.12-3.14 
0.82 (0.90) 
0.05-3.66 
FreeSurfer 0.90 (0.83) 
0.00-2.63 
1.99 (1.72) 
0.40-7.01 
1.66 (1.70) 
0.02-6.43 
1.32 (1.43) 
0.01-4.14 
Occipital 
Mean repeatability (Standard Deviation) 
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Range 
SPM 8 Unified 
Segment 
1.00 (1.24) 
0.25-5.84 
2.03 (2.01) 
0.04-7.31 
1.55 (1.84) 
0.05-8.44 
1.38 (1.20) 
0.10-3.91 
SPM 8 New 
Segment 
0.52 (0.31) 
0.02-1.07 
0.82 (0.61) 
0.01-2.36 
0.58 (0.44) 
0.01-1.45 
0.67 (0.60) 
0.02-2.10 
SPM 12 
 
1.27 (1.02) 
0.03-4.33 
1.34 (1.32) 
0.00-4.65 
0.90 (0.71) 
0.02-2.18 
1.49 (1.20) 
0.32-4.53 
Atropos 
 
1.56 (1.68) 
0.15-6.95 
1.44 (1.40) 
0.02-6.44 
1.19 (1.27) 
0.00-4.47 
1.25 (1.15) 
0.07-4.49 
MALP-EM 
 
1.05 (0.67) 
0.05-2.82 
0.98 (0.91) 
0.02-3.99 
0.84 (0.73) 
0.03-2.91 
0.80 (0.72) 
0.06-2.42 
FAST 
 
1.39 (1.00) 
0.14-4.15 
0.94 (0.80) 
0.10-2.57 
1.17 (0.73) 
0.13-2.63 
0.86 (0.79) 
0.11-3.72 
Fre
eSurfer 
1.47 
(1.24) 
0.17-
4.96 
2.25 
(2.02) 
0.13-
7.06 
1.59 
(1.35) 
0.09-
5.90 
1.14 
(1.13) 
0.09-
4.54 
Insula 
Mean repeatability (Standard Deviation) 
Range 
 
SPM 8 Unified 
Segment 
0.82 (1.00) 
0.01-3.21 
1.43 (1.36) 
0.06-4.45 
1.02 (0.99) 
0.01-4.53 
1.03 (0.93) 
0.08-3.39 
SPM 8 New 
Segment 
0.81 (0.63) 
0.02-2.08 
0.80 (0.44) 
0.09-1.56 
0.60 (0.38) 
0.02-1.33 
0.53 (0.43) 
0.08-1.37 
SPM 12 
 
0.86 (0.95) 
0.11-3.88 
1.08 (1.04) 
0.09-4.00 
0.75 (0.67) 
0.04-2.65 
0.97 (0.84) 
0.02-3.36 
Atropos 
 
1.26 (0.73) 
0.08-2.37 
0.77 (0.90) 
0.02-3.73 
1.02 (0.72) 
0.02-2.82 
1.08 (0.92) 
0.09-3.13 
MALP-EM 
 
0.89 (0.65) 
0.00-2.09 
0.59 (0.44) 
0.01-1.39 
0.74 (0.48) 
0.02-1.92 
0.92 (0.60) 
0.01-1.79 
FAST 
 
0.95 (0.63) 
0.07-2.10 
0.69 (0.48) 
0.07-1.90 
0.72 (0.56) 
0.05-1.87 
0.71 (0.64) 
0.10-1.93 
FreeSurfer 1.64 (1.05) 
0.26-4.08 
2.72 (2.88) 
0.34-13.31 
1.95 (2.26) 
0.03-7.95 
2.62 (2.27) 
0.15-7.77 
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Table 3: Spearman’s ranked correlation for segmentations of total GM for all HD participants 
included in the current study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 SPM 8 
Unified 
Segment 
SPM 8 New 
Segment 
SPM 12 
Segment 
ANTs 
Atropos 
MALP-EM FSL FAST 
PreHD-A 
SPM 8 Unified Segment 1      
SPM 8 New Segment 0.777 1     
SPM 12 Segment 0.896 0.666 1    
ANTs Atropos 0.732 0.833 0.737 1   
MALP-EM 0.808 0.950 0.749 0.844 1  
FSL FAST 0.741 0.785 0.770 0.926 0.874 1 
FreeSurfer 0.865 0.959 0.752 0.805 0.952 0.802 
PreHD-B 
SPM 8 Unified Segment 1      
SPM 8 New Segment 0.770 1     
SPM 12 Segment 0.932 0.889 1    
ANTs Atropos 0.726 0.934 0.851 1   
MALP-EM 0.842 0.964 0.941 0.919 1  
FSL FAST 0.883 0.848 0.917 0.857 0.878 1 
FreeSurfer 0.871 0.925 0.952 0.838 0.938 0.887 
HD1 
SPM 8 Unified Segment 1      
SPM 8 New Segment 0.737 1     
SPM 12 Segment 0.857 0.672 1    
ANTs Atropos 0.847 0.818 0.779 1   
MALP-EM 0.793 0.955 0.702 0.886 1  
FSL FAST 0.845 0.731 0.815 0.917 0.841 1 
FreeSurfer 0.884 0.857 0.875 0.829 0.895 0.826 
HD2 
SPM 8 Unified Segment 1      
SPM 8 New Segment 0.441 1     
SPM 12 Segment 0.758 0.555 1    
ANTs Atropos 0.644 0.820 0.671 1   
MALP-EM 0.633 0.917 0.719 0.860 1  
FSL FAST 0.827 0.738 0.768 0.908 0.853 1 
FreeSurfer 0.605 0.802 0.796 0.681 0.883 0.726 
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Table 4: Spearman’s ranked correlation for segmentations of cortical GM for all HD 
participants included in the current study.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 SPM 8 
Unified 
Segment 
SPM 8 New 
Segment 
SPM 12 
Segment 
ANTs 
Atropos 
MALP-EM FSL FAST 
PreHD-A 
SPM 8 Unified Segment 1      
SPM 8 New Segment 0.815 1     
SPM 12 Segment 0.883 0.722 1    
ANTs Atropos 0.865 0.901 0.844 1   
MALP-EM 0.836 0.970 0.755 0.886 1  
FSL FAST 0.848 0.848 0.847 0.920 0.874 1 
FreeSurfer 0.868 0.955 0.811 0.917 0.973 0.923 
PreHD-B 
SPM 8 Unified Segment 1      
SPM 8 New Segment 0.747 1     
SPM 12 Segment 0.926 0.863 1    
ANTs Atropos 0.762 0.943 0.896 1   
MALP-EM 0.830 0.974 0.922 0.947 1  
FSL FAST 0.818 0.934 0.925 0.916 0.955 1 
FreeSurfer 0.887 0.836 0.935 0.848 0.874 0.925 
HD1 
SPM 8 Unified Segment 1      
SPM 8 New Segment 0.734 1     
SPM 12 Segment 0.868 0.716 1    
ANTs Atropos 0.869 0.898 0.844 1   
MALP-EM 0.735 0.973 0.711 0.914 1  
FSL FAST 0.820 0.764 0.862 0.902 0.782 1 
FreeSurfer 0.820 0.893 0.898 0.910 0.901 0.854 
HD2 
SPM 8 Unified Segment 1      
SPM 8 New Segment 0.411 1     
SPM 12 Segment 0.826 0.576 1    
ANTs Atropos 0.692 0.814 0.741 1   
MALP-EM 0.638 0.910 0.749 0.869 1  
FSL FAST 0.803 0.699 0.835 0.919 0.860 1 
FreeSurfer 0.729 0.729 0.887 0.832 0.868 0.880 
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Table 5: Spearman’s ranked correlation for segmentations of frontal GM for all HD groups 
included in the current study. 
 SPM 8 
Unified 
Segment 
SPM 8 New 
Segment 
SPM 12 
Segment 
ANTs 
Atropos 
MALP-EM FSL FAST 
Controls 
SPM 8 Unified Segment 1.000      
SPM 8 New Segment 0.807 1.000     
SPM 12 Segment 0.918 0.935 1.000    
ANTs Atropos 0.800 0.972 0.951 1.000   
MALP-EM 0.860 0.975 0.953 0.954 1.000  
FSL FAST 0.891 0.879 0.940 0.907 0.925 1.000 
FreeSurfer 0.863 0.940 0.914 0.900 0.965 0.902 
PreHD-A 
SPM 8 Unified Segment 1.000      
SPM 8 New Segment 0.811 1.000     
SPM 12 Segment 0.919 0.749 1.000    
ANTs Atropos 0.839 0.865 0.859 1.000   
MALP-EM 0.832 0.962 0.737 0.841 1.000  
FSL FAST 0.820 0.638 0.802 0.776 0.692 1.000 
FreeSurfer 0.835 0.925 0.758 0.878 0.943 0.788 
PreHD-B 
SPM 8 Unified Segment 1.000      
SPM 8 New Segment 0.761 1.000     
SPM 12 Segment 0.902 0.926 1.000    
ANTs Atropos 0.770 0.971 0.935 1.000   
MALP-EM 0.821 0.968 0.949 0.943 1.000  
FSL FAST 0.856 0.830 0.892 0.824 0.847 1.000 
FreeSurfer 0.826 0.950 0.949 0.932 0.958 0.917 
HD1 
SPM 8 Unified Segment 1.000      
SPM 8 New Segment 0.806 1.000     
SPM 12 Segment 0.818 0.689 1.000    
ANTs Atropos 0.851 0.914 0.803 1.000   
MALP-EM 0.761 0.976 0.630 0.908 1.000  
FSL FAST 0.678 0.713 0.677 0.803 0.713 1.000 
FreeSurfer 0.875 0.896 0.868 0.925 0.875 0.762 
HD2 
SPM 8 Unified Segment 1.000      
SPM 8 New Segment 0.582 1.000     
SPM 12 Segment 0.869 0.704 1.000    
ANTs Atropos 0.738 0.805 0.791 1.000   
MALP-EM 0.662 0.970 0.777 0.881 1.000  
FSL FAST 0.839 0.681 0.788 0.877 0.784 1.000 
FreeSurfer 0.738 0.889 0.893 0.818 0.916 0.777 
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Table 6: Spearman’s ranked correlation for segmentations of temporal GM for all HD 
participants included in the current study. 
 
 
 
 
 
 
 
 
 
 
 
 SPM 8 
Unified 
Segment 
SPM 8 New 
Segment 
SPM 12 
Segment 
ANTs 
Atropos 
MALP-EM FSL FAST 
Controls 
SPM 8 Unified Segment 1.000      
SPM 8 New Segment 0.863 1.000     
SPM 12 Segment 0.972 0.932 1.000    
ANTs Atropos 0.861 0.972 0.930 1.000   
MALP-EM 0.874 0.967 0.949 0.981 1.000  
FSL FAST 0.928 0.947 0.954 0.944 0.937 1.000 
FreeSurfer 0.918 0.956 0.951 0.956 0.939 0.975 
PreHD-A 
SPM 8 Unified Segment 1.000      
SPM 8 New Segment 0.853 1.000     
SPM 12 Segment 0.865 0.826 1.000    
ANTs Atropos 0.908 0.944 0.856 1.000   
MALP-EM 0.844 0.937 0.818 0.964 1.000  
FSL FAST 0.914 0.908 0.890 0.970 0.943 1.000 
FreeSurfer 0.904 0.949 0.878 0.952 0.944 0.946 
PreHD-B 
SPM 8 Unified Segment 1.000      
SPM 8 New Segment 0.767 1.000     
SPM 12 Segment 0.941 0.901 1.000    
ANTs Atropos 0.800 0.990 0.926 1.000   
MALP-EM 0.824 0.971 0.934 0.970 1.000  
FSL FAST 0.908 0.895 0.962 0.899 0.925 1.000 
FreeSurfer 0.896 0.896 0.956 0.890 0.916 0.974 
HD1 
SPM 8 Unified Segment 1.000      
SPM 8 New Segment 0.768 1.000     
SPM 12 Segment 0.892 0.689 1.000    
ANTs Atropos 0.842 0.868 0.874 1.000   
MALP-EM 0.830 0.943 0.737 0.895 1.000  
FSL FAST 0.820 0.773 0.785 0.821 0.863 1.000 
FreeSurfer 0.821 0.723 0.889 0.833 0.809 0.874 
HD2 
SPM 8 Unified Segment 1.000      
SPM 8 New Segment 0.641 1.000     
SPM 12 Segment 0.886 0.749 1.000    
ANTs Atropos 0.779 0.829 0.839 1.000   
MALP-EM 0.770 0.925 0.865 0.935 1.000  
FSL FAST 0.794 0.827 0.922 0.844 0.863 1.000 
FreeSurfer 0.746 0.893 0.907 0.866 0.926 0.926 
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Table 7: Spearman’s ranked correlation for segmentations of parietal GM for all HD 
participants included in the current study. 
 
 
 
 
 
 
 
 
 
 
 SPM 8 
Unified 
Segment 
SPM 8 New 
Segment 
SPM 12 
Segment 
ANTs 
Atropos 
MALP-EM FSL FAST 
Controls 
SPM 8 Unified Segment 1.000      
SPM 8 New Segment 0.791 1.000     
SPM 12 Segment 0.925 0.879 1.000    
ANTs Atropos 0.854 0.947 0.942 1.000   
MALP-EM 0.833 0.981 0.877 0.951 1.000  
FSL FAST 0.846 0.937 0.905 0.912 0.932 1.000 
FreeSurfer 0.898 0.937 0.900 0.928 0.967 0.935 
PreHD-A 
SPM 8 Unified Segment 1.000      
SPM 8 New Segment 0.845 1.000     
SPM 12 Segment 0.908 0.764 1.000    
ANTs Atropos 0.854 0.884 0.847 1.000   
MALP-EM 0.812 0.959 0.741 0.871 1.000  
FSL FAST 0.869 0.892 0.845 0.964 0.862 1.000 
FreeSurfer 0.878 0.944 0.830 0.944 0.928 0.971 
PreHD-B 
SPM 8 Unified Segment 1.000      
SPM 8 New Segment 0.731 1.000     
SPM 12 Segment 0.920 0.863 1.000    
ANTs Atropos 0.785 0.941 0.931 1.000   
MALP-EM 0.856 0.956 0.940 0.943 1.000  
FSL FAST 0.866 0.863 0.952 0.899 0.914 1.000 
FreeSurfer 0.800 0.926 0.922 0.931 0.947 0.961 
HD1 
SPM 8 Unified Segment 1.000      
SPM 8 New Segment 0.762 1.000     
SPM 12 Segment 0.899 0.705 1.000    
ANTs Atropos 0.901 0.916 0.863 1.000   
MALP-EM 0.787 0.968 0.761 0.944 1.000  
FSL FAST 0.908 0.853 0.881 0.937 0.881 1.000 
FreeSurfer 0.904 0.884 0.902 0.949 0.925 0.970 
HD2 
SPM 8 Unified Segment 1.000      
SPM 8 New Segment 0.587 1.000     
SPM 12 Segment 0.836 0.768 1.000    
ANTs Atropos 0.681 0.928 0.815 1.000   
MALP-EM 0.632 0.959 0.777 0.934 1.000  
FSL FAST 0.744 0.947 0.899 0.925 0.938 1.000 
FreeSurfer 0.692 0.869 0.883 0.896 0.869 0.938 
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Table 8: Spearman’s ranked correlation for segmentations of occipital GM for all HD 
participants included in the current study. 
 
 
 
 
 
 
 
 
 SPM 8 
Unified 
Segment 
SPM 8 New 
Segment 
SPM 12 
Segment 
ANTs 
Atropos 
MALP-EM FSL FAST 
Controls 
SPM 8 Unified Segment 1.000      
SPM 8 New Segment 0.712 1.000     
SPM 12 Segment 0.907 0.854 1.000    
ANTs Atropos 0.761 0.930 0.914 1.000   
MALP-EM 0.826 0.956 0.898 0.928 1.000  
FSL FAST 0.877 0.879 0.921 0.911 0.942 1.000 
FreeSurfer 0.863 0.895 0.875 0.883 0.939 0.914 
PreHD-A 
SPM 8 Unified Segment 1.000      
SPM 8 New Segment 0.871 1.000     
SPM 12 Segment 0.886 0.770 1.000    
ANTs Atropos 0.893 0.859 0.793 1.000   
MALP-EM 0.859 0.940 0.794 0.887 1.000  
FSL FAST 0.908 0.856 0.793 0.958 0.902 1.000 
FreeSurfer 0.871 0.908 0.794 0.883 0.946 0.910 
PreHD-B 
SPM 8 Unified Segment 1.000      
SPM 8 New Segment 0.553 1.000     
SPM 12 Segment 0.848 0.814 1.000    
ANTs Atropos 0.639 0.899 0.850 1.000   
MALP-EM 0.753 0.902 0.911 0.857 1.000  
FSL FAST 0.815 0.737 0.902 0.812 0.848 1.000 
FreeSurfer 0.657 0.774 0.868 0.762 0.862 0.764 
HD1 
SPM 8 Unified Segment 1.000      
SPM 8 New Segment 0.746 1.000     
SPM 12 Segment 0.958 0.741 1.000    
ANTs Atropos 0.899 0.851 0.917 1.000   
MALP-EM 0.844 0.956 0.844 0.905 1.000  
FSL FAST 0.976 0.788 0.967 0.935 0.881 1.000 
FreeSurfer 0.922 0.787 0.958 0.922 0.878 0.949 
HD2 
SPM 8 Unified Segment 1.000      
SPM 8 New Segment 0.665 1.000     
SPM 12 Segment 0.931 0.794 1.000    
ANTs Atropos 0.755 0.892 0.841 1.000   
MALP-EM 0.785 0.959 0.877 0.850 1.000  
FSL FAST 0.896 0.865 0.932 0.919 0.899 1.000 
FreeSurfer 0.809 0.832 0.890 0.800 0.898 0.896 
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Table 9: Spearman’s ranked correlation for segmentations of insula GM for all HD participants 
included in the current study. 
 
 
 SPM 8 
Unified 
Segment 
SPM 8 New 
Segment 
SPM 12 
Segment 
ANTs 
Atropos 
MALP-EM FSL FAST 
Controls 
SPM 8 Unified Segment 1.000      
SPM 8 New Segment 0.830 1.000     
SPM 12 Segment 0.925 0.930 1.000    
ANTs Atropos 0.818 0.961 0.874 1.000   
MALP-EM 0.704 0.791 0.709 0.811 1.000  
FSL FAST 0.839 0.939 0.868 0.953 0.837 1.000 
FreeSurfer 0.832 0.883 0.819 0.890 0.884 0.925 
PreHD-A 
SPM 8 Unified Segment 1.000      
SPM 8 New Segment 0.922 1.000     
SPM 12 Segment 0.928 0.853 1.000    
ANTs Atropos 0.950 0.965 0.902 1.000   
MALP-EM 0.866 0.944 0.731 0.920 1.000  
FSL FAST 0.937 0.914 0.893 0.971 0.863 1.000 
FreeSurfer 0.919 0.947 0.848 0.965 0.907 0.968 
PreHD-B 
SPM 8 Unified Segment 1.000      
SPM 8 New Segment 0.922 1.000     
SPM 12 Segment 0.928 0.853 1.000    
ANTs Atropos 0.950 0.965 0.902 1.000   
MALP-EM 0.866 0.944 0.731 0.920 1.000  
FSL FAST 0.937 0.914 0.893 0.971 0.863 1.000 
FreeSurfer 0.919 0.947 0.848 0.965 0.907 0.968 
HD1 
SPM 8 Unified Segment 1.000      
SPM 8 New Segment 0.878 1.000     
SPM 12 Segment 0.916 0.937 1.000    
ANTs Atropos 0.908 0.965 0.973 1.000   
MALP-EM 0.874 0.881 0.776 0.815 1.000  
FSL FAST 0.938 0.958 0.979 0.982 0.851 1.000 
FreeSurfer 0.887 0.929 0.928 0.928 0.866 0.959 
HD2 
SPM 8 Unified Segment 1.000      
SPM 8 New Segment 0.746 1.000     
SPM 12 Segment 0.829 0.790 1.000    
ANTs Atropos 0.826 0.850 0.917 1.000   
MALP-EM 0.753 0.872 0.777 0.808 1.000  
FSL FAST 0.928 0.857 0.878 0.904 0.851 1.000 
FreeSurfer 0.811 0.979 0.818 0.869 0.869 0.908 
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